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ABSTRACT 
 
Aberrant DNA methylation is a well known characteristic of cancer genomes. It can be used 
as a way of identifying important genes in tumourigenesis and can have diagnostic/prognostic 
value.  
Using a genome-wide methylated DNA affinity enrichment approach this work identified five 
genes (DBC1, CIDE-A, EMILIN2, FBLN2 and SALL1) that are hypermethylated in sporadic 
breast cancer. Methylation of one of these genes, EMILIN2, was found to associate with 
worse disease free survival (DFS). A second genome wide approach assessing over 27,000 
CpG loci was carried out on sporadic breast cancer patient samples and identified greater 
overall methylation in ER positive tumours and those that relapsed. Individual locus analysis 
identified six genes where methylation associated with worse DFS. Of these, promising 
candidates for further analysis were identified, including RECK, ACADL and C1orf114.  
Candidate gene approaches also identified methylation of two newly characterised cancer-
related genes, RASSF10 and KIBRA. Analysis of a range of solid cancers identified 
hypermethylation in multiple tumour types for RASSF10, the most frequent being gliomas. 
Frequent hypermethylation of KIBRA was identified in childhood acute lymphocytic 
leukaemia (ALL).  
This study has used genome wide methods and candidate gene approaches to identify several 
novel methylated genes in a range of tumour types.  
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CHAPTER 1 
INTRODUCTION 
1.1 CANCER  
Cancer is ‘a disease caused by an uncontrolled division of abnormal cells in a part of the 
body’ (Oxford English Dictionary).  
1.1.1 Cancer incidence  
Cancer is the leading cause of death worldwide and second leading cause of death in 
developing countries (Jemal et al¸ 2011). In 2008, over 12 million cases of cancer were 
diagnosed worldwide in males and females combined. In total, 2008 saw 4.2 and 3.3 million 
deaths occurring as a result of cancer in males and females respectively (Jemal et al, 2011). 
The most common forms of cancer diagnosed worldwide are lung cancers in males and breast 
cancers in females, these two cancers are also responsible for the greatest number of cancer 
attributable deaths worldwide (figure 1.1). Due to differences in healthcare, cancer mortality 
rates are higher in economically developing countries, occurring at a frequency of 1.7 times 
that in developed countries. For example, more than 85% of cervical cancer cases and deaths 
occur in developing countries as a result of a lack of screening techniques to detect pre-
cancerous lesions which are now commonplace in many developed countries (Jemal et al, 
2011). In the UK, approximately 309,500 people were diagnosed with cancer in 2008; based 
on this 2008 data, breast cancer is the most common cancer in females, accounting for 31% of 
all adult female cancers, whilst prostate cancer is the most common cancer in males, 
accounting for 24% of all adult male cancers. For both males and females, the next most 
common cancers are lung and colorectal (CRUK cancer statistics) (figure 1.2). Despite the
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Figure 1.1_Worldwide cancer incidence and death rates
This figure has been taken from Jemal et al, 2011 and shows the estimated
numbers of diagnoses and deaths attributable to different cancer types in 2008.
Frequencies are broken down into males and females, and are shown for
developed and developing countries both combined and separately.
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Figure 1.2_The top ten most commonly diagnosed cancers in the UK
The top ten most commonly diagnosed cancers in the UK in 2008 are
shown for males (a) and females (b). These graphs have been taken from
the Cancer Research UK (CRUK) website (www.cancerresearchuk.org).
24% 
15% 14% 
5% 
4% 4% 4% 3% 3% 3% 
19% 
(a)
(b)
31% 
12% 12% 
5% 
4% 4% 4% 
3% 2% 
18% 
2% 
•Colorectum including anus (C18-C21) 
** 3% of all male cases are registered without 
specification of the primary site 
•Colorectum including anus (C18-C21) 
** 4% of all female cases are registered without 
specification of the primary site 
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overwhelming proportion of breast cancers occurring in females, the disease had the third 
highest mortality rate in 2005, accounting for 8% of all UK cancer deaths. However, the 
highest mortality rate in females was still from lung cancer, as in males (CRUK cancer 
statistics). The most common childhood cancers in the UK are leukaemias and brain and CNS 
cancers, accounting for approximately 30% and 20% respectively of all childhood cancers 
(CRUK cancer statistics).  
In the developed world the incidence of cancer has been increasing, and is likely to continue 
to increase as a result of an ageing population and changes in lifestyle. For example, the 
incidence of breast cancer increased in many Western countries between the 1980s and 1990s 
as a result of changes in reproductive factors such as the increasing use of post-menopausal 
hormone therapies. Colorectal cancer incidences have also been increasing as a result of 
changes in diet, increased obesity and smoking, while lung cancer has seen an increase in 
Asian and African countries as a result of increased/unchanged smoking habits. Liver cancers 
are increasing as a result of increasing obesity rates and hepatitis C infection (Jemal et al, 
2011). However, it is important to note that a proportion of these increased cases are 
attributable to the development and increased usage of effective screening techniques. Since 
the rapid increase in breast cancer rates in the 1980s and 1990s in Western countries, the 
incidence rates decreased in the 2000s due to the heavily sequestered use of post-menopausal 
hormone therapy after its causative effects were realised (Colditz, 1998). Despite the overall 
increasing incidence rates of many cancers, the death rates of cancers including lung, 
colorectal, breast and prostate cancers have been decreasing in the Western world as a result 
of earlier detection through screening methods and better treatment of the cancer through 
increased understanding of the disease. This is exemplified by testicular cancer for which the 
survival rate has increased massively, even for advanced disease (Feldman et al, 2008). 
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Additionally, due to the unrelenting efforts of research into all aspects of cancer, disease 
specific tailored therapy is now available for many cancer types, such as the much publicised 
use of trastuzumab (Herceptin) (an inhibiting monoclonal antibody against HER2) in late 
stage HER2/neu (ERBB2) over-expressing breast tumours (Hudis et al, 2007) and the 
development of the tyrosine kinase inhibitor, gefitinib, against specific EGFR mutations in 
non-small cell lung cancer (Lynch et al¸ 2004; Paez et al, 2004). These developments have 
markedly increased the outcome for many patients, although unfortunately the effects of this 
have been observed primarily in developed countries. However, the impact of a cancer 
diagnosis on an individual and their family members remains huge, as does the burden of 
cancer on healthcare services across the World. Further identification of good therapeutic 
targets and prognostic, diagnostic and treatment outcome markers are essential for benefitting 
patient outcome.  
1.1.2 Cellular basis of cancer  
Whist there are over 100 types of cancers consisting of multiple subtypes able to form in a 
single organ or tissue type, the majority of cancers can be classified, on a very general level, 
based on their tissue site of origin. The most common form of cancer, accounting for over 
80% of all cancers, arises in epithelial cells; these cancers are termed carcinomas. The 
majority of carcinomas may be split into squamous cell carcinomas or adenocarcinomas 
depending on whether the epithelial cells of origin are part of the protective epithelial layer 
(squamous cell carcinomas) or have secretory properties (adenocarcinomas) (Weinberg, 
2007). Examples of squamous cell carcinomas include squamous cell carcinoma of the skin 
and squamous cell carcinoma of the cervix, whilst adenocarcinomas include adenocarcinomas 
of the breast and colon. Although some carcinomas can be defined as pure squamous cell 
carcinomas or adenocarcinomas, many carcinomas are located where both cell types co-exist. 
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After carcinomas, the majority of malignancies are either sarcomas, haematological or arise 
within the central or peripheral nervous system (Weinberg, 2007). Sarcomas arise from 
mesenchymal cells such as connective tissue, adipocytes or osteoblasts. Examples include 
bone cancers, such as osteosarcomas and chondrosarcomas, and muscle tissue based 
malignancies, such as rhabdomyosarcomas. Haematological malignancies can be split into 
leukaemias and lymphomas; leukaemias arising from various lineages of white blood cells 
and lymphomas arising from lymphoid lineages that then go on to form solid tumour masses. 
Central and peripheral nervous system tumours include gliomas, neuroblastomas and 
medulloblastomas, among others. There are a small number of other cancers, such as 
melanomas, that do not fit into any of the above categories (Weinberg, 2007).  
Despite the site of origin of malignancies, cells must acquire various biological traits to form 
a malignant tumour. Reviewed in Hanahan et al (2000), these biological attributes include: 
i. Self-sufficiency in growth i.e. not requiring external growth signals to proliferate. 
ii. Insensitivity to antigrowth signals i.e. becoming able to block the inhibition of 
proliferation initiated by external growth signals. 
iii. The ability to evade apoptosis – the majority of cancer cells have acquired some 
mechanism of resistance to apoptosis. 
iv. Potentially limitless replication – overcoming the intrinsic switch to senescence after 
numerous cell divisions 
v. Sustained angiogenesis – angiogenic properties are normally tightly regulated but 
essential for transition from an aberrant proliferative lesion to a larger malignant 
tumour entity 
vi. Ability to invade surrounding tissue and metastasize – tumours only become 
malignant upon invasion of surrounding tissue.  
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To be able to acquire these biological properties that enable malignant tumour growth a 
multitude of genetic changes must occur within the cell.  
1.1.3 Cancer Genetics  
Many alterations within the genome, both germline and somatic, can influence the process of 
tumourigenesis. Mutations, genome rearrangements, amplifications, deletions, genome 
instability and epigenetic changes, such as DNA methylation and histone modifications, can 
all contribute to the tumourigenic process. The view of cancer genetics has changed 
dramatically over the past 100 years and provides an almost unending wealth of knowledge 
that could be discussed. Figure 1.3 provides a timeline of major discoveries and initiatives 
during this time. The work in this thesis concentrates on a specific type of somatic alteration 
that can occur during tumourigenesis and tumour progression, DNA methylation. This 
introduction will provide a brief overview of the other forms of somatic alterations before 
going into details concerning epigenetics and specifically DNA methylation. 
1.1.3.1 Tumour Suppressor Genes  
In a normal cellular context, tumour suppressor genes are responsible for keeping cell 
behaviour under control. When inactivated, associated normal cell functions can spiral out of 
control causing, or adding to, the tumourigenic process. In most cases, both copies of a 
tumour suppressor must be inactivated to lead to cancer formation. This theory, Knudson’s 
‘two hit hypothesis’ was first suggested in 1971, based on hereditary aspects of 
retinoblastoma (Knudson, 1971). Occurring almost exclusively as either heritable bilateral 
cancers or sporadic unilateral cases, it was proposed that unilateral retinoblastomas occurred 
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Figure 1.3_Timeline of major developments in cancer genetics over the past 100 years
The above diagram shows a timeline of major developments in cancer genetics including the first
descriptions of cancer specific translocations, oncogenes, tumour suppressors, epigenetic changes and
sequencing initiatives. This figure was taken from Bell, 2010.
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as a result of acquired mutations in a then unknown causative gene during development. 
Bilateral retinoblastomas on the other hand, occurred when a germline copy of the then 
unknown causative gene was already mutated and therefore only one mutation was required to 
occur during development, making cancers bilateral and earlier events. The causative gene, 
RB1 (Retinoblastoma 1), was subsequently isolated as the first tumour suppressor in 1987 
(Lee et al, 1987; Fung et al, 1987). It remains a classical example of a tumour suppressor 
gene, involved heavily in cell cycle regulation. Inactivation of the RB1 protein product, pRb, 
via phosphorylation by Cyclin D/Cdk-4 or -6 results in the activation of the E2F transcription 
factor which is required for upregulation of genes required for S phase initiation, such as 
cyclin E. Loss of pRb result in unregulated E2F activity and therefore unregulated cell cycle 
progression (Hanahan et al, 2000). This, however, is only one of the mechanisms by which 
RB1 is able to function as a tumour suppressor gene – RB1 has additionally been shown to be 
involved in chromosomal instability, angiogenesis and autophagy in response to hypoxia 
(Burkhart et al, 2008). In addition to retinoblastomas, RB1 inactivation has been observed in 
many other cancers, including breast, prostate, lung and oesophageal cancers, among others 
(Burkhart et al, 2008) Other classical tumour suppressor genes include TP53 (Bourdon, 2007; 
Vousden and Lane, 2007) and CDKN2A (Rocco and Sidransky, 2001) in multiple tumour 
types and VHL in kidney cancer (Latif et al, 1993).  
1.1.3.2 Oncogenes  
Oncogenes were first described in 1976, with the discovery that alteration of the normal 
activity of certain genes resulted in oncogenic transformation of cells. Altered, oncogenic 
versions of these genes are termed oncogenes while the unaltered version is called a proto-
oncogene. SRC (v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)), a 
homologue of the Rous sarcoma virus transforming gene, v-src, which causes sarcomas in 
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chickens, was the first proto-oncogene to be described (Stehelin et al, 1976). SRC functions as 
a tyrosine-kinase that becomes overactive in many cancers. Oncogenic mutation is common 
but unusual in the sense that the protein sequence must be altered to effect function and/or 
expression control but not result in either rendering the protein ineffective or resulting in 
complete loss of protein expression, as is the case with tumour suppressor genes. Mutations in 
oncogenes therefore have a tendency to be limited to specific mutation of single amino acids 
or specific genomic rearrangements, as discussed below. A good example of an oncogene is 
the PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide) gene. It codes for the 
p110α protein, a class I PI 3-kinase catalytic substrate. PIK3CA mutations have been observed 
in numerous cancer types and, to date, PIK3CA represents the most frequently somatically 
mutated gene in breast cancer (Samuels et al, 2004; Campbell et al, 2004). This gene also 
demonstrates the specificity of oncogenic mutation, as for the 1435 instances of PIK3CA 
mutation in breast cancer listed by COSMIC (catalogue of somatic mutations in cancer – 
http://www.sanger.ac.uk/genetics/CGP/cosmic/), mutation of 1366 are represented by 
alterations to just three residues (p.E542 – 159 mutations, pE545 – 300 mutations, p.H1047 – 
907 mutations).  
1.1.3.3 Regions of chromosomal loss and gain  
Regions of chromosomal loss and gain are also a common feature of cancer genomes, often 
termed copy number alterations. Both large regional aberrations and more focal aberrations 
are common and are capable of affecting well known tumour suppressor genes and 
oncogenes. For example, amplification of PIK3CA has been observed in numerous cancers 
including those with infrequent mutation of PIK3CA such as prostate cancer (Agell et al, 
2011) and those with a higher mutation rate such as pituitary tumours, demonstrating 
mutation in approximately 9% of tumours and genomic amplification in 20-40% in one recent 
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study (Lin et al, 2009). PIK3CA amplification and amplification of associated PIK3 pathway 
members is a common alteration associated with bad prognosis in ovarian cancer, 
demonstrating the importance of over-activating an oncogenic pathway by numerous 
mechanisms (Huang et al, 2011). Up to 80% of sporadic chordomas have shown genomic loss 
of the well known tumour suppressor gene CDNK2A (Le et al, 2011) in addition to CDKN2A 
loss in other cancers such as paediatric astrocytomas (Schiffman et al, 2010), ovarian cancer 
(Gorringe et al, 2009) and gastric cancer (Belinsky et al, 2009). A recent genome wide study 
across just over 3000 cancers encompassing 26 histological subtypes identified a large 
number of somatic copy number alterations (SCNAs). On average, each sample demonstrated 
24 gains and 18 losses (Beroukhim et al¸ 2010). In general, arm-level SCNAs were more 
common which will affect numerous genes rather than focal SCNAs which are likely to only 
affect only one or two (Beroukhim et al, 2010). The most common focal SCNAs affected 
MYC via amplification and CDKN2A/B via deletion.  
1.1.3.4 Genomic Rearrangements  
Genomic rearrangements are common facets of the cancer genome, particularly in 
haematological cancers. The first structural chromosomal abnormality was identified in 1960 
by Nowell and Hungerford in chronic myeloid leukaemia (CML). The translocation was 
identified between chromosomes 9 and 22 [t(9;22)(q34;q11)] that results in an elongated form 
of chromosome 9 and a truncated version of chromosome 22 (the Philadelphia chromosome) 
(Nowell et al, 1960). A fusion protein between BCR (breakpoint control region) and ABL 
(Abelson) is produced on the Philadelphia chromosome that gives rise to a constitutively 
active tyrosine kinase capable of activating numerous pathways resulting in increased cell 
division, checkpoint inhibition and subsequent genomic instability (Laurent et al, 2001). This 
novel loss of functional control due to the production of a fusion protein is typical of this type 
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of rearrangement having potent oncogenic properties, although such rearrangements can also 
result in the disruption of tumour suppressor genes as an alternative to mutation, deletion or 
methylation. The Philadelphia chromosome is an extremely common event in CML, 
occurring in approximately 95% of cases (Nowell et al, 1960). Some adulthood and childhood 
acute lymphocytic leukaemia (ALL) patients also harbour this translocation at frequencies of 
25-30% and 2-10% respectively (Chissoe et al, 1995). As an overactive tyrosine-kinase, 
BCR/ABL patients respond to tyrosine-kinase inhibitors such as Imatinib (Glivec) (Deininger 
et al, 2003). A common translocation in childhood ALL is the [t(12;21)(p13;q22)] 
translocation resulting in the ETV6/RUNX1 fusion protein, which, like BCR/ABL, is a 
constitutively active tyrosine-kinase. This translocation is present in approximately 25% of 
childhood ALL cases (Shurtleff et al, 1995).  
Genomic translocations producing potent oncogenic fusion proteins are much less common in 
solid cancer genomes. To date, the most well-known solid tumour translocations have been 
observed in prostate cancer, producing the TMPRSS2-ERG/ETV1 fusion protein (Tomlins et 
al, 2005) in approximately 45% of cases (Mosquera et al, 2009) and in lung cancer, producing 
the EML4/ALK fusion protein, although this was only observed in approximately 6% of non-
small cell lung cancers (NSCLC) (Soda et al, 2007). However, a recent study across 24 breast 
cancers (15 of which are were primary samples, the remaining being cell lines) using massive 
parallel paired end sequencing, identified a multitude of somatic rearrangements, suggesting 
genomic rearrangements in solid tumours may be more common than first thought (Stephens 
et al, 2009). In total, 2166 rearrangements were observed among all the samples, 50% of 
which occurred within protein coding genes. Of these, 29 were expected to produce in-frame 
fusion proteins. Another, more recent study, identified a median of 90 somatic rearrangements 
per prostate cancer genome when performing whole genome sequencing on 7 prostate cancers 
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and their corresponding normal counterparts (Berger et al, 2011). Again suggesting that 
although potent oncogenic fusion proteins have been primarily observed in haematological 
cancer genomes, somatic rearrangements in solid tumours are possibly a much more prevalent 
alteration than first thought.  
1.1.3.5 Genome wide analysis  
Recent technology advances have made it possible to perform large scale genome wide 
approaches including whole exome (all the coding genome sequence) and whole genome 
sequencing at a relatively affordable cost. This has given rise to cancer genome sequencing 
consortiums such as the International Cancer Genome Consortium (ICGC), the Cancer 
Genome Project (CGP) based at the Wellcome Trust Sanger Institute and The Cancer Genome 
Atlas (TCGA) based at the US National Institute of Health (NIH). Studies by these large 
consortiums and independent laboratories have produced a multitude of studies in various 
cancers.  
Sequencing of coding regions of breast and colorectal cancers suggest that somewhere 
between 80 and 90 non-synonymous changes are present in an individual tumour (Sjöblom et 
al, 2006; Wood et al, 2007). Following this, the sequencing of 20,661 protein coding genes in 
24 prostate cancers identified a total of 1,562 somatic mutations, of which 25.5% were 
synonymous changes (3.8% nonsense mutation, 62.4% missense mutation, 5%  small 
insertions/deletions and 3.3% splice site/untranslated region (UTR) mutation). Classification 
of the mutated genes identified in this study highlighted 12 core pathways that harbour 
mutations in 67-100% of all the prostate cancers studied (Jones et al, 2008). These pathways 
are; TGFβ signalling, JNK signalling, integrin signalling, Wnt/Notch signalling, Hedgehog 
signalling, control of the G1/S phase transition, apoptosis, DNA damage control, small 
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GTPase signalling, invasion, homophillic cell adhesion and K-RAS signalling (Jones et al, 
2008). This work, and data from other studies, allowed for two important propositions to be 
made. Firstly, due to the large number of observed mutations, not all mutations within a 
cancer cell are directly related to tumourigenesis. Some mutations are thought of as driver 
mutations, necessary for tumourigenesis or tumour progression, and the rest as passenger 
mutations, randomly selected alongside driver mutations and thus retained. Secondly, that all 
these important cancer specific genetic alterations occur within the highlighted 12 core 
pathways (Jones et al, 2008; Ledford, 2010; Bell, 2010). 
Recent exome sequencing studies have also identified novel tumour type specific somatic 
mutations in GRIN2A in 33% of metastatic melanoma cases and recurrent mutations of 
TRAPP in 4% of metastatic melanomas (Wei et al, 2011), frequent truncating mutations of the 
PBRM1 gene in 41% of clear cell renal cell carcinomas (Varela et al, 2011) and mutations of 
BAP1 in 81% of metastasizing uveal melanomas of the eye (Harbour et al, 2010). 
These new techniques provide powerful new ways to look at the alterations at the base pair 
level for the whole genome of cancerous cells, providing important information. This 
information could also be combined with methods for looking at the genome wide epigenetic 
alterations to give a more complete picture of the cancer associated alterations as exemplified 
by a recent study in ovarian cancer where sequencing data, copy number data, DNA 
methylation data, and mRNA and microRNA expression data have all been combined (The 
Cancer Genome Atlas Network, 2011). 
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1.2 CANCER EPIGENETICS  
There are two major epigenetic mechanisms that have a role in cancer; histone modifications 
and DNA methylation. The work in this thesis concentrates on the role of aberrant DNA 
methylation in specific cancers, but it is important to note that other forms of epigenetic 
control exist and can work both separately and in conjunction with DNA methylation.  
1.2.1 Histone modifications in cancer  
There are currently nine types of histone modifications known; acetylation, methylation, 
phosphorylation, ubiquitination, sumoylation, ADP-ribosylation, deimination, proline 
isomerism and propionylation (Sawan et al, 2010). In a normal cell, histone modifications 
function primarily in chromatin remodelling, various modifications or groups of 
modifications being able to adjust the chromatin from a less accessible heterochromatin form 
to a more accessible euchromatin form and vice-versa (Quina et al, 2006). Histone 
modifications are therefore able to have profound effects on gene transcription, DNA repair 
and DNA replication. Histone acetylation and methylation are the most commonly associated 
modifications associated with cancer.  
Histone acetylation occurs at lysine residues. By removing the histone tail’s positive charge, 
lysine acetylation of histones results in a weakening of nucleosome-nucleosome and 
nucleosome-DNA interactions, resulting in changes in chromatin conformation that render 
DNA more accessible. Acetylation of histones is achieved by histone acetylatransferases 
(HATs) and removed by histone deacetylases (HDACs). Both HATs and HDACs have been 
demonstrated to be involved in cancer. Two HATs, p300 and CBP, are considered tumour 
suppressor genes and both proteins are involved in fusion proteins in leukaemias (Suganuma 
et al, 2002; Ida et al, 1997; Giles et al¸ 1997) and loss of heterozygosity (LOH) at the p300 
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lcous is associated with hyperacetylation in numerous cancers (Tillinghast et al, 2003; 
Koshiishi et al, 2004). Aberrant expression of HDACs has been shown in multiple cancers; 
upregulation of HDAC2, 3, 8, 6 and 7 has been observed in childhood ALL (Moreno et al, 
2010), HDAC1, 2 and 3 upregulation has been observed in ovarian cancer (Hayashi et al, 
2010), upregulation of HDAC6 has been observed in breast cancer and oral squamous cell 
carcinoma (Sakuma et al, 2006) and HDAC2 upregulation has been observed in numerous 
cancers (Langer et al, 2010; Mutze et al¸ 2010; Adams et al¸ 2010; Jin et al, 2008). Due to the 
overexpression of numerous HDACs in cancer they have become useful therapeutic targets, as 
discussed later.  
Histone methylation can occur on arginine or lysine residues and is catalysed by different 
enzymes depending on where the methylation occurs. Arginine residues can be mono- or di-
methylated whilst lysine residues can also be tri-methylated (Sawan et al, 2010). The effects 
of histone methylation on chromatin conformation are dependent on the context, aiding either 
a euchromatin or heterochromatin conformation. LSD1 (lysine (K)-specific demethylase 1A), a 
histone demethylase, has been shown to be aberrantly expressed in cancer with 
overexpression observed in bladder cancer (Hayami et al, 2011), oestrogen receptor negative 
breast cancer (Lim et al, 2010) and neuroblastoma (Schulte et al, 2009). Recent genome wide 
sequencing studies have also identified mutations within lysine methyltransferase genes 
MLL2 (myeloid/lymphoid or mixed-lineage leukemia 2) and MLL3 (myeloid/lymphoid or 
mixed-lineage leukemia 3) in medulloblastomas (Parsons et al, 2011) and the demethylase 
gene UTX (lysine (K)-specific demethylase 6A) in various cancers (Dalgliesh et al, 2010; van-
Haaften et al, 2009), reinforcing the potential role of histone methylation regulation in 
tumourigenesis. Additional mutations within the SWI/SNF (SWItch/Sucrose 
NonFermentable) chromatin remodelling complex genes, including PBRM1 (polybromo 1) in 
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renal cell carcinoma (Varela et al, 2011) and ARID1A (AT rich interactive domain 1A (SWI-
like)) in ovarian cancer (Jones et al, 2010; Wiegand et al, 2010), provide additional evidence 
for the important role of chromatin remodelling in cancer.  
1.2.2 DNA methylation 
DNA methylation is the addition of a methyl group to a DNA nucleotide. It occurs in many 
organisms, primarily at the carbon five position of cytosines, producing 5-methylcytosine 
(5mC). Methylation of other nucleotides can occur, for example, although DNA methylation 
in general is uncommon in bacteria, a small proportion of adenine nucleotides are sometimes 
methylated, along with cytosines, as a host defense mechanism (Strachan and Read, 2004). In 
multicellular organisms, the level of methylation varies between species. In drosophila, 
methylation is uncommon but when present often occurs at cytosines that are part of a CpT 
dinucleotide, whereas in mammals, methylation is common and occurs predominantly at 
cytosines that form part of CpG dinucleotides, although a small amount of methylation also 
occurs at CpNpG sequences, where N can be A, T or C. Due to the overwhelming proportion 
of methylation occurring at CpG dinculeotides rather than any other sites in the human 
genome, these other potential sites, although possible, are not normally considered when 
assessing methylation levels in human DNA.  
A further possible modification of 5mC is the addition of a hydroxyl group producing 5-
hydroxymethylcytosine (5hmC) and, until the recent discovery of 5hmC in human and mouse 
brains (Kriaucionis et al, 2009; Tahiliani et al, 2009), it was not thought to be present in 
higher organisms. Catalysis of 5hmC production can be achieved by the enzymes TET1 (tet 
oncogene 1), TET2 (tet oncogene family member 2) and TET3 (tet oncogene family member 
3) (Tahiliani et al, 2009). Although it has been suggested that 5hmC may be produced as an 
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intermediary molecule during demethylation of 5mC (Kriaucionis et al, 2009; Tahiliani et al, 
2009), the true significance and proportion of 5hmC in the human genome remains to be 
determined. A recent plethora of studies have tried to develop methods that reliably 
differentiate between 5hmC and 5mC for quantification of the levels of 5hmC in various 
tissues (Ficz et al, 2011; Globisch et al, 2011; Song et al, 2011; Szwagierczak  et al, 2010). In 
the most recent study, by Ficz et al (2011), the greatest detection of 5hmC was at regions of 
euchromatin with 5mC being underrepresented at gene promoters and CpG islands. Studies of 
5hmC in embryonic stem cells (ES cells) suggest 5hmC is likely to have a role in lineage 
commitment and pluripotency (Ficz et al, 2011). Recent studies have identified mutations in 
TET2 in leukaemias (Ko et al, 2010; Figueroa et al, 2010; Abdel-Wahab et al  ¸2009). TET2 
mutated acute myeloid leukaemia (AML) samples demonstrate an increase in the levels of 
hypermethylation in the much the same way as IDH1/2 mutated samples (Figueroa et al, 
2010). Since the discovery of 5hmC is very recent and the true importance of its presence is 
not yet fully known, all further discussion will only refer to 5mC, as will the work in this 
thesis. However, it is important to bear in mind that the discovery of 5hmC in the human 
genome and recent demonstration of TET2 mutations in human cancer is likely to add a new 
aspect to the field of cancer epigenetics over the coming years.  
The average human genome content of G/C nucleotides is approximately 41%, however, the 
proportion of CpG dincleotides only occurs at about 20% of the statistically expected 
frequency based on the overall levels of G/C nucleotides (Lander et al, 2001 - International 
Human Genome Sequencing Consortium). This is due to the fact that cytosines at CpGs often 
become methylated, producing 5mCpG, and the 5mC is highly susceptible to sponataneous 
deamination, producing thymine. Following DNA replication, the mismatched T/G is repaired 
to T/A, producing a permanent alteration/mutation within the DNA sequence. Spontaneous 
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deamination of unmethylated cytosine produces uracil, which is recognised by the cell and 
corrected, unlike the thymine. As a result of this, the mutation rate of cytosine to thymine is 
much higher than the average nucleotide, estimated to be 8.5 times higher (Cooper et al, 
2000), resulting in the loss of many CpG dinucleotides over time. Although the general level 
of CpG dinucleotides within the genome is low, high levels are observed at long repetitive 
sequences and regions known as CpG islands. CpGs at long repetitive sequences are often 
methylated whilst CpG islands are often unmethylated.  
1.2.2.1 CpG islands  
The accepted definition of a CpG island is a region having a GC content greater than 50% and 
an observed CpG to expected CpG ratio of greater than 60% (Gardiner-Garden et al, 1987). 
The overall G/C content within CpG islands is approximately 60% and the number of CpG 
dinucleotides can be ten times greater than any other similarly sized region of the genome. 
There are estimated to be approximately 27 000 CpG islands within the human genome 
(Lander et al - International Human Genome Sequencing Consortium, 2001) with 
approximately 50-60% of genes having at least one CpG island associated with them, a large 
number of which are important housekeeping genes (Wang et al, 2004; Larsen et al, 1992). 
Similarly, there are about 15 500 CpG islands within the mouse genome (Mouse Genome 
Sequencing Consortium, 2002). Often, but not exclusively, located at the 5’ end of genes and 
in some cases extending over hundreds of nucleotides, the methylation status of CpG islands 
can have a large impact on gene expression, mainly via chromatin modifications. In general, it 
is thought that CpGs in CpG islands are much less likely to be methylated than other CpGs 
throughout the genome due to the selective pressure for them to remain unmethylated and 
active (Bird, 2002). Although it has now been shown that CpG islands can be methylated in 
normal tissues (Weber et al, 2005) this may relate to different types of cell differentiation and 
20 
 
activity. Also, a recent study identified regions of DNA that show differential methylation 
levels between different tissue types that are up to 2kb away from CpG islands, known as 
CpG shores (Irizarry et al, 2009). These regions have a median size of 255bp and have been 
suggested to be responsible for the majority of tissue differential methylation, rather than CpG 
islands (Irizarry et al, 2009). Differential methylation at these regions has also been 
implicated in cancer (Irizarry et al, 2009). Figure 1.4 illustrates examples of the locations of 
notable CpG regions within the genome and their general states of methylation in normal and 
cancer genomes. 
1.2.2.2 DNA methylation machinery  
DNA methylation is laid down by two classes of DNA methyltransferase enzymes, DNMT1 
(DNA methyltransferase 1) and DNMT3a and 3b (DNA methylatransferase 3a and 3b 
respectively). Originally named DNMT1 and DNMT3 because of an additional molecule, 
DNMT2, discovered at the same time with high levels of similarity. However, little evidence 
for the ability of DNMT2 to methylate cytosine was discovered and it has since been 
determined that DNMT2 catalyses the methylation of position 38 in aspartic acid of tRNA 
(Goll et al, 2006). It is now also referred to as TRDMT1 (tRNA aspartic methyltransferase 1).  
Whilst both DNMT1 and DNMT3a/b use the same methyl donor, S-adenosyl methionine, the 
two classes of enzyme target different states of DNA to methylate.  
DNMT1 
DNMT1 is often known as maintenance methyltransferase since it primarily methylates hemi-
methylated DNA on the nascent strand of DNA following DNA replication (Bestor, 1992), 
thus providing a mechanism by which methylation status of DNA is maintained in daughter 
cells. DNMT1 has been shown to be essential for maintaining DNA methylation patterns in 
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Figure 1.4_Distribution of CpG dinucleotides throughout the genome
This figure illustrates the location of CpG dinucleotides within the genome and whether they are methylated in
normal or cancerous tissue.
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proliferating cells (Li et al, 1992). Because of this, DNMT1 is also essential for development, 
Dnmt1-/- mice demonstrate complete genome demethylation and developmental arrest at E8.5 
(Li et al, 1992). DNMT1 lacks a methyl binding domain and therefore it is unknown exactly 
how DNMT1 is recruited to hemi-methylated DNA during replication. Binding of DNMT1 
has been observed with a methyl-binding domain containing protein, MeCP2 (Kimura et al, 
2003) and so this has been proposed as a possible mechanism. 
DNMT3a and 3b 
DNMT3a and 3b are both considered de novo methyltransferases, required to establish new 
DNA methylation patterns (Okano et al, 1999). It is likely that DNMT3a and 3b have 
different functions as Dnmt3a-/- mice demonstrate gut malformation, defects in 
spermatogenesis and are born alive, although die at around 4 weeks (Okano et al, 1999), 
whilst Dnmt3b-/- mice are embryonic lethal at E14.5-E18.5 demonstrating complete 
demethylation of minor satellite DNA and mid neural-tube defects (Okano et al, 1999). 
DNMT3b has been shown to interact with CENPC (centromere protein C), recruiting 
DNMT3b to pericentromeric satellite repeats; loss of either protein results in increased 
misalignment and segregation defects during mitosis (Gopalakrishnan et al, 2009). Mutations 
within DNMT3b cause ICF syndrome (Immunodeficiency-centromeric instability-facial 
anomaly syndrome), a rare autosomal recessive disease characterised by facial dysmorphism, 
immunoglobulin deficiency, branching of chromosomes 1, 9 and 16 after PHA 
(phytoheamaglutanin) stimulation of lymphocytes. A small number of patients also show 
hypomethylation of a fraction of the genome, which is likely to be a direct result of impaired 
DNMT3b.  
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1.2.2.3 DNA methyltransferases and cancer  
A study by Chen et al (2007) demonstrated the necessity of cancer cells for functioning 
DNMT1. A conditional DNMT1 knockout colorectal cancer cell line, HCT116, was made that 
demonstrated a reduction of CpG-CpG dyads within the genome and arrest at the G2 phase of 
the cell cycle, suggesting DNMT1 is essential for maintenance of methylation in cancer cells 
and required for proliferation and survival (Chen et al, 2007). Whilst inhibition of DNMT3a 
and 3b appear to have a lesser effect on cancer cells (Rhee et al, 2002; Robert et al, 2003), 
downregulation of the miRNA (miR)-29 family (29a, 29b, and 29c), which have 
complementary sites within the 3’-UTRs of DNMT3a and DNMT3b, in lung cancers have 
shown upregulation of DNMT3a and 3b, associating with worse prognosis (Fabbri et al, 
2007). Upon re-expression of the miRNAs, normal patterns of DNA methylation were 
restored, as was the expression of some methylation silenced tumour suppressor genes (Fabbri 
et al, 2007). A recent study identified mutations in DNMT3a present in 22.1% of acute 
myeloid leukaemia patients (Ley et al, 2010). Whilst mutations were associated with worse 
overall survival, no significant differences in overall 5mC levels were observed in patients 
with mutations, however, it was noted that some regions showed significantly less 
methylation in a fraction of patients (Ley et al, 2010). Since this study, mutations in DNMT3a 
have also been identified in acute monocytic leukaemia (Yan et al¸ 2011) and myelodysplastic 
syndromes (Walter et al, 2011). 
1.2.2.4 DNA methylation and gene expression  
DNA methylation has little effect on gene expression if the DNA is not assembled into 
chromatin, as it would be in vivo, indicating the importance of the interactions affected by the 
methylation rather than the methylation itself. For the vast majority of genes, promoter CpG 
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island methylation results in the down regulation of gene expression and it is this effect that is 
observed as a frequent event in cancers (Feinberg et al 2004). However, DNA methylation 
has also been shown to produce enhanced expression, as seen with the IGF2 locus, by 
blocking the binding of repressor proteins to a silencer element within a gene promoter (Bell 
et al, 2000). Although this work concerns aberrant cancer related DNA methylation, DNA 
methylation is involved in the normal control of the cell. DNA methylation occurs on a large 
scale to cause the selected X chromosome inactivation early in embryogenesis (Heard, 2004), 
and on a single gene level when involved with imprinting, the specific methylation of either 
the maternal or paternal allele, resulting in single allelic expression, (Reik et al, 2003), or de 
novo methylation alteration associated with cell differentiation (Arney and Fisher, 2004). 
Repression of gene expression can be bought about by DNA methylation by either direct 
blocking of transcription factor binding or, as is more common, via the actions of methyl 
DNA binding proteins (Clouaire et al, 2008). Although this mechanism is rare in vivo, direct 
blocking of transcription factor binding by the presence of DNA methylation has been 
described in some instances. For example, the GFAP (glial fibrillary acidic protein) is a 
developmentally regulated gene activated during astrocyte differentiation. The GFAP gene 
promoter contains a STAT3 transcription factor binding site and upon removal of DNA 
methylation within this region, the GFAP gene is expressed due to STAT3 binding 
(Shimozaki et al, 2005).  
1.2.2.5 Recruitment of methyl DNA binding proteins 
The most common mechanism for DNA methylation to induce repression of gene expression 
is via the recruitment of DNA binding proteins and subsequent modification of chromatin 
organisation. There are three families of methyl DNA binding proteins:  the Kaiso-like family 
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of proteins, the SRA (SET- and RING-associated) domain proteins and the methyl binding 
domain family of proteins.  
The Kaiso-like family currently consists of three members, Kaiso, ZBTB4 and ZBTB38. 
Kaiso-like family members show affinity for both unmethylated and methylated DNA 
suggesting multiple roles are likely for this family. Kaiso itself is able to interact with the N-
coR (nuclear receptor co-repressor) co-repressor complex which contains HDAC3 and 
therefore is capable of bringing about chromatin modification. For instance, the recruitment of 
Kaiso and N-coR due to DNA methylation of the MTA2 promoter is capable of causing 
MTA2 gene silencing (Yoon et al, 2003).  
Little is known about the SRA (SET- and RING-associated) domain family of proteins other 
than one of the mammalian homologues, Np95, may have an important role in epigenetic 
inheritance and that the SRA domain is able to bind to CpNpG in addition to CpG (Johnson et 
al, 2007).  
The methyl biding domain proteins are by far the biggest players in bringing about gene 
repression as a result of DNA methylation. The family consists of 5 members; MBD1, 
MBD2, MBD3, MBD4 and MeCP2, although not all can bind methylated DNA. The methyl 
binding domain is 75 amino acids long with a binding affinity dependent upon the presence of 
four specific residues, the loss of one of these residues in MBD3 renders it unable to bind 
methylated DNA (Hendrich et al, 1998).  
MBD1  
In the majority of cases, MBD1 brings about chromatin modification in a deacetylation-
independent manner and most commonly acts via histone methylation. It has been shown to 
be able to interact with two histone H3 lysine 9 (H3K9) methyltransferases, SETDB1 (SET 
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domain, bifurcated 1) and SUV39H (suppressor of variegation 3-9 homolog), and thus upon 
binding with SETDB1, histone H3K9 becomes methylated. During the S phase of the cell 
cycle, the MBD1/SETDB1 complex is temporarily displaced and forms a comlpex with the 
p150 subunit of the chromatin assembly factor, CAF-1 (chromatin assembly factor 1), 
providing a mechanism by which the H3K9 chromatin modifications are transmitted to 
daughter cells (Sarraf et al, 2004).  
MBD2 AND MBD3  
Although MDB3 does not bind methylated DNA directly, both MBD2 and MBD3 separately 
interact with the DNA-binding NuRD (nucleosome remodelling and histone deacetylation) 
complex (Le Guezennec et al, 2006) which contains, among other things, a chromatin 
remodelling ATPase, HDAC1 and HDAC2.  
MeCP2  
MeCP2 contains a methyl binding domain and a transcriptional repression domain and is 
capable of binding both hemi-methylated and fully-methylated DNA. MeCP2 appears to be 
particularly important in neuron maturation; mutations in MeCP2 can cause Rett syndrome, a 
disorder characterised by mental retardation, small hands and feet, repetitive hand movements 
and encephalopathy (Amir et al, 1999). Mutations in MeCP2 have also been associated with 
autism (Swanberg et al, 2009). Gene repression by MeCP2 is achieved by recruitment of 
HDACs to remove the acetyl group from H3K9, methylation of H3K9 and subsequent 
recruitment of proteins that cause chromatin to become condensed, thus resulting in 
repression of gene expression (Bird et al, 1999) Interestingly, MeCP2 is able to both enhance 
and repress gene expression (Chahrour et al, 2008). Figure 1.5 shows a simplified schematic 
of how DNA methylation affects expression.  
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Figure 1.5_Gene transcriptional silencing due to DNA methylation
This figure illustrates how DNA methylation can induce transcriptional
silencing. Areas of transcriptionally active chromatin regions tend to be
acetylated and lack methylation to remain uncondensed and allow transcription
factor binding. Transcriptionally silenced methylated regions have gained 5-
methyl cytosines, via the action of DNA methylatransferases, which result in
the recruitment of methyl-CpG binding proteins, histone deacetylases and other
chromatin remodeling enzymes. Thus the region loses its acetylation and any
bound transcription factors and the chromatin becomes condensed resulting in
gene silencing and loss of transcription factor binding. This silencing would be
replicated in any further DNA copies produced. This image was taken from:
http://www.med.ufl.edu/biochem/keithr/fig1pt2.html
28 
 
1.2.3 Aberrant DNA methylation changes in cancer  
1.2.3.1 DNA hypomethylation  
Despite cancer acquired hypermethylation of many genes, the overall 5mC levels within a 
cancer cell are often reduced due to global loss of methylation/hypomethylation. A common 
hallmark of cancer, hypomethylation most commonly occurs at repeat sequences, such as Alu 
and LINE1 elements, juxtacentromeric satellite 2 and tandem centromeric satellite α regions, 
possibly contributing to tumorigenicity by increasing the likelihood of genomic 
rearrangements and activating transposable elements (Ehrich et al, 2009). Although rarer, 
regional gene associated hypomethylation also occurs; for example, hypomethylation of 
synuclein γ has been demonstrated in breast and ovarian cancers (Gupta et al, 2003; 
Czekierdowski et al, 2006). Initially, it was supposed that hypomethylation was involved in 
more global events, such as genomic rearrangements, while hypermethylation was a gene 
specific event occurring as an alternative method of tumour suppressor gene silencing. 
However, more recently, an increasing number of gene specific hypomethylation studies have 
been performed. For example, a study in salivary gland adenoid cystic carcinoma 
demonstrated 8 genes that were tuomour specifically up-regulated due to loss of methylation 
(Shao et al, 2011). Nevertheless, there are far fewer examples of this and the overwhelming 
majority of studies involving cancer focus primarily on aberrant DNA hypermethylation. 
1.2.3.2 DNA hypermethylation  
Gene specific DNA hypermethylation in cancer cells as a form of gene inactivation was first 
demonstrated in 1986 with the discovery of hypermethylation and down regulation of the 
calcitonin gene in small cell lung cancer (Baylin et al, 1986). Subsequent analysis of bone fide 
tumour suppressor genes such as RB1 (retinoblastoma 1) in retinoblastoma (Greger et al, 
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1989; Sakai et al, 1991), VHL (von Hippel-Lindau) in renal cell carcinoma (Herman et al, 
1994) and CDKN2A (cyclin-dependent kinase inhibitor 2A) in multiple tumour types (Herman 
et al, 1995) demonstrated promoter hypermethylation as a common mechanism for 
inactivating certain tumour suppressor genes. Since then, many genes have been shown to be 
inactivated in this manner. In some cases, such as CDH1 (E-cadherin), hypermethylation 
provides the ‘second hit’ to a tumour suppressor gene (Grady et al, 2000). In other cases, 
exemplified by RASSF1A (Ras association (RalGDS/AF-6) domain family member 1) and 
HIC1 (hypermethylated in cancer 1), methylation is the only known mechanism of 
inactivation other than deletion. RASSF1A methylation is a common event in many cancers 
including lung, breast, glioma, colorectal and RCC (Dammann et al, 2000; Dammann et al, 
2001; Hesson et al, 2004; van Engerland et al¸ 2002; Morrissey et al, 2001), yet no cancer 
acquired mutations have ever been identified (Lee et al, 2001; Dammann et al, 2000). HIC1 
methylation was first observed in leukaemias and breast cancers (Issa et al, 1997; Fujii et al, 
1998; Melki et al, 1999) but has since been shown in multiple malignancies. The number of 
genes now shown to be hypermethylated in any cancer is well into the hundreds. Due to the 
large number of methylated genes in cancer it is unreasonable to think that they could all be 
bone fide tumour suppressor genes although many may contribute towards tumourigenicity or 
tumour progression, whilst others may be a by-product of general genome deregulation. They 
can be looked upon in a similar manner to the larger number of mutations per genome that are 
now being identified by next generation sequencing, where some are driver mutations 
(necessary for tumourigenesis) and the others are passenger mutations (randomly selected 
along with the driver mutations). 
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1.2.3.3 DNA hypermethylation events as biomarkers  
The detection of single gene methylation status is a quick and easy procedure that could be 
undertaken in a diagnostic setting using PCR based techniques such as MSP and 
pyrosequencing, which will be discussed later. The presence of circulating cancer cells in 
bodily fluids for some types of cancer (for example, urine in prostate cancer and sputum in 
lung cancer), also allows for analysis of potential methylation markers from non-invasive 
techniques, an important consideration from the patients’ point of view. Determination of 
gene specific DNA methylation events can be used to detect a small level of cancer cells (not 
visible by current imaging techniques), identify pre-cancerous lesions that are more likely to 
develop into cancers, aid in disease prognosis and indicate drug treatment outcomes. The 
following examples demonstrate these potential biomarker functions in numerous cancer 
types. 
The GSTP1 (glutathione-S-transferase pi 1) gene, located at 11q13 is involved in 
detoxification and has a large CpG island susceptible to tumour specific hypermethylation in 
multiple cancer types including prostate, breast and renal cell carcinoma (Esteller et al, 1998). 
In prostate cancer, very frequent methylation (80-90%) has been shown in cancerous tissue 
but not benign hyperplastic or normal prostate tissues (Jéronimo et al, 2001). Some success 
has been observed in studies trying to detect GSTP1 methylation in urine/serum samples, 
which, if developed further, could offer the opportunity for diagnosis of malignant from 
benign prostate lesions using an easy, non-invasive technique. This could be used in 
combination with the prostate-specific antigen (PSA) test to improve prostate cancer 
prediction. 
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As previously mentioned, hypermethylation of CDKN2A is a common event in many cancers. 
It is a potent tumour suppressor gene and as such, cellular inactivation is likely to drive the 
tumourigenic process. For this reason, high levels of methylation are also observed in pre-
cancerous lesions and often associate with those that become cancerous. For example, the 
detection of CDKN2A methylation in Barrett’s oesophagus significantly associates with 
progression to oesophageal cancer (Schulman et al, 2005; Wang et al, 2009), a scenario that 
has also been observed in lung, colon and liver lesions (Licchesi et al, 2008; Kukitsu et al, 
2008; Jicai et al, 2006).  
The SEPT9 (septin 9) gene, located at 17q19, is involved in cell cycle control and methylation 
has been observed in colorectal and head and neck cancers (Lofton-Day et al, 2008; Stanbery 
et al, 2010). When this tumour specific methylation is present in colorectal cancer, it can be 
detected in patient plasma samples and subsequently developed assays have demonstrated a 
high sensitivity of CRC detection from plasma samples (de Vos et al, 2009). This is 
potentially exploitable as a sensitive, non-invasive diagnostic or general screening technique 
for a cancer type that can often lie undetected for an unfortunately long amount of time before 
presenting as advanced disease.  
The DAPK1 (death associated protein kinase 1) gene, located at 9q21.33, is involved in 
apoptosis regulation and frequent promoter hypermethylation has been observed in many 
cancers including colorectal, NSCLC and cervical (Pehlivan et al, 2010; Feng et al, 2008; 
Missaoui et al, 2011). Methylation in NSCLC has been shown to significantly associate with 
poor patient outcome with numerous studies showing a significant association between 
patients demonstrating DAPK1 methylation in an early tumour grade that go on to have poor 
disease free- and overall-survival (Lu et al, 2004; Buckingham et al 2010). Similar results for 
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other cancers also look promising but remain to be confirmed in multiple studies and large 
cohorts.  
The MGMT (O-6-methylguanine-DNA methyltransferase) gene, located at 10q26, is a DNA 
repair gene responsible for removing alkyl groups from the O6 position of guanine. If not 
removed, alkyl groups can form cross linking of the DNA strands resulting in double strand 
breaks, ultimately resulting in cell death. Some cancer drugs, such as carmustine and 
temozolomide, exploit this mechanism by directly causing massive amounts of alkylation to 
greatly increase the DNA cross-linking. Therefore, when MGMT is down-regulated, the 
increased and unrepaired alkylation shifts the cells’ fates rapidly towards cell death, thus 
improving the efficiency of these drugs. Cancer specific hypermethylation has been observed 
in many cancer types but in gliomas the methylation status of MGMT is both frequent (40%) 
and highly clinically relevant (Esteller et al, 1999; Esteller et al, 2000a). MGMT methylation 
status has been shown to indicate response to alkylating drugs such as carmustine and 
temozolomide (Esteller et al, 2000a) and is now used in a diagnostic setting to identify those 
patients most likely to benefit from alkylation based drug therapy. This is a wonderful 
example of how methylation status can be used to help tailor successful treatments. Other 
examples include BRCA1 methylation and ABCB1 and GSTP1 methylation in breast cancer 
indicating increased sensitivity to cisplatin and doxorubicin respectively; CHFR methylation 
in endometrial cancer and increased sensitivity to taxanes; and ASC/TMS1 methylation and 
increased resistance to 5-fluorouriacil in gastric cancer (Deng et al, 2010).  
1.2.3.4 CpG island methylator phenotype (CIMP)  
Studies in colorectal cancer identified a subset of cancers that showed a specific increase in 
both the number of methylated genes and the levels of methylation at these loci, often with 
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subsets of specific genes being methylated in these samples (Toyota et al, 1999a). This led to 
the proposal of the CpG island methylator phenotype (CIMP) (Toyota et al, 1999a). In 
colorectal cancer, CIMP is strongly associated with microsatellite instability and methylation 
of the mismatch repair gene, MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2 (E. 
coli)), although four molecular subtypes have been described: CIMP positive & MSI 
negative; CIMP & MSI positive; CIMP negative & MSI positive, and CIMP & MSI negative 
(Toyota et al¸ 2000). Although CIMP is mostly associated with colorectal cancer, other 
tumour types, such as gastric and ovarian (Toyota et al¸1999b; Strathdee et al¸ 2001), have 
exhibited a CIMP like phenotype. A CIMP phenotype in gliomas, termed G-CIMP has 
recently been described that is most prevalent in IDH1 mutated samples (Noushmehr et al, 
2010).  
1.2.3.5 Loss of Imprinting (LOI) in cancer  
Loss of imprinting (LOI) in cancer has been described both on a germline and somatic level, 
but is an unusual event. Some imprinting disorders, such as Beckwith-Weiderman syndrome 
(BWS), are associated with an increase in the likelihood of developing tumours; 5-10% of 
BWS patients develop tumours including Wilms Tumour, neuroblastomas and 
rhabodomyosarcomas (Lim et al, 2010). BWS (and Silver Russell syndrome) are caused by 
imprinting disorders at the 11p15.5 region which contains multiple genes, including IGF2, 
which is implicated in BWS. In addition to the increased likelihood of BWS patients 
developing cancers, somatic LOI of IGF2 can occur as an early event in Wilms Tumour, 
colorectal cancer and ovarian cancer (Lim et al, 2010). Other imprinted regions, such as 
14q32, are involved in cancer acquired changes, where hypermethylation of either the 
differential methylated region involved in the imprinting control or promoter region of GLT2 
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have been described in neuroblastomas, Wilms Tumour and phaeochromocytomas (Lim et al, 
2010).  
1.2.3.5 Cancer epigenomics  
The development of genome wide techniques to assess DNA methylation, as described later, 
has changed the field from predominantly analysis of a single locus, candidate gene to using 
global aberrant DNA methylation data as a method of identifying multiple novel important 
loci as well as profiling whole cancer genomes with respect to their global methylation 
changes according to biological factors, such as clinical features. Recent studies include 
identifying candidate genes associating with longer progression free intervals in ovarian 
cancer (Bauerschiag et al, 2011) and prediction of relapse in prostate cancer (Kobayashi et al, 
2011). Methylation profiles have also been described that associate with translocation events 
in acute myeloid leukaemia (Alvarez et al, 2010) and, as previously mentioned, CIMP in 
gliomas that associated with IDH1 (isocitrate dehydrogenase 1) mutation and better survival 
(Noushmehr et al, 2010; Christensen et al, 2011). These studies are applicable to all cancer 
types and have been and will be extremely useful for identifying methylation patterns and 
methylated genes that associate with specific clinical features and tumour sub-types, thus 
producing biomarkers that are complete profiles of gene methylation as well as single or 
groups of genes. Further examples will be discussed later with specific association to breast 
cancer. 
1.2.3.6 Epigenetic therapies  
Due to the intrinsically reversible nature of DNA methylation and chromatin modifications, 
compounds or drugs designed to readjust the cancer acquired changes in these gene 
expression modifiers are attractive therapeutic targets for restoring more normal expression.  
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Drugs designed to block the DNA methyltransferases (DNMTs) have proved to be useful in 
cancer management, against haematological malignancies in particular. There are currently 
two DNMT inhibitors that have been approved for use in the clinical setting; ‘Vidaza®’ (5-
aza-deoxycitidine) (Celgene Corporation) and ‘Decitibine/Dacogen®’ (5-aza-2’-
deoxycitidine) (SuperGen, Inc.), both of which have been approved for the treatment of 
myelodysplastic syndrome. There are many more DNMT inhibiting drugs that are being 
developed, for example Zebularine, Procaine and Hydralazine. Unfortunately, due to their 
common mechanism of action, the DNMT inhibitors often affect the transcription of off-
target, non-cancer involved genes, although still having an effect on genes important in 
leukaemogenesis (Rodrίguez-Paredes et al, 2011). Clinical trials are also underway to assess 
the benefits of epigenetic drugs in solid tumours. A trial has been started in non-small cell 
lung cancer using a combination of Vidaza® and a HDAC inhibitor that is showing some 
signs of success (Kaiser, 2010).  
A large abundance of drugs designed to block chromatin modifications are also being 
developed. HDAC inhibitors are currently the most heavily researched, falling into one of 
four categories; short chain fatty acids, hydroxamic acids, cyclic peptides and benzamide 
derivatives. Two HDAC inhibitors have so far been accepted for patient treatment, 
‘Vorinostat’ and ‘Romidepsin’; as with the DNMT inhibitors, the most promise for HDAC 
inhibitors has been observed in haematological malignancies. The HDAC inhibitors most 
commonly bring about anti-cancer effects via cell cycle arrest at the G1or G2-M phase, 
induction of differentiation and apoptosis (Rodrίguez-Paredes et al, 2011). A range of other 
targets for drug induced blocking of chromatin modifications are also being investigated, for 
example, inhibitors of histone acetylases, methylases and demethylases along with SIRT 
inhibitors (Rodrίguez-Paredes et al, 2011).    
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1.3 ANALYSIS OF DNA METHYLATION  
DNA methylation status can be analysed on the scale of an individual gene or on a larger 
scale, such as a whole chromosome or the entire genome, although in reality, even when using 
large scale approaches, it is often necessary to further analyse selected targets in an individual 
manner. There are now many ways in which this can be achieved.  
Since DNA methylation is not retained by artificial PCR based DNA amplification, most 
analysis is based around techniques that first modify the DNA, using sodium bisulphite to 
permanently retain the methylation markers, even after PCR has subsequently been 
performed. This modified, amplified DNA can be assessed for methylation.  
Previous to this discovery, general methylation status could be ascertained using large 
amounts of unamplified genomic DNA using paired methylation sensitive or methylation 
insensitive restriction endonucleases such as HpaII and MspI. Both HpaII and MspI recognise 
the sequence 5’-CCGG-3’; however HpaII is 5mC sensitive and MspI is 5mC insensitive; 
therefore cleavage with HpaII will only occur when methylation is not present, and MspI will 
cleave DNA regardless. Analysis of results post digestion by 2 dimensional (2D) Southern 
Blotting will give an indication of methylation status and produce specific fragments due to 
methylation. This technique is labour intensive and requires the use of radioactive material for 
labelling and has now been almost entirely replaced by more modern methods, although it 
was used as recently as 2006 (Giotopoulos et al, 2006). A PCR based technique was also 
developed, HpaII-PCR, based on HpaII digestion where PCR primers were designed to 
surround a HpaII site, therefore only producing a product if DNA remained undigested, 
indicating CpG methylation (Singer-Sam et al, 1990). This technique is now also very rarely 
used.  
37 
 
1.3.1 DNA modification by sodium bisulphite treatment 
It was discovered in the early 1970s that treatment of denatured DNA with sodium bisulphite 
caused rapid deamination of cytosine to uracil, whilst 5-methylcytosine (5mC) remained 
unaffected (Shapiro et al, 1970; Hayatsu et al, 1970). This discovery revolutionised the way 
5mC levels in DNA were analysed. PCR of the bisulphite converted DNA resulted in the 
incorporation of T nucleotides where bisulphite conversion had produced deamination of 
cytosine to uracil whilst 5-methylcytosine nucleotides were unaffected and therefore 
incorporated as cytosines in the PCR reaction. This was first used to demonstrate the 
methylation status of cytosine residues within the DNA in a study by Frommer et al (1992) 
where PCR products were sequenced to demonstrate that retained Cs were originally 
methylated and newly created Ts occurred where no methylation was present.  
Since then, many techniques have been developed to assess the methylation levels in 
particular DNA sequences, the majority of which rely on bisulphite conversion and 
subsequent PCR; a few of these will now be discussed below. It is important to note that 
sodium bisulphite will convert 5-hydroxymethycytosine as well as 5-methylcytosine and so 
does not allow for any discrimination between these two different types of methylation 
(Huang et al, 2010). 
1.3.2 CoBRA (combined bisulphite restriction analysis) 
CoBRA (combined bisulphite restriction analysis) was developed as a rapid way of detecting 
methylation in bisulphite modified DNA (Xong et al, 1997). Following bisulphite conversion, 
PCR amplification is performed on the region of interest, and subsequently digested with an 
enzyme that will only cleave DNA if methylation was present in the original unmodified 
DNA. The two most commonly used enzymes are BstUI and TaqαI. BstUI recognises the 
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sequence 5’-CGCG-3’ and therefore if originally methylated, the DNA will remain 5’-CGCG-
3’ following bisulphite modification and subsequent PCR, whereas if originally unmethylated, 
the sequence will become 5’-TGTG-3, therefore only retaining a BstUI restriction site if 
methylated. TaqαI recognises the sequence 5’-TCGA-3’ and therefore if originally 
methylated, the bisulphite modified and subsequently amplified DNA will remain 5’-TCGA-
3’ whilst unmethylated DNA will become 5’-TTGA-3’, rendering the DNA uncleaved 
following incubation with TaqαI. Additionally, TaqαI has the advantage of also being more 
specific to successfully modified DNA since if the original methylated DNA had the sequence 
5’-CCGA-3’, the 5’-C will become T, producing a TaqαI restriction site (if the following C is 
methylated). Despite this, BstUI is more commonly used as BstUI sites are more common 
within CpG islands and digestion only occurs if both CpGs are methylated, implying a greater 
depth of methylation. A schematic is shown in figure 1.6 of the CoBRA assay.  
CoBRA assay is very commonly used to assess methylation status as it is a reliable, cost 
effective and rapid way of determining methylation status. Additionally, the PCR products 
from the CoBRA reactions can be cloned into bacteria vectors, grown and subsequently 
sequenced to give an indication of the range and depth of methylation throughout the 
investigated region (numerous clones are picked and sequenced to produce a ratio of 
unmethylated to methylated for a given region and/or individual CpG) 
1.3.3 Methylation specific PCR (MSP)  
Methylation specific PCR (MSP) is another commonly used PCR based technique on 
bisulphite modified DNA. It is based upon designing primers that are capable of specifically 
amplifying either methylated DNA or unmethylated DNA. Thus for each sample, two PCRs 
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ACGTCGCGTAGCTACGTAC
Bisulphite conversion of 
denatured DNA converts 
unmethylated cytosines to uracils
ACmeGTCmeGCmeGTAGCTACmeGTAC
AUGTUGUGTAGUTAUGTAU
PCR amplification of bisulphite 
modified DNA incorporates thymines
where uracils are present  
ACGTCGCGTAGTTACGTAT ATGTTGTGTAGTTATGTAT
Methylated DNA Unmethylated DNA 
ACmeGTCmeGCmeGTAGUTACmeGTAU
TGCAGCGCATCAATGCATA TACAACACATCAATACATA
Figure 1.6_CoBRA assay for analysis of single gene methylation status
This figure shows a representative sequence of DNA in a methylated and unmethylated state as it goes through the
bisulphite modification, subsequent PCR and digestion with a CG containing restriction endonuclease, in this example
BstUI.
ACGTCGCGTAGTTACGTAT ATGTTGTGTAGTTATGTAT
TGCAGCGCATCAATGCATA TACAACACATCAATACATA
BstUI BstUI
ACGTCG   CGTAGTTACGTAT ATGTTGTGTAGTTATGTAT
TGCAGC   GCATCAATGCATA TACAACACATCAATACATA
PCR amplified DNA is digested with 
BstUI (5’-CGCG-3’)
BstUI digestion fragments DNA only 
where methylation was present in 
the original genomic DNA. 
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are performed, one designed to only amplify methylated DNA, the MSP (methylation specific 
PCR), and the other designed to only amplify unmethylated DNA, the USP (unmethylated 
specific PCR) (Herman et al, 1996). This technique can offer a more sensitive approach to 
detecting methylation than CoBRA and is often used to assess the methylation of known 
commonly methylated genes such as RASSF1A and MGMT. Due to the nature of primer 
design, it is often advantageous to know the regions of commonly methylated DNA first to 
ensure a sensitive assay. The only methylation assessed areas in a MSP lie directly beneath 
the primers, so for well characterised genes where the regions of important methylation 
alteration are known this is a very useful technique. Whilst MSP assays can be designed for 
the analysis of novel genes, prior information gathered from sequencing of CoBRA products 
can prove very useful.  
1.3.4 Pyrosequencing 
Pyrosequencing of methylated DNA was developed as a sensitive and quantitative method for 
analysing methylation status of CpGs. The basic pyrosequencing technique is based on 
incorporation of new dinucleotides to a template that are released in a pre-determined order; 
when the correct nucleotide is released, it binds to the template strand, releasing 
pyrophosphate. In turn, the pyrophosphate is converted during an enzyme catalysed reaction 
to produce light emissions, quantification of which gives a reading of the proportion of the 
incorporation of one nucleotide to another. The technique is therefore highly amenable to 
determining the proportion of C or T dinucleotides at a given CpG following bisulphite 
modification and PCR, allowing for quantitative assessment of single CpG methylation within 
a given sample (England et al, 2005; Uhlman et al, 2002). The technique offers a quantitative 
way of assessing methylation, which CoBRA and MSP assays both lack, however, the 
technique is less cost effective and is limited by relatively short sequence read-lengths and so 
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should be directed at a known region of importance. Figure 1.7 illustrates the pyrosequencing 
technique.  
1.3.5 MethyLight™ 
The MethyLight™  method uses quantitative PCR techniques of the TaqMan™ system, 
which utilises a sequence specific probe, designed to anneal to PCR products, emitting a 
fluorescent signal when binding occurs which can be accurately measured throughout the 
PCR reaction. By performing qPCR on bisulphite modified DNA using a methylation pattern 
specific TaqMan probe, quantitative measurements can be made that determine the levels of 
methylation that lie within that particular probe sequence within a sample (Eads et al, 2000). 
The technique is quantitative, sensitive, rapid, amenable to high throughput analysis and 
relatively cost effective compared to some other methods however it is limited to analysing 
the methylation status at a specific, short sequence. It has become a common method of DNA 
methylation analysis since its discovery.  
1.3.6 EpiTYPER™ 
EpiTYPER™ is a method commercialised by Sequenom to quantitavely measure 5mC levels 
at CpG sites by the use of MALDI-TOF (Matrix-assisted laser desorption/ionization-time-of-
flight) mass spectrometry. It is based on a study by Ehrich et al (2005) in which it was 
demonstrated that bisulphite treatment followed by PCR and then in vitro transcription leads 
to a single stranded RNA molecule that can be base-specifically cleaved by an 
endoribonuclease, producing a mixture of fragments, the mass of which will depend on the 
CG content. Examination of the mixture of fragments by MALDI-TOF mass spectrometry 
provides enough information to calculate exactly which cytosines are methylated. Whilst this 
technique offers a quantitative way of assessing methylation without sequencing, it is a rather  
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Figure 1.7_Schematic of the pyrosequencing technique
This figure shows the pyrosequencing technique for DNA methylation
analysis. Bisulphite treated DNA is PCR amplified by using primers located
around the CpGs of interest and a single strand loaded onto the beads. The
bead probe is extended one nucleotide at a time by the sequential
introduction of all four possible nucleotides, A, C, G or T. Incorporation of
the dNTP creates by-products that result in an enzymatically produced light
signal. This signal is measured after the introduction of each nucleotide and
thus the sequence can be read. If the amplified region is partially methylated
a percentage of amplified fragments will give a signal with the introduction
of C and some with the introduction of T. The light signal can be accurately
quantified and produce a quantitative level of DNA methylation. This figure
was taken from http://www.dna-sequencing-service.com/dna-
sequencing/pyrosequencing/
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a cost heavy procedure. Recent uses have included validation of genome wide arrays 
(Christensen et al, 2010; Flanagan et al, 2010) and methylation studies of known candidate 
genes in clinically variable samples for biomarker discovery (Vanaja et al, 2009). Figure 1.8 
illustrates the EpiTYPER™ technique.  
1.3.7 Larger Scale/Genome wide methylation analysis  
1.3.7.1 De-methylation (5azaDC) specific mRNA expression array analysis  
This technique utilises expression array data generated from the total mRNA extracted from 
cell line samples either treated or untreated with the de-methylating drug 5-aza-2’-
deoxycitidine (5azaDC). Analysis of the comparative gene expression with and without 
treatment can identify sets of genes that are up-regulated following de-methylation for each 
sample, suggesting gene methylation in the untreated sample is restricting expression. These 
arrays have the advantage of identifying methylated genes that are more likely to be 
biologically relevant, as the result of de-methylation is re-expression or up-regulation. 
However, this can only be performed on cell lines due to the necessity of 5azaDC treatment. It 
is also important to note that the up-regulated genes do not necessarily have to be themselves 
methylated. Methylation of upstream control genes, such as transcription factors, can also be 
removed and thus result in the up-regulation of their targets. This leads to a high degree of 
false positive gene selection and investigation of these genes often demonstrates no tumour 
specific DNA methylation within the cell lines (Morris et al, 2010; Dr C.J. Ricketts, personal 
communication). Nevertheless, numerous successful studies include the identification of 
potential methylation markers in lung cancer (Shames et al, 2006) and potential tumour 
suppressor genes in melanoma (Mithani et al, 2011), and renal cell carcinoma (Morris et al, 
2010). 
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Bisulphite treatment of genomic DNA
In vitro transcription
PCR and SAP treatment
Uracil-specific cleavage
MALDI-TOF MS analysis produces 
signal pattern pairs indicating 
unmethylated and methylated DNA
Figure 1.8_Schematic of the EpiTYPER technique
This figure illustrates the EpiTYPER technique. Bisulphite treated DNA is
PCR amplified by using primers located around the CpGs of interest with
one primer tagged with a T7 promoter sequence. The PCR product is
transcribed into a RNA transcript and cleaved in a base specific manner.
Cleavage products are analyzed by matrix-assisted laser desorption/
ionization – time of flight (MALDI-TOF) mass spectrometry (MS) and a
characteristic mass signal pattern can be obtained, here the blue signal
represents unmethylated DNA and red represents methylated DNA. This
image was taken from Ehrich et al, 2005.
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1.3.7.2 Methylated DNA enrichment assays  
Following an initial experiment in 1994 that demonstrated that methylated CpG island DNA 
could be immunoprecipitated and enriched for by using an antibody specific to the methyl 
binding protein, MECP2 (Cross et al, 1994), further techniques have been developed that also 
allow for either the pull-down or immunoprecipitation of methylated DNA from a pool of 
short DNA fragments produced by whole genomic DNA sonication. These methods use either 
antibodies directly against the 5mC itself or methyl binding proteins, such as MBD1. When 
coupled with microarrays, these techniques offer a way of identifying differential methylation 
between samples without bisulphite modifying the DNA.  
Methylated DNA immunoprecipitation (MeDIP) 
The most widely used commercially available approach is MeDIP (methylated DNA 
immunoprecipitation) which utilises an antibody against 5-methylcytosine to pull down 
methylated DNA fragments (Weber et al, 2005). The approach is then coupled with 
microarray analysis to compare the immunoprecipitated, methylation enriched DNA to a 
control sample, most commonly used are the CpG island specific microarrays. The technique 
has been used for many studies; including assessing methylation levels in several cancers, 
such as colorectal cancer (Keshet et al, 2006), testicular cancer (Chueng et al, 2010) and RCC 
where the MeDIP technique was used on 9 RCC tumours and 3 normal kidney tissue samples 
to identify novel methylated genes in RCC (Morris et al, 2011). A recent study has also used 
the MeDIP technique to assess the methylation differences between familial BRCA1, BRCA2 
and BRCAn mutated breast cancer samples (Flanagan et al¸ 2010).  
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Methylated CpG island recovery assay (MIRA) 
The main alternative to MeDIP is the methylated CpG island recovery assay (MIRA). This 
method involves the pull-down of fragmented methylated DNA through the use of methyl 
binding domain (MBD) proteins. The assay relies on the affinity of the MBD protein, 
MBD2b, for methylated DNA. The affinity of MDB2b for methylated DNA is enhanced by 
the MBD-like protein, MBD3L1 and therefore the MIRA assay uses a complex of full length 
glutathione-S-transferase (GST)-tagged MBD2b and His tagged MBD3L1 (Rauch et al, 
2005).  
The fragmentation of genomic DNA was initially performed by sonication, but now is more 
commonly achieved via restriction endonuclease digestion with an enzyme with an AT rich 
cut-site such as MseI (5’-TTAA-3’) to avoid cleavage within CpG rich regions. DNA is 
incubated with the MBD2b/MBD3L1 protein complex and subsequently pulled-down with 
glutathione coated GST beads. The resultant methylation enriched DNA has been both PCR 
screened for the presence/absence of a particular gene (Rauch et al, 2005) and compared to 
normal control DNA by hybridisation to CpG island specific microarrays (Rauch et al, 2006) 
(figure 1.9). Analysis has shown the pull-down of methylated fragments is sensitive to a small 
number of methylated CpGs (Rauch et al, 2005). 
To date, the MIRA technique has been used to successfully assess tumour acquired 
methylation in lung cancer (Rauch et al, 2007; Rauch et al, 2006), ductal carcinoma in situ 
(DCIS) (Tommasi et al, 2009), childhood acute lymphocytic leukaemia (Dunwell et al, 2010), 
breast cancer (Chapter 3; Hill et al, 2010) and astrocytomas/gliomas (Wu et al, 2010). In each 
case, novel methylated genes in these cancers have been identified, showing MIRA to be a 
useful technique when trying to identify novel methylated targets in cancers.  
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and MBD3L1 
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PCR amplification of MIRA 
enriched fraction
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island array 
Methylated CpG island Unmethylated CpG island MBD2b and MBD3L1 
protein complex  
Hyperrmethylated loci 
FIGURE 1.9_Schematic of the MIRA coupled with microarray technique
This figure shows a schematic of the MIRA assay. Briefly, genomic DNA is
digested with MseI to fragment the DNA outside of CpG islands. Fragmented
DNA is then incubated with an MBD2b and MBD3L1 protein complex to pull
down methylated DNA fragments. Samples are ligated with MseI linkers and then
PCR amplified and labelled with either Cy3 (normal) or Cy5 (tumour).
Hybridisation to a CpG island microarray determines which fragments are
hypermethylated in tumour DNA.
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1.3.7.3 Direct hybridisation of sodium bisulphite modified DNA to microarrays 
The Illumina methylation bead chip assays currently offer the only possibility of direct array 
hybridisation of sodium bisulphite modified DNA. There are currently three bead chip assays 
available from Illumina; GoldenGate, Infinium HumanMethylation27 and Infinium 
HumanMethylation450. All assays use the same Bead Chip technology originally designed to 
assess single nucleotide polymorphisms (SNPs), which has been adapted to assess the 
methylation of a single CpG locus based on the C or T status following bisulphite 
modification and PCR of 5mC and C respectively. Bead probe design is based much like an 
MSP or USP primer, with any upstream CpG dinculeotides of the one being assessed altered 
to correspond with the last nucleotide of the probe, which is either C (methylated) or T 
(unmethylated). Correct binding of methylated or unmethylated DNA to the bead chip results 
in single base extension with the addition of a fluorescently labelled nucleotide. For each 
probed CpG locus, numerous methylated and unmethylated probes are scattered throughout 
the chip and measurement of the fluorescence of all the probes for each locus bead type gives 
a quantitative representation of the amount of methylated and unmethylated alleles in the 
analysed sample. A schematic of the assay is shown in figure 1.10. The three types of 
methylation bead chip assays differ only in terms of array content. GoldenGate covers 1536 
CpGs across a relatively small selection of genes (n=807) which were selected based on either 
being useful for cancer research, being X-linked or being imprinted. Infinium 
HumanMethylation27 covers 27, 578 CpGs across 14,475 consensus coding sequence 
(CCDS) genes, the majority of assessed CpGs being within Illumina defined CpG islands. 
The most recently available, Inifnium HumanMethylation450, covers a more comprehensive 
selection of the genome, with >450 000 CpG sites across a large number of genes and non-
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and subsequent amplification
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and subsequent amplification
Unmethylated DNA will bind sufficiently only to the 
unmethylated bead resulting in single base extension of 
the unmethylated probe, producing a fluorescent signal 
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methylated bead resulting in single base extension of the 
methylated probe, producing a fluorescent signal 
Unmethylated locus Methylated locus 
Unmethylated Bead Type Methylated Bead Type Unmethylated Bead Type Methylated Bead Type 
Figure 1.10_Schematic of the Illumina Infinium Methylation Assay
This figure shows a schematic of the Illumina Infinium methylation assay. Binding of unmethylated and methylated
alleles to the two different bead types for each locus on the array are shown. This figure has been adapted from the
Illumina website (www.illumina.com)
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coding regions, CpG island shore regions, miRNA promoter regions, and CpG sites outside of 
CpG islands. The GoldenGate technique has been used to successfully identify differing 
pathways of cancer development in invasive and non-invasive urothelial cancer (Wolff et al¸ 
2010), methylation hypermethylation profiles associating with IDH mutation in gliomas 
(Christensen et al, 2011) and a potential CIMP phenotype in renal cell carcinoma (McRonald 
et al  ¸2009). The Illumina Infinium HumanMethyation27 array, providing more coverage than 
the GoldenGate assay and a more global genomic profile, has been used to identify a CIMP 
phenotype in gliomas (Noushmehr et al, 2010) and lymphoma subtype specific DNA 
hypermethylation events and an enrichment for hypermethylation of polycomb group targets 
in lymphomas (Martín-Subero et al, 2009a), among many other studies. The Illumina 
Infinium HumanMethylation450 array has only been available for a short time and currently 
the only published study using this technique is an array validation study in a colorectal 
cancer cell line (Sandoval et al, 2011).  
1.3.8 DNA methylation analysis methods and 5-hydroxymethylcytosine  
The recent discovery of 5-hydroxymethycytosine (5hmC) within the human genome has had a 
big effect on this field and the perceived effectiveness of the existing techniques used to 
investigate methylation. Of the methods discussed for DNA methylation analysis, only the 
affinity enrichment based approaches (MeDIP and MIRA) differentiate between 5mC and 
5hmC, binding only to 5mC (Jin et al, 2010). Bisulphite modification approaches are 
currently inadaptable due to sodium bisulphite converting both 5mC and 5hmC to uracil 
(Huang et al, 2010). The presence of 5mC and 5hmC is therefore undetermined by the 
majority of methods currently used to assess the methylation status of DNA. Companies are 
now producing a number of products allowing for the specific investigation of just 5mC or 
just 5hmC and these will undoubtedly prove useful in the future.  
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1.4 BREAST CANCER  
Breast cancer is the most commonly diagnosed cancer in women both worldwide and in the 
UK. During 2008, 1,383,500 women were diagnosed globally (Jemal et al, 2011) of which, 
47,693 were diagnosed in UK women with an additional 341 cases in UK men (CRUK cancer 
statistics). Mortality rates associated with breast cancer are the highest for any type of cancer 
in women worldwide and second highest in the UK, accounting for 14% of the total 
worldwide cancer deaths and 6.8% of the total UK cancer deaths (Jemal et al, 2011; CRUK 
cancer statistics). Higher worldwide breast cancer mortality rates are attributable to the large 
discrepancies between developing and developed countries. Whilst economically developed 
areas such as Western Europe, Australia/New Zealand and Northern America have some of 
the highest incidence rates, mortality rates are on a par with less economically developed 
countries such as Northern and Western African regions where breast cancer incidence rates 
are among some of the lowest (figure 1.11). The unfortunate discrepancies between breast 
cancer mortality rates in both developed and undeveloped countries highlights the importance 
of access to quality healthcare, both in order to detect cancers earlier and treat more 
effectively when diagnosed. The stage at which breast cancer is diagnosed and the age of the 
patient at diagnosis are hugely influential factors on survival (figure 1.12). Breast cancer 
incidence has been increasing over the past few decades and continues to increase, however 
the death rates are falling, largely as a result of the increase in screening techniques and 
therefore earlier detection of the disease (figure 1.13).  
The overall lifetime risk of developing breast cancer for women is estimated at 1 in 9 in the 
UK (CRUK cancer statistics). Factors associated with increased risk include a family history 
of breast cancer, incidence of benign breast disease, increased age (Feuer et al, 1993), post-
52 
 
Figure 1.11_Worldwide breast cancer incidence and death rates
This graph shows worldwide age standardised breast cancer
incidence and death rates split by geographical region. This graph
has been taken from Jemal et al, 2011.
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(a)
(b)
Figure 1.12_Influence of cancer stage and patient age at diagnosis on
survival/mortality rates in the UK
(a) The graph shows the influence of cancer stage at diagnosis on survival
rates of breast cancer patients in the UK diagnosed between 1990 and
1994. (b) The graph shows the influence of patient age at diagnosis on the
mortality rates of patients from breast cancer in 2007. Both graphs are
taken from the CRUK website (www.cancerresearchuk.org).
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Figure 1.13_ Breast cancer European age-standardised incidence and mortality rates in the UK 1975-2008
The figure shows a graph of European age-standardised incidence and mortality rates in the UK for breast cancer
between 1975 and 2008. This graph has been taken from the Cancer Research UK website
(www.cancerresearchuk.org).
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menopausal hormone therapy with HRT (hormone replacement therapy) (ICRF, 1997), long 
term use of oral contraceptives (although this is believed to be a short term effect) (Milne et 
al¸ 2005), early menarche and late menopause (Brinton et al, 1988), increased age at first full 
term pregnancy (Chie et al, 2000; Lambe et al, 1996), reduced parity (Lambe et al, 1996), 
increased breast tissue density (Chen et al, 2006), being overweight (Wolin et al, 2010) 
increased exposure to radiation (Helzlsouer et al, 1995) and increased alcohol intake 
(Hamajima et al, 2002).  
1.4.1 Breast cancer subtypes and classification   
The normal breast consists largely of stromal and epithelial tissue, stromal tissue consisting of 
fat and fibrous tissue that supports the epithelial component of the breast which contains the 
functional and structural elements connected by multiple branching ducts (Hayes et al¸ 2000). 
The roles and overall contribution of these tissue types to breast anatomy vary greatly 
throughout a woman’s lifetime. At birth, there is very little stromal component and only 
rudimentary branching ducts, however, through puberty and adulthood the stromal component 
has massively expanded and the epithelial ducts have given rise to sacular buds ready for 
expansion of the epithelial component during pregnancy. Post-lactation changes result in 
glandular atrophy and the stromal component again comprising most of the breast volume. 
Post-menopause, the stromal component loses its fibrous connective tissue and becomes 
mainly adipose tissue whilst the epithelial component begins to atrophy resulting in a 
decrease in lobular compartments whilst ductal regions remain (Hayes, 2000).  
The majority of breast cancers form within the ductal regions of the breast although other 
regions can also give rise to cancers, the next most common region being the lobular 
component. Breast cancer disease can be classified as either in situ carcinomas or invasive 
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(infiltrating) carcinomas. In situ carcinomas are often considered as pre-cancerous lesions and 
a form of benign breast disease despite their name containing ‘carcinoma’. They can be 
further sub-classified as ductal or lobular based on location within the breast. The rarer 
lobular carcinoma in situ (LCIS) demonstrates low histological variation whilst the more 
common ductal carcinoma in situ (DCIS) can be classified as either Comedo, Cribiform, 
Micropapillary, Papillary or Solid (Malhotra et al, 2010). These classifications are based 
entirely on histological findings rather than molecular markers. Invasive or infiltrating 
carcinomas can be split into six types; tubular, ductal lobular, invasive lobular, infiltrating 
ductal, mucinous (colloid) or medullary (Malhotra et al, 2010). Of these, infiltrating ductal is 
the most common; accounting for 70-80% of all invasive breast cancers, the next major 
subtype is invasive lobular carcinoma (Li et al, 2005). The work in this thesis concentrates 
upon the common infiltrating ductal carcinomas. Figure 1.14 illustrates the normal anatomy 
of a breast and the disruption of normal breast architecture during carcinoma.  
Further characterisation of invasive carcinomas is based on gene expression signatures 
characterised during studies in the early 2000s. The epithelial component of the breast 
consists of basal and luminal cells. An expression study on a cohort of 86 breast samples 
(consisting primarily of invasive ductal carcinomas - some of which were paired before and 
after treatment with doxorubicin - and a mixture of lobular carcinomas, breast cancer cell 
lines and normal breast tissue samples) demonstrated that gene expression signatures are able 
to classify breast carcinomas as either luminal, basal, ERBB2 gene (encoding HER2/neu – 
Human Epidermal growth factor Receptor 2) overexpressing or normal-like (Perou et al, 
2000). Overexpression of the ERBB2 oncogene is an important event in breast cancer and is 
thought to be present in approximately 30% of cases (Slamon et al, 1987). ERBB2 
overexpression forms the basis of treatment with the drug trastuzumab (Herceptin). 
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(a) 
(b) 
Figure 1.14_Normal and cancerous breast anatomy
(a) A simple schematic of normal breast anatomy is shown indicating stromal and epithelial components (left) and a more
detailed schematic of epithelial terminal duct lobular units (right). The locations of breast diseases, both benign and
malignant are also indicated. This figure has been taken from ‘Atlas of Breast Cancer Second Edition’ edited by Daniel F
Hayes. (b) A high magnification histology section of the distinct architecture of normal breast anatomy indicating the milk
duct and surrounding stromal region is shown (top). Below this, a high magnification histology section of breast carcinoma
is shown, note the loss of distinctive architecture around the duct and epithelial cell invasion of the stroma. This figure has
been taken from ‘The Biology of Cancer’ by Robert A Weinberg.
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(Ménard et al, 2003). Luminal and basal subtypes both express genes consistent with known 
markers for these cell types, luminal tumours also express the oestrogen receptor (ER) whilst 
basal tumours do not. Normal-like cells express genes consistent with normal basal epithelial 
breast cells whilst ERBB2 over-expressing tumours have low levels of ER and overexpression 
of ERBB2 (Perou et al, 2000). Subsequent validation of this work in separate cohorts 
confirmed the subtypes described plus an additional splitting of the luminal subtype into 
luminal A and luminal B sub-classifications. Luminal A tumours have the highest expression 
of ER and ER related genes whilst luminal B tumours remain ER positive but have lower 
expression of ER and ER related genes (Sørlie et al, 2001; Sørie et al, 2003). Overall survival 
analysis of subtype specific cancers has shown that basal-like and ERBB2 overexpressing 
cancers have the worst overall and metastases free survival of all subtypes whilst luminal A 
tumours have the best outcomes (Sørlie et al, 2001). Recently, a further subtype, claudin-low, 
has been described which is characterised by low expression of claudin 3, claudin 4, claudin 7 
and E-cadherin (Herschkowiitz et al, 2007; Prat et al, 2010). Whilst the previous 
classifications of breast cancer demonstrated markers of epithelial cells, the claudin-low 
subtype demonstrates markers of a class of cells called TICs (tumour initiation cells). The 
detection of TICs that are unlike basal or luminal epithelial cells adds to the theory that breast 
cancers can arise as a result of cancer stem cells. Despite these studies the Claudin-low 
subtype classification is yet to be widely accepted.  
Other expression studies on breast cancer have enabled the development of microarray tests to 
aid in identifying patients who will benefit most from particular treatments. For example, a 
study in 2002 on 98 breast cancers identified a 70 gene signature capable of predicting poor 
prognosis and therefore enabling prediction of patients who would benefit from more severe 
treatments (van t’Veer et al, 2002). The study has led to the development of MammaPrint, a 
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microarray test developed by Agendia that is now approved by the FDA in the USA for the 
detection of breast cancers that are most likely to metastasise and therefore would benefit 
from more severe treatments (Glas et al, 2006). Other, similar studies, have developed a gene 
expression signature associated with survival (van de Vijver et al, 2002) and a reduced gene 
signature of 50 genes from the original breast cancer subtyping studies (Perou et al, 2000; 
Sørlie et al, 2001; Sørie et al, 2003) that can predict clinical outcome (Parker et al, 2009). A 
second commercially developed microarray test, Oncotype DX, has been produced that uses a 
21 gene expression panel to determine the likelihood of relapse (Cobleigh et al, 2005). These 
studies, whilst extremely beneficial to patients, rely on mRNA expression studies which 
present more inherent problems than DNA based studies and therefore identification of 
further predictive markers would be useful.  
1.4.2 Breast cancer genetics  
The genetics of breast cancer patients, like the genetics of most forms of cancer, can be split 
into two distinct groups. By far the largest group consists of individuals who acquire somatic 
mutation and genetic/epigenetic alterations throughout their lifetimes, possibly affected by 
numerous environmental influences, which combine to initiate and enable the tumourigenic 
process. A smaller group consists of individuals who inherently carry a pre-existing genetic 
fault that increases their risk of developing breast cancer; these individuals are usually found 
as members of breast cancer predisposed families. 
1.4.2.1 Familial/Inherited Predisposition to Breast cancer 
Typically, breast cancer families exhibit autosomal dominant inheritance of a predisposition 
to breast and ovarian cancers with the affected allele demonstrating incomplete penetrance. 
Familial breast cancers often occur at an earlier age of onset than sporadic cancers, occurring 
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primarily before the age of 50, and are more commonly bilateral than sporadic cancers. Breast 
cancer families can also sometimes have affected males. These families, although unfortunate, 
have allowed for the identification of important genes associated with breast cancer 
susceptibility.  
The most commonly mutated genes conferring an inherited risk of breast cancer are BRCA1 
(breast cancer 1) and BRCA2 (breast cancer 2), both of which were identified through 
linkage analysis of breast cancer families. The first breast cancer susceptibility gene, BRCA1, 
was identified at 17q21 through linkage analysis of 23 affected families (Hall et al, 1990; 
Miki et al, 1994) and BRCA2 was identified at 13q12.3 through linkage analysis and 
sequencing of single individuals from 46 affected families (Wooster et al, 1995). BRCA1 is a 
81 kb gene with 23 exons encoding a 207 kDa protein and BRCA2 is a 84 kb gene with 27 
exons encoding a 390 kDa protein. Although both genes do not have similar functions they 
have been shown to be involved in similar pathways. In normal cells, BRCA1 protein is able 
to act as a scaffold protein for p53 phosphorylation by ATM. BRCA1 deficient cells are 
therefore lacking active p53, resulting in a block on p53 mediated induction of p21 and 
therefore p21 induced G1/S arrest. BRCA1 deficient cells are therefore unable to activate the 
G1/S checkpoint, allowing cell cycle progression in the presence of DNA damage (Fabbro et 
al, 2004). The S phase check point is also affected by BRCA1 deficiency, due to loss of 
regulation of Chk1 kinase activity and specific Ser1387 phosphorylation of BRCA1 by ATM 
following ionizing radiation (Xu et al, 2001). In a similar fashion to the S phase checkpoint, 
BRCA1 regulates Chk1 activity at the G2/M checkpoint and is itself activated by 
phosphorylation at Ser1423 by ATM (Xu et al, 2001). A role for BRCA1 has also been 
implicated in the non-homologous end-joining (NHEJ) and homologous recombination (HR) 
methods of DNA repair (Fu et al¸2003; Greenberg et al, 2006). Whilst the role of BRCA1 in 
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NHEJ is somewhat controversial the role of BRCA1 in HR has been well defined. During the 
repair process, BRCA1 interacts directly with the MRN (Mre11/Rad50/NBS1) complex, 
which, along with ATM, is essential for converting double stranded broken ends into single 
stranded DNA, the first step of HR (Greenberg et al, 2006). In addition, BRCA1 has been 
shown to interact with PALB2 protein (Sy et al¸ 2009) and BRCA2 protein (Zhang et al, 
2009a, b) at DNA damage sites, both PALB2 and BRCA2 are functional partners of Rad51, a 
member of the MRN (MRE11, RAD50 and NBS1) complex, and have been shown to aid the 
formation of single stranded DNA from double strand breaks. BRCA1 deficiency reduces the 
stability of PALB2 and BRCA2 at DNA damage sites, affecting Rad51 isolation at DNA 
lesions, ultimately impairing HR repair (Zhang et al, 2009a, b).  
Due to their roles in DNA repair, both BRCA1 and BRCA2 deficient cells are sensitive to 
PARP (poly (ADP-ribose) polymerase) inhibitors. PARP is involved in the repair of single-
strand breaks by inducing double strand breaks at the point of damage which are then repaired 
via HR. Inhibition of PARP results in an accumulation of single strand breaks, which, when 
combined with an already DNA repair compromised state in BRCA1 and BRCA2 deficient 
cells, results in cell death due the sheer amount of unrepaired DNA damaged sites. PARP 
inhibitors are routinely used in treatment of BRCA1 and BRCA2 mutated breast cancers 
(Bryant et al, 2005; Farmer et al, 2005).  
Other germline mutated genes in breast cancer are ATM (ataxia telangiectasia mutated), 
PALB2 (partner and localizer of BRCA2), CDH1 (cadherin 1, type 1, E-cadherin), TP53 
(tumour protein p53), BRIP1 (BRCA1 interacting protein C-terminal helicase 1), CHEK2 
(checkpoint kinase 2 homolog), RAD54L (RAD54 like (S.cerevisiae)) and RAD51A (RAD51 
homolog (RecA homolog, E. coli) (S. cerevisiae)).  
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PALB2 is a binding partner of BRCA2 and as such was assessed for mutations within 
BRCA1/2 mutation negative breast cancer families. Truncating mutations were identified in 
1% (10/923) of assessed families, conferring a 2-3 fold higher risk of breast cancer in PALB2 
mutated individuals (Rahman et al, 2007). PALB2 frameshift mutations have also been 
identified in Finnish breast cancer families (Erkko et al, 2007). Germline mutations of CDH1 
have been identified in a gastric cancer and early-onset breast cancer family (Guilford et al, 
1999) in addition to a lobular breast cancer patient with an affected mother but otherwise 
unaffected family (Masciari et al, 2007). Additionally, somatic mutations in lobular breast 
cancer patients have also been observed in CDH1 (Berx et al, 1997). A further BRCA1 
interacting partner, BRIP1 (BRCA1 interacting protein 1), has been shown to be mutated in 
BRCA1/2 unmutated breast cancer families (Cantor et al. 2004; Seal et al, 2006). CHEK2 
mutations were demonstrated to cause an alternative form of LiFraumeni syndrome (usually 
caused by inherited mutation of the TP53 gene), of which breast cancer is a common feature 
(Bell et al, 1999). Subsequent analysis of CHEK2 in BRCA1/2 unmutated families identified 
truncating CHEK2 mutations in 5.1% of affected individuals compared to 1.1% of unaffected 
controls (Meijers-Heijboer et al, 2002). The increased risk of breast cancer in specific CHEK2 
mutation carriers was estimated to be 2-fold greater than in CHEK2 unmutated individuals 
(The CHEK2 Breast Cancer Case-Control Consortium, 2004).  
In some cases, very infrequent mutation has been identified, for example, only one RAD54L 
mutation has been identified in 1 out of 95 analysed patients (Matsuda et al, 1999) and one 
specific RAD51A mutation has been documented in two unrelated patients with familial breast 
cancer (both patients exhibited bilateral breast cancer) (Kato et al, 2000). Interestingly, a SNP 
(singe nucleotide polymorphism) in RAD51A has also been implicated in increased breast 
cancer susceptibility. The CC homozygous allele of the 135G-C SNP in the RAD51A 5’UTR 
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has been shown to increase breast cancer susceptibility in BRCA2 mutation carriers (Wang et 
al, 2001; Levy-Lahad et a, 2001; Antoniou et al, 2007).  
Additionally, breast cancer susceptibility can occur as a component of more generic cancer 
susceptibility syndromes such as Li-Fraumeni syndrome, Ataxia Telangiectasia, Peutz-
Jehgers syndrome and Cowden syndrome. Li-Fraumeni syndrome (MIM ID 151623) is 
caused by germline mutations of the p53 gene, TP53 (Malkin et al, 1990). The syndrome 
exhibits autosomal dominant inheritance and predisposes affected individuals to multiple, 
early-onset tumours. The most common cancers forming part of Li-Fraumeni syndrome are 
soft tissue sarcomas and osteosarcomas however breast cancer, brain tumours, adrenocortical 
carcinomas and leukaemias are also common. The estimated risk of developing breast cancer 
by age 45 as a Li Fraumeni affected individual is 50-60% (Chompret et al, 2000). Cowden 
syndrome (MIM ID 158350) is caused by mutation of the PTEN tumour suppressor in about 
80% of cases (Liaw et al, 1997). Phenotypes include hamartomatous polyps of the 
gastrointestinal tract, mucocutaneous lesions and increased risk of developing cancers, the 
most common being gastrointestinal, breast and thyroid. Benign breast disease, including 
ductal hyperplasia, intraductal papillomatosis, adenosis, lobular atrophy, fibroadenomas and 
fibrocystic change are common features of Cowden syndrome in women and many go on to 
develop malignant tumours (Schrager et al, 1998). The estimated risk of Cowden syndrome 
patients developing breast cancer by the age of 70 years is 30-50% (Guénard et al¸ 2007). 
Peutz-Jeghers syndrome (MIM ID 175200) is an autosomal dominantly inherited disorder 
caused by mutations of the STK11 gene (Jenne et al, 1998). Phenotypic manifestations 
include melanocytic macules of the lips, buccal mucosa and digits, gastrointestinal 
hamartomatous polyps and various cancers including breast. The risk of Peutz-Jeghers 
syndrome patients developing breast cancer by the age of 70 has been estimated at 45% 
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(Hearle et al, 2006). Ataxia telangiectasia is an autosomal recessive disorder caused by 
mutations of ATM gene (Savitsky et al, 1995). The disease is characterised by increased 
sensitivity to ionizing radiation, progressive cerebellar ataxia, frequent infections and an 
increased susceptibility to cancer. Leukaemias are common in childhood ataxia telangiectasia 
patients and epithelial cancers, including breast cancer, are common in adulthood. ATM is 
required for the phosphorylation of CTIP, a BRCA1 associated protein, which, when 
phosphorylated, dissociates from BRCA1, allowing BRCA1 to repress GADD45, a decrease 
in ATM levels can therefore affect the amount of active BRCA1 (Li et al, 2000). Despite this, 
screening of breast cancer patients for ATM truncating mutations has not detected inactivating 
heterozygous ATM mutation as a common event. However, missense mutations have been 
identified that have been shown to affect biological activity of ATM (Scott et al, 2002) and 
that are associated with ataxia telangiectasia. The relative risk of breast cancer associated with 
these ATM mutations has been estimated at 2.37 (Ahmed et al, 2006). Table 1.1 shows breast 
cancer susceptibility genes.  
1.4.2.2 Somatic Genetic Alterations associated with Breast cancer 
Despite the number of genes where germline mutations have been described in breast cancer, 
the overwhelming majority of sporadic breast cancers do not have these germline events and 
instead genetic and/or epigenetic events are tumour acquired. The Catalogue of Somatic 
Mutations (COSMIC) database (http://www.sanger.ac.uk/genetics/CGP/cosmic/), which 
contains sequencing results for specifically selected genes, lists 1346 genes that have been 
shown to be mutated out of 25578 breast cancer samples. However, it is the frequency of 
mutation of each gene that is more relevant than the total number of genes, for instance only 
the top three genes, PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide), TP53 
and CDH1, demonstrated mutations in greater than 8% of samples (26%, 23% and 22% 
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PENETRANCE GENE/LOCUS
RELATIVE 
RISK OF 
BREAST 
CANCER 
CARRIER 
FREQUENCY
BREAST CANCER 
SUBTYPE 
OTHER CANCERS IN 
MONOALLELIC CARRIERS
SYNDROME IN 
MONOALLELIC CARRIERS 
SYNDROME IN 
BIALLELIC 
CARRIERS 
High 
BRCA1 >10 0.10% Basal (ER-negative) Ovarian
Breast and ovarian cancer 
predisposition
-
BRCA2 >10 0.10% - Ovaran, prostate
Breast and ovarian cancer 
predisposition
Fanconi 
anaemia D1 
TP53 >10 <0.1% - Sarcomas, adrenal, brain Li Fraumeni syndrome -
Uncertain
PTEN 2-10 <0.1% - Thyroid, endometrium Cowden syndrome
STK11 2-10 <0.1% - Gastric Peutz-Jeghers syndrome  -
CDH1 2-10 <0.1% lobular Gastric - -
Intermediate
ATM 2-3 0.40% - - -
Ataxia 
telangiectasia
CHEK2 2-3 0.40% - - - -
BRIP1 2-3 0.10% - - -
Fanconi 
anaemia J
PALB2 2-4 <0.1% - - -
Fanconi 
anaemia N
Low
10q26; 
16q12; 2q35; 
8q24; 5p12
1.08-1.26 24-50% ER-positive - - -
11p15; 5q11 1.07-1.13 28-30% - - - -
2q33 1.13 0.87 - - - -
Table 1.1_Breast cancer susceptibility genes
This table lists genes known to provide an inherited predisposition to breast cancer. Genes are split into allelic penetrance of
high, uncertain, intermediate and low. The estimated relative risk of developing breast cancer is given for each gene as well
as the carrier frequency. If mutations are associated with a particular breast cancer subtype this is also provided. Inherited
cancer syndromes caused by monoallelic inheritance are given alongside other cancers that these syndromes confer
susceptibility to. Syndromes caused by biallelic inheritance are also shown. This table has been modified from Turnbull et
al, 2008.
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respectively). BRCA1 and BRCA2 are both mutated in 2%, whilst the twentieth gene, HRAS 
(v-Ha-ras Harvey rat sarcoma viral oncogene homolog), is only mutated in 1% of samples 
analysed. The top twenty most significantly mutated genes are shown in figure 1.15. They 
include well known tumour suppressor genes such as TP53, RB1, PTEN, CDKN2A, APC, 
ATM, BRCA1 and BRCA2 all of which have already been mentioned, and all except CDKN2A 
and APC are involved in inherited breast cancer susceptibility syndromes (section 1.4.2.1). 
The remaining genes in this list include well known oncogenes such as KRAS (v-Ki-ras2 
Kirsten rat sarcoma viral oncogene homolog), BRAF (v-raf murine sarcoma viral oncogene 
homolog B1) and NRAS (neuroblastoma RAS viral (v-ras) oncogene homolog) (COSMIC - 
http://www.sanger.ac.uk/genetics/CGP/cosmic/).  
Recent genome wide sequencing studies have identified an average of 80-90 genes mutated 
per genome in breast and colorectal cancers (Sjöblom et al, 2006; Wood et al, 2007). Also, 
sequencing of a primary basal-like breast cancer, associated brain metastasis sample and 
xenograft model produced from the primary cancer identified 50 novel somatic point 
mutations and small insertions and deletions, 28 large deletions, 6 inversions and 7 
translocations within this single patient (Ding et al, 2010). Although many of the mutations 
observed in the localised primary breast tumour were maintained throughout progression to 
the distant brain metastasis, many were also lost, providing a smaller range of mutations, 
suggesting only cells carrying a subset of the original mutations metastasize (Ding et al, 
2010). A similar study in a lobular breast cancer sample and associated metastasis sample 
produced similar results (Shah et al, 2009). The spectrum of mutations in breast cancer 
appears to be slightly different to prostate and colorectal cancers, which has been suggested to 
indicate a different DNA repair mechanism in normal breast tissue (Jones et al, 2008).  
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Figure 1.15_ The top 20 most significant genes somatically mutated in breast cancer
This graph illustrates the number of samples analysed (red bars at the back) and the number of samples found to be
mutated (blue bars at the front) for each of the top 20 most significantly somatically mutated genes in breast cancer.
This graph has been re-drawn from COSMIC.
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The COSMIC data and results from recent large sequencing studies illustrate the high 
frequency of genetic alteration in breast cancer genomes that contribute to tumourigenesis in 
sporadic breast cancers. In addition to this, multiple chromosomal rearrangements occur in 
breast cancer genomes, as exemplified by the recent study by Stephens et al (2009). 
Nevertheless, a large number of these mutations may turn out to be carrier mutations, 
unimportant in regards to tumourigenesis, and numerous tumours still lack mutation or 
chromosomal rearrangements involving major tumour suppressor genes. This seems 
indicative of other forms of genomic and epigenetic alterations being heavily involved in 
breast cancer; in the case of epigenetics this has been shown to be true.  
1.4.3 Breast cancer epigenetics and epigenomics 
Although cancer genomes are generally demethylated, hypomethylation events are generally 
associated with repeat regions rather than specific genes (Ehrich, 2009). Despite this, a 
number of recent studies have detected gene specific hypomethylation in breast cancers. IL-10 
(Interleukin 10) methylation has been demonstrated to be present in 59% of normals and 30% 
of tumours; this decreased methylation in tumours was also shown to correlate with higher 
expression levels (Son et al, 2010) and the MDR1 (multidrug reistance 1) gene promoter has 
been shown to be hypomethylated in 47% of tumours and 44% of associated patient serum 
(Sharma et al, 2010). Additional genes include FEN1 (flap structure-specific endonuclease 1), 
NAT1 (N-acetyltransferase1) and CDH3 (cadherin 3) (Singh et al, 2008; Kim et al, 2008; 
Paredes et al, 2005). A recent study has illustrated one of the potential implications of 
genome wide hypomethylation whereby the TLR9 (Tol-like receptor 9) gene binds to 
unmethylated DNA and so becomes increasingly expressed in cells showing greater overall 
hypomethylation levels. TLR9 gene expression was greatest in hormone receptor negative 
cancers suggesting that these cancers may have the greatest level of hypomethylation. It was 
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also demonstrated that TLR9 expression enhanced the migratory ability of cells (Berger et al, 
2010).  
Nonetheless, the number of genes demonstrated to be hypermethylated in breast cancer is 
substantially larger and constantly increasing. Use of the search term ‘breast cancer 
methylation’ in PubMed produces over 1500 hits and searching the PubMeth website 
(http://www.pubmeth.org/ - a slightly outdated website aiming to catalogue published 
methylated genes in various cancers) for genes methylated in breast cancer gives what is 
likely to be a large underestimate of 100 genes. Combined with the plethora of recent genome 
wide studies, which often publish lists of tens or hundreds of candidate methylated genes at a 
time, it is not feasible to discuss or even provide a table of all methylated genes in breast 
cancer. However, classical tumour suppressor genes and commonly methylated genes such as 
CCND2 (cyclin D2), CDKN2A (cyclin dependent kinase inhibitor 2A), BRCA1 (breast cancer 
1), APC (adenomatous polyposis coli), RASSF1A (Ras association (RalGDS/AF-6) domain 
family member 1 isoform A) and RARβ (retinoic acid receptor β) have all been shown to be 
hypermethylated in breast cancer. CDKN2A is a cell cycle regulator and potent tumour 
suppressor, causing familial melanoma when mutated in the germline (Hussussian et al, 
1994). As previously mentioned, methylation of CDKN2A was one of the first tumour 
suppressor genes to be shown to be inactivated by hypermethylation in numerous cancers, of 
which breast cancer was one (Herman et al, 1995). Since there is no evidence of CDKN2A 
methylation in DCIS samples, it is likely to be an event occurring during the progression of 
invasive ductal carcinomas (Muggerud et al, 2010). Another cell cycle regulator, CCND2, is 
frequently methylated in breast cancer; methylation has been observed at a frequency of 46% 
in breast cancers and correlates with low expression at the mRNA and protein levels (Evron et 
al, 2001). In addition, frequent methylation has also been observed in DCIS (Evron et al, 
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2001), suggesting CCND2 methylation is an early event that could contribute towards the 
initiation of breast carcinogenesis. The role of BRCA1 in breast cancer has already been 
discussed, but it is worth noting that in sporadic cases, BRCA1 inactivation is sometimes 
achieved via promoter hypermethylation, however this a rare event, occurring in 
approximately 13% of cases, although there seems to be some bias for BRCA1 methylation 
occurring in medullary breast carcinomas (Dobrovic et al, 1997; Esteller et al, 2000b). APC is 
a tumour suppressor gene involved in Wnt signalling inhibition which causes familial 
adenomatous polyposis (FAP) when mutated (Groden et al, 1991), and has been shown to be 
tumour-specifically methylated in 36% of breast cancers (Jin et al, 2001). RASSF1A¸which 
will be discussed in more detail in section 1.5, has been shown to be methylated in 62% of 
breast cancers (Dammann et al¸ 2001). RARβ is a commonly methylated gene in many 
cancers, including invasive and in situ breast carcinomas (Fackler et al¸ 2003). The most 
heavily analysed genes for methylation in breast cancer (according to PubMeth) are shown in 
figure 1.16.  
In breast cancer, numerous recent studies have started to investigate the importance of the 
epigenome and to give insight into the role of global methylation differences in association 
with breast cancer subtypes and clinical features. A study in 2009 used a microarray approach 
to identify methylation events in 241 breast tumours, identifying a set of 14 methylated genes 
that associated with a shortened time before the occurrence of distant metastases (Hartmann et 
al, 2009). A set of 4 of these methylated genes showed promise as biomarkers of prognosis 
and identification of the patients that could benefit from most severe treatments (Hartmann et 
al, 2009). In a recent study by Bediaga et al (2010) using the Illumina GoldenGate 
Methylation Cancer Panel I (Illumina, San Diego, CA, USA) array, genes were identified 
where methylation status associated with the basal-like subtype, including HOXA9 (homeobox 
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Figure 1.16_Methylation of the top 20 most analysed genes in breast cancer
This graph shows the top 20 most analysed genes in breast cancer for DNA methylation. The data for this graph was
obtained from PubMeth (www.pubmeth.org). The number of samples analysed is represented by red bars at the back and
the number of samples where methylation was detected is indicated by blue bars at the front. The frequency of
methylation for each gene is shown as a percentage. These percentages are given by PubMeth as a average of that
observed in numerous studies therefore the percentages given may differ from that quoted elsewhere in the text.
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A9) and SOX1 (SRY (sex determining region Y)-box 1), and genes where methylation status 
associated with the luminal B subtype, including RASSF1A, FGF2 (fibroblast growth factor 2 
(basic)), and NPY (neuropeptide Y) (Bediaga et al, 2010). The authors suggest that novel 
methylation profiles of relatively small numbers of genes would be of use in classifying 
tumours within a particular subtype. Another study using the Illumina GoldenGate method 
identified individual genes associated with particular clinical features and that the DNA 
methylation profiles were influenced by tumour size and alcohol and folate intake 
(Christensen et al, 2010). Further evidence for subtype specific methylation alteration was 
demonstrated in Holm et al (2010), where the authors again assessed quantitative methylation 
levels using the Illumina GoldenGate method in 189 breast tumours. In this panel of cancer 
related genes, approximately 31% of all analysed CpGs (approximately two per gene) were 
affected by tumour specific changes. Methylation based cluster groups organised samples 
primarily based on ER status, with subgroups sitting together within these ER based clusters. 
The greatest increases in methylation were observed in luminal B subtype tumours and the 
lowest in basal-like tumours. The authors were also able to demonstrate correlation with 
increased gene methylation and decreased mRNA expression (Holm et al, 2010). A recent 
genome-wide familial study of 33 BRCA1/BRCA2 or BRCAn breast cancer cases clustered 
samples based on mutation status, with BRCA1 mutated samples clustering together and 
BRCA2/BRCAn mutated samples clustering together. BRCA1 mutated cancers were 
significantly more methylated that BRCA2 or BRCAn mutated samples. In these familial 
samples, mutation status was the overriding factor associating with differing methylation 
levels (Flanagan et al, 2010). These results suggest that BRCA1 mutated samples may be 
more prone to developing changes in methylation although mechanisms behind this are not 
yet clear. The field of epigenomics is expanding at a rapid rate with more and more platforms 
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available for the investigation of the global levels of CpG island and genome methylation 
which will aid in further elucidation of methylation changes in breast cancer.  
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1.5 THE RASSF FAMILY  
The RASSF gene family currently consists of ten members (RASSF1-10) and represents a 
family of genes with tumour suppressor properties that are often downregulated in cancers as 
a result of hypermethylation. They encode proteins of the RASSF protein family which is 
characterised by the presence of a Ras-association (RalGDS/AF-6) domain (RA domain), 
although it should be noted that not all RA-domain proteins are RASSF family members. The 
family was originally defined as having both an RA domain and a SARAH (Sav-RASSF-
Hpo) domain. However, a new subsection of the RASSF family, described as an evolutionary 
distinct group of RASSF proteins, have recently been described that lack the SARAH domain 
(Sherwood et al, 2008). The family is now split into two groups; the classical RASSFs 
(RASSF1-6) and the N-terminal RASSFs (RASSF7-10), defined by the position of the RA-
domain and the presence/absence of a SARAH domain. Classical RASSFs contain an RA-
domain and a SARAH domain at their C-terminus. RASSF1 and RASSF5 also contain a C1 
(phorbol esters/diacylglycerol binding) domain (Richter et al, 2009). The N-terminal RASSFs 
differ from the classical RASSFs by the lack of a SARAH domain and positioning of the RA-
domain at the N-terminus (Sherwood et al¸ 2008) (figure 1.17). RA domains are characteristic 
of Ras-effectors and Ras-related-GTPases (Ponting et al¸1996). SARAH domains are 
involved in homo/heterodimerisation (Scheel et al, 2003). No enzymatic activity is known for 
the RASSFs, they are considered to most likely act as scaffolds for larger multi-protein 
complexes (Pfeifer et al, 2010).  
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Figure 1.17 Major isoforms of RASSF family members 
This figure shows the relative positions and sizes of functional 
domains within the major isoforms of RASSF proteins 1-10. 
This figure was redrawn and modified from Richter et al, 2009. 
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1.5.1 Mechanisms of tumour suppressor effects  
Multiple functions of the RASSFs contribute to their tumour suppressor protective effects. 
The presence of an RA-domain means that RASSFs have the potential to act as RAS 
effectors, although functioning as such has not been confirmed for all members of the family. 
RAS genes are a family of oncogenes that when active in their GTP-bound form are 
responsible for transcriptional upregulation of certain genes, often resulting in cell 
proliferation (Malumbres et al¸ 2003). In addition, RAS genes have an additional mechanism 
of apoptotic protection by interacting with the PI3K (phosphoinositide 3-kinase) pathway 
(Malumbres et al¸ 2003). Binding of RASSFs to RASs has been shown to have an inhibitory 
effect on RAS activity and RASSFs 1A, 1C, 2, 4 and 5 have been shown to use this 
mechanism to mediate some of their apoptotic effects (Ortiz-Vega et al¸ 2002; Vos et al¸ 
2000; Vos et al, 2003a; Eckfield et al¸ 2004; Vos et al, 2003b). RAS genes are frequently 
mutated in multiple tumour types and in pancreatic, colorectal and endometrial cancers, 
RASSF1A methylation has been shown to be lower in samples with K-RAS mutations 
(Dammann et al, 2003; van Engerland et al, 2002; Kang et al, 2006), suggesting dual 
mechanisms for increased cell proliferation of cancer cells by this mechanism.  
As mentioned, classical RASSFs contain a SARAH (SALVADOR-RASSF-HIPPO) domain. 
SALVADOR and HIPPO are part of the SWH (Salvador/Warts/Hippo) pathway in 
Drosophila melanogaster. This pathway is involved in cell and tissue size and is capable of 
tumour suppressor effects when activated by inhibiting the transcriptional activity of the 
downstream member of the pathway, Yorkie (human homologue YAP1) (see section 6.2 for 
more information on the SWH pathway). The D.melanogaster orthologue of RASSF has been 
shown to inhibit Hippo activity by competing with Salvador (Polesello et al, 2006). Human 
homologues of Salvador, Warts and Hippo are SAV1, LATS1/2 and MST1/2 respectively. 
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RASSF members 1A, 1C, 2, 3, 4 and 5 have all been shown to bind with MST1 and in some 
cases, MST2 also, upon binding MST1/2 pro-apoptotic signals are activated (Praskova et al, 
2004; Guo et al, 2007; Eckfield et al, 2004; Khokhlatchev et al, 2002).  
RASSFs have been associated with inducing/promoting apoptosis by many mechanisms. 
Results from various studies have implicated interactions of RASSF1A with multiple proteins 
to bring about apoptosis including CNK1, C19ORF5, MOAP-1, MST1, RAS, RASSF5 (Vos 
et al, 2006; Rabizadeh et al, 2004; Liu et al, 2005). RASSF1C, RASSF2, RASSF4, RASSF5 
and RASSF6 have also been shown to promote apoptosis (Kitagawa et al, 2006; Vos et al, 
2003b; Akino et al, 2005; Eckfield et al, 2004; Khokhlatchev et al, 2002; Ikeda et al, 2007). 
RASSF1A has also been implicated in cell cycle control (Agathanggelou et al, 2003; 
Shivakumar et al, 2002; Deng et al, 2008).  
1.5.2 The Classical RASSFs and promoter hypermethylation  
RASSF1 is located on chromosome 3p (3p21.3) and was discovered due to it being within a 
commonly deleted region of lung cancer (Dammann et al, 2000). Although seven RASSF1 
isoforms have been described (RASSF1A – RASSF1G), only RASSF1A and RASSF1C have 
known biological activity (Richter et al, 2009). RASSF1A and RASSF1C contain 6 and 5 
exons respectively and are transcribed by separate promoters, both of which contain CpG 
islands. The initial study by Dammann et al (2000) identified hypermethylation of RASSF1A 
in 40% primary lung tumours. Since then, a large number of studies have described frequent 
methylation of RASSF1A in numerous cancer types including primary breast tumours 
(Dammann et al, 2001), primary renal cell carcinoma (Morrissey et al, 2001), primary 
colorectal tumours (van Engerland et al, 2002) and primary glioma tumours (Hesson et al, 
2004). Many subsequent studies have confirmed these results and shown frequent methylation 
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of RASSF1A in many other tumour types and found diagnostic and prognostic potential of 
RASSF1A methylation status (see Hesson et al, 2007 for a review and references therein). 
RASSF1A is ubiquitously expressed in normal tissue but frequently downregulated in multiple 
tumour types (Dammann et al, 2000; Agathanggelou et al, 2005). Hypermethylation of 
RASSF1 appears to be specific of the RASSF1A CpG island (Dammann et al, 2000; Burbee et 
al, 2001).  
RASSF2, located at 20q13, exists as two isoforms, RASSF2A and RASSF2C, of which only 
RASSF2A is transcribed from a CpG island region. Promoter hypermethylation of the 
RASSF2A CpG island and subsequent downregulation of RASSF2A has been associated with 
multiple tumours, including colorectal (Hesson et al¸2005; Akino et al, 2005; Park et al, 
2007), gastric (Endoh et al, 2005), nasopharyngeal (Zhang et al, 2007) and thyroid cancers 
(Schagdarsurengin et al, 2010).  
RASSF3 is located at 12q14.2, has five exons and is transcribed as a single isoform from a 
CpG island region. Promoter hypermethylation of RASSF3 has not been detected in any of the 
cancers studied to date nor has downregulation been observed in cancer cell lines (Hesson et 
al, 2005).  
As with the other classical RASSFs, RASSF4 is transcribed from a CpG island region. It is 
located on chromosome 10 (10q11.21) and contains 11 exons. RASSF4 mRNA has been 
detected in most normal tissues but downregulated in many cancer types (Eckfield et al¸ 
2004). Hypermethylation has been demonstrated for RASSF4 in kidney, lung and breast 
cancer cell lines and in the respective primary tumours (Eckfield et al, 2004). In addition, 
downregulation resulting from hypermethylation can be reversed using 5-aza-2’-deoxycitidine 
treatment and over-expression of RASSF4 has been shown to be capable of inhibiting growth 
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and inducing apoptosis in cancer cell lines, suggesting biological relevance of RASSF4 
hypermethylation (Eckfeld et al, 2004).  
There are three RASSF5 isoforms, RASSF5A-RASSF5C, of which all are transcribed from 
CpG island regions. RASSF5A and RASSF5B are transcribed from a 1208 bp CpG island 
region containing 135 CpGs whilst RASSF5C is transcribed from a smaller, 511bp CpG island 
region containing 60 CpGs. RASSF5 was originally named NORE1 (Novel Ras Effector 1) and 
is sometimes still referred to as such. Confusingly, RASSF5A is known as NORE1A whilst 
RASSF5C is known as NORE1B. Both RASSF5A and RASSF5C are expressed in most normal 
tissues (Tommasi et al¸ 2002) and have been extensively studied for promoter 
hypermethylation. It appears to be a rare event in the cancers analysed to date and any 
methylation detected appears to be predominantly in RASSF5A rather than RASSF5C 
(Tommasi et al, 2002; Hesson et al, 2003). The highest frequency of RASSF5A methylation 
detected in primary tumours to date is in lung cancer, in which methylation was present in 
24% of samples and specific for the NSCLC subtype (Hesson et al, 2003). Whilst methylation 
is uncommon, downregulation has been demonstrated in some cancer cell lines (Tommasi et 
al, 2002).  
RASSF6 is located at 4q13.3 and is transcribed from a small 214bp CpG island region 
containing 20 CpGs. RASSF6 promoter hypermethylation is a rare occurrence, having been 
only observed frequently in childhood acute lymphocytic leukaemias (ALL) but none of the 
solid tumours analysed to date (Hesson et al, 2009). 
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1.5.3 The N-terminal RASSFs  
1.5.3.1 RASSF7  
RASSF7 is located at 11p15.5 and is transcribed from a promoter region containing a 1015bp 
CpG island with 115 CpGs. Originally named HRC1 (HRAS1 related cluster protein 1), the 
RASSF7 gene produces three transcripts from alternative splicing resulting in varying C-
terminal ends. All three protein variants contain an RA domain at their N-termini. 
Hypermethylation of the RASSF7 CpG island has been searched for in a large number of 
various cancer cell lines but no methylation has been identified (Recino et al, 2010). Selected 
cancer cell lines were also sequenced for mutations but to no avail (Recino et al, 2010). 
However, unusually for a RASSF family member, upregulation of RASSF7 has been observed 
in several cancers, including pancreatic ductal carcinoma, endometrial cancer and clear cell 
ovarian cancer (Brandt et al¸ 2007; Friess et al¸ 2003; Logsdon et al, 2003; Lowe et al¸ 2007; 
Mutter et al¸ 2001; Tan et al, 2009). RASSF7 has been shown to have roles in cell growth, 
apoptosis and mitotic progression (Sherwood et al, 2008; Recino et al, 2010; Hitomi et al¸ 
2008; Goshima et al¸ 2007).  
1.5.3.2 RASSF8  
Located at 12p12.3, RASSF8 contains 6 exons that are alternatively spliced to form four 
predicted variants, giving rise to two isoforms of 419 and 392 amino acids, each containing an 
RA domain at its N-terminus. RASSF8 is unbiquitously expressed in normal tissue (Lock et 
al, 2010). The UCSC genome browser does not recognise a CpG island at the 5’ end of 
RASSF8, however use of the EBI (European Bioinformatics Institute) CpG plot program 
detects a CpG island of 1201bp containing 182 CpGs situated upstream of and including the 
transcritption start site of RASSF8. CoBRA analysis of this region has been carried out in 
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numerous solid tumour cancer cell lines but no methylation has been found (Lock et al, 
2010). Methylation was observed in 33% of leukaemia cell lines, although this proved to be 
infrequent when analysed in leukaemia patient samples (10% in childhood T-ALL and 9% in 
childhood B-ALL) (Hesson et al, 2009). Despite the lack of methylation detected in RASSF8, 
significant downregulation has been observed in lung cancer, and, when re-introduced to 
RASSF8 deficient cells, RASSF8 is able to inhibit anchorage-independent growth (Falvella et 
al, 2006). Knockdown of RASSF8 in expressing lung tumour cell lines results in increased 
anchorage-independent growth and loss of contact-dependent growth inhibition (Lock et al, 
2010). RASSF8, therefore, behaves much like a classical RASSF family member in terms of 
tumour suppressor properties despite the lack of hypermethylation in cancers. The 
mechanisms by which this loss occurs remain to be elucidated.  
1.5.3.3 RASSF9  
RASSF9 was previously known as P-CIP1 (PAM COOH-terminal interactor-1) and is located 
at 12q21.31. It is a two exon gene producing a 435 amino acid protein. Neither the UCSC 
genome browser nor the EBI CpG plot program were able to detect a CpG island located at or 
near the 5’ end of RASSF9. Little is known about RASSF9 function, but it is predicted to be 
widely expressed and the RASSF9 protein has shown preferential binding to N-RAS and K-
RAS (Rodriguez-Viciana et al, 2004).  
1.5.3.4 RASSF10  
RASSF10 (previously known as LOC644943), located at 11p15.2, is the latest member of the 
RASSFs to be described and was identified through sequence homology to RASSF9 
(Sherwood et al, 2008). Human genome browsers described RASSF10 (LOC644943) as a two 
exon gene producing a 615 amino acid protein. Previous work in this laboratory identified an 
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alternative transcription start site that would result in a single exon gene producing a 507 
amino acid protein along with 5’ and 3’ UTRs (untranslated regions) which were not 
described in human genome browsers (Hesson et al, 2009). Expression of RASSF10 has since 
been shown in multiple tissues (Hesson et al, 2009; Schagdarsurengin et al, 2009) and, as 
already mentioned, promoter region hypermethylation has been shown in childhood ALL and 
thyroid cancers (Hesson et al, 2009; Schagdarsurengin et al, 2009). Little else is known about 
RASSF10 but the diverse nature of leukaemia and thyroid cancer suggests RASSF10 may play 
a general role in tumour suppression like classical RASSF family members.  
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1.6 THE SWH PATHWAY  
The Salvador/Warts/Hippo (SWH) pathway interacts with the classical RASSF family 
members via their SARAH domain. Deregulation of the SWH pathway by multiple 
mechanisms, RASSF downregulation included, is common in many cancers (Pan, 2010). A 
new member of the family, KIBRA (kidney and brain protein) has recently been described 
(Yu et al, 2010; Genevet et al, 2010) and presents a new and interesting target for 
investigation. There are many facets to the SWH pathway that could, and have been, 
discussed in great depth (Pan, 2010; Grusche et al, 2010), however a brief summary of the 
pathway should elucidate its importance and the importance of finding a new member.  
The Salvador/Warts/Hippo (SWH) pathway was discovered in Drosophila melanogaster as a 
modifier of growth (Tapon et al, 2002). Loss of function of the originally identified core 
SWH members results in an overgrowth phenotype exhibiting high proliferation and low 
levels of apoptosis (Justice et al¸1995; Tapon et al, 2002; Wu et al, 2003; Lai et al, 2005). 
This function has since been shown to be conserved in mammals. As a result, the SWH 
pathway is capable of affecting tissue and organ size, making disruption of the pathway a 
target for tumourigenesis. Members of the pathway can be loosely classified as either core 
components, upstream members or downstream members Although the classification of genes 
into these groups sometimes differs, for the purposes of this introduction, the core 
components will be considered as Sav, Warts, Hippo and Mats.  
1.6.1 Core SWH components  
There are four members of the pathway in Drosophila melanogaster considered core 
components; two serine/threonine kinases, Warts (Wts) and Hippo (Hpo) and two adapter 
proteins, Mob as tumour suppressor (Mats) and Salvador (Sav) (Justice et al¸1995; Tapon et 
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al, 2002; Wu et al, 2003; Lai et al, 2005). These four members exist as six respective 
homologues in Homo sapiens; two paired serine/threonine kinases, LATS1/2 and MST1/2,  
and two adapter proteins, MOBKL1A/B and SAV1 (Tao et al, 1999; Yabuta et al, 2000; 
Harvey et al, 2003; Tapon et al, 2002; Lai et al, 2005).  
Core components are involved in control of cell growth, proliferation and apoptosis via 
inactivation of the downstream transcriptional co-activator Yorkie (Yki), human homologues 
YAP1 and TAZ (Grusche et al, 2010).  
1.6.2 Downstream SWH pathway members  
The main downstream member of the SWH pathway, through which all regulation is currently 
known to occur, is Yki (human homologues YAP1 and TAZ). Yki is a transcriptional co-
activator and mediates its effects by binding to DNA-binding transcription factors, such as 
Scalloped (human homologues TEAD1-4) (Wu et al  ¸ 2008). Potential targets of Yki include 
Diap1 (human homologue BIRC2), Cyclin E (human homologue CCNE1) and Bantam (Bam) 
(human homologue unknown). Diap1 is thought to confer resistance to apoptosis, Cyclin E is 
thought to mediate ectopic proliferation and the Bantam locus encodes a miRNA capable of 
inhibiting apoptosis and promoting growth; however little is currently known about its target 
genes (Harvey et al, 2007).  
1.6.3 Upstream SWH pathway members  
There are many upstream members of the SWH pathway known to regulate the core SWH 
components and novel modifiers are frequently being identified. Currently, upstream 
members can be split into those that signal via Fat (human homologue FAT1-4), those that are 
part of the Kibra-Expanded-Merlin complex and those that are apico basal polarity proteins 
(Grusche et al, 2010). Activation of these members/pathways results in activation of Hpo by 
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phosphorylation, which in turn phosphorylates Sav, Mats and Warts. This results in 
inactivation of Yki by phosphorylation culminating in repression of its transcriptional targets 
and subsequent reduction in cell number, hence controlling tissue and organ size.  
Figure 1.18 shows a schematic of the SWH pathway. It can be seen from this diagram that the 
pathway is more intricate than discussed here, particularly in drosophila, and that there are 
multiple ways in which the activity of pathway members can be modified.  
1.6.4 The SWH pathway and cancer  
The core components of the SWH pathway were identified through drosophila screening 
experiments for tumour suppressor genes. Since then, deregulation of the human/mammalian 
SWH pathway has been observed in several cancer types.  
Mechanisms include mutations (Mer/NF2 in neurofibromatosis 2 and MOBKL11 in 
melanoma and mouse mammary carcinoma), deletions (SAV1 in RCC cell lines), 
hypermethylation (MST1/2 in soft tissue sarcoma and LATS1/2 in astrocytoma and breast 
cancer) and general downregulation (MOBKL1 in colorectal and lung and Mst1/2 in colorectal 
and prostate cancers) (Rouleau et al, 1993; Lai et al, 2005; Tapon et al, 2002; Seidel et al, 
2007; Jiang et al 2006; Takahashi et al, 2005; Kosaka et al, 2007; Sasaki et al, 2007). All of 
the above mechanisms result in inactivation of the relevant genes. In contrast, the YAP1/TAZ-
TEAD transcription factor complex is considered to have oncogenic properties. Locus 
amplification has been observed in many types of mouse and human cancers and YAP1 
overexpression has been observed in many cancers including lung, medulloblastomas and 
esophageal (Dai et al, 2003; Fernandez-L et al¸2009; Imoto et al, 2001). In addition, both 
TAZ and TEAD have shown either locus amplification and/or gene upregulation in a smaller 
variety of cancers; TAZ overexpression has been observed in breast cancer (Chan et al, 2008) 
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Figure 1.18 SWH pathway  in drosophila and mammals 
This figure has been taken from Pan, 2010. It nicely shows the complex 
interactions in the SWH pathway for both drosophila and mammals. 
Due to the complexity of the pathway, not all genes in the drosophila 
pathway have been discussed.  
87 
 
whilst TEAD4 amplification has been observed in ovarian and fallopian tube carcinomas 
(Nowee et al, 2007). Both downregulation of SWH pathway members upstream of YAP1 and 
upregulation of the YAP1/TAZ-TEAD complex would result in similar phenotypic activity of 
YAP1 transcriptional targets. However, there is also evidence to suggest YAP1 is capable of 
acting as a tumour suppressor by promoting apoptosis via p73 (Yuan et al, 2008; Basu et al, 
2003). It is thought these conflicting effects of YAP1 may be reliant on cellular context (Pan, 
2010).  
KIBRA (kidney and brain protein), also known as WWC1 (WWC and C2 domain containing 
1), was only recently described as an SWH pathway member and has been shown to function 
in a tumour suppressor capacity in drosophila melanogaster (Yu et al, 2010; Genevet et al, 
2010). KIBRA therefore represents a good candidate gene for genetic analysis, including 
hypermethylation analysis, in various cancers.  
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1.7 RESEARCH AIMS  
Hopefully this introduction has highlighted the reasons why the identification of 
hypermethylated genes in cancer can be of use both scientifically and clinically within the 
cancer research field and how identification of such genes can be achieved. Broadly, the aims 
of this thesis are to identify hypermethylated genes in cancer to aid in this research. The main 
focus will be on sporadic breast cancer, using two approaches;  
(i) To use the Methylated CpG Island Recovery Assay (MIRA), a genome wide 
affinity pull-down approach, coupled with CpG island microarrays, on 5 breast 
cancer cell lines. To analyse the data from this approach to identify a list of 
frequently hypermethylated genes in cell lines that can then be used to selectively 
screen sporadic breast cancer patient samples for novel frequently 
hypermethylated genes.   
(ii) To use the Illumina Infinium HumanMethylation27 BeadChip array, a direct 
quantitative microarray based assessment of DNA using single CpG specific 
probes within or within close proximity to known CpG islands, to screen a 
clinically well characterised cohort of breast cancer patient DNA samples. Clinical 
comparisons can then be made to identify differences in overall methylation 
between differing clinical features and single genes that show an association 
between methylation and particular clinical features.  
This section of this research will hopefully identify genes where the demonstration of 
hypermethylation will either be of use to those investigating the cellular basis of breast 
(and/or other cancers) or those investigating molecular markers that can be of use clinically 
for breast cancer patients.   
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The final section of this research aims to analyse potentially good candidate genes that are 
part of families or pathways already known to be involved in various cancers. Recently 
identified members of the RASSF family of tumour suppressors (RASSF10) and the SWH 
signalling pathway (KIBRA) will be analysed for hypermethylation in a range of cancers to 
enhance knowledge of members of this family and pathway that are involved in cancer. This 
research will be of use to those working in the RASSF family and SWH pathway fields and 
hopefully those working in particular cancer fields both scientifically and clinically.  
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 MATERIALS  
All primers were supplied from either Invitrogen or Alta Biosciences. All materials were 
acquired using the suppliers and product numbers cited within the text. Suppliers addresses 
are listed below:  
Alta Bioscience 
Alta Bioscience, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. 
AMS Biotechnology (Europe) Ltd.  
184 Milton Park, Abingdon, OX14 4SE, UK. 
Bioline 
16 The Edge Business Centre, Humber Road, London, NW2 6EW, UK. 
Fermentas  
Sheriff House, Sheriff Hutton Industrial Park, York, YO60 6RZ, UK. 
Invitrogen Ltd.  
3 Fountain Drive, Inchinnan Business Park, Paisley, UK, PA4 9RF, UK. 
National Diagnostics USA 
National Diagnostics USA, 305 Patton Drive, Atlanta, Georgia, 30336, UK. 
New England Biolabs 
75/77 Knowle Piece, Wilbury Way, Hitchin, Hertfordshire, SG4 0TY, UK. 
PAA Laboratories Ltd.  
Termare Close, Houndstone Business Park, Yeovil, Somerset, BA22 8YG, UK.  
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Promega Corporation 
2800 Woods Hollow Road, Madison, WI 53711-5300, USA.  
Roche Diagnostics Ltd.  
Charles Avenue, Burgess Hill, West Sussex, RH15 9RY.  
Sigma-Aldrich 
Sigma-Aldrich Company Ltd., Dorset, England, UK.  
Qiagen 
Qiagen House, Fleming Way, Crawley, West Sussex, RH10 9NQ, UK. 
 
2.2 DNA SAMPLES 
2.2.1 Cell lines  
2.2.1.1 Breast cell lines  
A total of nine breast cancer cell lines were analysed in this study; HCC1806, HCC1937, 
HCC1395, HCC1419, HCC1143, MCF-7, T-47D, MDA-MB-231 and HTB19. All HCC lines 
were kindly donated by Professor John D. Minna (Hamon Center for Therapeutic Oncology 
Research, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, 
USA). T-47D and MCF-7 were donated by Dr. Feodor Berdichevsky (Cancer Research UK 
Institute of Cancer Studies, Birmingham University, Birmingham, UK). MDA-MB-231 and 
HTB19 were already available within the laboratory. Two normal human mammary epithelial 
cell lines (NHMEC) were also used in this study and were also donated by Professor John D. 
Minna (Hamon Center for Therapeutic Oncology Research, The University of Texas 
Southwestern Medical Center at Dallas, Dallas, Texas, USA).  
92 
 
2.2.1.2 Lung cell lines 
Fourteen lung cancer cell lines were used in this study (H1993, H157, H1792, H143, H1648, 
H1155, H1299, H2122, A549, H2171, H460, H187, H838, H1395). All lung cancer cell lines 
were kindly donated by Professor John D. Minna (Hamon Center for Therapeutic Oncology 
Research, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, 
USA).  
2.2.1.3 Glioma cell lines 
Seven glioma cell lines were analysed in this study (Hs683, A172, H4, U343, T17, U87 and 
U373), all kindly provided by Prof. Dietmar Krex (Klinik und Poliklinik für Neurochirurgie, 
Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, 
Germany).  
2.2.1.4 Kidney cell lines  
Twelve renal cell carcinoma (RCC) cell lines were used in this study (SKRC18, SKRC39, 
SKRC47, SKRC54, UMRC3, UMRC2, SKRC45, 786-O, KTCL140, KTCL26, RCC4 and 
CAKI) all kindly provided by Professor Eamonn R. Maher (Medical and Molecular Genetics, 
School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, 
University of Birmingham, Birmingham, B15 2TT, UK).  
2.2.1.5 Prostate cell lines  
Five prostate cancer cell lines (DU-145, PC3, LNCaP, 22Rv1 and VCaP) were kindly donated 
by Dr. Tapio Visakorpi (Professor of Cancer Genetics, Institute of Medical Technology, 
University of Tampere, Biokatu 6, FI-33520 Tampere, Finland) for use in this study.  
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2.2.1.6 Leukaemia cell lines  
Seven leukaemia lines (JURKAT, NALM6, U937, SUP-T1, CEM, DND41 and THP1) were 
used in this study, all donated by Dr. Raffaella Chiaramonte (Department of Medicine, 
Surgery and Dentistry, Università degli Studi di Milano, via Di Rudinì 8, 20142 Milan, Italy).  
2.2.1.7 Colorectal cell lines  
Seven colorectal cancer (CRC) cell lines were used in this study (LS411, DLD1, SW60, 
SW480, 174T, HVT116 and LOVO), all kindly provided by Professor Dion Morton (Medical 
and Molecular Genetics, University of Birmingham, Birmingham, UK).  
Appendix A provides details of major cancer cell lines used in this study.  
2.2.2 Patient samples  
All primary tumour samples have been anonymised and collected following ethical approval. 
2.2.2.1 Breast tissue DNA  
Forty breast ductal carcinoma samples were provided by Dr. Ivan Bieche (Oncogenetic 
Laboratory, INSERM U 735, Centre René Huguenin, Saint Cloud, France). These samples are 
listed in table 4.1 along with the corresponding clinical features. A further twenty pairs of 
breast ductal carcinoma samples along with corresponding non-cancerous breast tissue DNA 
were also used in this study, kindly donated by Dr. Cheryl Lewis (Department of Surgery, 
University of Texas Southwestern Medical Center, Dallas, Texas, USA). Normal breast tissue 
DNA and RNA samples were purchased from AMS biotechnology (Cat.Nos: D1234086-50 
and R1234086-50 respectively). Samples were not microdissected. 
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2.2.2.2 Glioma samples  
A total of 68 primary glioma tumour DNA samples consisting of 10 WHO grade I 
astrocytomas, 10 WHO grade II astrocytomas, 10 WHO grade III astrocytomas, 20 WHO 
grade IV primary glioblastoma multiforme (pGBM) and 18 WHO grade IV secondary 
glioblastoma multiforme (sGBM), 11 of which also had available DNA from the 
corresponding earlier grade lesion. All glioma tumour DNA samples were kindly donated by 
Prof. Dietmar Krex (Klinik und Poliklinik für Neurochirurgie, Universitätsklinikum Carl 
Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany). Prof. Krex also 
generously provided 15 non-cancerous brain samples for use as a control.  
2.2.2.3 Childhood acute lymphoblastic leukaemia samples  
Seventy childhood acute lymphoblastic leukaemia (ALL) samples were provided by Dr. 
Daniel Catchpoole (The Children’s Hospital at Westmead, Locked Bag 4001, Westmead, 
NSW, 2145. Australia). A further five sets of paired childhood ALL DNAs, with DNA 
samples extracted from both diagnosis stage tissue and the disease remission stage tissue, 
were obtained from a local tissue bank. Normal bone marrow was purchased from AMS 
biotechnology.  
2.2.2.4 NSCLC tumours  
Twenty pairs of NSCLC cancerous tissue DNA and corresponding non-cancerous lung tissue 
DNA were kindly provided by Professor John D. Minna (Hamon Center for Therapeutic 
Oncology Research, The University of Texas Southwestern Medical Center at Dallas, Dallas, 
Texas, USA). Samples were not microdissected. 
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2.2.2.5 RCC tumours  
Sixteen RCC tumour samples were kindly provided by Professor Eamonn R. Maher (Medical 
and Molecular Genetics, School of Clinical and Experimental Medicine, College of Medical 
and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK) for use in this 
study. Samples were not microdissected. 
2.2.2.6 Ovarian tumours 
Twenty ovarian cancer DNA samples were kindly provided by Dr. Massimo Broggini 
(Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy).  
 
2.3 NUCLEIC ACID EXTRACTION  
2.3.1 DNA Extraction 
DNA was extracted from cell line pellets (see section 2.8.6 for cell pellet preparation) using 
the Qiagen DNeasy Blood and Tissue Kit (Cat.No. 69506). Manufacturers’ instructions were 
followed using the Spin-Column protocol for ‘Total DNA extraction from Animal blood or 
Cells’. Briefly, following pellet resuspension in 200μl PBS (phosphate buffered saline), 20μl 
proteinase K and 200μl buffer AL were added and mixed by vortexing. Samples were 
incubated at 56˚C for 10 minutes. Following this incubation period, 200μl 100% ethanol was 
added and samples were vortexed until a homogenous solution was produced. After transfer 
to a DNeasy Mini spin column with a 2ml collection tube, samples were centrifuged for 1 
minute at 11,200 x g at room temperature. Flow-through was discarded and a clean 2ml 
collection tube attached to the spin column. After the addition of 500μl buffer AW1, samples 
were centrifuged for 1 minute at 11200 x g at room temperature and again the flow-through 
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was discarded and a new 2ml collection tube attached to the spin column. 200μl buffer AW2 
was added to the column and samples centrifuged for 3 minutes at 11200 x g at room 
temperature. This final flow-though was discarded carefully to ensure that it did not come into 
contact with the membrane and the 2ml collection tube replaced with a labelled 1.5ml 
microcentrifuge tube. DNA was eluted from the membrane by adding 200μl of buffer AE 
directly to the membrane, allowing samples to incubate at room temperature for 1 minute 
followed by centrifugation at 11,200 x g for 1 minute. The extracted DNA was stored at -
20°C. 
2.3.2 RNA extraction   
RNA was extracted from cell pellets (see section 2.8.6 for cell pellet preparation) using RNA-
Bee reagent (AMS Biotechnology; Cat. No: CS-105B). Cells were first homogenised by 
resuspension of the cell pellet in 1ml RNA-Bee reagent. Samples were incubated at room 
temperature for 5 minutes prior to the addition of 200μl chloroform (200μl per 1ml RNA-Bee 
reagent), samples were then shaken vigorously for 15-30 seconds and incubated on ice for 5 
minutes. Subsequent centrifugation at 12,000 x g for 5 minutes at 4˚C separated the 
homogenate into 3 distinct phases; a lower blue phenol-chloroform phase, an opaque, white 
interphase and an upper colourless aqueous phase. The aqueous phase (containing the entirety 
of the RNA) was transferred, being careful not to disrupt the interphase layer, into a clean 
RNase free 1.5ml microcentrifuge tube. To precipitate the RNA, 500μl isopropanol (500μl per 
1 ml RNA-Bee reagent) was added, mixed and samples were allowed to incubate at room 
temperature for 5-10 minutes prior to centrifugation at 16,300 x g for 5 minutes at 4˚C. A 
visible pellet was produced and, taking care not to disturb the pellet, the supernatant was 
removed and 1ml 75% ethanol was added to the pellet. Samples were vortexed and 
centrifuged at 7,500 x g for 5 minutes at 4˚C. The supernatant was removed, again taking care 
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not to disrupt the pellet, and samples allowed to briefly air-dry before resuspension in 50μl 
RNase free water. The extracted RNA was stored at -80°C. 
2.3.3 Quantification of nucleic acid preparations 
A NanoDrop 1000 Spectrophotometer from NanoDrop Technologies was used to quantify 
DNA and RNA preparations. Initially, 2μl of the solution used to elute nucleic acids during 
preparation (i.e. buffer AE or RNase free water) was used as a reference for zero absorbance. 
2μl of undiluted nucleic acid preparation was then added to the spectrophotometer. The 
NanoDrop was set to read absorbance at 260nm and 280nm. NanoDrop output readings 
consisted of a 260/280 ratio and a ng/μl concentration. Purity of the DNA and RNA 
preparations was assessed using the 260/280 ratio; DNA was considered pure if the ratio was 
~1.8 and RNA considered pure if the ratio was ~2.0. The spectrophotometer calculated the 
ng/μl concentrations using a modification of the Beer-Lambert equation that correlates 
absorbance with concentration: c = (A*e)/b       
Where c is the nucleic acid concentration in ng/μl, A is absorbance at 260nm in AU, and e is 
the wavelength dependent extinction coefficient in ng-cm/μl for either double stranded DNA 
(50ng-cm/μl) or RNA (40ng-cm/μl). 
 
2.4 DNA MODIFICATION FOR METHYLATION ANALYSES  
2.4.1 Bisulphite modification of DNA  
The studies in this thesis used one of two methods to bisulphite modify DNA; (i) a traditional 
in-house method or, (ii) by use of a Qiagen EpiTect Bisulphite Kit (48) (Cat.No.59104). Work 
from chapter 3 (MIRA array study) was achieved using the traditional method and chapters 4, 
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5 and 6 (Illumina Inifinium array, RASSF10 and KIBRA studies respectively) using the 
Qiagen kit.  
2.4.1.1 Bisulphite modification of DNA using the traditional method 
Preparation of sodium bisulphite reagent  
Firstly, fresh sodium bisulphite reagent (3.12M sodium metabisulphite, 0.3M NaOH, 5mM 
hydroquinone, pH 5.0) was made. For 20mls, 11.86g sodium metabisulphite (Sigma; 
Cat.No.243973) was dissolved in 15mls of distilled water by heating at 100˚C with 
intermittent vortexing to ensure complete solubilisation. Once dissolved, the solution was 
made up to a total volume of 20mls with distilled water allowing for the addition of 2mls 3M 
sodium hydroxide (Sigma; Cat.No. 255556). Finally, 100μl freshly prepared 1M 
hydroquinone (Sigma; Cat.No H9003) was added in a fume hood. As both the sodium 
metabisulphite mix and hydroquinone are light sensitive all solutions were covered with foil 
at all times.  
Bisulpite conversion reaction   
1μg DNA was prepared for bisulphite conversion by the addition of 1μl 3M NaOH and the 
necessary amount of distilled water to produce a total volume of 10μl with water. Following 
incubation of the samples at 37˚C for 15 minutes, 500μl freshly prepared bisulphite reagent 
was added to each sample in a fume hood and overlaid with mineral oil to prevent evaporation 
during the subsequent steps. Samples were then incubated for 20 cycles of [99˚C for 15 
seconds followed by 50˚C for 15 minutes] in a Hybaid Omn E thermocycler. 
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Clean up of modified DNA  
Bisulphite converted DNA was purified using a Promega Wizard DNA clean-up system 
(Promega Cat.No.7280). The bisulphite conversion reactions were added to 1ml DNA clean-
up resin in a 1.5ml microcentrifuge tube, taking care to transfer as little mineral oil as 
possible. Samples were mixed by inversion and then transferred to syringe barrels attached to 
spin columns, which in turn were attached to a vacuum manifold. The DNA/resin mix was 
drawn through the spin columns using the vacuum manifold. Subsequently, 2mls 80% (v/v) 
isopropanol was added to each syringe barrel and drawn through to wash the spin columns. 
The spin columns were removed and placed in 1.5ml microcentrifuge tubes and centrifuged at 
room temperature for 2 minutes at 16,300 x g. The spin columns were placed in fresh 1.5ml 
microcentrifuge tubes and 50μl of distilled water was added to each spin column membrane 
followed by a 5 minute incubation at room temperature. Samples were centrifuged at room 
temperature for 1 minute at 16,300 x g to elute the DNA from the column and 5μl 3M sodium 
hydroxide was added to each sample and allowed to incubate for 10 minutes at room 
temperature. To precipitate the DNA, 5μl sodium acetate and 125μl 100% ethanol was added 
to each sample followed by an overnight incubation at -20˚C. Samples were centrifuged at 
room temperature for 30 minutes at 16,300 x g, the supernatant was discarded and samples 
were washed with 100μl 70% (v/v) ethanol. Samples were again centrifuged at room 
temperature for 1 minute at 16,300 x g followed by removal of the supernatant prior to air 
drying and resuspension in 50μl distilled water. Eluted DNA was ready for use at a 
concentration of approximately 20ng/μl and was stored at -20°C.  
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2.4.1.2 Bisulphite modification of DNA using the Qiagen EpiTect Kit  
Aliquots of bisulphite mix were dissolved in 800μl RNase-free water and vortexed until 
completely dissolved. The bisulphite reaction was prepared for 1μg DNA by addition of 
RNase-free water to a total volume of 20μl, followed by addition of 85μl bisulphite mix. 35μl 
of green DNA protect buffer was added to each sample and pipetted up and down until a 
homogenous blue colour change was produced, indicating sufficient mixing and correct pH. 
The bisulphite reaction was carried out in a Perkin Elmer Gene Amp PCR system 9700 
(Applied Biosystems) thermal cycler using the conditions shown in table 2.1.  
Following the bisulphite conversion the reactions were transferred to 1.5ml microcentrifuge 
tubes and 560μl freshly prepared buffer BL containing 10μg/ml carrier RNA was added to 
each sample. Samples were then vortexed and centrifuged briefly before transfer to an 
EpiTect spin column. Samples were then centrifuged at room temperature for 1 minute at 
16,300 x g, flow-through was discarded and samples were washed with 500μl buffer BW. A 
further centrifugation step was carried out at room temperature for 1 minute at 16,300 x g. 
Flow-through was discarded and samples desulphonated by incubation at room temperature 
for 15 minutes in 500μl buffer BD, being careful to keep the lids closed. Samples were 
centrifuged at room temperature for 1 minute at 16,300 x g. Flow-through was again 
discarded and samples washed twice with 500μl buffer BW with 1 minute centrifugation steps 
(room temperature, 16,300 x g) each time. Samples were then spun again in clean collection 
tubes at room temperature for 1 minute at 16,300 x g to remove any residual liquid prior to 
elution. Elution of bisulphite modified DNA was achieved by adding 20μl buffer EB directly 
to the column and centrifugation at room temperature for 1 minute at 16,300 x g into clean 
1.5ml microcentrifuge tubes. This elution step was repeated to increase the total yield of 
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Table 2.1_Bisulphite modification conditions for use in EpiTect kit.
Conditions are shown for bisulphite modification when using Qiagen
EpiTect kit.
Step Temperature (˚C) Time (minutes)
Denaturation 95 5
Incubation 60 25
Denaturation 95 5
Incubation 60 85
Denaturation 95 5
Incubation 60 175
Hold 20 Indefinite
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bisulphite modified DNA, to produce a final volume of 40μl. Bisulphite modified DNA was 
stored at -20°C. 
 
2.5 COMBINED BISULPHITE RESTRICTION ANALYSIS (CoBRA) AND 
METHYLATION SPECIFIC PCR (MSP) 
2.5.1 CoBRA primer design  
In chapters 3, 5 and 6 (MIRA array, RASSF10 and KIBRA studies respectively), CoBRA 
primers were designed to be within a UCSC defined CpG island and situated upstream of, and 
in some cases, incorporating the transcription start site. However, for the work in chapter 4 
(Illumina Infinium array study) primers were specifically designed to be around the 
methylated probe within the array (where possible), irrelevant of its position within the CpG 
island. 
All CoBRA primers used in this thesis were designed manually for this study unless otherwise 
stated. The CoBRA PCR was initially carried out using semi-nested primers in all cases 
unless the PCR yield was poor or non-specific, in which case fully nested primers were 
designed and used. To maximise the effectiveness of the CoBRA primers two important 
factors were incorporated into the design of the primers; (i) the most specific region, the 
3’end, of forward and reverse primers, were designed to be situated at ACC or CAC genomic 
sites, becoming ATT or TAT in forward primers and TAA or ATA in reverse primers, and (ii) 
the central primer sequence ideally contained a string of genomic C nucleotides, becoming T 
in forward primers and A in reverse primers. This should provide a strong initial binding point 
and a high specificity to bisulphite modified DNA. It was important to ensure that CoBRA 
primers were unbiased towards methylation status. For this reason, the incorporation of CG 
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dinucleotides within the primer were avoided wherever possible, however if this was not 
possible C nucleotides were ordered as Y (designating a 50:50 ratio of C or T nucleotide 
incorporation) in forward primers, and R (designating a 50:50 ratio of G or A nucleotide 
incorporation) in reverse primers. The incorporation of BstUI restriction sites (CGCG) or 
TaqαI restriction sites (TCGA) within primers were strenuously avoided. Annealing 
temperatures of primers were calculated using the following equation: [(41 x GC)/N]  + [64.9-
(600/N)] where GC is the total number of C and G nucleotides in the primer sequence (Y and 
R counted as 0.5) and N is the total number of nucleotides within the primer. CoBRA primer 
sequences used in chapters 3, 4, 5 and 6 of this thesis are shown in appendices B.I, C.I, D.I, 
and E.I, respectively.  
2.5.2 CoBRA PCR  
All CoBRA assays consisted of using semi or fully nested primers and therefore two rounds 
of PCR were carried out per assay. Both primary and secondary reactions contained 1x 10X 
buffer (500mM Tris-HCL (pH 8.3), 100Mm potassium chloride, 50mM ammonium sulphate), 
2mM magnesium chloride, 2.5mM dNTP mix, 1x 5X GC-RICH solution, 0.8μM forward 
primer, 0.8μM reverse primer and either 0.5ᴜ (primary reaction) or 1.0ᴜ (secondary reaction) 
FastStart Taq DNA polymerase (Roche; Cat.No.12158264001). Reactions were made up to 
25μl or 50μl for primary and secondary reactions respectively with distilled water. Primary 
reactions used 2μl (0.04μg) bisulphite modified DNA as starting material and secondary 
reactions used 5μl primary product as starting material.  
Primary CoBRA PCR programs were either a standard PCR program or touchdown PCR, see 
tables 2.2a and b for program details. All primer sequences and annealing temperatures are 
shown in appendices B.I, C.I, D.I and E.I.  
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Primary 
CoBRA
Secondary 
CoBRA
95 5 minutes 
95 1 minute
35 cycles 40 cycles annealing 1 minute 
72 2 minutes 
72 10 minutes 
Primary CoBRA Secondary CoBRA 
95 5 minutes 
95 45 seconds 5 cycles with annealing 
temperature decreasing by 1˚C 
each cycle
5 cycles with annealing 
temperature decreasing by 1˚C 
each cycle
annealing 45 seconds 
72 45 seconds 
95 45 seconds 
37 cycles 42 cycles annealing 45 seconds 
72 45 seconds 
72 10 minutes 
(a)
(b)
Table 2.2_Standard and touchdown CoBRA PCR programs
(a) A table showing the PCR conditions used for primary and secondary CoBRA reactions done
using the standard CoBRA PCR program. (b) A table showing the PCR conditions used for primary
and secondary CoBRA reactions done using the touchdown CoBRA PCR program.
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2.5.3 Agarose gel electrophoresis 
PCR products were visualised with 2% (w/v) agarose (Bioline; Cat. No. BIO-41025) gels 
containing ethidium bromide (Sigma Aldrich; Cat. No: E8751). Gels were made by adding 
4grams agarose to 200ml of 1X TBE (Tris-Borate-EDTA) diluted from 10X TBE (National 
Diagnostics Cat. No.EC-860) and heated until dissolved. Once cooled sufficiently, 5μl of 
10mg/ml ethidium bromide was added to the gel to a final concentration of 0.25mg/ml and 
then poured. Gels were allowed to set at room temperature. Samples were loaded with 5% 
(v/v) loading buffer (50% glycerol, 48.5% distilled water, 1% EDTA and 0.5% Orange G). 
When loaded, DNA was migrated through the gel at 180 volts until ready to be visualised 
under UV light using a SynGene InGenius GelDoc system. 
2.5.4 Restriction digest  
A suitable volume of PCR product, between 5 and 20μl, depending on the intensity of the 
PCR band as determined by agarose gel electrophoresis (section 2.5.3) was digested with 
either BstUI (Fermentas;Cat.No ER0921) or TaqαI (New England Biolabs; Cat.No: R0149L). 
Due to the greater prevalence of CGCG sites over TCGA sites within CpG islands BstUI 
digestion was used as the primary screening method.  
BstUI digests were carried out with 1ᴜ BstUI, 1x 10X buffer R, the relevant amount of PCR 
product and made up to a total volume of 25μl with distilled water. Samples were incubated 
overnight at 37˚C.  
Samples being digested with TaqαI were incubated at 65˚C for three hours with 20ᴜ TaqαI, 
0.01μl BSA, 1x 10X NEB buffer 4, the relevant amount of PCR produce and made up to a 
total volume of 25μl with distilled water. 
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Undigested and digested PCR products were run simultaneously, alongside each other on a 
2% (w/v) agarose gel (section 2.5.3) to visualise the results.   
2.5.5 Methylation Specific PCR (MSP) 
Methylation specific PCR (MSP) and unmethylated specific PCR (USP) reactions were 
carried out with 1x 10X buffer (500mM Tris-HCL (pH 8.3), 100Mm potassium chloride, 
50mM ammonium sulphate), 3mM magnesium chloride, 2.5mM dNTP mix, 1x 5X GC-RICH 
solution, 0.8μM forward primer, 0.8μM reverse primer and 1.0ᴜ FastStart Taq DNA 
polymerase (Roche; Cat.No.12158264001). Reactions were made up to 50μl with distilled 
water. MSP and USP reactions used 3μl (0.06μg) and 4μl (0.08μg) bisulphite modified DNA 
as starting material respectively. PCR reactions were performed using the standard PCR 
program listed in table 2.2a with annealing temperatures described in appendix C.II. 
2.6 BISULPHITE SEQUENCING ANALYSIS  
2.6.1 PCR product purification  
PCR products selected for cloning were first purified from agarose gels using a Gel Extraction 
Kit (Qiagen; Cat.No. 28704). Once PCR products were resolved using standard agarose gel 
electrophoresis (see section 2.5.3) the bands were cut out of the gel using a scalpel and 
transferred to 1.5ml microcentrifuge tubes. Gel slices were weighed and 3 x mass (mg) in 
volume (μl) of buffer QG was added to samples prior to incubation at 50˚C for 10 minutes to 
dissolve the agarose gel. To ensure the agarose gel was completely dissolved intermittent 
vortexing was carried out during the 10 minute incubation. Once completely dissolved, 1 x 
mass (mg) in volume (μl) of 100% isopropanol was added to the solution and mixed. The 
solution was transferred to a QIAquick spin column and centrifuged at room temperature for 1 
minute at 16,300 x g. The flow-through was discarded and a further 500μl buffer QG added to 
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the column before a second centrifugation step as before. Flow-through was again discarded 
and 500μl buffer PE was added to the column. Samples were centrifuged once as before and 
the flow-through discarded and then centrifuged again to ensure no residual ethanol remained. 
After placing the column in a fresh 1.5ml microcentrifuge tube, 30μl distilled water was 
added directly to the column membrane and left to incubate at room temperature for 1 minute 
prior to a 1 minute centrifugation step at room temperature to elute the purified DNA from the 
column. The purified PCR product was either used immediately or stored at -20°C. 
 2.6.2 Ligation of PCR products into plasmid vector  
The pGEM-T Easy vector system (Promega; Cat.No. A1360) was used to introduce PCR 
products into bacterial cells for cloning. The ligation reaction was set up with 0.5μl pGEM 
vector, 1μl T4 DNA ligase and 5μl 2X ligation buffer. This was then added to 3.5μl purified 
PCR product. Samples were left to incubate at 4˚C overnight for maximum ligation 
efficiency. A plasmid map for the pGEM-T easy vector is shown in figure 2.1.  
2.6.3 Transformation of bacterial cells with PCR product ligated into the pGEM-T easy 
vector 
Prior to the transformation reaction, LB agar plates were prepared by mixing 35g/l LB agar 
(Sigma Aldrich; Cat. No: L2897) with distilled water before autoclaving. When sufficiently 
cooled, ampicillin (Sigma Aldrich; Cat. No:H0166) was added to achieve a final 
concentration of 100μg/ml. Agar was then poured into petri dishes and allowed to set before 
transfer to 4°C for storage. 
To begin the transformation reaction, α-select silver efficiency chemically competent cells 
(Bioline; Cat.No. BIO-85026) were defrosted on ice and 40μl of the competent cells were 
aliquoted into 1.5ml microcentrifuge tubes. 4μl (10% volume of cells) of pGEM/PCR product 
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Figure 2.1_pGEM T-easy plasmid map
The above figure shows a plasmid map of the
pGEM T-easy vector used for cloning of PCR
products.
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ligation was added to each aliqout defrosted competent cells and the solution was mixed by 
gentle swirling to avoid cell damage. Samples were incubated on ice for 20 minutes prior to a 
30 second heat shock at 42˚C. Cells were then returned to ice for 2 minutes before adding 
500μl SOC media (Invitrogen; Cat.No.15544034) and incubating for one hour on a rotating 
shelf at 37˚C. During this incubation, 20μl of 50mg/ml X-gal (Bioline; Cat. No: BIO37035) 
was added to each required LB plate and allowed to dry before 200μl of each culture was 
plated out and incubated for 16 hours at 37°C. 
2.6.4 Single colony PCR  
To ensure the greatest chance of picking colonies containing the insert, only white colonies 
were picked, preferentially those surrounded by blue colonies. This is due to an intrinsic 
feature of the pGEM-T easy vector that the cloning site exists within the coding β-
galactosidase gene and successful insertion disrupts this gene. Undisrupted plasmids are 
capable of producing the β-galatosidase enzyme that can utilise the X-gal producing a blue 
by-product; thus blue colonies probably have empty plasmids while white colonies have 
inserts. Selecting a white colony surrounded by blue colonies merely suggests that plenty of 
X-gal was available to the colony therefore increasing the likelihood of picking successfully 
transformed cells. Colonies were transferred to 20μl distilled water and heated to 95˚C for 5 
minutes to rupture all the cellular membranes. Once cooled, 7μl was then used as starting 
material in a PCR reaction containing 3μl 10x buffer (500mM Tris-HCL (pH 8.3), 100Mm 
potassium chloride, 50mM ammonium sulphate), 2mM magnesium chloride, 2.5mM dNTP 
mix, 1x 5X GC rich solution, 0.8μM forward primer, 0.8μM reverse primer and 0.5ᴜ FastStart 
Taq DNA polymerase (Roche; Cat.No.12158264001) and made up to a final volume of 30μl 
with distilled water. Forward and reverse primers were designed to anneal to the pGEM 
backbone; forward primer: 5’-TAATACGACTCACTATAGGG-3; and reverse primer: 5’-
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ACACTATAGAATACTCAAGC-3’. Single-colony PCR reactions were carried out using a 
touchdown PCR as follows; 5 minutes at 95˚C, 3 cycles of [30 seconds at 95˚C, 30 seconds at 
60˚C and 30 seconds at 72˚C], 3 cycles of [30 seconds at 95˚C, 30 seconds at 58˚C and 30 
seconds at 72˚C], 34 cycles of [30 seconds at 95˚C, 30 seconds at 56˚C and 30 seconds at 
72˚C] and finally 10 minutes at 72˚C.  
2.6.5 PCR product clean-up for sequencing  
Prior to sequencing, single colony PCR products were cleaned-up using a combination of (a) 
FastAP thermosensitive alkaline phosphatase (Fermentas; Cat. No: EF0651) to remove excess 
dNTPs, and (b), ExonucleaseI (New England Biolabs; Cat. No: M0293S) to remove excess 
single stranded primer. A reaction was set up containing 10μl PCR product, 1ᴜ FastAP, 0.01ᴜ 
ExoI and 1x 10x FastAP buffer (100mM Tris-HCL (pH8), 50mM magnesium chloride, 1M 
potassium chloride, 0.02% Triton X-100 and 1mg/ml bovine serum albumin (BSA)). Samples 
were incubated for 30 minutes at 37˚C followed by an enzyme inactivation step for 20 
minutes at 80˚C.  
2.6.6 Sequencing reaction  
Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems; Cat. No: 4336917 ) 
was used for all sequencing. Following PCR clean up (see section 2.6.5) 5μl PCR  product 
was added to a reaction of 20 pmol forward or reverse primer, 0.5μl Big Dye, 2μl 5X buffer 
and made up to a total volume of 10μl with distilled water. The sequencing reaction was then 
carried out using the following program: 94˚C for four minutes followed by 35 cycles of [94 
˚C for 25 seconds, 50˚C for 25 seconds and 60˚C for four minutes]. Samples were wrapped in 
foil following the sequencing reaction and stored at -20˚C until precipitated and prepared to 
be read on the sequencer.  
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2.6.7 Ethanol precipitation following sequencing reaction 
Following the sequencing reaction, 3.5μl precipitation buffer (1.5M sodium acetate, 1.5M 
EDTA) and 100μl of 95% (v/v) ethanol were added to each sample prior to centrifugation at 
2,254 x g, 4˚C for 30 minutes. The supernatant was carefully removed and the samples were 
then briefly pulsed at 23 x g upside down before washing with 200μl 70% (v/v) ethanol and a 
further centrifugation step at 2,254 x g, 4˚C for 30 minutes. The supernatant was again 
carefully removed and samples pulsed at 23 x g upside down before a final wash with 200μl 
70% (v/v) ethanol and centrifugation at 2,254 x g, 4˚C for 30 minutes. The supernatant was 
removed and samples pulsed at 23 x g upside down before being allowed to air dry.  
To prepare precipitated samples for sequencing, pellets were resuspended in 10μl Hi-Di 
Formamide (Applied Biosystems; Cat. No: 4311320) and denatured at 95˚C for 5 minutes. 
Samples were run on a 3730 DNA Analyzer (Applied Biosystems) and output files analysed 
using sequencing analysis 5.2 (Applied Biosystems).  
 
2.7 GENE EXPRESSION ANALYSIS  
2.7.1 DNase treatment of RNA 
For the analysis of single exon genes (such as RASSF10, chapter 5), RNA was DNase treated 
before cDNA synthesis to remove any DNA contaminant. DNase treatment was achieved 
using DNase I (Fermentas; Cat.No. EN0521). For 1μg total RNA, a 10μl reaction was set up 
with 1x 10xbuffer (10mM Tris-HCL, (pH 7.5), 25mM magnesium chloride and 1mM calcium 
chloride) and 1ᴜ DNase I, made up to 10μl with RNase free water. Samples were incubated at 
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37˚C for 30 minutes before the reaction was terminated by the addition of 1μl 25mM EDTA 
and subsequent incubation at 65˚C for 10 minutes. 
2.7.2 cDNA synthesis 
cDNA was synthesised from 1μg total RNA using Superscript III (Invitrogen; Cat. No. 
18080-093) and random hexamer primers (Fermentas; Cat. No. S0142). An initial reaction 
was set up containing 1μg total RNA, 1μl of 100μM random hexamers and 1μl 10mM dNTP 
mix, made up to 13μl with RNase free water. Samples were incubated at 65˚C for 5 minutes. 
Samples were then transferred to ice for 1 minute prior to the addition of 4μl 5X First-Strand 
Buffer (250mM Tris-HCL (pH 8.3), 375mM potassium chloride, 15mM magnesium chloride) 
1μl 0.1M Dithiothreitol (DTT), 1μl (40ᴜ) RNaseOUTTM and 1μl (200ᴜ) SuperscriptTM III RT. 
Samples were then incubated for 5 minutes at 25˚C followed by 60 minutes at 50˚C. The 
reaction was inactivated by incubating at 70˚C for 15 minutes. cDNA was stored at -20˚C. 
2.7.3 Reverse transcript polymerase chain reaction (RT-PCR) primer design 
For multi exon genes, primers for expression analysis were designed to encompass one or 
more intronic regions to produce a product too large to amplify using conventional PCR 
methods and therefore ensuring successful amplification from cDNA and not any contaminant 
DNA from the RNA extraction process. Since cDNA is synthesised from the 3’ end, primers 
were preferentially designed to be located towards the 3’ end to ensure amplification of the 
best quality template cDNA. In most cases, primers were designed using the freely available 
Primer 3 program (http://frodo.wi.mit.edu/primer3/) using settings to design primers between 
250-400bp and not mis-match against repeats within the human genome. In some cases, 
primers were designed manually observing the following guidelines; making primers 20-25bp 
long, not having long strings of complimentary bases (i.e. As with Ts or Gs with Cs) to avoid 
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hairpin loops, an overall 50% GC content and a 3’ end containing either CC, CG, GG or GC. 
Primer sequences were then compared against the human genome using the NCBI BLAST 
program to check for specificity. Expression primer sequences are shown in appendices B.II, 
C.II, D.II and E.III.  
2.7.4 RT-PCR  
RT-PCR reactions were set up using 1μl prepared cDNA, 2.5μl 10X buffer (500mM Tris-
HCL (pH 8.3), 100Mm potassium chloride, 50mM ammonium sulphate), 2mM magnesium 
chloride, 2.5mM dNTP mix, 1x 5X GC rich solution, 0.8μM forward primer, 0.8μM reverse 
primer and 0.5ᴜ FastStart Taq DNA polymerase (Roche; Cat.No.12158264001) and made up 
to a final volume of 25μl with distilled water. RT-PCR reactions were carried out using a 
touchdown PCR as follows; 5 minutes at 95˚C, 3 cycles of [30 seconds at 95˚C, 30 seconds at 
60˚C and 30 seconds at 72˚C], 3 cycles of [30 seconds at 95˚C, 30 seconds at 58˚C and 30 
seconds at 72˚C], 34 cycles of [30 seconds at 95˚C, 30 seconds at 56˚C and 30 seconds at 
72˚C] and finally 10 minutes at 72˚C. GAPDH RT-PCR was carried out using the same 
program with the exception of a lower total cycle number (28 cycles).  
2.7.5 Real-time quantitative expression PCR 
Real-time RT-PCR was carried out for selected genes to assess gene expression in primary 
tumours. This work was carried out by Sophie Vacher in the laboratory of Dr. Ivan Bièche 
(Oncogenetic Laboratory, INSERM U 735, Centre René Huguenin, Saint Cloud, France). 
Real-time PCR used a SYBR green based assay described in Tozlu-Kara et al, 2007. Briefly, 
cDNA was synthesised from primary breast tumour and breast normal tissue RNA and 
subsequently used in the real time assay. Since this is a quantitative assay and it can be 
difficult to accurately assess the amount and quality of RNA/cDNA being used as starting 
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material all results were normalised on the basis of an endogenous RNA control, in this case, 
the TATA box-binding protein (TBP) gene. Measurements for the target gene were calculated 
from the initial detection of TBP until the end of the reaction to produce a result of N-fold 
difference between target gene and TBP. N-fold differences were determined by 2ΔCt sample 
where ΔCt sample is the equivalent of subtracting the mean ΔCt of the target gene from the 
mean ΔCt of TBP. ΔCt is the difference in parameter threshold cycle. The SYBR green PCR 
Core Reagents Kit (Perkin Elmer, Applied Biosystems. Cat. No:4304886) was used for the 
assay and PCR conditions consisted of 95˚C incubation for 10 minutes followed by 50 cycles 
of [95˚C for 15 seconds and 65˚C for 1 minute].   
2.8 TISSUE CULTURE  
Tissue culture work was carried out in class II hoods using a sterile technique at all times. All 
equipment was wiped down with 70% (v/v) industrial methylated spirits (IMS) before use in 
the hood. Since cell pellets and/or nucleic acid preparations from leukaemia lines were 
already available, only adherent cells were grown for this study.  
2.8.1 Preparation of growth media 
All solid tumour lines grown for this study were maintained in Dulbecco’s Modified Eagles 
Media (DMEM) (Sigma-Aldrich; Cat. No: D5671) supplemented with 10% (v/v) fetal bovine 
serum (FBS) (PAA Laboratories; Cat. No: A15-151), 2mM L-glutamine (Sigma Aldrich, Cat. 
No: G7513), penicillin (100ᴜ/ml) and streptomycin (100μg/ml) (Sigma Aldrich; Cat. No: 
P4333).  
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2.8.2 Resurrection of cell lines  
Cell line frozen stocks were removed from liquid nitrogen and placed into a 37˚C water bath. 
Cells were removed from the water bath as soon as they were defrosted and carefully 
transferred to 10mls pre-warmed (37˚C) culture media. To remove any cryopreservant from 
the media, cells were then centrifuged at room temperature for 4 minutes, 280 x g. 
Supernatant was carefully removed and cells very carefully resuspended in 1ml culture media 
prior to transfer to a 25cm
2
 tissue culture flask and the addition of a further 7mls growth 
media. Freshly revived cells were maintained at 37˚C, 5% carbon dioxide in a 25cm2 flask 
until ready for transfer to a 75cm
2
 flask.  
2.8.3 Maintenance and passaging of cell lines  
Cell lines were fed every two days by removing half the media volume and replacing with 
fresh pre-warmed media. Once the cell lines reached approximately 70%-90% confluency 
they were passaged into ratios of 1:3, 1:5 or 1:10 depending on the growth rate of the cell line. 
After the removal of media, cell lines were washed with 4mls pre-warmed phosphate buffered 
saline (PBS), followed by the addition of 3mls pre-warmed 1x 0.25% Trypsin-EDTA 
(Invitrogen; Cat.No: 25200056). Cells were then transferred back to 37˚C until the cells were 
dislodged from the flask surface. Cells were resuspended in 7mls media and split accordingly, 
with the desired volume of cells being returned to the flask and the unwanted cells discarded. 
Media was added to the cells to make up to 15mls and cells returned to the incubator.  
2.8.4 Counting of cells using a haemocytometer  
Cells were trypsinised as described in section 2.8.3 before being resuspended in 7mls fresh 
media prior to counting. The haemocytometer chamber and cover slip were first cleaned 
thoroughly with 70% (v/v) IMS before the cover slip was placed firmly onto the 
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haemocytometer chamber and an aliquot of 70μl cells was applied to each side of the 
haemocytometer underneath the coverslip. The cells in each side were counted under a 
microscope and an average calculated. Each millilitre of media contains 1x10
4
 of this average 
count.  
2.8.5 Treatment of cell lines with 5-aza-2’deoxycitidine 
5-aza-2’deoxycitidne (5-azaDC) was used to demethylate cell line genomic DNA to enable 
expression analysis of selected genes with and without methylation. Treatments were 
performed by myself and a laboratory technician, Dean Gentle. DNA demethylation by 5-
azaDC only occurs during DNA replication, therefore cells need to be dividing for effective 5-
azaDC treatment. For this reason, cell lines were grown to only 30-50% confluency for the 
start of 5-azaDC treatment; however this was dependent on particular cell line growth rates. 
Media supplemented with 5μM 5-azaDC (Sigma-Adrich; Cat. No: A3656) was added to cell 
lines and changed daily for five days. Cell pellets were then produced as described in section 
2.8.6 and stored for later nucleic acid extraction. A non-treated control for each cell line was 
grown concurrently, pelleted and stored for later extraction.  
2.8.6 Producing cell pellets  
Cell line pellets were prepared for extraction of nucleic acids. Once cells reached 90% 
confluency or the end of their 5-azaDC treatment, they were washed with PBS and detached 
from the flask using 1x trypsin-EDTA as described in section 2.8.3. Cells were resuspended 
in culture media and transferred to a 15ml falcon prior to centrifugation at 1000 x g, at 4° for 
4 minutes. Supernatant was removed and the cell pellet washed with 1ml PBS followed by a 
second centrifugation step as before and removal of the supernatant before being snap frozen 
in liquid nitrogen. Pellets were quickly transferred to -80˚C for storage until required.  
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2.8.7 Producing frozen aliquots  
Cells were first trypsinised, diluted to 10ml and counted as described in sections 2.8.3 and 
2.8.4. The cells were then transferred to a 15ml falcon, centrifuged at 1000 x g, at 4° for 4 
minutes, after which all the supernatant was removed. The cell pellet was resuspended in 
standard DMEM media containing an additional 10% (v/v) dimethyl sulphoxide (DMSO), to 
act as a cryopreservant during storage, to a final concentration of 1x10
6
 cells per ml. One 
millilitre was then transferred to a cryo-vial and put into a cryopreservation pot to ensure 
freezing occurred at -1˚C per minute. The cryopreservation pot was then transferred to -80˚C 
overnight before transfer of the vials to liquid nitrogen for long term storage.  
2.9 ARRAY ANALYSIS  
This study used two genome wide methylation assays/arrays; (a) methylated CpG island 
recovery assay (MIRA) coupled with a CpG island array (chapter 3) and (b) Illumina Infinium 
HumanMethylation27 BeadChip array (chapter 4).  
2.9.1 MIRA assay  
The MIRA assay and subsequent array were carried out by Dr. Stella Tommasi from 
Professor Gerd P. Pfeifer’s laboratory (Beckman Research Institute, City of Hope, 1500 E 
Duarte Road, Duarte, CA 91010. USA). Detailed descriptions of the MIRA assay can be 
found in Rauch et al, 2006 and Rauch et al, 2007. Briefly, with modifications as described in 
Tommasi et al, 2009, the MIRA procedure was carried out as follows: genomic DNA was 
double-digested with MseI (5’-TTAA-3’) and HhaI (5’-GCGC-3’) to produce small fragments 
allowing for collection of heavily methylated CpG island DNA and subsequently incubated 
overnight at 4˚C with a 1:1 mixture of MBD2b (GST-tagged) and MBD3L1 (His tagged) pre-
bound to glutathione beads. Following the incubation, pelleted glutathione beads were washed 
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with high salt buffer three times. Guanidium hydrochloride containing buffer was then used to 
elute methylated DNA enriched genomic DNA. DNA was then purified using QIAquick PCR 
purification kit (Qiagen), according to manufacturers’ instructions. Ligation of purified DNA 
fragments to MseI linkers was done prior to PCR amplification. Products were then labelled 
with either Cy5-dCTP (breast cancer cell lines) or Cy3-dCTP (NHMEC lines). Samples were 
then mixed and hybridized to a human CpG island microarray (Agilent Technologies). Raw 
data was provided in the form of ratio values of Cy5:Cy3 for each probe on the CpG island 
microarray. 
2.9.2 Illumina Infinium HumanMethylation27 BeadChip array 
The Illumina Infinium array was carried out by Ghazala Mirza at the Wellcome Trust Centre 
for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, UK. The study utilised the 
HumanMethylation27 BeadChip array. DNA was first bisulphite modified and then prepared 
and hybridized to the chip according to manufacturers’ instructions. Raw data was initially 
run through BeadStudio (Illumina) and provided as β-values that represented methylation 
levels for each probe on the array ranging from 0 (designating no methylation) to 1 
(Designating complete methylation).  
2.10 STATISTICAL METHODS  
2.10.1 Fisher’s exact test  
Fisher’s exact test was used to determine the significance of the frequency of methylated 
samples in a particular group. In single cases, GraphPad (http://graphpad.com) was used to 
determine significance and in multiple cases, as in chapter 4, a Macro was installed into 
Microsoft Excel. Both programs used the same Fisher’s exact test equation. In every case of 
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using Fisher’s exact test, p<0.05 was considered significant. However, when multiple tests 
were carried out p-values were subject to multiple correction, see section 2.10.5. 
2.10.2 Student’s t-test  
When testing the significance of two means, student’s t-test was utilised. Student’s t-tests 
were carried out in Microsoft Excel and in all cases were two-tailed, two sample unequal 
variance. P<0.05 was considered significant.  
2.10.3 ANOVA 
One-way analysis of variance (ANOVA) analysis, carried out using MedCalc 
(http://medcalc.be), was used to assess significance between more than one mean. 
Significance was taken as p<0.05 
2.10.4 Kaplan-Meier analysis 
To determine whether DNA methylation of a particular gene associated with survival 
outcome, Kaplan-Meier graphs were produced using MedCalc (http://medcalc.be), as with 
other statistical test, p<0.05 was considered significant.  
2.10.5 Multiple correction  
Statistical significance was taken at p<0.05, however, when conducting multiple tests on the 
same group of data, the occurrence of p<0.05 becomes 1 in 20 by chance. Therefore, when 
carrying out numerous tests, as in chapter 4, the occurrence of false positives can become 
quite high. Either Bonferroni correction or False Discovery Rate (FDR) corrections were used 
in this thesis.  
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Bonferroni correction  
Bonferroni correction involves adjusting the significance value by the number of tests carried 
out. For example, the significant value becomes p/n where p is the p-value considered 
significant and n is the number of tests carried out. Therefore, if carrying out 10 tests, a 
significance value of 0.05 becomes 0.005. Bonferroni correction is highly stringent and was 
used in this thesis on small datasets where it was most applicable.  
False discovery rate (FDR) 
This method is more suitable for large datasets than Bonferroni correction and is commonly 
used in microarray experiments. FDR correction works on a ranking basis, unadjusted p-
values are ranked smallest to largest and then each p-value is multiplied by its rank within the 
list i.e. the third most significant p-value (X) would become 3 x X. Statistical significance 
remained p<0.05 once p-values had been adjusted.  
2.11 BIOINFORMATICS  
2.11.1 Gathering gene structure information  
General gene structure information was obtained from the UCSC genome browser 
(http://genome.ucsc.edu/) using the most up to date human genome reference (either hg18 or 
hg19 for the work in this thesis).  
CpG island information was gathered from UCSC genome browser (http://genome.ucsc.edu/) 
and the European Bioinformatics Institute (EBI) CpG plot program 
(http://www.ebi.ac.uk/Tools/emboss/cpgplot/). 
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2.11.2 Functional annotation of gene lists  
The freely available Database for Annotation, Visualization and Integrated Discovery 
(DAVID) database was used for analysing large lists of genes to mine for functionally related 
groups of genes and genes within pathways.  
2.11.3 Individual gene information  
The National Centre for Biotechnology Information (NCBI) website 
(http://www.ncbi.nlm.nih.gov/) and GeneCards (http://www.genecards.org/) were used to 
gather information on the functions, published work and general information for individual 
genes.  
2.11.4 Gene mutation and methylation information  
The Catalogue Of Somatic Mutations In Cancer (COSMIC) website 
(http://www.sanger.ac.uk/genetics/CGP/cosmic/) was used to partially assess the known 
levels of mutation in selected individual genes. While, the PubMeth: Reviewed methylation 
database in cancer website (http://www.pubmeth.org/) was used to partially assess the known 
levels of methylation in selected individual genes. Further assessment for both these aspects 
was performed by specific literature searches using the NCBI PubMed website 
(http://www.ncbi.nlm.nih.gov/pubmed/).  
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CHAPTER 3 
USE OF THE METHYLATED CpG ISLAND RECOVERY ASSAY (MIRA) 
COUPLED WITH HUMAN CpG ISLAND ARRAYS TO IDENTIFY METHYLATED 
GENES IN BREAST CANCER 
 
3.1 ABSTRACT  
This study has used the methylated CpG island recovery assay (MIRA) coupled with human 
CpG island arrays on five breast cancer cell lines and two normal human mammary epithelial 
cell lines (NHMECs) to identify a large number of potentially methylated targets in breast 
cancer. Confirmation of 32 of these targets by combined bisulphite restriction analysis 
(CoBRA) identified 16 frequently methylated genes in breast cancer cell lines.  
Analysis of 16 targets in sporadic breast cancer patient samples identified nine genes that 
showed frequent methylation. Further analysis confirmed five of these genes, CIDE-A, DBC1, 
EMILIN2, FBLN2 and SALL1 show tumour specific methylation and can be re-expressed in 
methylated cell lines following treatment with the demethylating agent, 5-azaDC. In addition, 
mRNA levels of EMILIN2 in methylated patient samples were significantly lower than 
unmethylated samples (p = 0.018). This study has also demonstrated varying levels of 
methylation of the above five genes in other solid tumours. The most frequent being FBLN2 
in glioma tumours (45%).  
Association of methylation with breast cancer clinical features demonstrated FBLN2 
methylation associated with PR positive tumours (p = 0.013) and CIDE-A methylation 
associated with ER positive tumours (p = 0.016). EMILIN2 methylation associated with worse 
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disease free survival (p = 0.041), relapse (p = 0.031) and ER and PR receptor status (p = 
0.0009 and p = 0.0082 respectively).  
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3.2 INTRODUCTION 
Chapter one demonstrated that although frequently mutated genes in familial breast cancer, 
such as BRCA1, BRCA2, PTEN, BRIP1, and CHEK2 have been identified (Hall et al, 1990; 
Phelan et al, 1996; Liaw et al, 1997; Rutter et al, 2003; Meijers-Heijboer et al, 2002), very 
few sporadic cases have been shown to have such alterations. It is likely to be a build up of 
many factors that contribute to sporadic cases, such as mutations, chromosomal alterations 
and downregulation or upregulation of genes by other mechanisms. Recent studies have 
demonstrated the large number of alterations per breast cancer genome illustrating the 
magnitude of molecular changes required for sporadic tumourigenesis (Stephens et al, 2010; 
Ding et al, 2010; Shah et al¸ 2009; Sjöblom et al, 2006; Wood et al¸ 2007). In addition to 
genetic events, epigenetic events such as histone modification and DNA methylation could 
also contribute to these molecular changes that initiate and enable tumourigenesis. DNA 
hypermethylation events have been shown to be common in many cancers, including breast, 
both through the inactivation of genes with tumour suppressor properties such as RASSF1A, 
CCND2, VHL, PTEN and APC (Dammann et al, 2000; Evron et al, 2001; Herman et al, 1994; 
Goel et al, 2004; Esteller et al, 2000c), the identification of methylation profiles in relation to 
breast cancer clinical features (Christensen et al¸ 2010; Bediaga et al, 2010; Holm et al¸2010) 
and the identification of methylation markers of disease progression (Hartmann et al, 2009). 
The determination of hypermethylation events in the sporadic breast cancer genome can be of 
potential use in further understanding of the disease and identifying useful markers that can 
aid patient diagnosis, treatment plans and prognosis. Recent advances in genome-wide 
methods and isolation of methylated CpG islands have resulted in new technologies becoming 
available to identify such genes through analysis of large swathes of the genome.  
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The work in this chapter uses one of these methods, the methylated CpG island recovery 
assay (MIRA) in conjunction with a human CpG island microarray to identify methylated 
genes in breast cancer cell lines with the aim of using this information to identify genes that 
are frequently methylated in sporadic breast cancer patient samples that may relate to clinical 
features or provide potential in-roads to better disease understanding.  
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3.3 AIMS 
1. To use the MIRA assay (methylated CpG island recovery assay) and human CpG island 
microarrays to produce a list of hypermethylated genes in breast cancer cell lines  
2. To analyse selected candidate genes in the assayed breast cancer cell lines plus additional 
breast cancer cell lines and further confirm positively methylated candidates in sporadic 
ductal breast tumour samples  
3. To assess expression status of candidate genes pre and post treatment with 5-azaDC  
4. To assess tumour specificity in a further sporadic ductal breast cancer cohort with matched 
normal breast tissue  
5. To assess any association between positive methylation and clinical features in the sporadic 
ductal breast tumour cohort 
6. To determine the methylation status of positive candidate genes in other common solid 
tumour types  
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3.4 RESULTS  
3.4.1 Array analysis  
This study used the methylated CpG island recovery assay (MIRA) coupled with Agilent 
Human CpG island microarrays on five breast cancer cell lines (HCC1806, HCC1419, 
HCC1395, HCC1143 and HCC1937) and two normal human mammary epithelial cell 
(NHMEC) lines to assess methylation changes across 27,800 CpG islands. See section 1.3.7.2 
for more details on the MIRA assay.  
To isolate hypermethylated probes, methylation enrichment factors were calculated for all 
probes and then screened so that only genes demonstrating a >5-fold increase in the MIRA-
enriched fraction of tumour vs. normal in a single probe in 3 or more cell lines were retained. 
This resulted in 14,875 probes, representing 6,912 individual gene loci. From this were 
removed entries that did not represent a known, annotated gene opposed to a predicted 
mRNA, non-coding mRNA or genomic region (ORFs, chromosomal regions, miRNAs, 
LOCs, MGCs, FLJs, KIAs and Agilent plate related hits) and genes located on the X 
chromosome due to their intrinsic levels of methylation present in the inactivated X 
chromosome (all cell lines were female in origin as were subsequently analysed patient 
samples) and the confusion caused by loss of part or all of the active X chromosome, resulting 
in a list of 10,840 probes (3,347 genes). This low stringency list was further refined by the 
removal of all probes that were not located within a promoter or divergent promoter region, 
resulting in 3352 probes (1268 genes). Due to this large number of genes, a second, more 
stringent list was created, consisting only of probes that demonstrated a >10-fold increase in 4 
or more cell lines, resulting in 895 probes (276 genes) (figure 3.1). The list of 276 genes from 
the high stringency list is provided in appendix A.III. 
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Methylation enrichment factors 
calculated  for all probes 
Probes selected with > 5-fold increase in 
the methylated fraction of tumour vs. 
normal in at least 1 probe in >3 cell lines 
Low stringency High stringency 
14, 875 probes; 6, 912 genes 
Removed ORFs, miRNAs, predicted genes 
(LOCs, MGCs, FLJs, KIAs) and agilent plate 
related hits 
10, 840 probes; 3,347 genes 
Removed all probes 
that did not show >10-
fold increase in >4 cell 
lines 
895 probes; 276 genes 
Removed all probes that 
were not located within a 
promoter or divergent 
promoter region 
3352 probes; 1268 genes 
Figure 3.1 Flow-through of MIRA list analysis
This diagram illustrates the method used to generate a working list of
candidate genes from the raw MIRA array data.
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From these lists, target genes were chosen to be analysed further by the use of DAVID 
(Database for Annotation, Visualization and Integrated Discovery) functional analysis tool, 
literature searching, SAGE (serial analysis of gene expression) expression data and oncomine 
gene expression data. In total, 32 genes were selected for further analysis: ABT1, BARHL2, 
BUB3, CCNJ, CD44, CDH24, CENPJ, CIDE-A, COMP, DBC1, DDEF2, DLGAP1, 
EMILIN2, EPSTI1, FBLN2, FOXF2, FOXQ1, GSC, KLF11, KLF13, LYPD5, MADL1L1, 
NRXN2, ONECUT1, PAX9, PHF2, POU4F1, SALL1, SALL3, SESN3, SIM2 and TP53INP1 
(table 3.1).  
3.4.2 Analysis of selected genes in breast cancer cell lines  
Targets identified from the array were analysed by CoBRA in the cancer cell lines used for 
the array, additional breast cancer lines and a normal breast DNA sample. This was done to 
confirm the frequent methylation in a wider range of breast cancer cell lines and the absence 
of methylation in normal breast tissue DNA. The aim of the array was to identify genes where 
methylation resulted in downregulation of the gene, therefore, where possible, primers were 
situated around the gene transcription start point regardless of array probe position as this is 
the most likely region for hypermethylation to result in gene inactivation and therefore have 
biological relevance.  
In total, 32 genes were analysed in cell lines. Of these, 16 (50%) showed methylation in 
greater than 30% of samples and no methylation in the normal breast tissue DNA sample 
(CD44, CIDE-A, COMP, DBC1, EMILIN2, EPSTI1, FBLN2, FOXF2, GSC, NRXN2, PAX9, 
POU4F1, SALL1, SESN3, SIM2, TP53INP1) (table 3.2 and figure 3.2). Of the remaining 16 
genes, 11 (34.4%) did not show methylation in the region analysed by CoBRA (ABT1, BUB3, 
CCNJ, CDH24, CENPJ, DDEF2, KLF11, KLF13, MAD1L1, 
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GENE SYMBOL GENE NAME RELEVANT BACKGROUND
ABT1 ACTIVATOR OF BASAL TRANSCRIPTION 1 Novel Target - Down regulated in MDA-MB-231 Breast cell line
BARHL2 BARH-LIKE 2 (DROSOPHILA) Novel Target - Homeobox Gene
BUB3 BUB3 BUDDING UNINHIBITED BY BENZIMIDAZOLES 3 HOMOLOG (YEAST) Involved in control of mitotic checkpoint
CCNJ CYCLIN J Regulator of Cell Cycle Progression
CD44 CD44 ANTIGEN (INDIAN BLOOD GROUP) Methylated in Prostate Cancer, Connection to Breast cancer
CDH24 CADHERIN-LIKE 24 Under-expressed in Breast cancer (SAGE), Mutated in AML, Involved in Cellular Adhesion
CENPJ CENTROMERE PROTEIN J Microtubule cytoskeleton organization
CIDEA CELL DEATH-INDUCING DFFA-LIKE EFFECTOR A Involved in Apoptosis, Under-expressed in Breast cancer (SAGE)
COMP CARTILAGE OLIGOMERIC MATRIX PROTEIN Involved in TGF-beta signalling, cell adhesion and communication
DBC1 DELETED IN BLADDER CANCER 1 Associated with Bladder cancer, methylated in NSCLC
DDEF2 DEVELOPMENT AND DIFFERENTIATION ENHANCING FACTOR 2 Involved in differentiation, Regulation related to Oestrogen Receptor
DLGAP1 DISCS, LARGE (DROSOPHILA) HOMOLOG-ASSOCIATED PROTEIN 1 Novel Target
EMILIN2 ELASTIN MICROFIBRIL INTERFACER 2 Re-expressed after demethylation in ovarian cancer, Slightly under-expressed in Breast cancer (SAGE)
EPSTI1 EPITHELIAL STROMAL INTERACTION 1 (BREAST) Differentially expressed in Breast tissue, Under-expressed in Breast cancer (SAGE)
FBLN2 FIBULIN 2 In-House candidate gene
FOXF2 FORKHEAD BOX F2 Involved in cell morphogenesis and blood vessel development
FOXQ1 FORKHEAD BOX Q1 Novel Target - Transcription factor
GSC GOOSECOID Implicated in lung cancer (Potential hit on another MIRA array)
KLF11 KRUPPEL-LIKE FACTOR 11 Negative regulator of cell cycle progression
KLF13 KRUPPEL-LIKE FACTOR 13 Suppresses K-RAS by down regulated of Cyclin B
LYPD5 LY6/PLAUR DOMAIN CONTAINING 5 Novel Target - Slightly under-expressed in Breast cancer (SAGE)
MAD1L1 MAD1 MITOTIC ARREST DEFICIENT-LIKE 1 (YEAST) Mitotic spindle assembly checkpoint protein ,Mutated in multiple cancers
NRXN2 NEUREXIN 2 Associated with Prostate cancer, Cell Adhesion, under-expressed in Breast cancer (SAGE)
ONECUT1 ONE CUT DOMAIN, FAMILY MEMBER 1 Methylated in Cervical cancer, 
PAX9 PAIRED BOX GENE 9 Involved in Development, Implicated in lung cancer (Potential hit on another MIRA array)
PHF2 PHD FINGER PROTEIN 2 Novel Target
POU4F1 POU DOMAIN, CLASS 4, TRANSCRIPTION FACTOR 1 Expression enhanced when BRCA1 reduced, Implicated in lung cancer (Potential hit on another MIRA array)
SALL1 SAL-LIKE 1 (DROSOPHILA) Methylated in Leukaemia, Because SALL3 was also a hit
SALL3 SAL-LIKE 3 (DROSOPHILA) Because SALL1 was also a hit
SESN3 SESTRIN 3 Methylated in Endometrial cancer, Induced by p53
SIM2 SINGLE-MINDED HOMOLOG 2 (DROSOPHILA) Potential Tumour Suppressor Gene
TP53INP1 TUMOR PROTEIN P53 INDUCIBLE NUCLEAR PROTEIN 1 Involved in Apoptosis, Interacts with p53
Table 3.1_Reason for selecting the 32 genes for analysis in cell lines 
Each of the 32 gene symbol and names are given along with the reason they were chosen to be analysed further. 
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GENE NAME GENE PRODUCT CELL LINE NORMAL BREAST 
SESN3 sestrin 3 6/6 0/1 
SIM2 single-minded homolog 2 (Drosophila) 7/7 0/1 
CIDE-A cell death-inducing DFFA-like effector a 7/8 0/1 
EPSTI1 epithelial stromal interaction 1 (breast) 5/6 0/1 
PAX9 paired box 9 4/5 0/1 
POU4F1 POU class 4 homeobox 1 6/8 0/1 
COMP cartilage oligomeric matrix protein 4/6 0/1 
FOXF2 forkhead box F2 6/9 0/1 
SALL1 sal-like 1 (Drosophila) 4/6 0/1 
FBLN2 fibulin 2 3/5 0/1 
EMILIN2 elastin microfibril interfacer 2 5/9 0/1 
CD44 CD44 molecule 3/6 0/1 
TP53INP1 tumor protein p53 inducible nuclear protein 1 3/6 0/1 
DBC1 deleted in bladder cancer 1 2/6 0/1 
GSC goosecoid homeobox 3/9 0/1 
NRXN2 neurexin 2 2/6 0/1 
BARHL2 BarH-like homeobox 2 2/8 0/1 
FOXQ1 forkhead box Q1 1/6 0/1 
DLGAP1 discs, large (Drosophila) homolog-associated protein 1 5/5 1/1 
SALL3 sal-like 3 (Drosophila) 3/4 1/1
LYPD5 LY6/PLAUR domain containing 5 3/6 1/1 
ABT1 activator of basal transcription 1 0/5 0/1 
BUB3 budding uninhibited by benzimidazoles 3 homolog (yeast) 0/9 0/1 
CCNJ cyclin J 0/6 0/1 
CDH24 cadherin 24, type 2 0/9 0/1 
CENPJ centromere protein J 0/9 0/1 
DDEF2 development and differentiation enhancing factor 21 0/6 0/1 
KLF11 Kruppel-like factor 11 0/9 0/1 
KLF13 Kruppel-like factor 13 0/6 0/1 
MAD1L1 MAD1 mitotic arrest deficient-like 1 (yeast) 0/6 0/1 
ONECUT1 one cut homeobox 1 0/9 0/1 
PHF2 PHD finger protein 2 0/6 0/1 
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Table 3.2_CoBRA results for 32 selected genes in breast cancer cell lines 
Gene names and gene products are shown for each of the 32 genes selected for
CoBRA analysis in breast cancer cell lines. The methylation frequency by CoBRA
is given for each gene along with the result from the normal breast tissue DNA
sample. Genes highlighted in dark grey were excluded from further analysis
because of methylation in the normal breast tissue DNA, genes highlighted in
light grey were excluded from further analysis because no methylation was
detected, genes highlighted in light blue were excluded from further analysis
because of infrequent methylation and genes highlighted in blue were selected for
further analysis.
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SIM2
HCC1806
U D
HCC1395
U D
HCC1143
U D
HCC1419
U D
MCF7
U D
Normal 
U D
POU4F1
HCC1806
U D
HCC1395
U D
HCC1419
U D
MCF7
U D
MDA-MB-231
U D
Normal 
U D
CIDE-A
HCC1806
U D
HCC1419
U D
HCC1143
U D
HCC1395
U D
MDA-MB-231
U D
Normal 
U D
EMILIN2 
HCC1806
U D
HCC1143
U D
HCC1395
U D
T47D
U D
MDA-MB-231
U D
Normal 
U D
GSC
HCC1806
U D
HCC1395
U D
HCC1143
U D
MCF7
U D
MDA-MB-231
U D
Normal 
U D
BUB3
HCC1806
U D
HCC1395
U D
HCC1937
U D
HCC1419
U D
MDA-MB-231
U D
Normal 
U D
DBC1
HCC1143
U D
T47D
U D
MCF7
U D U D
MDA-MB-231
U D
Normal 
U D
HTB19 
FBLN2  
HCC1806
U D
HCC1419
U D
HCC1937
U D U D
HCC1395
U D
Normal 
U D
MCF7
KLF11
HCC1395
U D
HCC1937
U D
HCC1143
U D U D
HCC1419
U D
Normal 
U D
HTB19 
Frequently 
methylated 
genes 
Unmethylated 
genes 
HCC1806
U D
HCC1395
U D
HCC1937
U D
MCF7
U D
HTB19
U D
Normal 
U D
Methylated in 
normal breast 
DLGAP1
* * * * *
***
* * * * *
***
* *
****
***
* * * * * *
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Figure 3.2 CoBRA results for selected genes in cell lines
CoBRA results are shown for selected genes that demonstrated
either frequent methylation, no methylation or additional
methylation in normal breast. Undigested products (U) are run
next to digested products (D). * indicates methylated samples.
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ONECUT1 and PHF2), two (6.3%) showed infrequent methylation (<30%) in breast cancer 
cell lines (BARHL2 and FOXQ1) and three (9.4%) showed methylation in both the cancer cell 
lines and normal breast tissue DNA (DLGAP1, LYPD5 and SALL3) (table 3.2 and figure 3.2). 
Genes showing frequent methylation in the cell lines were selected for further analysis in 
primary breast tumour samples (n=16).  
3.4.3 Analysis of selected genes in primary breast tumour samples  
To determine whether methylation was present in primary tumours and not just cell lines 
specific, the 16 genes showing frequent methylation in cell lines were analysed by CoBRA in 
a cohort of 40 ductal breast tumours. Frequent tumour methylation (>25%) was observed in 
nine of the 16 genes (CIDE-A, COMP, DBC1, EMILIN2, EPSTI1, FBLN2, SALL1, SESN3 
and SIM2) (table 3.3 and figure 3.3). Methylation frequencies ranged from 26% (DBC1) to 
63% (SALL1). The remaining seven genes were either unmethylated (TP53INP1, NRXN2) or 
infrequently (<25%) methylated (CD44, FOXF2, GSC, PAX9, POU4F1) (table 3.3 and figure 
3.3). The nine frequently methylated genes were selected for further analysis.  
3.4.4 Expression analysis of selected genes  
To assess whether methylation of the nine genes showing frequent methylation in primary 
breast tumours may have functional relevance, breast cancer cell lines were treated with the 
demethylating agent 5-aza-2’-deoxycitidine (5-azaDC). Of the nine genes analysed for mRNA 
expression pre and post 5-azaDC treatment, eight (CIDE-A, COMP, DBC1, EMILIN2, 
EPSTI1, FBLN2, SALL1 and SIM2) showed either increased expression or complete re-
expression in methylated cell lines (figure 3.4). Only SESN3 did not show either 
increased/complete re-expression in methylated samples (figure 3.4). SESN3
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Table 3.3 CoBRA results for selected genes analysed in primary breast tumour samples 
CoBRA results are shown for each of the genes analysed in primary tumour samples. Genes highlighted in dark
blue showed frequent methylation and have been selected for further analysis. Genes highlighted in light blue
showed infrequent methylation in tumours and genes highlighted in grey were unmethylated in primary tumour
samples.
GENE NAME GENE PRODUCT PRIMARY TUMOURS 
EPSTI1 epithelial stromal interaction 1 (breast) 13/36 (36%)
SIM2 single-minded homolog 2 (Drosophila) 24/29 (83%)
SESN3 sestrin 3 7/10 (70%)
SALL1 sal-like 1 (Drosophila) 25/40 (63%)
COMP cartilage oligomeric matrix protein 20/33 (61%)
CIDE-A cell death-inducing DFFA-like effector a 21/40 (53%)
EMILIN2 elastin microfibril interfacer 2 16/36 (44%)
FBLN2 fibulin 2 13/38 (34%)
DBC1 deleted in bladder cancer 1 8/31 (26%)
PAX9 paired box 9 8/39 (21%)
POU4F1 POU class 4 homeobox 1 4/27 (15%)
FOXF2 forkhead box F2 5/35 (14%)
CD44 CD44 molecule 1/24 (4%)
GSC goosecoid homeobox 1/40 (3%)
NRXN2 neurexin 2 0/12 (0%)
TP53INP1 tumor protein p53 inducible nuclear protein 1 0/18 (0%)
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Figure 3.3 CoBRA results for selected genes in primary tumour samples 
CoBRA results are shown for eight samples for eight genes representing those 
classified as frequently methylated, infrequently methylated or unmethylated. 
Undigested products (U) are shown adjacent to digested products (D). * 
indicates methylation.  
* * * * * * *
* * * * *
*****
* *
* * * * *
*
*
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MDA-MB-231
CoBRA Exp.
U       D - +
DBC1
GAPDH
DBC1
NB
HCC1395
Exp.
EPSTI1
- +U       D
CoBRA
EPSTI1
GAPDH
NB
HCC1395
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SESN3
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Exp.
COMP
- +U       D
CoBRA
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Figure 3.4 Expression analysis of selected genes. 
Expression results are shown for COMP, CIDE-A, DBC1, EMILIN2, SESN3 and EPSTI1. For each gene
expression results are given for the selected gene and GAPDH with (+) and without (-) treatment with 5azaDC.
Expression in normal breast (NB) is also shown. CoBRA results for the selected cell line is also shown alongside
with undigested (U) products run next to digested products (D).
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expression analysis failed to show any expression except for two cell lines, both of which 
were heavily methylated, and expression was observed both pre and post treatment with 5-
azaDC, indicating methylation does not influence expression of SESN3 in breast tissue. 
Expression was observed in normal breast tissue mRNA for all genes analysed. The 
methylation of the remaining eight genes was therefore considered to have some potential 
biological function, all eight genes were analysed further.  
3.4.5 Analysis of selected genes in primary breast tumour/normal paired samples  
Access to a second, independent cohort of 20 breast tumour samples with adjacent normal 
breast tissue DNA was available, therefore, to assess tumour specificity of DNA methylation 
all eight genes were analysed in this cohort of samples. Five of the eight genes (CIDE-A, 
DBC1, EMILIN2, FBLN2 and SALL1) showed greater levels of methylation in tumour 
samples compared to adjacent normal tissue and in most cases, when methylation was 
observed in the tumour sample, none was observed in corresponding normal samples (figure 
3.5). Tumour specific methylation was observed in 4 of the 8 genes at frequencies of 4/11 
(36.4%) for EMILIN2, 6/19 (31.6%) for FBLN2, 4/16 (25%) for DBC1, and 7/14 (50%) for 
CIDE-A. SALL1 was the only gene to demonstrate some methylation in adjacent normal 
tissue, 9/20 (45%) samples were methylated in the tumour only and 1/20 (5%) of samples 
showed a lower level of methylation in the adjacent normal tissue of a methylated tumour. For 
the remaining three genes (COMP, EPSTI1 and SIM2), methylation was detected at a similar 
level in both tumour and normal tissue, demonstrating that methylation is a not a cancer-
specific event in these genes. 
Taken together, the cancer cell line and primary tumour methylation results, expression 
results pre and post 5-azaDC treatment and tumour specificity of methylation, five genes were 
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Figure 3.5 Tumour specificity analysis of selected genes
CoBRA results for 6 of the 8 genes analysed for tumour specificity. For
each gene CoBRA results are shown for four tumour (T)/normal (N) pairs.
Undigested products (U) are run next to digested products (D). * indicates
methylation
* *
* *
* * *
* *
* * * *
* *******
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identified that represented good candidates. For three of these five good candidate genes, 
EMIILIN2, CIDE-A and SALL1, clone sequencing was performed on methylated primary 
tumour samples (figures 3.6, 3.7 and 3.8 respectively). Results from this confirmed the 
methylation observed by CoBRA digest and demonstrated the extent of the methylation 
throughout the investigated region of each genes CpG island. Methylation indexes (MIs) were 
high for CIDE-A and SALL1 demonstrating extensive methylation throughout whilst the MIs 
were relatively low for EMILIN2 (34% and 36%).  
3.4.6 Association of methylation and clinical features  
Relapse, survival, ER (oestrogen receptor) and PR (progesterone receptor) status, presence of 
lymph node metastases, menopause status and age at diagnosis data were available for the 
cohort of 40 breast tumour samples. Methylation was significantly associated with ER 
positive tumours in CIDE-A (p=0.016) and PR positive tumours in FBLN2 (p=0.013). In 
EMILIN2, methylation was significantly associated with ER and PR positive tumours 
(p=0.0009 and p=0.0082 respectively), relapse (p=0.031) and, most importantly, with poor 
disease free survival (p=0.041) (figure 3.9).  
3.4.7 Expression of EMILIN2 in primary tumour samples  
Clinically, methylation of EMILIN2 was determined to be the most interesting and therefore 
expression of EMILIN2 was assessed in primary tumour samples by quantitative real-time 
RT-PCR. This work was done by Dr. Sophie Vacher in Dr. Ivan Bieche’s laboratory 
(Oncogenetic Laboratory, INSERM U 735, Centre René Huguenin, Saint Cloud, France). 
Results demonstrated significantly decreased expression in methylated samples compared to 
unmethylated samples (p=0.018) (figure 3.10), suggesting 
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MI=34.4%
MI=33.6%
CpG island – 1610bp with 146CpGs
Figure 3.6_Sequencing results for EMILIN2 
A gene schematic of EMILIN2 is shown to demonstrate the region being analysed. Clone sequencing results are shown for two
methylated samples, each line represents a single allele and black and white circles represent methylated and unmethylated
CpGs respectively. Methylation indexes (MIs) are calculated as a percentage of methylated CpGs out of the total number of
CpGs assessed.
EMILIN2
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CpG island – 942bp with 85CpGs
CIDE-A
Figure 3.7_Sequencing results for CIDE-A 
A gene schematic of CIDE-A is shown to demonstrate the region being analysed. Clone sequencing results are shown for four
methylated samples, each line represents a single allele and black and white circles represent methylated and unmethylated
CpGs respectively. Methylation indexes (MIs) are calculated as a percentage of methylated CpGs out of the total number of
CpGs assessed.
310 
MI = 44.4% 
375 
MI = 48.1% 
385 
MI = 21.3% 
436 
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145 
 
CpG island – 5064bp with 366CpGs
SALL1 
320
MI=34%
409
MI=54%
1122
MI=53%
1128
MI=38%
Figure 3.8_Sequencing results for SALL1
A gene schematic of SALL1 is shown to demonstrate the region being analysed. Clone sequencing results are shown for four
methylated samples, each line represents a single allele and black and white circles represent methylated and unmethylated
CpGs respectively. Methylation indexes (MIs) are calculated as a percentage of methylated CpGs out of the total number of
CpGs assessed.
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Figure 3.9 Kaplan-Meier analysis for EMILIN2
The Kaplan-Meier graph is shown for the association
between EMILIN2 methylation and poor disease free
survival. This analysis was performed on results from
35 tumour samples. The minimum and median
follow-up times were 247 days and 2501 days
respectively. For non-relapsing tumours, the
maximum period of follow-up was 5185 days.
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Figure 3.10 EMILIN2 expression in primary tumour samples 
This graph shows the expression levels of unmethylated and methylated tumours as determined by quantitative real-time
RT-PCR. The mean expression levels of unmethylated tumours (grey bar) and methylated tumours (black bar) are shown
on the far-right of the graph. The statistical significance of the difference in these means (using Student’s T-test is) also
shown. Data for these graphs were obtained by Dr. Sophie Vacher from Dr. Ivan Bieche’s laboratory (Oncogenetic
Laboratory, INSERM U 735, Centre René Huguenin, Saint Cloud, France).
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methylation of EMILIN2 is correlated with loss of EMILIN2 expression in primary tumours 
and therefore likely to have a biological effect.  
3.4.8 Analysis of CIDE-A, DBC1, EMILIN2, FBLN2 and SALL1 in other common solid 
tumour types  
Hypermethylation of genes is often not restricted to one tumour type and so for the five good 
candidates methylation was assessed in other available common solid tumour types. Cancer 
cell lines were available for glioma, lung, colorectal and prostate. Frequent methylation was 
observed in all cancer types for all genes with the exception of SALL1, which was 
unmethylated in glioma cell lines (table 3.4). DBC1 was not tested in lung cancer cell lines as 
methylation in lung cancer is known (Izumi et al, 2005).  
The frequent methylation in cell lines led to analysing these genes in primary tumour samples. 
Due to the frequent nature of methylation in the multiple cell line types analysed ovarian 
primary tumour samples were also analysed despite ovarian cancer cell lines not being 
available. In-house, primary lung, glioma and ovarian tumour samples were available. 
Analysis of colorectal and prostate tumours was carried out by others in the laboratories of 
Dr. Luke Hesson (Prince of Wales Clinical School, University of New South Wales, Sydney, 
Australia) and Dr. Reinhard Dammann (Institute for Genetics, Justus Liebig University 
Giessen, Heinrich-Buff-Ring 58-62, D-35392 Giessen, Germany) respectively. 
3.4.8.1 EMILIN2  
The only frequent primary tumour methylation observed for EMILIN2 was in colorectal 
tumours. CoBRA assay demonstrated frequent methylation in colorectal tumours (19/57; 
33.3%) compared to normal colon tissue (1/82; 1.2%). Colorectal adenomas also showed 
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Table 3.4 Results of other solid tumour analysis
This table shows the results of cell line and primary tumour analysis of EMILIN2, SALL1, FBLN2, CIDE-A and DBC1 in
colorectal, lung, gliomas, prostate and ovarian tumours. Primary tumour (and normal tissue) analysis of colorectal and
prostate tissue DNA was carried out in the laboratories of Dr. Luke Hesson (Prince of Wales Clinical School, University of
New South Wales, Sydney, Australia) and Dr. Reinhard Dammann (Institute for Genetics, Justus Liebig University
Giessen, Heinrich-Buff-Ring 58-62, D-35392 Giessen, Germany) respectively.
EMILIN2 SALL1 FBLN2 CIDE-A DBC1
Colorectal 
Cell lines 4/5 (80%) 6/6 (100%) 4/4 (100%) 8/8 (100%) 8/8 (100%)
Tumours 19/57 (33.3%) 44/53 (83.0%) 54/58 (93.1%) 7/8 (87.5%) 8/8 (100%)
Adenomas 7/22 (31.8%) 17/19(89.5%) 23/23 (100%) 7/7 (100%) 8/8 (100%)
Normal tissue 1/82 (1.2%) 30/79 (38.0%) 74/80 (92.5%) 16/16 (100%) 16/16 (100%)
Lung
Cell lines 4/10 (40%) 4/13 (30.8%) 7/9 (77.8%) 11/15 (73.3%) -
Tumours 2/9 (22.2%) 2/15 (13.3%) 0/10 (0%) 2/18 (11.1%) -
Normal tissue 1/7 (14%) 3/17 (17.6%) 0/10 (0%) 0/16 (0%) -
Glioma
Cell lines 3/6 (50%) 0/7 (0%) 7/7 (100%) 7/7 (100%) 3/7 (42.9%)
Tumours 2/11 (18.2%) - 5/11 (45.5%) 3/19 (15.8%) 0/13 (0%)
Normal tissue 0/1 (0%) - didn't work 0/4 (0%) 0/4 (0%)
Prostate 
Cell lines 2/5 (40%) 3/4 (75%) 1/5 (20%) 3/4 (75%) 2/5 (40%)
Tumours 0/14 (0%) 5/14 (35.7%) 5/14 (35.7%) 3/14 (21.4% 1/14 * (7.1%)
Normal tissue 0/4 (0%) 1/4 (25.0%) 0/4 (0%) 1/4 (25.0%) 2/4 * (50%)
Ovarian 
Cell lines - - - - -
Tumours 0/18 (0%) 3/19 (15.8%) 3/18 (16.7%) 1/9 (11.1%) 3/15 (20%)
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frequent methylation (7/22; 31.8%), indicating that EMILIN2 methylation may be an early 
event in colon carcinogenesis. All remaining tumours analysed for methylation of EMILIN2 
showed either infrequent or no methylation; NSCLC (2/9; 22.2%), gliomas (2/11; 18.2%), 
prostate (0/14; 0%) and ovarian (0/18 ,0%) (table 3.4). 
3.4.8.2 SALL1  
Colorectal and prostate tumours both showed frequent methylation of SALL1. Colorectal 
tumours demonstrated methylation in 44/53 (83%) of samples compared to 30/79 (38%) of 
normal colorectal tissue samples. As for EMILIN2, SALL1 showed a high level of methylation 
in colorectal adenomas 17/19 (89.5%). Prostate tumours demonstrated methylation in 5/14 
(35.7%) of tumours and 1/4 (25%) of normal prostate tissue samples. Both lung and ovarian 
tumours showed infrequent levels of methylation (2/15; 13.3%) and 3/19 (15.8%) respectively 
(table 3.4). Gliomas were not analysed for methylation since cell lines were unmethylated.  
3.4.8.3 FBLN2  
Frequent methylation of FBLN2 was observed in gliomas and prostate tumours. Gliomas 
showed methylation in 5/11 (45.5%) tumour samples and 1/14 (7%) normal brain samples. 
Prostate tumours were methylated in 5/14 (35.7%) of samples and 0/4 (0%) normal prostate 
tissue. Infrequent methylation was observed in ovarian cancer samples (3/18; 16.7%) and no 
methylation was observed in lung tumour samples (0/10) (table 3.4). Methylation was highly 
prevalent in colorectal cancers, adenomas and normal colorectal tissue suggesting FBLN2 
may be normally methylated in this tissue type.  
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3.4.8.4 CIDE-A 
Infrequent methylation of CIDE-A was observed for all tumour types analysed, methylation 
frequencies ranged from 11% in lung and ovarian cancers to 21.4% in prostate cancers (table 
3.4). As for FBLN2, high methylation levels were observed for CIDE-A in cancer, adenoma 
and normal colorectal tissues, suggesting CIDE-A is normally methylated in colorectal tissue.  
3.4.8.5 DBC1  
DBC1 has previously been shown to be methylated in lung cancer (Izumi et al, 2005) and has 
therefore not been analysed in lung cancer in this study. Low level methylation of DBC1 was 
observed in prostate cancer samples (1/14; 7%), but was present at a higher level in normal 
prostate tissue (2/4; 50%). The only cancer type to show more frequent methylation of DBC1 
was ovarian (3/15; 20%) (table 3.4). As for FBLN2 and CIDE-A, high levels of methylation 
were observed in cancer, adenoma and normal colorectal tissue, suggesting DBC1 is normally 
methylated in this tissue.  
From this analysis, relevant levels of methylation have been observed in prostate (SALL1 and 
FBLN2), colorectal (EMILIN2) and gliomas (FBLN2) (figure 3.11).  
3.4.9 miRNA analysis  
Analysis of probes considered to be associated with miRNAs identified 66 probes that 
showed a 5-fold enrichment in at least three out of five breast cancer cell lines compared to 
NHMECs. These 66 probes represented 25 miRNAs, of which three were located on the X 
chromosome and therefore discarded from any further analysis. Of the remaining 22, 7 were 
represented within the list by multiple probes and the remaining 15 were represented by single 
probes only. Of the 7 represented by multiple probes, 5 (hsa-mir-183, hsa-mir196a1, hsa-mir-
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Figure 3.11 CoBRA results for other solid tumour samples
CoBRA results are shown for two cancer types each for EMILIN2,
SALL1, FBLN2, CIDE-A and DBC1. Undigested products (U) are shown
next to digested products (D). For lung samples, results for associated
tumour (T) and normal (N) tissue are shown for each patient sample. *
indicates methylation
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596, hsa-mir-9-3 and hsa-mir-181c) were within a promoter region rather than downstream. 
Promisingly, one of these 5 miRNAs detected, hsa-mir-196a-1, has previously been shown to 
have the associated CpG island methylated in breast cancer (Hoffman et al, 2009), one has 
been shown to have altered expression in lung cancer, hsa-mir-183 (Cho et al, 2009) and 
another, hsa-mir-181c, has two associated family members (hsa-mir-181a and hsa-mir-181b) 
that have been shown to have tumour suppressor effects in glioma cells (Shi et al, 2008). 
Although confirmed analysis of methylated miRNAs was not a planned part of this 
investigation, an initial analysis was performed upon the best candidate, hsa-mir-183 (has-
mir196a-1 having already been previously demonstrated to be methylated in breast cancer), 
due to the number of positive probes and the possible biological significance. CoBRA assays 
of the breast cancer cell lines were performed to assess the region of the has-mir-183 CpG 
island with the greatest representation of probes and demonstrated infrequent methylation 
(1/9; 11%) in this region. Further investigation was not performed.  
155 
 
3.5 DISCUSSION  
Breast cancer represents the most common cancer in women both worldwide and in the UK 
(Jemal et al, 2011; CRUK cancer statistics) and the second most common form of cancer 
related deaths in women in the UK (CRUK cancer statistics). Death rates from breast cancer 
have been falling over the past 10 years (CRUK cancer statistics). This has been through a 
combination of increased disease understanding leading to better, more targeted therapies and 
earlier disease detection and preventative measures. Great leaps forward have been made in 
more personalised/targeted therapies for breast cancer patients such as trastuzumab 
(Herceptin) treatment for ERBB2 overexpressing tumours (Ménard et al, 2003; Hudis et al, 
2007), tamoxifen treatment for ER positive tumours (Jordan, 1993) and the development of 
MammaPrint and Oncotype DX expression profile assays to identify patients that are most at 
risk of relapse and therefore benefit from more rigorous therapy (Glas et al, 2006; Cobleigh et 
al, 2005). Preventative measures, such as a reduction in the use of post-menopausal hormone 
therapies, and the development of improved detection methods, such as nation-wide 
mammogram screening programs, have also had a dramatic effect on overall disease outcome. 
Nonetheless, breast cancer still remains the second most common cancer related death in the 
UK and the identification of further deregulated molecular targets are still required to enhance 
breast cancer outcomes. Identifying cancer specific DNA hypermethylation events represents 
a useful strategy for identifying genes that may be good targets for the identification of 
deregulated processes in cancer, but also as potential events that could be developed into 
biomarkers for diagnosis/prognosis/treatment plans. This study represents the first example of 
using the methylated CpG island recovery assay (MIRA) coupled with CpG island arrays in 
invasive breast cancer and one of the first studies to use a methylated DNA pull-down 
approach to identify methylated genes in breast cancer with other examples including a 
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MeDIP study on BRCA mutated primary patient samples (Flanagan et al, 2010) and a MeDIP 
approach coupled with sequencing on breast cancer cell lines (Ruicke et al, 2010).  
In addition to the present study, the MIRA assay in conjunction with CpG microarrays has 
now been used to assess the methylation status of lung cancers (Rauch et al, 2006), DCIS 
(Tommasi et al, 2009), childhood ALL (Dunwell et al, 2010) and astrocytomas (Wu et al, 
2010). In each case, the assay has been useful in identifying novel methylated genes in the 
respective cancers indicating the assay represents an effective methodology for such studies.  
Ductal carcinoma in situ (DCIS) is an early lesion of breast tissue that often acts as a 
precursor for invasive breast tumours. A MIRA study was carried out on 6 DCIS samples by 
the collaborators who performed the MIRA assay presented in this study using the same type 
of CpG island microarray. That study identified 81 target genes considered to be 
hypermethylated, and a further 27 target CpG islands that were unconnected to individual 
genes. Confirmation of some of these targets and subsequent analysis in invasive breast 
cancers found high levels of methylation to be both present and increased in invasive tumours 
(Tommasi et al, 2009). The study demonstrated one third of their target genes to be 
homeobox related family members and suggest methylation of multiple homeobox genes is a 
frequent and early event in breast cancer tumourigenesis (Tommasi et al, 2009). Comparison 
of the high stringency gene list from the work in this chapter against the 81 target genes from 
Tommasi et al identifies 27 genes that are within both lists, demonstrating a pleasing degree 
of overlap but also distinct differences. Of these, 13 (48%) are homeobox related family 
member genes. Of the 27 genes in both lists, two (BARHL2 and KLF11), were analysed in this 
chapter, both of which showed infrequent methylation when analysed by CoBRA in breast 
cancer cell lines and therefore were not analysed further.  
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Use of the MIRA assay in this study has identified five good candidate genes that are 
frequently methylated genes in breast cancer cell lines and sporadic ductal breast cancer 
patient samples. In addition, this study has also demonstrated frequent methylation of some of 
these genes in other cancers. Each gene, through known functions or association with other 
cancers, shows some promise as a factor that could be involved in the pathogenesis of breast 
cancers.  
3.5.1 CIDE-A 
This study has identified hypermethylation in 53% of analysed breast tumours, tumour 
specific methylation and re-expression following de-methylation in cell lines. No relevant 
levels of methylation were observed in other cancer types analysed, suggesting 
hypermethylation in cancer is so far specific to breast cancer.  
CIDE-A (cell death inducing DFFA-like effector a) is a 4 exon gene located at 18p11.2. It has 
a CpG island situated upstream of and across the transcription start point consisting of 942bp 
and 85 CpGs. Methylation of the CpG island has been shown to have a substantial effect on 
the expression of CIDE-A, providing a mechanism for tissue specific expression of the CIDE-
A gene (Li et al, 2008). To date, expression has been observed in adipose, heart, lymph node 
and from the present study, breast, tissues. Of other analysed tissues, no expression has been 
observed in liver, stomach, spleen and kidney (Li et al, 2008). The authors identified the 
minimal promoter region of CIDE-A to be within the CpG island and contain Sp1/Sp3 
transcription factor binding sites, which contain a CpG in the middle of their binding 
consensus sequence. They showed methylation of this region resulted in dramatically reduced 
expression of CIDE-A and that methylation was frequent in non-expressing tissues. They also 
demonstrated altered chromatin structure in methylated samples. The primers used in this 
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chapter amplify an overlapping region to that analysed in the study by Li et al (2008). 
Hypermethylation of CIDE-A has not previously been identified in cancer tissues respective 
to normal tissues, but the data from this study in breast cancer cell lines and Li et al (2008) 
suggests that the methylation detected is likely to reduce expression in methylated tumour 
samples. It would be nice to have data on the expression of CIDE-A in methylated and 
unmethylated primary breast tumours both at the mRNA and protein level. The work in this 
chapter also detected high levels of methylation in colorectal and prostate normal and 
cancerous tissues, suggesting expression of CIDE-A is unlikely in these tissues in their normal 
state.  
CIDE-A protein is a member of the CIDE family of proteins which consists of three members, 
CIDE-A, CIDE-B and CIDE-C. It is a 24kDa protein that has been shown to be able to 
activate apoptosis in a way which is unaffected by caspase inhibitors but inhibited by DFF45 
(DNA fragmentation factor 45kDa) (Inohara et al, 1998). CIDE-A also has a role in 
metabolism, in mice reduced CIDE-A levels produce a higher metabolic rate and lipolysis in 
brown adipose tissue accompanied by a resistance to diet-induced obesity and diabetes (Zhou 
et al, 2003). In cows, CIDE-A expression levels and that of an interacting partner, UCP1, are 
increased in mammary epithelial cells and lactating mammary glands when incubated with 
long chain fatty-acids and decreased when incubated with insulin. CIDE-A expression also 
appeared to be highest at periods of peak lactation (Yonezawa et al, 2009), suggesting a 
specific role for CIDE-A in normal mammary glands (in bovine tissue at least) and therefore 
conferring a possible role for CIDE-A deregulation in breast cells as a potential aggravating 
event for breast tumourigenesis. This functional information may also be relevant to the fact 
that CIDE-A methylation so far appears to be a breast cancer specific event.  
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The CIDE-A genes is located at 18p11.2, a region of LOH (loss of heterozygosity) in 
esophageal squamous cell carcinoma (Karkera et al, 2000) suggesting CIDE-A loss as a 
possible factor in esophageal squamous cell carcinoma.  
Two mutations have been described in CIDE-A in the COSMIC database (COSMIC – 
http://www.sanger.ac.uk/genetics/CGP/cosmic/), one in an ovarian tumour and one in a 
glioma tumour. Both mutations are single base substitutions resulting in amino acid changes 
of which one was predicted to be probably damaging by PolyPhen2 
(http://genetics.bwh.harvard.edu/pph2/) and the other intolerant by SIFT 
(http://sift.jcvi.org/www/SIFT_BLink_submit.html) but not vice versa (table 3.5). Taken 
together with the results from this study and the normal function of CIDE-A protein, CIDE-A 
appears to be a promising candidate for a role in tumourigenesis specifically in  breast and 
possibly in esophageal squamous cell carcinoma. Further research on the potential role of 
CIDE-A in breast cancer is warranted to investigate this further.  
3.5.2 DBC1 
This study has identified frequent (26%), tumour specific methylation of DBC1 in breast 
cancer. Methylation has also been demonstrated in ovarian cancer at a lower frequency (20%). 
DBC1 expression has been shown to be affected by methylation status in breast cancer cell 
lines.  
DBC1 (deleted in bladder cancer 1), NM_014618, not to be confused with deleted in breast 
cancer 1 (DBC1/KIAA1967), is an eight exon, 202kb gene. It has a CpG island consisting of 
1128bp containing 104 CpGs situated upstream of and including the transcription 
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GENE
Number of 
mutations in breast 
Number of mutations in other 
cancer types 
PolyPhen2 analysis      
(score)
SIFT analysis         
(p-value)
CIDE-A 0/11
p.P116T (Ovarian - 1/1) Probably damaging (0.967) Tolerant (0.49)
p.E203K (Glioma - 1/21) Benign (0.029) Intolerant (0.00)
DBC1 0/48
p.G109C (Ovarian -1/2) Possibly damaging (0.773) Intolerant (0.01)
p.G448S (Ovarian - 1/2) Probably damaging (0.990) Intolerant (0.00)
p.V562I (Glioma - 1/446) Possibly damaging (0.632) Tolerant (0.31)
p.G684D (Glioma - 1/446) Benign (0.140) Intolerant (0.01)
p.P712T (Colorectal - 1/37) Probably damaging (0.955) Intolerant (0.00)
EMILIN2 0/11 p.T245K (Ovarian - 1/1) Possibly damaging (0.326) Tolerant (0.14)
FBLN2 0/11 p.A1101E (Ovarian - 1/1) Possibly damaging (0.698) Tolerant (0.20) 
SALL1 0/11
p.T66P (Ovarian - 1/3) Probably damaging (0.975) Intolerant (0.01)
p.P577H (Ovarian 1/3) Possibly damaging (0.726) Tolerant (0.37)
p.E859D (Ovarian - 1/3) Possibly damaging (0.447) Tolerant (0.26)
Table 3.5_Mutational data of CIDE-A, DBC1, EMILIN2, FBLN2 and SALL1 from COSMIC
This table shows the mutational data from COSMIC for each of the five good candidate genes. The number of
mutations identified for breast and other cancers are shown along with PolyPhen2 and SIFT predictions on whether
these mutations are likely to be damaging/tolerant. COSMIC: http://www.sanger.ac.uk/genetics/CGP/cosmic/.
PolyPhen2: http://genetics.bwh.harvard.edu/pph2. SIFT: http://sift.jcvi.org/www/SIFT_BLink_submit.html.
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start point. The gene produces an 88 kDa protein. DBC1 was initially identified as a potential 
tumour suppressor gene in bladder cancer due to its location at 9q32-q33, a common region 
for LOH in this cancer (Habuchi et al, 1998). The Habuchi study (1998) also showed it to be 
frequently hypermethylated in bladder cancer but not mutated. Subsequently, 
hypermethylation has also been identified in NSCLC (Izumi et al, 2005), ALL (San José-
Enériz et al, 2006) and oral squamous cell carcinoma (Gao et al, 2004). In the COSMIC 
database, DBC1 is listed as having been assessed for mutation in 533 samples, covering 
ovarian, breast, large intestine and glioma tumours. Five mutations have been identified, 2 in 
ovarian (out of 2 samples), 1 in large intestine (out of 37 samples) and 2 in gliomas (out of 
446 samples). All mutations identified were base substitutions resulting in amino acid 
changes, 3 predicted to be damaging and intolerant by PolyPhen2 and SIFT while one was 
predicted to be probably damaging by PolyPhen2 and the other intolerant by SIFT but not 
vice versa (table 3.5).  
The DBC1 gene protein product is thought to function in cell cycle regulation, deregulation of 
which is highly amenable to tumourigenesis. Overexpression of DBC1 decreases cell growth 
without appearing to affect apoptosis, cells appear to have a reduced ability to progress from 
the G1 to S phases of the cell cycle (Nishiyama et al, 2001). The data obtained in this study, 
the function of DBC1 and involvement in other cancers suggests DBC1 downregulation is a 
good candidate for contribution to the pathogenesis of breast cancer.  
3.5.3 EMILIN2  
This study has identified EMILIN2 as being frequently methylated in breast and colorectal 
cancers (44% and 33.3% respectively). In both cases EMILIN2 methylation was specific for 
the tumour and in colorectal cancers is potentially an early event. In addition, methylation has 
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been shown to be capable of repressing expression of EMILIN2 in cell lines and 
downregulation of EMILIN2 associates with methylation in primary tumour samples. 
EMILIN2 methylation in breast cancer associated with ER status of tumours and, more 
importantly, associated with relapse and poor disease free survival.  
EMILIN2 (elastin microfibril interfacer 2) is a 67kb 8 exon gene and has a CpG island 
consisting of 1610bp containing 146 CpGs situated upstream of and across the transcription 
start site. It produces a 115kDa protein that forms a homotrimer. EMILIN2 was the second of 
three identified members of the EMILIN family. The family are a group of extracellular 
matrix glycoproteins characterised by a C-terminal gC1q domain and an N-terminal EMI 
domain (Colombatti et al, 2000). EMILIN2 is capable of inducing apoptosis by interacting 
with the TRAIL death receptor, DR4 in both in vitro and in vivo model systems (Mongiat et 
al, 2007).  EMILIN2 has been shown to have contrasting effects on tumour cells. 
Confusingly, it behaves both as a pro-apoptotic agent and a pro-angiogenic agent (Mongiat et 
al, 2010). When introduced into both in vitro and in vivo models, EMILIN2 was able to 
reduce growth via a pro-apoptotic mechanism utilising caspase-8 via DR4 receptor binding, 
however, in vivo, the remaining tumour had greater vessel density than untreated controls 
suggesting a proangiogenic effect. In combination with an antiangiogenic drug, tumours could 
be completely reduced in vivo, suggesting a potentially exploitable mechanism for treatment 
utilising EMILIN2. If this ever comes to fruition, whether tumours are methylated for 
EMILIN2 may help to identify patients who would be most susceptible to this treatment.  
EMILIN2 is located at 18p11.3 which has been shown to be a common region of LOH in 
breast cancer (Kittiniyom et al, 2001). In the Kittiniyom study (2001) the authors detected a 
high frequency of LOH (63%) at 18p11.3 that was prevalent in a high proportion of early 
grade DCIS (ductal carcinoma in situ) lesions, suggesting that this chromosomal event occurs 
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at an early stage in breast cancer progression. LOH at this locus associated with microsatellite 
instability and LOH at other common sites in breast cancer (3p, 9p, 17p, 17q). LOH at this 
locus has also been described in CRC (Kawakami et al, 2002), the association of LOH at this 
locus with microsatellite instability in breast cancer may therefore be of relevance to the CRC 
data obtained in this chapter and it would be interesting to see if methylation of EMILIN2 
associates with microsatellite unstable CRC tumours.  
EMILIN2 has not previously been shown to be methylated in cancer and the frequencies 
identified in this study suggest that methylation is most likely specific to a subset of cancers. 
The COSMIC database lists one mutation in EMILIN2 out of 45 samples assessed (consisting 
of a range of ovarian, breast, large intestine and glioma tumours). The mutation was a 
heterozygous mutation found in ovarian cancer consisting of a C to A substitution 
(c.734C>A) resulting in a threonine to lysine substitution at the amino acid level (p.T245K) 
predicted only to be possibly damaging by PolyPhen2 (table 3.5). The low prevalence of 
mutations suggests this is unlikely to be a major mechanism for inactivation/altered activity in 
common cancers however, coupled with the location within a region of LOH in breast cancer, 
the frequent methylation levels in breast and CRC tumours, the potential early stage during 
which expression may be lost and its pro-apoptotic functions, EMILIN2 is a promising 
candidate for further work in breast cancer. In addition, the association between EMILIN2 
methylation status with relapse and poor disease free survival suggests that the detection of 
EMILIN2 methylation may not only be of use in terms of good candidate gene identification 
but also as a potential candidate for further analysis as a marker of disease outcome.  
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3.5.4 FBLN2 
This study has identified frequent methylation (34%) in breast cancer that has been 
demonstrated to be tumour specific. Frequent methylation levels were also observed in 
prostate (35.7%) and glioma tumours (45.5%). In addition, breast cancer cell lines showed re-
expression of FBLN2 following treatment with the demethylating drug, 5azaDC suggesting 
methylation is capable of reducing FBLN2 expression.  
FBLN2 (fibulin 2) is located at 3p25.1, part of the larger 3p region commonly deleted in many 
cancers (Pandis et al, 1997; Kok et al, 1997). Currently three isoforms have been 
demonstrated at the locus, all of which are transcribed from one of two CpG island regions. 
This study has analysed the larger of the CpG islands identified by the MIRA probes, which 
consists of 594bp and contains 84 CpGs and is situated across the transcription start of two of 
the isoforms. Expression analysis covered both of these isoforms. 
The FBLN2 protein is a 126kDa secreted protein that forms a homotrimer and resides in the 
extracellular matrix (ECM) where it is thought to act as a scaffold protein, binding various 
ECM proteins such as fibrillin, type IV collagen, fibronectin, laminins, agrecan and versican 
(Argraves et al, 2003). It is part of a family of six FBLN proteins that appear to have roles in 
development (Argraves et al, 2003).  
Frequent hypermethylation of FBLN2 has previously been described in childhood ALL at a 
frequency of 56% in B-ALL and 17% in T-ALL (Dunwell et al, 2009) and downregulation 
has been observed in both breast cancer cell lines and primary tumours (Yi et al, 2007). The 
study by Yi et al (2007) demonstrated loss of the FBLN2 mRNA and protein in breast cancer 
cell lines and significant loss of the FBLN2 protein in 14/17(82.4%) primary breast tumours. 
In addition, the authors were able to demonstrate reduced cell migration and invasion when 
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re-introducing FBLN2 into non-expressing cell lines. No differences were observed in growth 
rate or binding to other ECM proteins, suggesting FBLN2 most likely has a role in breast 
cancer progression rather than initiation (Yi et al, 2007). The frequency of methylation 
observed in this chapter is much lower than the level of downregulation observed in the study 
by Yi et al (2007), suggesting other mechanisms play a role in downregulating this gene in 
breast cancers. The COSMIC database lists one mutation in FBLN2, detected in ovarian 
cancer (out of the only ovarian cancer sample analysed), no mutations were identified in the 
11 breast cancer samples analysed nor any of the other cancer types, bringing the total number 
of samples analysed to 45 (table 3.5). This suggests other mechanisms are likely to be 
responsible for downregulation of FBLN2 and as it is situated on the commonly deleted 
chromosome 3p region, tumour specific somatic deletion could cause the loss of at least one 
allele. Hypermethylation and downregulation has also been observed in other members of the 
FBLN family, FBLN3 (EFEMP1) has shown reduced expression at the mRNA level and 
methylation in breast cancer cell lines (Sadr-Nabavi et al, 2009). Frequent methylation was 
also observed in primary breast tumour samples coupled with reduced expression on the 
protein level (Sadr-Nabavi et al, 2009). FBLN1, FBLN4 and FBLN5 have been shown to be 
downregulated in prostate cancer (Wazlinski et al, 2007). 
These results add to the notion that FBLN2 hypermethylation is a common event in many 
cancers and that it often results in downregulation. Coupled with other results that have 
demonstrated the effects of loss of FBLN2 on tumourigenic properties in breast cancer cells 
(Yi et al, 2007), FBLN2 is an excellent candidate gene for further analysis, as are the other 
members of the FBLN gene family.  
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3.5.5 SALL1 
Methylation was identified in 63% of breast tumours analysed. This study has also shown the 
methylation in breast tumours to be tumour specific and capable of reducing expression in 
breast cancer cell lines. Frequent methylation has also been demonstrated in prostate tumours 
(35.7%) and colorectal tumours (83%), although the methylation in their respective normal 
tissues (25% and 38% respectively) was notably higher than the small amount observed in 
normal breast tissues (5%).  
SALL1 (sal-like 1 (drosophila)) is a three exon gene located at 16q12.1. It has a CpG island 
consisting of 5064bp with 366 CpGs. It encodes for a 140 kDa protein that functions as a zinc 
finger transcriptional repressor. Mutations within SALL1 cause Townes-Brock syndrome, a 
disorder characterised by imperforate anus, abnormally shaped ears and hand malformations, 
among other developmental malformations, suggesting SALL1 transcriptional activity is 
required at particular stages of development.  
SALL1 involvement in cancer is also likely to be due to transcriptional activity, it has recently 
been demonstrated that SALL1 is able to promote angiogenesis via activation of VEGF-A 
(Yamamoto et al, 2010). Hypermethylation has previously been shown in two types of 
leukaemia, ALL (Kuang et al, 2008) and CLL (Tong et al, 2010). SALL1 also resides within a 
region of LOH in multiple cancers, including breast, prostate, ovarian and retinoblastoma 
(Argos et al, 2008; Chin et al, 2007). The COSMIC database lists three different mutations in 
three different ovarian cancer samples, each a single base substitution resulting in an amino 
acid change, all of which predicted to be damaging by PolyPhen2 and 2 of which predicted to 
be intolerant by SIFT. Other cancers, including breast, have been analysed but no additional 
mutations identified (table 3.5).  
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The results from this study suggest that SALL1 is frequently methylated in breast and prostate 
cancer and due to its known functions, LOH and implications in other cancers, it’s 
downregulation as a result of hypermthylation is likely to be biologically relevant in the 
progression of breast cancers.  
3.5.6 Conclusions  
The aims of this study were to identify frequently methylated genes in breast cancer cell lines 
by use of the MIRA pull down assay coupled to a human CpG island array and use this data 
to identify frequently methylated genes in sporadic ductal breast cancers. The study was 
successful in identifying frequently methylated genes in breast cancer cell lines, identifying 
16 genes that showed frequent methylation in cell lines and no methylation in a normal breast 
sample, nine of which also showed frequent methylation in primary tumour samples. 
However, 32 genes were analysed from the array initially, meaning only a 50% success rate of 
genes that showed methylation when analysed by CoBRA in cell lines i.e. a 50% false 
positive rate. There are multiple reasons why this may be the case. The MIRA assay itself is 
likely to have some degree of intrinsic false positive rate from non-specific pull-down. This 
may be altered and improved by optimisation of the pull-down reaction. However the 
screening methodology and subsequent laboratory confirmation are the influences most 
heavily affecting this high false positive rate. The regions analysed by CoBRA did not 
necessarily cover the region in which the positive probes were situated, instead, because the 
aim was to identify functionally relevant genes, CoBRA primers were designed upstream of 
and around the transcription start site. Therefore, it may be that the microarray probes that 
detected tumour specific methylation at a specific region were not within the region assessed 
by CoBRA. The regions that were chosen to be assessed by CoBRA may have either not 
contained any probes or may have been negative for enrichment. Similarly, in the cases where 
168 
 
methylation was present in the selected region in both the tumour and the normal sample, the 
positive enriched probes may again sit outside of the probed area. Nevertheless, the regions 
selected for study normally represent the most relevant region in respect to identifying 
epigenetic gene silencing, which was the object of the study and was successful. However, 
important regions may have not been enriched for in the MIRA assay or overlooked in the 
array analyses, providing false negatives. Additionally, the CoBRA digest screen used will 
only provide a positive result if the methylated CpGs reside within a BstUI restriction site, it 
is therefore possible that methylation could be present, resulting in enrichment during the 
MIRA pull-down but be missed by the CoBRA assay. This could be corrected for by 
analysing each candidate region by bisulphite sequencing opposed to CoBRA. In this study 
CoBRA was chosen for two reasons; firstly it is an accepted, fast and efficient method for 
accessing methylation in a region, while bisulphite sequencing is a costly and lengthy process, 
and secondly to detect an expansive level of general tumour specific methylation rather than 
small amounts of possibly non-specific methylation. CoBRA is an effective methodology for 
both of these aims.  
For this type of study, where cell lines were used as the starting material, it should be taken 
into account that cell lines are known to demonstrate increased methylation both in terms of 
the regions demonstrating methylation and the depth of methylation at given regions 
(Smiraglia et al, 2001). The lack of methylation in primary samples compared to breast cancer 
cell lines for some genes is therefore likely to be due to the cell lines having acquired 
additional methylation.  
One advantage of using a CpG island microarray is that many CpG islands are being assessed, 
including those that relate to miRNAs and other chromosomal locations, giving a global 
assessment of methylation. In contrast, one downside to the CpG island microarray is that 
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probes are designed to represent general areas and so a larger CpG island has more probes. 
Therefore, if, as in this study, selection criteria take into account the number of positive 
probes for a given feature, which is a sensible and logical approach to whittling down the 
number of candidate genes, there is an intrinsic bias to genes with large CpG islands. 
Nevertheless, the success of this study, and others, demonstrates the validity of this 
methodology but it should be noted that other methodologies may be equally as successful or 
may identify alterative candidates missed by this screen or not so strongly represented by this 
breast cancer tumour cohort. 
Additionally, the CpG island microarray identified a subset of miRNAs that were potentially 
methylated in breast cancer cell lines, including some good candidates that have previously 
been shown to be involved in breast and/or other cancers. Since this was neither an aspect 
which we normally study nor one of the main aims of this chapter it was not extensively 
investigated, but does present as something that would be interesting to do in the future.  
Overall, this study was successful in identifying five genes that were methylated in breast 
tumours, and in some cases other tumours also. The genes also represented good candidates to 
be downregulated in cancer. Only primary mRNA levels for EMILIN2 were assessed in this 
study, however, it would be nice to see the same data for the other genes and also to see 
downregulation at the protein level. It would also be advantageous to demonstrate tumour 
suppressor properties for those of the five genes that have not previously been shown in breast 
cancer cells. All of the findings of this study would also benefit from repeat confirmation in 
other, larger cohorts of the relevant cancer type, which would hopefully highlight the 
strongest candidates and remove any cohort specific positive results. In conclusion, this study 
has identified 5 good candidates for involvement in sporadic breast cancer, of which the 
methylation status of one, EMILIN2, also associates with disease outcome.  
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This work has now been published under Hill et al, 2010. Molecular Cancer 9(51). A copy is 
provided at the back of the thesis.   
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CHAPTER 4 
ILLUMINA INFINIUM METHYLATION ANALYSIS OF SPORADIC BREAST 
TUMOURS 
 
4.1 ABSTRACT  
Use of the Illumina Infinium HumanMethylation27 array on a panel of clinically well 
characterised sporadic ductal breast tumours and non-cancerous breast tissue has identified 
263 candidate tumour specific hypermethylated genes (291 CpG loci probes) within sporadic 
tumours.  
Hierarchical clustering based on methylation levels splits the samples into three groups 
characterised by high, medium or low level methylation of the 291 probes (p<0.0001). Certain 
clinical features, most notably relapse status and oestrogen and progesterone receptor (ER and 
PR) status, clustered within these groups. ANOVA analysis also confirmed overall 
methylation levels differ significantly between relapse (p=0.035), oestrogen and progesterone 
positive receptor status (p=0.001) and lymph node positive tumours (p=0.042).  
To identify individual genes associated with particular clinical features, Fisher’s exact tests 
(with FDR correction) were performed, identifying genes where methylation status correlated 
with relapse (n=9), lymph node (n=2) and ER and PR receptor status (n=19). Among these 
were RECK and ACADL, both of which are novel methylated genes in breast cancer and have 
shown reduced expression in methylated primary tumour samples. In both cases, methylation 
status also associated with disease free survival (p=0.0009).   
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4.2 INTRODUCTION  
Work in chapter 3 focused on identifying novel genes hypermethylated in breast cancer by 
using a genome wide approach involving the initial assessment of breast cancer cell lines. The 
use of primary tumours as opposed to cell lines should be more representative of epigenetic 
aberrations within the endogenous tumour, however, the increased heterogeneity of primary 
tumours requires the use of a larger sample number when looking for relatively less common 
events. As technology has improved it has become possible to use a lower amount of starting 
material and analyse more samples at once for a relatively low cost. This has given rise to a 
plethora of large genome wide methylation profiling studies (Christensen et al, 2011; 
Noushmehr et al, 2010; O’Riain et al, 2009; Martín-Subero et al, 2009a). This is particularly 
useful when it is desirable to look at DNA methylation in relation to clinical characteristics. 
There are many factors that can affect clinical and prognostic outcomes in breast cancer, for 
example, patient age, menopause status, lymph node status, parity, dietary factors, hormone 
exposure and receptor status of the oestrogen, progesterone and ERBB2 receptors. Survival 
data from patients can also be used in these studies to identify factors that relate back to either 
overall survival (OS) or disease free survival (DFS).  
In an attempt to profile genome wide methylation changes in sporadic breast tumours in 
relation to clinical features and to identify additional novel hypermethylated genes, this study 
has utilised the Illumina Infinium HumanMethylation27 array on a cohort of clinically well 
characterized sporadic ductal breast tumours.  
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4.3 AIMS  
1. To use the Illumina Infinium assay to create a list of hypermethylated genes within 
this cohort of breast tumours and cluster potential hypermethylated candidates to 
identify groups with similar methylation profiles 
2. To compare overall methylation levels between tumours with different clinical 
characteristics  
3. To identify individual genes where hypermethylation associates with specific clinical 
features 
4. To confirm selected hypermethylated genes associated with either clinical features or 
highly methylated/multiple positive probes 
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4.4 RESULTS 
4.4.1 Use of Illumina Infinium HumanMethylation27 BeadChip to measure genome wide 
DNA methylation changes  
This study used the Illumina Infinium HumanMethylation27 Bead Chip on a panel of 39 
clinically well characterized sporadic breast tumours and 4 further sporadic tumours along 
with matched normal breast tissue DNA from these 4 patients, see table 4.1 for clinical details 
of the 39 sporadic samples.  
The Infinium array assesses methylation levels of 27,578 single CpG dinucleotides within 
14,475 consensus coding sequencing (CCDS) genes. This results in an average of two probed 
CpG dinucleotides being measured for each gene, unless genes are known to be cancer related 
or imprinted, in which case the number of probed CpG dinucleotides raises to between 3 and 
20 per gene. In addition, 110 miRNAs are assessed using 254 probed CpG dinucleotides. 
Methylation levels are given as a quantitative numerical value (β value) ranging between 0 
and 1. This value represents the ratio of methylated signal to unmethylated signal, where 0 
indicates no methylation and 1 indicates complete methylation. The basis of Infinium CpG 
assay design was discussed in chapter one, see section 1.3.7.3 for more information.  
Scatter plots of all β values for a single sample against another demonstrates the amount of 
correlation between the two samples. Repetition of the Illumina assay on the same DNA 
sample shows a very high level of correlation, R
2
 = 0.9955, showing that the assay is highly 
reproducible (figure 4.1). It should be noted that the repetition sample is an RCC tumour done 
at the same time and on the same chip (each chip accommodating 12 samples) as some of the 
breast samples used in this study and not DNA of one of the tumours analysed in this study. 
This scatter plot has been provided courtesy of Dr. C.J. Ricketts. The four normal breast DNA 
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Tumour
Age at 
diagnosis 
(yrs)
Size 
(mm)
Grade 
(SBR)
Lymph node 
positive
Menopausal 
ER 
positive  
PR 
positive 
ERBB2 
overexpression  
Relapse 
Disease free 
survival (days) 
B1 – 43 36 22 3 1 0 1 0 0 0 5185
B2 – 129 45 33 2 1 0 1 1 0 1 4014
B3 – 132 50 16 2 1 1 1 1 0 0 4294
B4 – 182 54 30 3 1 1 0 0 0 1 3287
B5 – 198 50 20 2 1 0 1 1 0 0 4914
B6 – 207 66 52 3 1 1 0 0 1 0 4822
B7 – 304 60 40 2 1 1 0 1 0 1 2433
B8 – 309 57 22 2 1 1 1 1 1 1 2357
B9 – 310 63 22 1 1 1 1 1 0 1 3710
B10 – 320 44 30 2 1 0 1 1 0 1 2419
B11 – 346 56 36 2 1 1 1 0 0 1 5152
B12 – 375 50 60 3 1 0 0 0 0 0 3166
B13 – 379 64 29 2 1 1 1 0 1 1 2554
B14 – 385 35 35 2 1 0 1 1 0 0 3671
B15 – 406 60 25 3 1 1 1 0 1 0 3106
B16 – 409 83 45 2 1 1 1 1 0 1 1356
B17 – 436 73 25 2 1 1 0 1 0 0 2140
B18 – 439 39 NIA NIA 1 0 0 0 0 0 3235
B19 – 485 70 25 2 0 1 1 1 0 0 247
B20 – 505 86 30 2 0 1 0 0 0 0 694
B21 – 535 48 27 3 0 0 0 0 1 0 2968
B22 - 545 55 27 3 0 1 0 0 0 0 2534
B23 – 552 44 50 3 1 0 1 1 0 1 1697
B24 – 1116 63 30 3 0 1 0 0 0 0 4704
B25 – 1122 42 40 2 1 0 1 1 0 1 1029
B26 – 1128 60 26 3 0 1 0 0 1 0 4733
B27 – 1171 72 24 NIA 0 1 0 0 0 0 3382
B28 – 1173 51 14 2 1 1 1 1 0 0 3277
B29 – 1198 43 37 3 1 0 0 0 0 0 2308
B30 – 1209 66 25 3 1 1 0 0 0 0 2591
B31 – 1211 41 21 2 1 0 1 1 0 0 2702
B32 – 1213 71 29 3 0 1 0 0 0 0 2468
B33 – 1219 56 40 2 1 1 1 1 0 0 2501
B34 – 1227 41 25 2 1 0 1 1 0 1 1923
B35 – 1229 62 31 2 1 1 1 1 0 1 2498
B36 – 1265 51 31 3 1 0 1 0 1 1 2080
B37 – 1279 52 30 3 1 1 1 1 0 1 1807
B38 – 1282 43 25 2 1 0 0 1 1 1 729
B39 - 1291 53 20 2 1 1 0 1 0 1 1288
Table 4.1_Clinical features of the 39 sporadic breast tumours used in the array.
This table shows clinical features for the 39 tumours used in the array. Parameters cover; age at diagnosis (years), tumour size (mm),
grade (SBR), lymph node status (positive or negative), menopause status (positive or negative),ER status (positive or negative), PR
status (positive or negative), ERBB2 overexpression status (overexpressed or not overexpressed), relapse status (positive or
negative) and disease free survival (days since diagnosis until relapse event). 1=positive 0=negative.
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Figure 4.1_Correlation of a replicated sample
This graph shows the correlation between the array results for one
sample run twice on the Infinium array. This graph represents an RCC
tumour duplicated on the same run as some of the breast cancer
samples. The graph has been provided by Dr. Chris Ricketts
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samples showed high levels of correlation between them, ranging from R
2
=0.9302 (normal 1 
versus normal 4) to R
2
=0.974 (normal 2 versus normal 4) (figure 4.2), suggesting all normal 
samples have a similar spread of DNA methylation and little variation, making suitable 
controls to be used for further analysis. As expected, the correlation between tumour normal 
pairs showed a greater level of variation, particularly in pairs 1 and 2 which showed R
2 
values 
of 0.7243 and 0.8337 respectively, whilst pairs 3 and 4 showed less variation (R
2
=0.9381 and 
R
2
= 0.909 respectively) (figure 4.3). These results show that pairs 1 and 2 have much higher 
levels of DNA methylation alterations than pairs 3 and 4 which may be indicative of DNA 
methylation deregulation playing a larger role in the onset or progression of tumours 1 and 2. 
This may be due to DNA methylation changes acting as a driving factor within these two 
tumours as oppose to pairs 3 and 4 which may have alternative overriding factors, such as 
genetic events like mutation. Unfortunately extensive clinical details of these tumour normal 
paired samples is unavailable and therefore cannot be analysed for any obvious differences 
that may associate with these differential levels of DNA methylation changes.  
4.4.2 Identification of candidate hypermethylated loci 
The earliest Infinium published work and Illumina literature based on said work has shown a 
β-value below 0.25 as being representative of unmethylated DNA (Martín-Subero et al, 
2009a). For this reason, all probes showing β > 0.25 in any of the four normal samples were 
removed (n=11,211). The remaining probes (n=16,367) were analysed in two different ways; 
probes were removed if less than 20% exhibited either (a) a β-value above a certain cut off 
(cut-offs ranged from 0.4 to 0.6), or, (b) a difference in tumour and mean normal β-values 
above a certain cut-off (cut-offs ranged from a difference of 0.3 to 0.5). The number of probes 
detected as being hypermethylated by these methods ranged from 69 probes representing 64 
genes to 606 probes representing 524 genes, selection criteria being a β-difference cut-off of 
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R2=0.9528
Normal 1 vs. Normal 2 
R2=0.9506
Normal 1 vs. Normal 3 
R2=0.9302
Normal 1 vs. Normal 4 
Normal 2 vs. Normal 3 
R2=0.9605 R2=0.974
Normal 2 vs. Normal 4 Normal 3 vs. Normal 4 
R2=0.9483
Figure 4.2_β value correlation between normals.
Scatter plots are shown for comparisons of normal samples.
R2 = correlation coefficient.
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Figure 4.3_β value correlation between tumour normal paired samples.
Scatter plots are shown for each of the four tumour normal pairs used in
the array. R2 = correlation coefficient
Pair 1
Tumour 1 vs. Normal 1  
R2=0.7243
Pair 2
Tumour 2 vs. Normal 2 
R2=0.8337
Pair 3
Tumour 3 vs. Normal 3  R2=0.9581
Pair 4
Tumour 4 vs. Normal 4  
R2=0.909
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0.6 and a β-value cut off of 0.4 respectively (figure 4.4). To select a workable number of 
genes and also take into account the unfairness of a direct β-value cut-off on samples very 
close to the cut-off value, the lists for β-value >0.5 and β-difference >0.4 were combined, 
giving 153 genes that were in both lists, 81 only in β-value >0.5 and 30 only in β-difference 
>0.4 (figure 4.4) and an either/or list of 291 probes representing 264 genes, all genes are 
shown in appendix B.III. All genes on the X chromosome or known to be imprinted were 
removed from the analysis. The either/or list of 291 probes/264 genes was used for further 
analysis.  
4.4.3 Array validation  
The list contained a number of genes already known to be methylated in breast cancer, for 
example, APC, CCND2, GSTP1 and PTPRO (Jin et al, 2001; Evron et al. 2001; Esteller et al, 
1998; Ramaswamy et al, 2009) suggesting the list produced was suitable for further analysis, 
however, to confirm this further, the list was tested in two ways; (i) individual β-values were 
assessed, and (ii) the function of the genes within the list were considered.  
4.4.3.1 Assessment of individual β-values  
Three genes were chosen from the list previously shown to have an association with cancer, 
SFRP5, CLDN6, and SIPA1 (Veeck et al, 2008a, Tsuonda et al, 2009 and Gaudet et al, 2009), 
to be used for β-value validation. A region encompassing the significant CpG being measured 
by the Infinium probe was clone sequenced for DNA samples showing β-values considered to 
be methylated and unmethylated. 
For SFRP5, samples were sequenced with β-values of 0.54 (sample 304), 0.01 (sample 1116) 
and 0.04 (sample 43), all of which showed methylation at the probe CpG to be of a similar
181 
 
Probes Genes X-chromosome Imprinted 
0.4 606 524 4 12
0.5 261 241 1 6
0.6 69 66 0 2
0.7 6 6 0 0
Probes Genes X-chromosome Imprinted 
0.3 587 501 3 14
0.4 207 189 1 4
0.5 41 40 0 1
β-value cut off β-value difference cut off
153 
intersecting 
genes 
291 probes (264 genes) 
Figure 4.4_ Identification of hypermethylated loci.
The numbers of probes and genes for each selection criteria are shown, along with the numbers of X-chromosome genes
and imprinted genes. A Venn diagram representative of combining β-value >0.5 and β-difference >0.4 is also shown.
β-value 
difference >0.4 
β-value >0.5 
81 30
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 level to the β-value, 0.67, 0.14 and 0.00 respectively, and comparable methylation indexes 
(MIs) (76.0%, 1.93% and 2.4% respectively) (figure 4.5). The same trend was observed for 
SIPA1, where high β-values (0.53 (sample 1265) and 0.70 (sample 207)) showed both high 
probe values and MIs (figure 4.6) whilst the remaining low β-value sample (sample 43, β-
value = 0.13) showed a low probe value (0.00) and higher MI (20.0%). CLDN6 results show a 
similar trend of high β-values corresponding to high probe values and MIs (samples 375 and 
198, figure 4.7) with the only slight exception of sample 1178, showing a low β-value and a 
low probe value with a higher MI (33.9%). This is due to relatively frequent methylation 5’ 
(upstream) of the CpG being assessed by the Infinium assay (figure 4.7).  
Results for SFRP5, SIPA1 and CLDN6 demonstrate β >0.5 and β <0.25 represent methylation 
and no methylation at the CpG respectively but also that β-values appear to be indicative of 
methylation status of the immediate surrounding region. These results show the list criteria to 
be a reliable indicator of methylation.  
4.4.3.2 Functional assessment of gene list  
A good indication of whether the list produced is acceptable to do further work on is to assess 
the types of genes within the list. 
Funcassociate (http://llama.mshri.on.ca/funcassociate/) is a freely available program that 
identifies gene ontology (GO) terms within a set list of genes and determines whether any 
particular GO terms are over represented. When performed on this dataset, 21 GO terms are 
identified as being enriched, many of these GO terms are involved with development, for 
example, 84 genes, 16 genes and 33 genes are associated with the GO terms ‘developmental 
process’, ‘pattern specification process’ and ‘multicellular organismal development’ 
respectively.  
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Figure 4.5_β-value validation for SFRP5.
Clone sequencing results are shown for SFRP5 (NM_00315) for the region
surrounding Illumina ID (ILMNID) cg05937453. A gene schematic is shown with
exons in blue, introns as straight black lines and CpG islands in green. The schematic
illustrates the location of the region being sequenced (black dotted line) and the CpG
being assessed by the Infinium assay (highlighted in red). Sequencing results are
shown for three samples (304, 1116 and 43) with β-values, probe values (value
between 0 and 1 as determined by clone sequencing for CpG being assessed in
Infinium assay) and methylation index (MI) (given as a percentage of methylated
CpGs out of total CpGs analysed). For sequencing results, each black line represents a
single allele, black and white circles represent methylated and unmethylated CpGs
respectively.
β value = 0.54
β value = 0.01 
β value = 0.04 
SFRP5 
CpG
304
probe value = 0.67
MI = 76.0 %
1116
probe value = 0.00
MI = 1.9 %
43
probe value = 0.00
MI = 2.4 %
NM_003015    cg05937453
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37
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SIPA1
CpG
β value = 0.53
1265
probe value = 1.00
MI = 100%
β value = 0.70
207
probe value = 0.80
MI = 83.8%
β value = 0.13
43
probe value = 0.00
MI = 20.0%
NM_153253    cg25361844
1 3 5 7
1 3 5 7
1 3 5 7
Figure 4.6_β-value validation for SIPA1.
Clone sequencing results are shown for SIPA1 (NM_153253) for the region
surrounding Illumina ID (ILMNID) cg25361844. A gene schematic is shown with
exons in blue, introns as straight black lines and CpG islands in green. The schematic
illustrates the location of the region being sequenced (black dotted line) and the CpG
being assessed by the Infinium assay (highlighted in red). Sequencing results are
shown for three samples (1265, 207 and 43) with β-values, probe values (value
between 0 and 1 as determined by clone sequencing for CpG being assessed in
Infinium assay) and methylation index (MI) (given as a percentage of methylated
CpGs out of total CpGs analysed). For sequencing results, each black line represents a
single allele, black and white circles represent methylated and unmethylated CpGs
respectively.
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β value = 0.80
β value = 0.54
β value = 0.10
probe value = 1.00
MI = 95.7 %
probe value = 1.00
MI = 55.7 %
CLDN6
CpG
NM_021195    cg07384961
375
198
1178
probe value = 0.20
MI = 33.9%
1 3 5 7 9 11 13 15 17 19 21 23
1 3 5 7 9 11 13 15 17 19 21 23
1 3 5 7 9 11 13 15 17 19 21 23
Figure 4.7_β-value validation for CLDN6.
Clone sequencing results are shown for CLDN6 (NM_021195) for the region
surrounding Illumina ID (ILMNID) cg07384961. A gene schematic is shown with
exons in blue, introns as a straight black line and CpG islands in green. The schematic
illustrates the location of the region being sequenced (black dotted line) and the CpG
being assessed by the Infinium assay (highlighted in red). Sequencing results are
shown for three samples (375, 198 AND 1178) with β-values, probe values (value
between 0 and 1 as determined by clone sequencing for CpG being assessed in
Infinium assay (highlighted in red) and methylation index (MI) given as a percentage
of methylated CpGs out of total CpGs analysed. For sequencing results, each black
line represents a single allele, black and white circles represent methylated and
unmethylated CpGs respectively.
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The Database for Annotation, Visualization and Integrated Discovery (DAVID) 
(http://david.abcc.ncifcrf.gov/) was used to assess functional properties of genes within the 
list. The functional annotation chart tool identified the presence of many genes related to areas 
of carcinogenesis: cell adhesion (24 genes), regulation of cell proliferation (21 genes), 
negative regulation of cell death (15 genes), cell migration (12 genes), regulation of cell cycle 
(10 genes) and tumour suppressors (6 genes) (figure 4.8). Relevant pathways were also 
identified through the DAVID pathway analysis tool; pathways in cancer (12 genes), cell 
adhesion molecules (7 genes) and the Wnt signalling pathway (6 genes) (figure 4.8). 
Taken together, results from the β-value validation and assessment of genes within the list 
suggest the initial analysis of the β-values produces a suitable selection for further analysis. 
Further work on this list involved (i) looking at good candidate genes where breast cancer 
hypermethylation is a novel event and (ii) analysis of methylation with clinical features, both 
globally and individually.  
4.4.4 Analysis of candidate genes  
To analyse candidate genes from within the list prior to assessing clinical features, three genes 
were chosen each from those that were most highly methylated, and those that showed more 
than one probe within the list of 291.  
4.4.4.1 Highly methylated genes  
The use of two selection criteria means that a single sample can be considered 
hypermethylated in one of two ways. To simplify this for further analysis, samples were given 
a value of either 1 or 0 representing methylated and unmethylated respectively by either 
criteria. Probes could then be ranked in order of highest to lowest frequency of methylation.  
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DAVID functional chart analysis
Regulation of cell death; 26 genes (10.7%)
APC IHH CCK GSTP1 STAT5A DDAH2
BDNF POU4F1 CDKN2A NEUROD1 KIT EDNRB
CARD11 ACVR1 DCC PAX7 WRN FOXL2
GRIP2 RUNX3 RYR2 SFRP1 SST SOC2
TNFRSF10D BRAF
Cell adhesion; 24 genes (9.9%)
CD9 AEBP1 CDH9 IGFBP7 PDPN MCAM
APC CD34 CHL1 ICAM2 PCDHAC1 NCAM2
AJAP1 CNTNAP2 CLDN11 KIRREL2 PCDHGB7 RELN
AOC3 FLRT2 CLDN6 LAMA2 PCDHGA12 SCARF2
Regulation of cell proliferation; 21 genes (8.7%) 
IHH BTG4 APC CDKN2A RUNX3 PDGFRB
KLF11 BTG3 BDNF EDNRB STAT5A
CDX2 CLEC11A CARD11 IGFBP7 KIT
CCND2 CD9 PRKCQ PLAU SST 
Negative regulation of cell death; 15 genes (6.2%)
APC IHH DDAH2 PAX7 SOCS2 GSTP1
BDNF ACVR1 EDNRB SFRP1 TNFRSF10D NEUROD1
KIT STAT5A BRAF 
Cell migration; 12 genes (5%) 
POU4F1 CD34 APC EDNRB RELN PDGFRB
DCC ISL1 CCK PLAU KIT
Cell-cell adhesion; 11 genes (4.5%)
CLDN11 CD34 CLDN6 PPDN PCDHGA12 PCDHGB7
NCAM2 CDH9 ICAM2 PCDHAC1 SCARF2
Regulation of cell cycle; 10 genes (4.1%)
BTG4 CCND2 CDKN2A STAT5A
BTG3 PKIA RUNX3
APC PRKCQ SIPA1
Tumour supressor; 6 genes (2.5%) 
RASSF2 APC CDKN2A DCC KLK10 RECK
DAVID KEGG pathways 
Pathways in cancer; 12 genes (5%)
APC DCC GSTP1 RALBP1 STAT5A KIT
CDKN2A FZD10 HHIP LAMA2 PDGFRB BRAF 
Cell adhesion molecules; 6 genes (2.5%)
CD34 CLDN11 CLDN6 CNTNAP2 ICAM2 NCAM2
Wnt signalling pathway; 7 genes (2.7%)
CCND2 APC FXD10 SFRP2 SFRP5 SFRP4
SFRP1
Figure 4.8._DAVID analysis of hypermethylated loci
This figure shows the genes involved in functions and pathways relevant to
carcinogenesis as identified through DAVID chart analysis and KEGG pathway
analysis respectively. The numbers of genes in each functional group/pathway
is shown along with the percentage this accounts for out of total number of
genes.
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The top ten methylated probes represent eight genes, INPP5B (inositol polyphosphate-5-
phosphatase), ABCA3 (ATP-binding cassette, sub-family A (ABC1), member 3), COX7A1 
(cytochrome c oxidase subunit VIIa polypeptide 1 (muscle)), C12orf34 (chromosome 12 open 
reading frame), SST (somatostatin), ZNF154 (zinc finger protein 154), C1orf114 
(chromosome 1 open reading frame 114) and GPC2 (glypican 2). Of these eight genes, all but 
INPP5B and C12orf34 are assayed by the Infinium array within a ‘true’ CpG island 
(occasionally CpG probes lie outside of well-defined CpG islands, those that are within a 
well-defined CpG island are designated as being within a ‘true’ CpG island by Illumina) 
(figure 4.9). The top three of these genes, ABCA3 (69.2%), COX7A1 (69.2%) and SST 
(59.0%) were chosen to be analysed further.  
Firstly, to determine if methylation was likely to have a functional impact, gene expression in 
breast cancer cell lines was determined pre and post 5-azaDC treatment. Re-expression was 
observed in COX7A1 and SST but not ABCA3. Cell line methylation status was subsequently 
determined for COX7A1 and SST, both of which showed methylation by CoBRA assay in re-
expressing lines (figure 4.10). COX7A1 and SST CoBRA assays were further used on tumour 
normal paired samples to assess the wider presence of methylation and tumour specificity in a 
separate cohort (figure 4.11). High overall frequencies of methylation were observed for both 
COX7A1 and SST, 100% and 68.4% respectively. COX7A1 showed increased methylation in 
70.6% (12/17) of tumours compared with low levels of methylation present in corresponding 
normal tissue and a further 5 tumours showed equal amounts of low level methylation in both 
tumour and corresponding normal tissue. SST showed tumour-specific methylation in 31.6% 
(6/9) of pairs and increased methylation in a further 31.6% (6/19) of tumours compared with 
corresponding normal tissue. One tumour showed an equal amount of low level methylation 
in the tumour and normal. No methylation was observed in the remaining tumours.  
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Figure 4.9_Top ten highly methylated probes.
The figure shows the ten most methylated probes according to selection criteria ranked in order of methylation frequency.
Methylation status is indicated for each of the 39 sporadic tumours (B1-B39) with either a red circle (methylated) or green
circle (unmethylated). The frequency of methylated samples is also shown and whether the CpG being assessed resides in a
true CpG island (TRUE) or not (FALSE). Purple, blue and pink arrows are aligned to the three top genes with true CpG
islands.
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HCC1806
Exp. 
+ - + -
MCF-7
Exp.
+ -
T-47D
Exp.
Normal
Exp.
ABCA3
Figure 4.10_Cell line CoBRA and expression analysis for highly methylated genes.
Expression results (Exp.) are shown for ABCA3, COX7A1, SST and GAPDH. Three cell lines are shown in each case, all
with (+) and without (-) treatment with 5-azaDC. Expression for normal breast tissue RNA is also shown. Where re-
expression was seen (COX7A1 and SST) CoBRA results are also shown for the corresponding cell line. Undigested products
(U) are run next to digested products (D). * indicates methylated samples
HCC1806
Exp.
HCC1937
Exp.
HCC1395
CoBRA Exp.
U       D
Normal
Exp.
COX7A1
+ - + - + -U       DU       D
CoBRACoBRA
HTB-19
CoBRA Exp.
HCC1395
CoBRA Exp.
MDA-MB-231
CoBRA Exp.
Normal
Exp.
SST
U       D U       D U       D + -+ -+ -
* * *
* * *
SST
GAPDH
SST
GAPDH
SST
GAPDH
COX7A1
GAPDH
COX7A1
GAPDH
COX7A1
GAPDH
ABCA3
GAPDH
ABCA3
GAPDH
ABCA3
GAPDH
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T N
U     D
T N T N T N T N
T/N Pair 1966 T/N Pair 1153 T/N Pair 1206 T/N Pair 1656 T/N Pair 559
COX7A1
U     D U     D U     D U     D U     D U     D U     D U     D U     D
T N T N T N T N T N
SST
T/N Pair 1512 T/N Pair 1018 T/N Pair 677 T/N Pair 1434 T/N Pair 1693
U     D U     D U     D U     D U     D U     D U     D U     D U     D U     D
Figure 4.11_CoBRA tumour/normal pair results for COX7A1 and SST.
CoBRA results are shown for five tumour (T) and normal (N) paired samples with
undigested product (U) run adjacent to digested product (D). * indicates methylated
samples
* * * * * * * *
* * * * *
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4.4.4.2 Genes with multiple probes  
Twenty four genes were represented by more than one probe within the list of 291, four of 
which have previously been shown to be methylated in breast cancer, APC, CCND2, GSTP1, 
and PTPRO (Virami et al, 2001; Evron et al, 2001; Esteller et al, 1998; Ramaswamy et al, 
2009). Of the remaining twenty genes, three, LAMA2, CDKL2 and ZNF154, were selected for 
further analysis because of multiple probes (figure 4.12). A further four genes present within 
this list were analysed later in this chapter due to an association with clinical features (see 
4.4.5.3).  
Both CDKL2 and ZNF154 showed re-expression following treatment with 5-azaDC whilst 
LAMA2 showed uniform expression, subsequent CoBRA analysis of CDKL2 and ZNF154 in 
breast cancer cell lines showed methylation in re-expressing lines (figure 4.13). Tumour 
normal pairs demonstrated high tumour methylation levels for ZNF154 (87.5%), of which the 
majority (56.2%; 9/16) showed tumour specific methylation. Of the remaining samples, 25% 
(4/16) showed increased methylation in the tumour compared to corresponding normal, 6.3% 
(1/16) showed equal methylation in the tumour compared to normal and 12.5% (2/16) were 
unmethylated. High levels of methylation were also observed for CDKL2 (56.3%; 9/16). 
Tumour specific methylation was observed in 25% (4/16) samples, whilst 12.5% (2/16) of 
samples showed increased methylation in the tumour compared to normal, 18.8% (3/16) 
showed equal methylation in the tumour compared to normal and 43.8% (7/16) were 
unmethylated (figure 4.14).  
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cg22472290
ACADL
APC
C1orf114
CCND2
CDKL2
COL1A2
DCC
FOXL2
GRIA1
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HDAC9
HOXD9
INPP5B
KCNC3
LAMA2
MYO3A
NPY
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PPGB
PTPRO
TNFRSF10D
ZNF154
ZNF560
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9 (23.1%) 
8 (20.5%) 
10 (25.6%)
8 (20.5%)
20 (51.3%)
20 (51.3%)
14 (35.9%)
11 (28.2%)
10 (25.6%)
9 (23.1%)
9 (23.1%)
10 (25.6%)
8 (20.5%)
13 (33.3%)
8 (20.5%)
9 (23.1%)
8 (20.5%)
10 (25.6%)
9 (23.1%)
14 (35.9%)
9 (23.1%)
12 (30.8%)
10 (25.6%)
11 (28.2%)
8 (20.5%)
12 (30.8%)
11 (28.2%)
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22 (56.4%)
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14 (35.9%)
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13 (33.3%)
9 (23.1%)
13 (33.3%)
10 (25.6%)
9 (23.1%)
9 (23.1%)
18 (46.2%)
17 (43.6%)
10 (25.6%)
9 (23.1%)
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12 (30.8%)
22 (56.4%)
17 (43.6%)
15 (38.5%)
9 (23.1%)
14 (35.9%)
8 (20.5%)
Methylation 
frequency 
Gene 
symbol 
ILMNID
acyl-Coenzyme A dehydrogenase; long chain precursor
adenomatosis polyposis coli
hypothetical protein LOC57821
cyclin D2
cyclin-dependent kinase-like 2
alpha 2 type I collagen 
deleted in colorectal carcinoma 
forkhead box L2
glutamate receptor; ionotropic; AMPA 1
glutathione transferase
histone deacetylase 9 isoform 1 
homeobox D9
inositol polyphosphate—phosphatase; 75kDa
shaw-related coltage-gated potassium channel protein 3 
laminin alpha 2 subunit precursor 
myosin IIIA
neuropeptide Y
phosphatase and actin regulator 3 isoform 2 
protective protein for beta-galactosidase
receptor-type protein tyrosine phosphatase O isoform b precursor 
receptor-type protein tyrosine phosphatase O isoform d precursor 
zinc finger protein 154 (pHZ-92)
zinc finger protein 560
zinc finger protein 577
Gene product 
Previously methylated in breast cancer
Previously methylated in breast cancer
Previously methylated in breast cancer
Previously methylated in breast cancer
Selected for test analysis
Selected for test analysis
Selected for test analysis
Selected  by clinical criteria - relapse
Selected  by clinical criteria - ERPR
Selected  by clinical criteria - ERPR
Selected  by clinical criteria - ERPR
Figure 4.12_Genes with multiple probes.
The methylation status for all genes with multiple probes is represented by red and green circles for methylation and no
methylation respectively. Methylation frequencies and gene product names are also shown. Genes chosen to be analysed because of
multiple probes are highlighted with red arrows, genes previously shown to be methylated in breast caner are highlighted with blue
arrows and purple and green arrows highlight genes analysed because of an association with clinical characteristics (see 4.4.5.3).
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Figure 4.13_Cell line CoBRA and expression analysis for highly methylated genes.
Expression results (Exp.) are shown for LAMA2, CDKL2, and ZNF154 and GAPDH. Three cell lines are shown in each case,
all with (+) and without (-) treatment with 5-azaDC. Expression for normal breast tissue RNA is also shown. Where re-
expression was seen (CDKL2 and ZNF154) CoBRA results are also shown for the corresponding cell lines. Undigested
products (U) are run next to digested products (D). * indicates methylated samples
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Figure 4.14_CoBRA tumour/normal pair results for CDKL2 and ZNF154.
CoBRA results are shown for five tumour (T) and normal (N) paired samples with
undigested product (U) run adjacent to digested product (D). * indicates methylated
samples
* * * * *
* * * * * *
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4.4.5 Analysis of clinical features 
Overall tumour hypermethylation levels were assessed using Euclidean hierarchical clustering 
and analysis of variance.  
4.4.5.1 Hierarchical clustering 
Hierarchical clustering was performed upon the selected hypermethylated probes to cluster 
the 39 tumours into groups showing the greatest similarity in methylation profiles. Three 
distinct clusters were produced with two outliers (figure 4.15). Cluster 1 consisted of 18 
highly methylated tumours (mean β value = 0.433), cluster 3 (n=12) showed low overall 
methylation levels (mean β value = 0.176) and cluster 2 (n=7) showed an intermediary level 
of methylation (mean β value = 0.317) (p<0.0001; ANOVA) (figure 4.16a). Samples in 
cluster 1 were enriched in samples that relapsed (66.7% of samples compared to 14.3% and 
25% for clusters 2 and 3 respectively) and samples that had both oestrogen and progesterone 
receptors (ER and PR) (77.8% of samples compared to 14.3% and 16.7% for clusters 2 and 3 
respectively). Clusters 2 and 3 both contained high levels of samples with no ER and no PR 
expression (71.4% and 58.3% respectively). The most notable difference in clinical feature 
between clusters 2 and 3 was the high level of triple negative tumours in cluster 3 (58.3% 
compared to 28.6% in cluster 2). These results show different levels of methylation changes 
within the tumours are associated with clinical features. This association between global 
methylation and clinical feature is worthy of further analysis both on a global and individual 
gene level. 
4.4.5.2 Analysis of Variance (ANOVA) analysis  
Clustering results suggested an association between overall methylation levels and certain 
clinical features such as relapse and receptor status. To assess clinical features and overall 
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 Cluster 1 – High Methylation Cluster 3 – Low MethylationCluster 2 
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Figure 4.15_Hierarchical clustering splits tumour samples into three main groups
The dendogram can be seen aligned with sample information showing clinical status of: age at diagnosis (years),
tumour size (mm), SBR stage (1,2 or 3), lymph node status (LyN = lymph node positive; N = lymph node
negative), menopause status (MP = menopausal; N = not menopausal), relapse status (R= relapse; NR = no
relapse), estrogen and progesterone receptor status (ERPR = estrogen and progesterone positive; ERnoPR =
estrogen positive only; PRnoER = progesterone positive only; noR = estrogen and progesterone negative),
ERBB2 status (ERBB2 = ERBB2 overexpression, N=normal expression), triple negative (pink highlighting =
triple negative) and survival (disease free survival in days). The three cluster groups, showing high, medium and
low methylation are separated with thick black lines and labelled underneath. Two outliers can be seen on the
extreme left of the clustering image. Red and green refer to β-values >0.5 and <0.5 respectively.
199 
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Figure 4.16_ANOVA analysis of methylation and clinical features.
Results are shown for ANOVA analysis of overall methylation levels against
cluster groups (a), menopause status (b), relapse status (c), lymph node status
(d), ER and PR receptor status (e) and tumour stage (f). Central boxes within
the box-plot figures represent the interquartile range, lines within the central
box represent the median value and upper and lower horizontal lines
represent the highest and lowest values (circles above or below represent any
outliers).
(a) (b)
(c) (d)
(e) (f)
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methylation levels further, analysis of variance (ANOVA) testing was used. Overall 
methylation levels show significant differences in relapsing, lymph node positive and ER and 
PR receptor positive tumours (figures 4.16c, d and e respectively), in each case, presence of 
the particular clinical feature associated with a greater level of overall hypermethylation. 
Patient menopausal status and tumour stage did not show any significant association with 
methylation (figures 4.16b and f). For this cohort of samples, disease free survival (DFS) did 
not significantly associate with any clinical feature or methylation cluster groups. However, 
DFS and relapse was just below significance (0.052) (figure 4.17).  
4.4.5.3 Identification of individual genes with association to clinical features  
In order to identify individual gene loci where methylation status correlated with clinical 
features, Fisher’s exact tests were carried out on all 291 probes. After the use of false 
discovery rate (FDR) correction, 9 probes (9 genes; RECK, SFRP2, ITR, UGT3A1, SYDE1, 
UGT3A2, ACADL, UAP1L1 and PKRCB1) were identified where methylation status 
correlated significantly with relapse, 19 probes (18 genes; B3GAT1, TNFRSF10D, GRIA4, 
C1orf114, DNAJC6, C6orf34, CORIN, LAMA2, ITR, MCAM, C12orf34, NPY, COL1A2, 
RSNL2, ZNF660, ADAMTSL1, DPP4, MAT1A) where methylation status correlated with 
ER/PR receptor expression status and 2 probes (2 genes; LDHD and ZNF660) where 
methylation status significantly associated with lymph node positive tumours (table 4.2). 
Genes associating with relapse and ER/PR receptor status were chosen to be analysed further.  
Relapse  
The methylation status for the 9 relapse associated genes are shown in figure 4.18. Since 
probes specifically methylated in relapsing tumours should show strong correlations with 
DFS, Kaplan-Meier analysis was carried out on all nine probes/genes. Using Bonferroni 
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Figure 4.17_ANOVA analysis of disease free survival and clinical features.
Results are shown for ANOVA analysis of disease free survival levels against cluster
groups (a), menopause status (b), relapse status (c), lymph node status (d), ER and
PR receptor status (e) and tumour stage (f). Central boxes within the box-plot figures
represent the interquartile range, lines within the central box represent the median
value and upper and lower horizontal lines represent the highest and lowest values
(circles above or below represent any outliers).
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Clinical feature 
Number of 
probes 
Number of 
genes 
Gene names 
Relapse 9 9
RECK, SFRP2, ITR, UGT3A1, SYDE1, 
UGT3A2, ACADL, UAP1L1, PKRCB1 
ER and PR 19 18
B3GAT1, TNFRSF10D, GRIA4, C1orf114, 
DNAJC6, C6orf145, CORIN, LAMA2, ITR, 
MCAM, C12orf34, NPY, COL1A2, RSNL2, 
ZNF660, ADAMTSL1, DPP4, MAT1A
Lymph node 
positive 
2 2 LDHD, ZNF660
Table 4.2_Individual gene methylation associating with clinical features.
For relapse, ER and PR positive, triple negative and lymph node positive tumours,
the number of probes and genes are shown with gene names.
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Figure 4.18_Probes that show significant association between methylation and relapse.
The figure shows the nine significant probes associating with relapse status ranked in order of FDR corrected p-value.
Methylation status is indicated for each of the 39 tumours with either a red circle (methylated) or green circle
(unmethylated). The frequency of methylation is shown for relapsing and non-relapsing tumours along with FDR-
corrected p-values.
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correction, 6 genes (ACADL, RECK, SFRP2, UAP1L1, UGT3A1 and ITR) were identified that 
showed significant association between methylation status and DFS (figure 4.19).  
For the three most significant genes, ACADL, RECK, and SFRP2, it was determined whether 
the methylation detected at the single CpG dinucleotide in the Infinium array was indicative 
of a wider level of methylation and whether this could be capable of affecting expression, 
indicating possible functional importance in addition to clinical relevance. Cell line re-
expression after treatment with 5-azaDC and corresponding methylation in breast cancer cell 
lines was observed for all three genes (figure 4.20). CoBRA results of tumour normal paired 
samples showed frequent methylation of RECK (22.2%; 4/18), ACADL (30%; 6/20) and 
SFRP2 (57.1%; 8/14). All methylation of RECK was tumour specific whilst some methylation 
was observed at a lower level in corresponding normal tissue in a subset of methylated 
samples for ACADL (33.3%; 2/6) and SFRP2 (50%; 4/8). Clone sequencing of ACADL and 
RECK confirmed the CoBRA results, showing frequent, wide-spread, tumour-specific 
methylation (figures 4.21 and 4.22). In addition, quantitative real-time PCR data obtained by 
Dr. Sophie Vacher in Ivan Bieche’s laboratory (Oncogenetic Laboratory, INSERM U 735, 
Centre René Huguenin, Saint Cloud, France) showed significant downregulation of 
methylated tumour samples compared to a panel of normal controls for both RECK 
(p<0.0001) and ACADL (p = 0 043) (figure 4.23a and b), but not SFRP2, confirming a 
possible functional consequence of RECK and ACADL methylation.  
Oestrogen and progesterone receptor status 
Of the 19 probes associated with ER and PR receptor status, three of them also had multiple 
probes within the final list of 291, TNFRSF10D, C1orf114 and COL1A2 (figures 4.24 and 
4.12) and so were chosen for further analysis.  
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Figure 4.19_Kaplan-Meier analysis.
Kaplan-Meier survival graphs are shown for the six genes demonstrating a
significant association between methylation and disease free survival (DFS). This
analysis was performed on results from 39 tumour samples. The minimum and
median survival times were 257 days and 2554 days respectively. For non-relapsing
tumours, the maximum period of follow-up was 5185 days.
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Figure 4.20_Cell line CoBRA and expression analysis of RECK, ACADL and SFRP2.
Expression results (Exp.) are shown for RECK, ACADL, SFRP2 and GAPDH. Three cell lines are shown in each case,
all pre (-) and post (+) treatment with 5-azaDC. Expression for normal breast is also shown. CoBRA results are also
shown for the corresponding cell line. Undigested products (U) are run next to digested products (D). * indicates
methylation samples
* *
***
* *
RECK
GAPDH
RECK
GAPDH
RECK
GAPDH
ACADL
GAPDH
ACADL
GAPDH
ACADL
GAPDH
SFRP2
GAPDH
SFRP2
GAPDH
SFRP2
GAPDH
207 
 
 
1206
1018
281
Tumour Normal 
MI = 78.2% MI = 0.46% 
MI = 45.4% MI = 0.46% 
MI = 87.5% MI = 0% 
T N
U     D U     D
T/N Pair 1018
T N
U     D U    D 
T/N Pair 1206
T N
U    D U    D
T/N Pair 281
Figure 4.21_Clone sequencing and CoBRA results for RECK tumour normal pairs.
A gene schematic for RECK is shown illustrating the location the of the CpG island (green
box) and the region being analysed (black dotted lines). Exons and introns are represented
by blues boxes and black lines respectively. Clone sequencing and corresponding CoBRA
results are shown for three pairs. For each clone sequencing result black lines represent
single alleles and black and white circles represent methylated and unmethylated CpGs
respectively. MIs are shown for each sample as a percentage of methylated CpGs out of the
total number of CpGs analysed. CoBRA results are shown with undigested product (U) run
next to digested product (D). * indicates methylation
*
*
*
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Figure 4.22_Clone sequencing and CoBRA results for ACADL tumour normal pairs.
A gene schematic for ACADL is shown illustrating the location the of the CpG island (green
box) and the region being analysed (black dotted lines). Exons and introns are represented by
blues boxes and black lines respectively. Clone sequencing and corresponding CoBRA results
are shown for three pairs. For each clone sequencing result black lines represent single alleles
and black and white circles represent methylated and unmethylated CpGs respectively. MIs are
shown for each sample as a percentage of methylated CpGs out of the total number of CpGs
analysed. CoBRA results are shown with undigested product (U) run next to digested product
(D). * indicates methylated samples
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*
* *
*
209 
 
 
Methylated tumours 
0
0.2
0.4
0.6
0.8
1
1.2
p < 0.0001
0
0.5
1
1.5
2
2.5
3
3.5
4
Methylated tumours 
p = 0.043
RECK
ACADL
(a)
(b)
Figure 4.23_Quantitative real-time expression results for RECK and ACADL.
Graphs are shown for real-time results for both RECK (a) and ACADL (b). Mean
results are shown for normal and tumours in both cases alongside results for all
available methylated tumours. P-values are given for the significance of
downregulation in methylated tumour samples compared to normal samples
(Student’s t-test). Data for these graphs were obtained by Dr. Sophie Vacher from
Dr. Ivan Bieche’s laboratory (Oncogenetic Laboratory, INSERM U 735, Centre
René Huguenin, Saint Cloud, France).
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Figure 4.24_Probes showing a significant association between methylation and ER and PR expressing tumours
The 19 probes whose methylation status significantly associates with ER and PR positive tumours are shown, ranked
in order of p-values. Methylated and unmethylated samples are represented by red and green circles respectively.
Methylation frequency for each probe in ERPR positive tumours and ERPR negative tumours is also shown alongside
FDR corrected p-values. Purple, pink and blue arrows are aligned to genes that have been analysed further.
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All three genes demonstrated both increased expression in 5-azaDC treated cell lines and 
methylation in corresponding lines (figure 4.25). CoBRA analysis demonstrated frequent 
methylation in tumour normal paired samples for COL1A2, TNFRSF10D, and C1orf114. 
COL1A2 showed tumour specific methylation in 76.5% (13/17) of samples, the remainder 
being unmethylated. TNFRSF10D showed tumour specific methylation in 50% (8/16) of 
samples, increased methylation in the tumour compared with normal tissue in 18.8% (3/16) of 
samples, equal amounts of methylation in the tumour and normal tissue of 12.5% (2/16) of 
samples, whilst the remaining 3 samples (18.8%) were unmethylated. C1orf114 showed 
tumour specific methylation in 35.5% (6/17) of samples and increased methylation in tumour 
compared to corresponding normal tissue in 42.2% (7/17) of samples, the remaining 4 
samples (23.5%) were unmethylated (figure 4.26). Bisulphite sequencing of C1orf114 
demonstrated tumour specific methylation throughout the selected area of the CpG island 
(figure 4.27). Quantitative real-time RT-PCR by Sophie Vacher in Dr. Ivan Bieche’s 
laboratory (Oncogenetic Laboratory, INSERM U 735, Centre René Huguenin, Saint Cloud, 
France) demonstrated significant downregulation of TNFRSF10D (p=0.016) in methylated 
primary sporadic tumours compared to a panel of normal breast controls (figure 4.28). 
4.4.6 Analysis of MIRA genes  
The cohort of 39 sporadic breast tumours used in the Infinium array were the same samples 
used for confirmation of genes analysed in the MIRA array (chapter 3) In total, sixteen genes 
(EMIIN2, DBC1, FBLN2, COMP, SESN3, EPSTI1, CD44, TP53INP1, NRXN2, SIM2, PAX9, 
POU4F1, FOXF2, CIDE-A, GSC, SALL1) were assessed by CoBRA in chapter 3 and were 
also present on the Infinium array. Results for both assays are shown in table 4.3. Of the 16 
MIRA genes, 10 (EMILIN2, DBC1, FBLN2, COMP, SESN3, EPSTI1, SIM2, PAX9, CIDE-A 
and SALL1) were methylated in >20% primary tumours, as assessed by CoBRA. The 
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Figure 4.25_Cell line CoBRA and expression analysis for ER and PR associated genes.
Expression results (Exp.) are shown for TNFRSF10D, COL1A2, C1orf114 and GAPDH. Three cell lines are shown in each
case, all with (+) and without (-) treatment with 5-azaDC. Expression for normal breast tissue RNA is also shown. CoBRA
results are also shown for the corresponding cell lines. Undigested products (U) are run next to digested products (D). *
indicates methylated samples
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Figure 4.26_CoBRA tumour/normal pair results for TNFRSF10D, COL1A2 and C1orf114.
CoBRA results are shown for five tumour (T) and normal (N) paired samples with undigested product (U) run
adjacent to digested product (D). * indicates methylated samples
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Figure 4.27_Clone sequencing and CoBRA results for C1orf114 tumour normal pairs.
A gene schematic for C1orf114 is shown illustrating the location the of the CpG island (green
box) and the region being analysed (black dotted lines). Exons and introns are represented by
blues boxes and black lines respectively. For each clone sequencing result black lines represent
single alleles and black and white circles represent methylated and unmethylated CpGs
respectively. MIs are shown for each sample as a percentage of methylated CpGs out of the
total number of CpGs analysed.
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Figure 4.28_Qunatitative real-time expression results for TNFRSF10D .
A graphs is shown for real-time results for TNFRSF10D. Mean results are shown
for normal and tumours alongside results for all available methylated tumours. A
P-value is given for the significance of downregulation in methylated tumour
samples compared to normal samples (Student’s t-test). Data for these graphs were
obatined by Dr. Sophie Vacher in Dr. Ivan Bieche’s laboratory (Oncogenetic
Laboratory, INSERM U 735, Centre René Huguenin, Saint Cloud, France).
P = 0.016
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Gene 
CoBRA methylation  
frequency 
Infinium methylation 
frequency 
Infinium probe 
Present in Infinium 
list 
Reason for not being in list 
Overlapping region being 
analysed 
EMILIN2 16/36 (44.4%)
10/39 (25.6%) cg09009111 no >0.25 in at least 1 normal no
1/39 (2.6%) cg14133708 no
>0.25 in at least 1 normal and tumour 
frequency <20% yes
DBC1 8/31 (25.8%) 15/39 (38.5%) cg25935911 no >0.25 in at least 1 normal no
FBLN2 13/38 (33.3%)
6/39 (15.4%) cg00201234 no
>0.25 in at least 1 normal and tumour 
frequency <20% no
13/39 (33.3%) cg16604516 no >0.25 in at least 1 normal yes
COMP 20/33 (60.6%)
1/39 (2.6%) cg15784332 no
>0.25 in at least 1 normal and tumour 
frequency <20% no
21/39 (53.8%) cg09949775 no >0.25 in at least 1 normal no
SESN3 7/10 (70%)
2/39 (5.1%) cg11665588 no tumour frequency <20% no
0/39 (0.0%) cg13037275 no tumour frequency <20% no
EPSTI1 13/36 (36.1%)
2/39 (5.1%) cg14539231 no tumour frequency <20% no
0/39 (0.0%) cg22905097 no tumour frequency <20% no
CD44 1/24 (4.2%)
0/39 (0.0%) cg17640322 no tumour frequency <20% yes
0/39 (0.0%) cg18652941 no tumour frequency <20% no
0/39 (0.0%) cg01879488 no tumour frequency <20% yes
0/39 (0.0%) cg04125208 no tumour frequency <20% yes
0/39 (0.0%) cg08530414 no tumour frequency <20% no
0/39 (0.0%) cg08606356 no tumour frequency <20% yes
0/39 (0.0%) cg20143092 no tumour frequency <20% no
TP531NP1 0/18 (0.0%)
2/39 (5.1%) cg18059933 no tumour frequency <20% no
0/39 (0.0%) cg24434118 no tumour frequency <20% yes
NRXN2 0/12 (0.0%) 0/39 (0.0%) cg16718678 no tumour frequency <20% no
SIM2 24/29 (82.7%)
4/39 (10.3%) cg02672220 no tumour frequency <20% no
0/39 (0.0%) cg13694867 no tumour frequency <20% no
PAX9 8/39 (20.5%)
27/39 (69.2%) cg26620157 no >0.25 in at least 1 normal ?
27/39 (69.3%) cg00509670 no >0.25 in at least 1 normal ?
POU4F1 4/27 (14.8%)
13/39 (33.3%) cg08097882 yes - yes
0/39 (0.0%) cg15604467 no tumour frequency <20% yes
FOXF2 3/35 (8.6%)
0/39 (0.0%) cg03848675 no tumour frequency <20% no
4/39 (10.3%) cg08045570 no
>0.25 in at least 1 normal and tumour 
frequency <20% no
CIDE-A 21/40 (52.5%)
2/39 (5.1%) cg19883905 no tumour frequency <20% no
4/39 (10.3%) cg20950011 no
>0.25 in at least 1 normal and tumour 
frequency <20% no
GSC 1/40 (2.5%)
0/39 (0.0%) cg19224837 no tumour frequency <20% yes
0/39 (0.0%) cg20804555 no tumour frequency <20% no
SALL1 25/40 (62.5%) 0/39 (0.0%) cg22674717 no tumour frequency <20% no
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Table 4.3_Infinium results for genes identified through MIRA.
The sixteen genes analysed by CoBRA in chapter 3 and the infinium array are shown
with methylation frequencies for both assays. The single probe identified in both
assays is highlighted with a red arrow. The reasons for other probes not being
identified in the infinium list are shown.
218 
 
remaining 6 genes (CD44, TP53INP1, NRXN2, FOXF2 GSC, and POU4F1) were either 
unmethylated or methylated at a very low frequency by CoBRA assay. These results are also 
true for the Infinium assay, showing general agreement between the two methods for 
negligible methylation (table 4.3). The only slight discrepancy is POU4F1, there are two 
probes are present on the Infinium array for POU4F1, one of which shows both a higher level 
of methylation (33.3%) than the other (0%) and of the CoBRA result from chapter 3 (14.8%). 
Of the 10 positive genes, only 4 (EMILIN2, DBC1, FBLN2, COMP), showed similar 
methylation frequencies by CoBRA and Infinium assays (table 4.3). The remaining 6 (SESN3, 
EPSTI1, SIM2, PAX9, CIDE-A and SALL1) showed larger discrepancies between CoBRA and 
Infinium results. In most cases methylation was detected at a higher level by CoBRA, for 
example, 82.7% samples were methylated by CoBRA compared to 10.2% by Infinium for 
SIM2. The 16 genes analysed were represented by 34 probes, only one of which was picked 
up through the criteria used in the Infinium array and therefore present in the list of 291, 
POU4F1 (Infinium probe number: cg08097882). The remaining probes where CoBRA results 
were in general agreement were not within the list of 291 because of either (a) the frequency 
being <20%, (b) at least one normal with a β-value>0.25, or (c) a combination of the two 
(table 4.3). These results do not show a large amount of concordance between the two 
methods, however, it should be noted that in the majority of cases, the individual CpG being 
assessed by Infinium does not sit within the region assessed by CoBRA (table 4.3). 
Considering the more sensitive nature of the Inifinium assay, it is surprising that in general 
higher methylation frequencies were observed by CoBRA, however this is most likely due to 
the region being analysed being much larger. Despite this, it is reassuring that the lowly 
methylated samples are not picked up at high frequencies in either assay.  
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Analysis of both MIRA and Infinium candidate selections (irrelevant of any further laboratory 
analyses) identifies 34 genes which are present in both of the initial selection lists (table 4.4). 
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Gene 
symbol 
Gene product 
C1orf114 chromosome 1 open reading frame 114 
C6orf206 chromosome 6 open reading frame 206 
CCK cholecystokinin
CDKL2
cyclin-dependent kinase-like 2 (CDC2-related 
kinase)
CLDN6 claudin 6 
FZD10 frizzled homolog 10 (drosophila)
GHSR growth hormone secretagogue receptor 
HAND1 heart and neural crest derivatives expressed 1 
HIF3A hypoxia inducible factor 3, alpha subunit
HIST1H3J histone cluster 1, H3j 
HOXB13 homeobox B13 
KLF11 Kruppel-like factor 11 
LYPD5 LY6/PLAUR domain containing 5
NEUROD1 neurogenic differentiation 1
PAQR9
progestin and adipoQ receptor family member 
IX
PCDHAG12 protocadherin gamma subfamily A, 12 
POU4F1 POU class 4 homeobox 1 
RAB37 RAB37, member RAS oncogene family
RBP1 retinol binding protein 1, cellular 
RUNX3 runt-related transcription factor 3 
SFRP2 secreted frizzled-related protein 2 
SIX6 SIX homeobox 6 
SLC2A14
solute carrier family 2 (facilitated glucose 
transporter), member 14  
TBX20 T-box 20 
TF transferrin
VIPR2 vasoactive intestinal peptide receptor 2 
VSX1 visual system homeobox 1
ZNF132 zinc finger protein 132 
ZNF177 zinc finger protein 177 
ZNF560 zinc finger protein 560 
Table 4.4_Genes identified through both MIRA and Infnium analyses.
The table shows the gene symbol and product name of the 34 genes
identified in MIRA and Infinium lists irrelevant of any further laboratory
analyses.
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4.5 DISCUSSION  
Genome wide methylation studies have been successful for sometime in identifying 
methylated genes in cancer that may have tumour suppressor properties. Due to technology 
improvements it is now possible to use a smaller amount of starting material and cheaper to 
do many samples. This has made it feasible to assess a larger number of primary tumours, 
giving rise to many large scale methylation profiling studies (Christensen et al, 2011; 
Noushmehr et al, 2010; O’Riain et al, 2009; Martín-Subero et al, 2009a). On a smaller scale, 
this work has used the Illumina Infinium array to produce a profile of methylation at 14,475 
CpG loci in 39 sporadic ductal breast tumours and four tumour/normal paired samples. 
Results have shown that overall methylation profiles unsurprisingly differ between tumours 
and normals and that methylation changes are widely heterogeneous, in agreement with other 
similar studies (Van der Auwera et al, 2010; Christensen et al, 2010). This suggests that some 
tumours are less susceptible to changes in methylation, possibly as a result of powerful 
genetic events meaning tumour formation can occur and progress without a large prevalence 
of alternative epigenetic events. It may also be indicative of a lack of general deregulation of 
methylation in some tumours. A previous breast cancer Infinium study compared levels of 
DNMT3b, DNMT1 and DNMT3a between cluster groups with high and low mean β-values 
and found significantly increased DNMT3b expression and higher levels of DNMT1 
approaching significance in the high β-value clusters. Although, these associations were  not 
so strong when taking into account the expression of a cell proliferation marker and therefore 
the different rates of growth (Van der Auwera et al, 2010).  
A list of 291 probes representing 164 genes considered to be frequently hypermethylated in 
tumours was produced containing numerous genes already known to be methylated in breast 
222 
 
cancer. In addition, genes within the list were associated with functions or pathways involved 
in tumourigenicity indicating the list had produced a relatively probable and relevant set of 
methylated genes in breast cancer. Although this study has not confirmed wider methylation 
frequencies for all hypermethylated genes, the validation work and further analysis of 
candidate genes and genes associated with clinical features suggests that the β-value from one 
CpG will be generally indicative of the wider level of methylation surrounding it. Although 
this may be considered to be slightly biased, due to the selection for sequencing analysis 
being based upon genes previously shown to be hypermethylated in other cancers. 
Nonetheless, wider methylation was also been observed for novel genes that had not been 
previously analysed, for example, C1orf114 was found to be both extensively methylated and 
highly specific to tumours.  
Clustering and ANOVA analyses identified increased aberrant methylation associated with 
lymph node, hormone receptor (ER/PR) and relapse positive tumours, with a marked lack of 
hypermethylation in triple-negative tumours. This lack of altered methylation in triple 
negative (-ER, -PR, -ERBB2 amplification) tumours agrees with previous published work in 
basal-like breast cancers which are also triple negative (Holm et al¸ 2010)  
4.5.1 Oestrogen (ER) and progesterone (PR) positive tumours 
Recent breast cancer methylation profiling studies using either Illumina Infinium or 
GoldenGate platforms have shown a similar trend for ER and PR positive tumours (Li et al, 
2010 and Holm et al, 2010), suggesting that ER/PR positive tumours may be more susceptible 
to hypermethylation events. The presence of these hormone receptors are very import to 
breast cancer cells as they allow the cancer cells to react to outside hormones and bring about 
cellular changes through their transcription factor activity. Both receptors work as 
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transcription factors that are activated by their ligand binding. It is generally thought that at 
least some of their transcription targets are useful in tumourigenesis and this is evidenced by 
the negative response ER+ tumours can have to drugs that block oestrogen’s effects, such as 
tamoxifen (Jordan, 1993). It would make a reasonable amount of sense that not all the 
activated genes would be advantageous to tumourigenesis and these could well be 
counteracted by de novo methylation. 
This study identified 19 CpG loci (18 genes) where positive hypermethylation status 
correlated with ER and PR expression. Further analysis of three of these genes (TNFRSF10D, 
COL1A2 and C1orf114) showed extensive methylation levels around the CpG probe loci and 
that methylation of these genes can affect their expression, suggesting this may also be the 
case for the 15 remaining genes.  
4.5.1.1 TNFRSF10D 
TNFRSF10D (tumour necrosis factor receptor superfamily, member 10d, decoy with 
truncating death domain) is an eight exon gene located at 8p21 with a 532bp CpG island 
containing 53 CpGs. It is a member of the TRAIL (tumour necrosis factor-related apoptosis-
inducing ligand) family, a group of 5 receptors involved in apoptosis initiation. Binding of 
TRAIL to either of the death receptors TNFRSF10a (also known as DR4) or TNFRSF10b 
(also known as DR5) induces apoptosis via caspase-8/-10 however, binding of TRAIL to any 
of the three decoy receptors, such as TNFRSF10D does not induce apoptosis, in fact 
overexpression of the decoy receptors enhances protection against apoptosis (reviewed in 
Mahalingam et al, 2009), suggesting that downregulation of TNFRSF10D would not be 
advantageous to the tumour. Despite this, TNFRSF10D has previously been shown to be 
methylated in melanomas and colorectal cancers (Liu et al, 2008; Prabhu et al, 2009). After 
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carrying out this work, it was also noted that it had previously been shown to be 
hypermethylated in breast tumours and malignant mesothellomas (Shivapurkar et al, 2004), 
but reported under an uncommonly used synonym, DrC2. A GoldenGate study published after 
this work was done also showed that lower methylation was associated with basal-like 
tumours (predominantly triple-negative) compared to ERBB2 overexpressing tumours 
(Bediaga et al, 2010). Interestingly, this study did not find any association between lower 
methylation levels and triple negative tumours, but rather it was found that greater 
TNFRSF10D methylation levels were observed in ER/PR expressing tumours. This does not 
prove or disprove either of these associations, as they may just be differences due to the use of 
different cohorts of breast cancer tumours and further investigation in further cohorts will be 
needed to provide a more definitive answer.  
4.5.1.2 COL1A2 
COL1A2 (collagen, type 1, alpha 2) is a large gene situated at 7q22.1 consisting of 52 exons 
that produce a 129 kDa protein. Type I collagen alpha 2 chain is an integral part of the type I 
collagen triple helix. Mutations within COL1A2 can result in various forms of both Ehlers-
Danlos syndrome and Osteogeneis Imperfecta. Patients with these diseases do not have a 
predisposition to cancer however COL1A2 hypermethylation has been observed in many 
cancer types including medulloblastoma, bladder cancer and melanomas (Anderton et al, 
2008, Mori et al, 2009 and Koga et al, 2009). In agreement with our results, the three studies 
mentioned all showed lower expression in methylated cell lines compared with 5-azaDC 
treated lines. In addition, both Anderton et al (2008) and Mori et al (2009) showed decreased 
expression in primary tumour samples by quantitative real-time PCR. In medulloblastomas, 
reduced expression was also demonstrated at the protein level in cell lines (Anderton et al, 
2008). Mori et al were also able to demonstrate tumour suppressor effects of COL1A2 on cell 
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growth and proliferation when introduced back into a methylated, non-expressing line. These 
results suggest COL1A2 hypermethylation is a frequent event in cancers and can result in loss 
of expression and subsequent loss of tumour suppressing properties. The results from this 
study have demonstrated a possible role of COL1A2 involvement in breast cancer.  
Following this work, an Illumina GoldenGate study on 162 breast tumours showed 
differential methylation of COL1A2 associated with lymph node positive tumours and tumour 
size (Christensen et al, 2010). The work done within this thesis demonstrated neither a 
significant difference nor a trend towards this association with lymph node status. There are 
many factors that could contribute to this, for example, the sample size used in this thesis is 
much smaller than that used by Christensen et al and the identification of individual genes 
was carried out using a different approach. The cohort used in this thesis also had a very large 
number of lymph node positive tumours, making significant associations less likely. In this 
thesis, probes were identified as being hypermethylated by stringent criteria and then analysed 
for clinical association based on a methylated or unmethylated classification. Christensen et al 
compared average β-values using a linear regression model able to take into account the mean 
distribution of β-values. When data for this study is analysed on raw β-values using student’s 
t-test, one of the COL1A2 probes associated with lymph node positive tumours at just below 
significance (FDR corrected p-value=0.065).  
4.5.1.3 C1orf114  
C1orf114 (chromosome 1 open reading frame 114) is a 6 exon gene located at 1q24. It has a 
CpG island of 248bp containing 20 CpGs situated across the transcription start site. Although 
thought to produce a 509 amino acid protein, no information about any possible function is 
known. However, results from this study suggest hypermethylation is frequent and specific in 
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breast tumours. In addition, 5-azaDC studies suggest methylation is capable of altering 
expression of this gene and that mRNA is present in normal breast tissue. C1orf114 was also 
detected in the high stringency gene list from the MIRA assay on breast cancer cell lines 
(chapter 3) and in a MIRA assay on DCIS samples (Tomassi et al, 2009), although in both 
cases no further analysis was carried out. Taken together, these results suggest that it may be 
worth looking into the possible role of C1orf114 in breast cancer, particularly as the 
methylation in DCIS suggests it may be an early event in breast tumourigenesis. Due to the 
high frequency and specificity of methylation and novel value it may also be worth screening 
other cancers for promoter hypermethylation. Additionally, functional investigation of the 
protein product would be useful and aid in assessing the importance of loss of expression. 
Since the remaining 15 genes were not analysed any further they will not be discussed in 
detail, except to say that none of them have previously been shown to be hypermethylated in 
breast cancer nor have they been identified in any other Infinium/GoldenGate study at the 
time of writing.  
4.5.2 Relapse and DFS  
Although this is a small study, nearly all relapsing tumours were within the highly methylated 
group, suggesting an overall increase in hypermethylation events are more common in 
relapsing tumours. However, as factors were only considered on a univariate level, it would 
be necessary to do this on both a multivariate level and on different, larger cohorts to be 
certain of this association. 
4.5.2.1 SFRP2 
SFRP2 (secreted frizzled-related protein 2) is a three exon gene that generates a 295 amino 
acid protein. It has a CpG island situated across the transcription start point that is 1315bp 
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long with 112 CpGs. SFRP2 is a member of five Wnt signalling inhibitors and as such 
functions to sequester signalling of this pathway, known to be over-active in many cancers 
(Prosperi et al, 2010). Promoter hypermethylation of SFRP2 has been demonstrated in many 
cancers, including breast (Veeck et al, 2008b; Nojima et al, 2007; Urakami et al, 2006; 
Müller et al, 2004). The authors describe highly specific frequent methylation in primary 
breast tumours (83% of samples) and high levels of loss of SFRP2 expression in tumour 
tissue. No associations with clinical features were observed with either methylation or loss of 
expression. The results obtained in this thesis identified a lower overall frequency of 
methylation (34%) and found methylation to be associated with relapse status and DFS. The 
discrepancy between the two studies is most likely due to the assay being used, although the 
Inifnium array does seem to be representative of the wider region it is still only the 
methylation status of the actual CpG being assayed that has shown to have the association 
with relapse/DFS, therefore, if the wider region were to be analysed, the larger amount of 
methylation may no longer associate with relapse/DFS. However, this finding needs to be 
confirmed on a larger cohort of samples using the same assay to determine if there is a true 
association between methylation status and DFS in ductal breast tumours. Either way, if 
methylation at this specific probe does associate strongly with relapse, even if the total CpG 
island methylation does not, it could be used as a potential biomarker. 
4.5.2.2 RECK 
RECK (reversion-inducing-cysteine-rich protein with kazal motifs) is a 21 exon gene situated 
on chromosome 9p. RECK was initially identified through a cDNA screen for reversion-
inducing properties (the ability to reverse the transition of transformed malignant cells from 
flat to round morphology back to a flat morphology) (Takahashi et al, 1998). The 971 amino 
acid protein was found to inhibit the activity of matrix-metalloproteinase-9 (MMP-9) 
228 
 
(Takahashi et al, 1998) and subsequently MMP-2 and MT1-MMP (Oh et al, 2001). MMPs are 
a family of enzymes capable of breaking down extra-cellular matrix (ECM) proteins and as 
such have a role in tissue remodelling during developmental and cancer progression 
processes. Left unregulated, MMPs are capable of destroying the ECM, leaving cells 
susceptible to migration. They have been implicated in breast cancer cell invasion, epithelial 
to mesenchymal transition and motility (Radisky et al, 2010).  
Many cancers have demonstrated reduced levels of RECK and in most cases this associated 
with bad prognosis (Clark et al, 2007). RECK has a 766bp CpG island consisting of 73 CpGs 
and hypermethylation has been described in lung, colon, oral and gastric cancers as a 
mechanism of down regulation (Chang et al, 2007; Cho et al, 2007; Long et al, 2008; Du et 
al, 2010) and in most cases is associated with bad prognosis. I believe this to be the first 
example of RECK methylation in breast tumours although downregualtion has been shown in 
both breast cancer cell lines (Figueira et al, 2009) and primary tumours (Span et al, 2003). In 
the study by Span et al, tumours with low RECK expression levels also had significantly 
lower recurrence free survival and an association with lymph node positive tumours on a 
multivariate level. Results from this thesis showed methylated tumours had significantly 
lower expression levels than normal breast tissue and that methylation (measured by the 
Infinium assay) associates with relapse and DFS. This is promising as measurement of 
quantitative methylation at this position is relatively easy and could be set up diagnostically.  
RECK expression has been shown to be reduced by oncogenic Ras activity upregulating 
DNMT3b via the ERK signalling pathway and subsequently inducing downregulation of 
RECK by methylation (Chang et al, 2006). The relationship between RECK methylation and 
tumourigenesis may therefore be related to Ras activity. In lung cancer, RECK 
hypermethylation has been associated with k-Ras mutations (Chang et al, 2007) although not 
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all samples showing RECK methylation also harboured k-Ras mutations suggesting this is not 
the only possible mechanism responsible for RECK hypermethylation in cancer systems. 
None of the other RECK hypermethylation studies have looked at combined k-Ras mutation 
and RECK methylation status therefore it is uncertain how frequent this scenario is. However, 
it is an interesting example of how upregulation of an oncogene can cause downregulation of 
a tumour suppressor gene by hypermethylation. Interestingly, it therefore describes a scenario 
that would make certain tumours susceptible to specific hypermethylation events.  
4.5.2.3 ACADL 
ACADL (acyl-coenzyme A dehydrogensase, long chain) is an 11 exon gene situated at 2q34-
q35. It produces a 403 amino acid protein that forms a homotetramer responsible for the first 
step in breaking down long-chain fatty acids. Three other members are within the family, 
ACADS, ACADM and ACADVL, responsible for breaking down short-chain, medium-chain 
and very long-chain fatty acids respectively. Mutations in ACADL cause LCAD deficiency, a 
syndrome characterised by problems during periods of fasting. Changes in metabolism are 
common hallmarks of cancer, however, normally this involves a greater level of fatty acid 
metabolism to create more Acetyl-coA for entering the Krebs cycle, in which case, 
downregulation of ACADL would be advantageous to the cancer cell. Combined with this, 
ACADM mutations have been detected in breast cancer (Sjöblom et al, 2006) and ACADL has 
been shown to be reduced in a retinoic-acid-receptor-α dominant negative transgenic mouse 
model susceptible to fatty acid deposition and liver tumours (Yanagitani et al, 2004).  
Since the remaining six genes that showed an association with relapse were not analysed 
further they will be not discussed in detail. However, since they showed a high association 
between relapse and/or DFS it would be worth analysing them further in the future as 
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potentially they would be useful prognostic markers. As for SFRP2, RECK and ACADL, the 
association with methylation at the particular CpG with relapse/DFS needs to be repeated on a 
separate, larger cohort of samples using the same assay before these results can be considered 
as true potential markers of relapse/DFS. However, if this were confirmed it would be a 
relatively easy diagnostic test with highly relevant prognostic value.  
4.5.3 Use of Infinium array for candidate gene identification 
As a way of identifying candidate hypermethylated genes three of the most highly methylated 
genes and three multiple positive probe genes were analysed further.  
4.5.3.1 Highly Methylated Genes  
Of the three highly methylated genes analysed, ABCA3, COX7A1 and SST, only the latter two 
of the three showed re-expression following treatment with 5-azaDC and methylation in 
corresponding cell lines.  
COX7A1 
COX7A1 (cytochrome c oxidase subunit VIIa polypeptide 1 (muscle)) is a four exon gene 
situated at 19q13.1 with a 1258bp CpG island containing 85 CpGs. The protein product is 79 
amino acids long and functions as a member of the heteromeric complex of cytochrome c 
oxidase (COX).  
Results identified methylation and re-expression in all cell lines, with all lines showing 
complete methylation and complete re-expression, with no expression observed in any cell 
line prior to 5-azaDC treatment. Expression of mRNA was observed in the normal non-
cancerous breast sample. Whilst the high level of complete methylation and the implication 
that COX7A1 is expressed only in muscle tissue point to COX7A1 methylation being a 
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mechanism aiding lack of expression in non-muscle tissue, the presence of mRNA within the 
normal breast sample suggests this may not be the case. Analysis of tumour/normal paired 
samples detected methylation in 100% of tumour samples. Methylation frequencies of this 
magnitude are not commonly observed, especially with a relatively unsensitive assay such as 
CoBRA, again suggesting methylation may be used as a mechanism for suppression of 
COX7A1 expression in non-muscle tissue. However, methylation was detected at either an 
equal (29.4%; 5/19) or lower (70.6%; 12/17) level in corresponding normal tissue. These 
results are puzzling as they suggest tumour-enhanced methylation and COX7A1 mRNA 
expression in breast tissue when previous evidence suggests expression is only present in 
muscle tissue. Having said this, COX7A1 remains largely unstudied and perhaps further work 
on this gene may highlight functions within tissues other than muscle. It should be noted that 
the majority of corresponding normal samples do show methylation but at a lower level than 
the corresponding tumour. If assuming COX7A1 is normally expressed and lowly methylated 
in normal breast tissue these results suggest hypermethylation may be an early event in breast 
carcinogenesis or merely an enhancement of the methylation already present.   
SST  
SST (somatostatin) is a two exon gene located at 3q28. It has a CpG island consisting of 265 
bp containing 25 CpGs. Hypermethylation of this region has been observed in esophageal, 
cervical, colon and gastric cancers (Jin et al, 2007; Ongenaert et al, 2008; Mori et al, 2006; 
Jackson et al, 2010). In primary methylated esophageal and gastric tumours reduced 
expression at the RNA level has also been shown (Jin et al, 2007; Jackson et al, 2010). In 
addition, studies of early esophageal lesions suggest SST methylation is an early event in this 
cancer (Jin et al, 2007). Results obtained in this thesis show that SST is also highly methylated 
in breast cancer. Methylation was detected in 59% samples by the array and 68.4% by 
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CoBRA assay on a separate cohort. In adjacent normal tissue, methylation was undetected by 
CoBRA in 31.6% (6/19) of samples while lower levels of methylation were observed in 
31.6% (6/19) of normal samples compared to tumours, with 1 sample showing an equal 
amount of methylation in the normal as its corresponding tumour. These results suggest SST 
methylation may be an early event in breast cancer development and possibly occurs at a low 
level early on throughout the tissue. It would be nice to be able to look in breast DCIS 
samples for SST methylation to determine if methylation is present in these early lesions.  
SST is a hormone capable of inhibiting secretion of growth factors and has been shown to be 
able to inhibit cell proliferation. SST interacts with one of five receptors to bring about its 
effects, at least four of these receptors (SSTRs) have been shown to be expressed on breast 
tumour cells, and patients that express SSTRs have longer DFS times (reviewed in Watt et al, 
2008). Therapeutically, SST analogues have been used in clinical trials however no 
significant improvement has been observed in OS times so far (reviewed in Watt et al, 2008). 
Due to the role of SST in breast and other cancers, the status of SST hypermethylation coupled 
with assessment of SSTR receptor status may offer a distinguishing characteristic that could 
be used to decide which patients may or may not benefit from SST targeted treatments.  
4.5.3.2 Multiple probe genes  
CDKL2 
CDKL2 (cyclin dependent kinase-like 2 (CDC-2-related kinase)) is a 12 exon gene situated at 
4q21.1 with a CpG island of 713bp with 56 CpGs situated upstream of and across the 
transcription start site. CDKL2 is largely unstudied and definitive functions are unknown. It is 
a member of a large family of CDC2-related serine/threonine kinases, known to be involved 
in cell cycle control. A recent study has also identified CDKL2 as having a single nucleotide 
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polymorphism (SNP) that associated with early age diagnosis of breast cancer (Bonifaci et al, 
2010). A missense mutation has also been identified in CDKL2  in a large muti-cancer study 
of primary tumours (Greenman et al, 2007) and a truncating mutation has been observed in 
the breast cancer cell line HCC2218 (Stephens et al, 2005). CDKL2 has shown both tumour 
specific methylation and re-expression following demethylation, this, combined with the 
potential function of a CDC2-related kinase and previously described mutational status, 
suggest CDKL2 is a good candidate for further analysis in breast cancer.  
ZNF154  
ZNF154 (zinc finger protein 154 (pHZ-92)) is a three exon gene situated at 19q13.4. It has a 
328kb CpG island containing 31 CpGs positioned in the first exon and into the first intronic 
region. Very little is known about ZNF154 except that it most likely functions in 
transcriptional regulation. Results from this thesis have shown a high level of methylation 
(87.5%, 64.3% of which was tumour specific). The level of methylation by CoBRA assay is 
very high (87.5%) and coupled with the relatively high frequency of methylation in the 
adjacent normal tissue (35.7%), suggests ZNF154 methylation may be an early event in breast 
cancer development, however studies in DCIS samples would need to be carried out to 
confirm this. 
4.5.4 Comparison with the MIRA study (chapter 3) 
Comparisons between genes identified in the MIRA chapter and Infinium chapter does not 
show a large level of agreement. However, it is not particularly surprising that the same 
targets were not identified in both studies due to large differences in the assays and samples 
used. The 16 genes analysed by CoBRA in chapter 3 and Infinium in chapter 4 on the same 
samples were generally in agreement, and the majority that were not were being analysed in 
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two different regions of their CpG islands. It is interesting that, in general, all genes that were 
found to be methylated by CoBRA in chapter 3 were picked up at a lower frequency by 
Infinium, possibly due to the differing levels of criteria between candidate selection, making 
the Infinium selection more stringent and therefore underestimating the true level of 
methylation, although this is preferable to overestimation.  
The Infinium HumanMethylation27 array represents an affordable method of assaying a 
relatively large number of patient samples. Separate studies using the same assay are also 
more comparable due to the consistency between probed regions as oppose to the affinity 
enrichment approaches. However, the use of a small number of probes per gene, irrelevant of 
the size of the CpG island, placed only within (or within close proximity to) CpG islands 
means an underrepresentation of some regions. The newly available HumanMethylation450 
array should help to combat some of these issues.  
In general, both methods have their advantages and disadvantages and perhaps the best 
approach is to perform both types of methodology on any given set of samples if enough 
material is available. This would provide a subset of high confidence candidates identified by 
both methodologies as well as those targets that may only be detected by one assay due to 
intrinsic aspects of each methodology.  
4.5.5 Final Conclusions  
The initial aims of this chapter were to use the Infinium array to create a list of 
hypermethylated genes and analyse potential candidates, to compare overall methylation 
levels between tumours with differing clinical characteristics and to identify genes where 
hypermethylation associates with specific clinical features.  
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The list of genes produced contains numerous novel potentially methylated genes in breast 
cancer and further work has highlighted at least two novel genes, SST and CDKL2, worth 
investigating further based on methylation alone without taking clinical associations into 
consideration. There are multiple ways a list such as this can be mined for good candidates. 
Because this study was primarily interested in finding clinical associations the analysis for 
good potential tumour suppressor gene candidates was rather superficial. These candidates 
would have benefited from further functional investigation to demonstrate any potential 
tumour suppressor activity in breast cancer. It would therefore be beneficial to have analysed 
the list more comprehensively for good candidates that were not necessarily associated with 
clinical features. This is something that could be done in the future by myself or others now 
this work has been published and the gene lists are in the public domain.  
The analysis of clinical features on an overall and individual level has produced some 
interesting and clinically relevant results, in particular, the association of 6 genes with DFS. 
However, a particular weakness of this study is the use of such a definitive classification of 
hypermethylation. Although the work done suggests that what was deemed methylated and 
unmethylated were true, this classification was then used to assess clinical associations. To 
determine if these associations are real a much larger, separate cohort would need to be 
analysed using the same, or at least similar assay (such as pyrosequencing or EpiTYPER
TM
). 
However, if even one of the 6 genes identified in this study held the association in a large 
cohort of samples this may be beneficial to developing markers for patient prognosis. If the 
information had been available, it would have been nice to identify and assess genes whose 
methylation status associated with drug treatment outcomes. It would have also been 
beneficial to know the molecular subtype of the samples with regards to luminal A/B etc. 
rather than just receptor status.  
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This work has now been published under Hill et al (2011) Cancer Research 71(8): 2988-
2999. A copy is provided at the back of this thesis.   
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CHAPTER 5 
DNA METHYLATION ANALYSIS OF RASSF10 IN COMMON SOLID TUMOURS 
 
5.1 ABSTRACT  
Frequent methylation of the newest RASSF family member, RASSF10, has been described in 
childhood acute lymphocytic leukaemia (ALL) (Hesson et al, 2009) and thyroid cancer 
(Schagdarsurengin et al, 2009) suggesting methylation of RASSF10, as is the case for other 
selected RASSF members, may be a common event in multiple cancers. To continue these 
studies, the work in this chapter assesses the methylation status of RASSF10 across a panel of 
common solid tumours.  
Frequent methylation was observed in all cell line types analysed and in lung (25%), 
colorectal (31%), breast (25%), kidney (25%) and glioma (57%) primary tumours. Due to the 
higher methylation frequency in gliomas, this study concentrated on further analysis of 
RASSF10 epigenetic inactivation in this cancer type. The frequency of methylation in glioma 
tumours differed between WHO grades; grade I astrocytomas were unmethylated, whilst 
grade II and III astrocytomas had methylation frequencies of 60% and 80% respectively. 
Grade IV gliobastoma multiforme (GBM) samples showed methylation in 65% and 69% of 
primary GBM and secondary GBM respectively. In secondary grade IV glioblastoma 
multiforme (sGBM), RASSF10 methylation was an independent prognostic factor, associating 
with worse overall survival and worse progression-free survival. Very little methylation (6%) 
was found in non-cancerous brain tissue. Glioma cell lines showed re-expression of RASSF10 
at the mRNA and protein level following treatment with the demethylating agent, 5-azaDC.  
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This work has shown frequent methylation in common solid tumour types, in particular 
gliomas, and may offer the possibility of developing a prognostic marker for secondary GBM.  
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5.2 INTRODUCTION  
As discussed in chapter one, the RASSF gene family represent a well documented family of 
genes with multiple links to cancer. Biological roles of the RASSFs include affecting RAS 
behaviour, interaction with the SWH pathway, apoptosis and cell cycle regulation. When 
coupled with common downregulation in various cancers, RASSF family gene members 
become attractive candidates for analysis. Because of this, the methylation status of RASSF 
family members has been extensively screened in multiple cancers. Many members of the 
family (RASSF1A, RASSF2, RASSF4, RASSF6 and RASSF10) have now been demonstrated to 
be downregulated as a result of hypermethylation in various cancer types (Dammann et al, 
2000; Dammann et al, 2001; Hesson et al, 2004; Hesson et al, 2005; Endoh et al, 2005; 
Eckfield et al, 2004; Hesson et al, 2009). In addition, the methylation status of RASSF1A has 
been associated with multiple clinical features of various cancers offering diagnostic and 
prognostic potential (Hesson et al, 2007). The most recently identified member, RASSF10, has 
been found to be expressed in multiple tissue types and demonstrate frequent methylation in 
ALL and thyroid cancers (Hesson et al, 2009; Schagdarsurengin et al, 2009). Since these 
represent quite diverse cancers, it seems likely that RASSF10 methylation may be a common 
event in many cancer types. The work in this chapter focuses on analysis of RASSF10 DNA 
methylation in common solid tumour types.  
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5.3 AIMS  
1. To assess the methylation status of RASSF10 in common solid tumour cell lines.  
2. To assess the methylation status of RASSF10 in primary tumour types of methylated 
cell lines and to determine tumour specificity of methylation in positive tumour types. 
3. To assess the methylation status of RASSF10 in relation to clinical features.  
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5.4 RESULTS 
5.4.1 Methylation analysis of solid tumour cell lines  
Due to frequent methylation of RASSF10 in childhood ALL (Hesson et al, 2009) and thyroid 
cancer (Schagdarsurengin et al, 2009) the panel of available solid tumour cell lines were 
analysed at the same region (figure 5.1). Frequent methylation was observed in all cell line 
types analysed; breast (33%), colorectal (83%), lung (40%), kidney (33%) and glioma (83%) 
(figure 5.2; table 5.1). For one of the highest methylated cancer cell line types, gliomas, no 
RASSF10 expression was observed at the mRNA level of methylated cell lines and re-
expression was observed following treatment with the demethylating agent 5-azaDC (figure 
5.3). In addition, further work by Dr. Nick Underhill-Day showed re-expression of RASSF10 
protein in 5-azaDC treated glioma cell line A172 and expression pre and post treatment in the 
unmethylated cell line, H4 (figure 5.3). These results show that RASSF10 is commonly 
methylated in a range of common solid tumour cell lines and that methylation is capable of 
suppressing expression of RASSF10 in gliomas in addition to thyroid cancers and childhood 
ALL.  
5.4.2. Methylation analysis of primary solid tumour samples  
All tumour types showing methylation in cell lines were analysed in primary tumours and in 
addition, because methylation was high in all cell line types analysed, some tumours were 
also analysed for which cell lines were unavailable. No methylation was observed in 
medulloblastomas (0/21) and infrequent methylation was observed in ovarian tumour samples 
(3/18; 17%). More frequent methylation was observed in lung, breast, kidney colorectal and 
glioma tumours. Lung tumours showed methylation in 4/20 (25%) primary tumour samples 
and 0/4 (0%) of non-cancerous adjacent lung tissue for the methylated
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Exon 1: 1521 bp
3’UTR: 478 bp5’UTR: 431 bp
CpG island: 2254 bp ; 209 CpGs
CTGCCCTTGCTGTCCTCGCCGCCCCAGCAGACCCCGGCCGGACCTGCCACCTGCGCCCTGGTTGCGCCATGGATCC
TTCGGAAAAGAAGATATCGGTGTGGATCTGCCAGGAAGAGAAGCTGGTGTCCGGCCTCTCCCGCCGCACCACTTGC
TCCGACGTTGTGCGAGTGCTTTTGGAGGACGGCTGCCGGCGGCGACGGAGACAGCGGCGGAGCCGGCGGCTGGGGT
CGGCCGGCGACCCGCATGGCCCGGGAGAGCTGCCCGAACCCCCGAACGAGGACGACGAGGACGACGACGAGGCGCT
GCCGCAGGGCATGCTGTGCGGGCCCCCGCAGTCTATTGCATCGTGGAGAAGTGGCGCGGCTTTGAGCGCATCCTCC
CCAACAAGACGCGCATCTTGCGCCTCTGGGCTGCCTGGGGCGAAGAGCAAGAGAATGTGCGCTTCGTGCTAGTGCG
CAGCGAGGCATCGCTGCCTAACGCCGGCCCCCGCAGCGCCGAGGCGCGCGTAGTGCTGAGCCGAGAGCGCCCCTGT
CCGGCCCGCGGGGCCCCGGCGCGGCCCAGCCTGGCCATGACCCAGGAGAAACAGCGGCGAGTGGTGCGCAAGGCCT
TTCGCAAACTGGCCAAGCTCAACCG
RASSF10 COBRA F
RASSF10 COBRA FN
RASSF10 COBRA RN
RASSF10 COBRA R
1 2 3
4 5 6 7 8 9 10 11 12 13 14 15
16 17 18 19 20 21 22 23 24 25 26 27 28 29
30 31 32 33 34 35 36
37 38 39 40 41 42 43
44 45 46 47 48 49 50 51 52 53 54 55
56 57 58 59 60 61
Figure 5.1_RASSF10 CoBRA region 
A schematic of RASSF10 gene structure as determined by Hesson et al, 2009 is shown in blue with the CpG island 
below in green. The region analysed by CoBRA is indicated with dashed lines and the sequence displayed 
underneath. CpGs assessed in the CoBRA region are numbered 1-61 and BstUI sites are in red. Primer locations are 
underlined. 
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Figure 5.2_RASSF10 CoBRA results for solid tumour cell lines
CoBRA results are shown with undigested PCR product (U) run next to 
digested PCR products (D). Three samples each are shown for colorectal, 
breast, lung and kidney cancer cell lines. * indicates methylated samples 
* * *
** *
* *
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Figure 5.3_Methylation analysis of glioma cell lines 
CoBRA results are shown for glioma cell lines with undigested PCR products (U) run next to digested PCR products (D). * 
indicates methylated samples (a). Expression results are shown pre (-) and post (+) treatment of 5-azaDC. Results are shown 
for both RASSF10 and GAPDH. No RT controls are also shown for RASSF10 and GAPDH to show there is no DNA 
contamination as RASSF10 is a single exon gene (b). (c) RASSF10 protein expression can be seen only after treatment with 
5-azaDC by Western blot analysis and (d) Immunoflourescence results are shown for H4 and A172 untreated and treated 
with 5azaDC.  Work done for (c) and (d) was carried out by Dr. Nick Underhill-Day. 
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samples, therefore showing tumour specific methylation. Breast tumour samples showed 
tumour specific methylation in 4/16 (25%) tumour normal paired samples (figure 5.4). Kidney 
tumours showed methylation in 4/16 (25%) and no methylation was seen in 6/8 normal 
kidney DNA samples. Colorectal tumour samples showed a slightly greater level of 
methylation in 5/16 (31%) of samples (figure 5.4; table 5.1), unfortunately adjacent normal 
tissue was unavailable for these samples. The greatest level of methylation in primary 
tumours was detected in gliomas and therefore further work concentrated on this tumour type.  
5.4.3 Methylation analysis of primary glioma samples  
Glioma world health organisation (WHO) grades I-III astrocytomas and grade IV 
glioblastoma multiforme (GBM) samples were analysed. Grade I astrocytomas were 
unmethylated (0/10), grades II and III astrocytomas were methylated in 6/10 (60%) and 8/10 
(80%) respectively (table 5.1). Grade IV GBM can be classified as either primary GBM 
(pGBM) or secondary GBM (sGBM) depending on whether earlier grade lesions were present 
that progressed to grade IV GBM (sGBM) or whether the tumour presented at grade IV 
without early lesions (pGBM). There is evidence that pGBM and sGBM have distinct genetic 
profiles (Parsons et al, 2008; Yan et al, 2009) and so have been analysed separately for 
RASSF10 methylation status. Both forms of grade IV GBM tumours showed a lower level of 
methylation than grade III astrocytomas. pGBM showed methylation in 13/20 (65%) of 
samples and sGBM showed a comparable level of methylation, 9/13 (69%) of samples. Very 
little methylation was observed in non-cancerous brain tissue (1/15, 6%) (table 5.1). Clone 
sequencing of glioma samples from different grades shows methylation is widespread 
throughout the region being analysed and that the CoBRA results are representative of the 
wider levels of methylation (figures 5.5 and 5.6). For 7 of the 9 methylated sGBM samples, 
DNA from the early grade lesion (grade II) was also available. 
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Figure 5.4_CoBRA analysis of primary colorectal, lung, kidney and breast 
samples 
CoBRA results are shown for five each of primary colorectal, lung and kidney 
tumour samples. Three breast tumour (T) and adjacent normal (N) breast tissue 
paired samples are shown for breast cancer. All CoBRA results are shown with 
undigested PCR products (U) run next to digested PCR products (D).  * 
indicates methylated samples.     
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247 
 
 
A3 MI = 1.4%
A20 MI = 44.5%
A26 MI = 82.8%
G3 MI = 59.6%
N05 MI = 2.2%
U D
NO5
U D
A3
U D
A20
U D
A26
U D
G3
N
o
n
-
ca
n
ce
ro
u
s 
b
ra
in
 t
is
su
e 
G
ra
d
e
 I
a
st
ro
cy
to
m
a
G
ra
de
 II
as
tr
oc
yt
om
a
G
ra
de
 II
I
as
tr
oc
yt
om
a
G
ra
de
 IV
G
B
M
Figure 5.5_CoBRA and sequencing of primary glioma tumour samples and
non-cancerous brain tissue I
CoBRA results are shown for five samples, one each of non-cancerous brain
tissue, grades I, II and III astrocytomas and grade IV GBM. In all cases,
undigested PCR products (U) are run next to digested PCR products (D).
Results from clone sequencing are also shown for each sample. Each line
represents a single allele, white and black circles represent unmethylated and
methylated CpGs respectively. MIs are calculated as a percentage of
methylated CpGs out of the total number of CpGs analysed.
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Figure 5.6_CoBRA and sequencing of primary glioma tumour samples and
non-cancerous brain tissue II
CoBRA results are shown for five samples, one each of non-cancerous brain
tissue, grades I, II and III astrocytomas and grade IV GBM. In all cases,
undigested PCR products (U) are run next to digested PCR products (D).
Results from clone sequencing are also shown for each sample. Each line
represents a single allele, white and black circles represent unmethylated and
methylated CpGs respectively. MIs are calculated as a percentage of
methylated CpGs out of the total number of CpGs analysed.
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Assessment of RASSF10 methylation status in these early lesions showed methylation in 6 out 
of the 7 samples, suggesting RASSF10 methylation is an early event in sGBM gliomagenesis 
(figure 5.7).  
Methylation of another RASSF family member, RASSF1A, is a common event in glioma 
tumours (Hesson et al, 2004), as is methylation of O-6-methylguanine-DNA 
methyltransferase (MGMT) (Esteller et al, 1999). To determine if RASSF10 methylation is 
independent of these events the methylation status of RASSF1A and MGMT was determined 
for this cohort of gliomas (only pGBM, not sGBM samples were analysed). RASSF1A was 
methylated in 84% of samples and MGMT was methylated in 26% of samples (figure 5.8). No 
associations were identified between RASSF10 methylation and either RASSF1A or MGMT. 
In addition, mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes are 
prevalent in gliomas, particularly sGBM, and associate with good prognosis (Parsons et al, 
2008; Yan et al, 2009). Work done by K Robel in Dr. Dietmar Krex’s laboratory (Klinik und 
Poliklinik für Neurochirurgie, Universitätsklinikum Carl Gustav Carus, Technische 
Universität Dresden, 01307 Dresden, Germany) identified IDH1 mutations in 10 of the 20 
grade II and III astrocytomas, 4 out of 10 sGBM and 2 out of 20 pGBM samples, no IDH2 
mutations were detected in any samples from this cohort. No associations were observed 
between IDH mutation status and either RASSF10 or RASSF1A methylation. 
5.4.4 Association of RASSF10 methylation with survival  
Overall survival (OS) and progression-free survival data was available for glioma tumours 
used in this study. RASSF10 methylation in sGBM tumours associated significantly with 
worse OS and worse PFS (p=0.0318 and p=0.0231 respectively) (figure 5.9). With Cox 
proportional hazard regression analysis, RASSF10 methylation and age at first operation were 
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Figure 5.7_RASSF10 methylation at grade II and IV gliomas
CoBRA results are shown for grade II and grade IV lesions for two 
patients. Results are shown with undigested PCR products (U) run next to 
digested PCR products (D). 
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Selected MSP results are shown for RASSF1A (a) and MGMT (b). MSP 
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also shown.   
L
L
252 
 
 
 
unmethylated
methylated
p= 0.0318
unmethylated
methylated
p= 0.0231
Time (days) Time (days)
Su
rv
iv
al
 p
ro
b
ab
li
li
ty
(%
)
Su
rv
iv
al
 p
ro
b
ab
li
li
ty
(%
)
0
20
40
60
80
100
0
20
40
60
80
100
Overall survival (OS) 
Progression-free 
survival (PFS) 
Figure 5.9_Kaplan-Meier analysis for RASSF10 in sGBM tumours
Graphs are shown for Kaplan-Meier analysis of RASSF10 methylation in sGBM tumours. An association 
with overall survival (OS) and progression-free survival (PFS) was observed. 
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independent prognostic factors for OS (p=0.01952 and p=0.02404 respectively and PFS 
(p=0.02724 and p=0.3223 respectively). IDH1 mutations were an independent prognostic 
factor for OS (p=0.02699) but did not reach significance for PFS (p=0.06723). 
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5.5 DISCUSSION  
Results from this study have added to those by Hesson et al, 2009 and Schagdarsurengin et al, 
2009 to show that RASSF10 methylation is a common event in many tumour types, 
particularly gliomas. 
5.5.1 RASSF10 methylation 
RASSF10 methylation was initially identified in childhood ALL samples (Hesson et al, 2009). 
Results showed that methylation was highly prevalent in T-ALL (80%) but not B-ALL (17%). 
Leukaemia cell lines were also highly methylated (100%) and showed re-expression of 
RASSF10 following treatment with 5-azaDC. A subsequent study in thyroid cancer identified 
frequent methylation in both cell lines (100%) and primary tumours (66%) (Schagdarsurengin 
et al, 2009). Expression levels of RASSF10 mRNA were found to be lower in thyroid cancer 
cell lines than normal human thyroid tissue. Expression could be re-expressed in thyroid 
cancer cell lines using 5-azaDC. The authors found differing frequencies of methylation in 
different subtypes of primary thyroid cancer, the highest being in medullary thyroid 
carcinoma (100%) and the lowest in undifferentiated thyroid cancer (40%). Due to the 
neuroendocrine basis of medullary thyroid carcinoma it was suggested by the authors that 
there may be an association between RASSF10 methylation and tumours with a 
neuroendocrine origin. Results from the current study have now shown frequent methylation 
in lung, colorectal, kidney, breast and glioma tumours, ranging from 25% in lung and breast 
tumours up to 80% in grade III astrocytomas. Methylation of glioma tumours proved 
particularly interesting, with high but differing levels of methylation in multiple stages of 
disease. RASSF10 methylation appears to occur as an early event and associated with worse 
OS and PFS in this cohort of sGBM, although the sGBMs available for survival analysis and 
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those with corresponding early lesions formed only a small cohort and therefore the 
association with survival and analysis in early and late lesions of the same patient would 
benefit from being observed in a separate, larger cohort. Table 5.1 shows a summary of all 
methylation data known to date for RASSF10. All data now available on RASSF10 
methylation in various cancers shows methylation is a common event in many cancers, the 
most frequent being childhood ALLs, thyroid cancers and gliomas. Only medulloblastomas 
and ovarian cancers have shown no or infrequent methylation. Some non-small cell lung 
cancers (NSCLCs) show neuroendocrine features whilst small cell lung cancers (SCLCs) do 
not, based on the higher level of methylation in thyroid cancers with a neuroendocrine origin 
it would be interesting to see whether SCLC and NSCLC show different frequencies of 
RASSF10 methylation. All methylation work in this chapter was carried out by CoBRA and in 
some cases bisulphite sequencing, however, due to the common nature of RASSF10 
methylation across multiple cancer types the setting up of an MSP or pyrosequencing assay 
may benefit future work in this area.  
5.5.2 RASSF10 methylation in gliomas  
Brain and central nervous system (CNS) tumours account for a relatively small proportion of 
all cancers diagnosed in the UK (4785 cases out of 309,527; 1.5%) and, due to the generally 
bad prognosis of these tumours, a slightly larger proportion of cancer related deaths (3674 out 
of 156,232; 2.4%) (CRUK cancer statistics). The majority of brain and CNS cancers are 
gliomas, consisting of astrocytomas (including glioblastoma multiforme), ependymomas, 
oligodendrogliomas and mixed gliomas, which consist of a mixture of the other subtypes. Of 
these, astrocytomas/glioblastoma multiforme are the most frequent in adults, accounting for 
more than 50% (Adamson et al, 2009). Prognosis is poor for patients diagnosed with 
glioblastomas (grade IV astrocytomas/glioblastoma multiforme), the median survival time 
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CANCER SUBTYPE
METHYLATION 
FREQUENCY 
REFERENCE
Childhood acute lymphocytic 
leukaemia 
cell lines 7/7 (100%)
Hesson et al, 2009
B-ALL 8/51 (16%)
T-ALL 23/26 (88%)
Pre-B-ALL 0/1 (0%)
Unclassified childhood 
leukaemias 0/5
Thyroid cancer 
cell lines 9/9 (100%)
Schagdarsurengin et al, 
2009
follicular thyroid carcinoma 5/10 (50%)
papillary thyroid carcinoma 9/12 (75%)
medullary thyroid carcinoma 5/5 (100%)
unclassified thyroid 
carcinoma 2/5 (40%)
Breast cancer 
cell lines 33%
This study 
primary tumours 4/16 (25%)
Lung cancer 
cell lines 40%
This study 
NSCLC 4/20 (25%)
Colorectal cancer 
cell lines 83%
This study 
primary tumours 5/16 (31%)
Kidney cancer
cell lines 33%
This study 
primary tumours 4/16 (25%)
Glioma 
cell lines 83%
This study; Hill et al, 2011
Grade I astrocytomas 0/10 (0%)
Grade II astrocytomas 6/10 (60%)
Grade III astrocytomas 8/10 (80%)
Grade IV pGBM 13/20 (65%)
Grade IV sGBM 9/13 (69%)
Ovarian primary tumours 3/18 (17%) This study 
Medulloblastomas primary tumours 0/21 ((0%) This study 
Table 5.1 Methylation frequency of RASSF10 in multiple cancers 
Methylation frequencies of RASSF10 in all cancers assessed at the time of writing. 
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after diagnosis being in the range of only 14 months. For this reason, GBM genetic and 
epigenetic alterations have been extensively studied. GBM tumours are most commonly 
primary GBM (pGBM), presenting as de novo tumours rather than with earlier lesions and are 
most prevalent in males (Adamson et al, 2009). In contrast, secondary GBM (sGBM) tumours 
account for approximately 5% of GBM cases and present with earlier grade II or III 
astrocytoma lesions. sGBM are more evenly distributed between males and females and are 
more prevalent in younger patients (Adamson et al, 2009). sGBM generally have a better 
prognosis than pGBM with greater overall survival times. Genetic alterations in GBM include 
overexpression of EGFR (Watanabe et al¸1996), inactivating mutation of TP53 (Ishii et al, 
1999) and loss of heterozygosity (LOH) at 10q25 (Rasheed et al, 1995). Recent sequencing 
studies have also identified frequent mutations in the isocitrate dehydrogenase 1 and 2 genes 
(IDH1 and IDH2) that associate with good prognosis and are more prevalent in sGBM 
(Parsons et al¸2008; Yan et al, 2009).  
Hypermethylation is a common event in gliomas and methylation has been described in many 
genes including RASSF1A (Hesson et al, 2004), HIC1 (Li et al, 1998), PTEN (Baeza et al, 
2003) and RB1 (Nakamura et al, 2001) amongst many others (reviewed in Hesson et al, 
2008). Whilst not necessarily the highest methylated gene in gliomas, the most clinically 
significant is MGMT. MGMT is a DNA repair enzyme that removes alkyl groups from the O6 
position of guanine. Alkylation at this position often results in cross-linking between DNA 
strands, causing cell death when not repaired. Some cancer drugs exploit this mechanism and 
cause alkylation of the DNA resulting in cell death. As MGMT inhibits cross-linking by 
repairing alkylation, inactivation of MGMT is beneficial for alkylating agents as the cross-
linking mechanism is no longer inhibited. Methylation of MGMT in gliomas was first 
described as being prevalent in 40% of gliomas (Esteller et al, 1999) and was later shown to 
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associate with a positive response to alkylating agents (Esteller et al, 2000a). The methylation 
status of MGMT is an excellent example of how DNA hypermethylation can be used to aid 
treatment and prognosis.  
There have been numerous studies that have assessed the glioma epigenome, recent studies 
include Martinez et al, 2009; Noushmehr et al, 2010 and Wu et al, 2010. In the study by 
Noushmehr et al, 2010 as part of a TCGA (the cancer genome atlas) group study, a subset of 
tumours were identified with a characteristic DNA methylation profile similar to the CpG 
island methylator phenotype (CIMP) previously observed in colorectal cancers. For this 
reason, it was termed glioma-CIMP (G-CIMP). G-CIMP tumours were found to associate 
with the proneural expression group previously identified in another TCGA group study 
(Verhaak et al, 2010), be of lower age at diagnosis and have better OS. IDH1 mutations were 
also associated with G-CIMP tumours (Noushmehr et al, 2010). The study by Wu et al, 2010, 
used the MIRA assay to assess the epigenome of the tumours used in this chapter (the 30 
astrocytomas and 20 pGBM samples) and found many DNA methylation alterations. The 
study also found that methylation was of increasing prevalence from grade I to III 
astrocytomas and then dropped slightly in pGBM, in accordance with the findings for 
RASSF10.  
The results from this study add to the ever growing list of hypermethylated genes in gliomas, 
which, when expression is lost, is likely to have a detrimental effect in the glioma cell. In 
addition, RASSF10 methylation appears to be an early event in sGBM and could have 
potential for prognosis, although a separate and much larger cohort of samples needs to be 
analysed to provide more evidence for this.  
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5.5.3 RASSF10 as a tumour suppressor  
High methylation of the newest RASSF member, RASSF10, in multiple cancers suggests it, 
like the classical RASSFs, is likely to behave as a tumour suppressor. In addition to the work 
described in this chapter Dr. Nick Underhill-Day carried out some functional work in cancer 
cell lines to demonstrate the importance of loss of RASSF10 in the tumourigenic process.  
Using an in-house generated RASSF10 specific antibody, RASSF10 was shown to localise 
primarily within the cytoplasm, with relocation to the nucleus during mitosis (Hill et al, 
2011). siRNA knockdown of RASSF10 in expressing glioma cell lines showed a significantly 
increased ability to metabolize resazurin (p<0.001), suggesting loss of RASSF10 leads to an 
increase in the viable cell population. In addition, loss of RASSF10 appeared to lead to an 
increase in DNA synthesis and thus cell proliferation (Hill et al, 2011).  
Overexpression of RASSF10 in non-expressing (due to hypermethylation) glioma cell lines 
U343 and H4 showed reduced colony forming ability compared to their empty vector 
transfected counterparts (p=0.0098 and p=0.0174 respectively) (figure 5.10). Knockdown of 
RASSF10 showed an increased ability to grow in soft agar, showing that RASSF10 can 
inhibit growth in an anchorage-independent manner. Overexpression of RASSF10 in U343 
and H4 cell lines did not show any reduced ability to migrate during a scratch would-healing 
assay. Taken together, these results suggest RASSF10 is capable of suppressing growth in 
cancer cells but does not affect cell migration (in glioma cells) (Hill et al, 2011). In 
combination with the hypermethylation of RASSF10 in many cancer types, these results 
provide promising evidence towards a tumour suppressor role for RASSF10.  
 
 
260 
 
 
%
 c
o
n
tr
o
l
U343 
0
20
40
60
80
100
120
140
Control RASSF10
0
20
40
60
80
100
120
140
Control RASSF10
%
 c
o
n
tr
o
l
H4 
P=0.0098 P=0.0174 
Figure 5.10_RASSF10 colony forming ability 
RASSF10 overexpressing U343 and H4 cell lines show reduced colony forming ability compared to control 
transfected cell lines. Graphs are shown for each cell line with colony forming ability of RASSF10 overexpressing
cells as a percentage of control transfected cells. Representative photographs are also shown underneath in each case. 
This work was carried out by Dr. Nick Underhill-Day and Dr. Mark Morris.  
261 
 
5.5.4 RASSF10 as a member of the N-terminal RASSFs 
The high levels of hypermethylation observed for RASSF10 in multiple cancers and the 
tumour suppressor effects of RASSF10 on the growth of cancer cell lines suggests that 
RASSF10 is a candidate tumour suppressor gene (Hill et al, 2011). Although there is now 
abundant evidence for the tumour suppressor roles of classical RASSF family members there 
is much less evidence for the N-terminal members. 
Hypermethylation of the N-terminal RASSFs is uncommon. RASSF7 has a large CpG island 
that has been assessed for hypermethylation in many cancers but none has been detected 
(Recino et al, 2010). RASSF8 does not have a CpG island according to UCSC, however, use 
of EBI CpG plot detects a CpG island upstream of and across the transcription start site. A 
region of this CpG island has been assessed for methylation in many cancer cell lines however 
no methylation was detected (Lock et al, 2010). Since RASSF9 does not have a CpG island, 
RASSF10 is the only N-terminal RASSF to be hypermethylated in tumours. However, 
RASSF8 has been described as a candidate tumour suppressor gene for many reasons 
(reviewed in Underhill-Day et al, 2011). Amongst other reasons, it has been shown to be 
downregulated in lung adenocarcinoma and able to inhibit anchorage-independent growth 
when re-introduced into lung cancer cell lines (Falvella et al, 2006). In addition, in vivo work 
has shown enhanced cell proliferation in Xenopus laevis when overexpressed and solid 
tumour formation in mice when RASSF8-depleted cells were introduced into SCID (severe 
combined immunodeficiency) mice (Lock et al, 2010). In contrast to RASSF8, RASSF7 has 
been shown to be upregulated in many cancers including pancreatic ductal carcinoma, islet 
cell tumours, endometrial cancer and ovarian clear cell carcinoma (Brandt et al, 2004; Friess 
et al, 2003; Logsdon et al, 2003; Lowe et al, 2007; Mutter et al, 2001; Tan et al, 2009). It is 
thought the upregulation of RASSF7 may be a by-product of hypoxic conditions in solid 
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tumours (Underhill-Day et al, 2011; Sherwood et al, 2010). RASSF7 has been shown to be 
required for mitosis and therefore cell cycle progression and cell survival (Sherwood et al, 
2008) and has been implicated in nectroptosis (Hitomi et al, 2008). Little is known about 
RASSF9 function, although it has been shown to associate with R-RAS, K-RAS and N-RAS 
(Rodriguez-Viciana et al, 2004).  
The work described in this chapter has identified frequent methylation of RASSF10 in many 
common solid tumour types, in particular gliomas, which has shown a very high frequency of 
methylation and appears to occur at an early stage of sGBM tumours. Although further work 
is needed in a much larger cohort, RASSF10 may provide prognostic value in sGBM tumours. 
In addition, the further work done by Dr. Nick Underhill-Day has shown tumour suppressor 
properties of RASSF10. This work adds to the little known information on N-terminal 
RASSFs, providing further evidence for tumour suppressor properties of N-terminal as well 
as classical RASSF members.  
 
 
This work has now been published under Hill et al, 2011 Oncogene 30(8):978-989. A copy of 
this publication is provided at the back of this thesis.  
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CHAPTER 6 
DNA METHYLATION ANALYSIS OF THE NEWLY IDENTIFIED 
SALVADOR/WARTS/HIPPO PATHWAY MEMBER, KIBRA 
 
6.1 ABSTRACT  
The Salvador/Warts/Hippo (SWH) pathway was identified in Drosophila melanogaster as a 
control mechanism for organ and tissue size (Tapon et al¸ 2002). This function is conserved in 
mammals and is often deregulated in cancer. Recently, the WW-domain protein gene, Kibra 
was identified as part of the pathway in D.melogaster (Yu et al, 2010; Genevet et al, 2010; 
Baumgartner et al, 2010). The work in this chapter has assessed the methylation status of the 
human homologue, KIBRA, across a range of cancer cell lines. Frequent methylation was 
detected in leukaemia cell lines but not solid tumour cell lines. Methylation correlated with 
gene silencing which could be reversed by treatment with the demethylating agent 5-aza-2’-
deoxycitidine. Primary childhood acute lymphocytic leukaemia samples showed a high 
frequency of methylation, predominantly in B-cell acute lymphoblastic leukaemia (B-ALL) 
rather than T-cell acute lymphoblastic leukaemia (T-ALL) samples (70% compared to <20%; 
p=0.0019). In addition, methylation associated with the ETV6/RUNX1 {t(12;21)(p13;q22)} 
chromosomal translocation (p=0.0082), suggesting that KIBRA may play an important role in 
t(12;21) leukaemogenesis. In B-ALL paired samples at diagnosis and remission KIBRA 
methylation was seen in diagnostic but not in any of the remission samples. In accordance 
with this, KIBRA mRNA expression was only observed in remission samples. KIBRA 
methylation is therefore common in B-ALL and linked to a specific genetic event. 
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6.2 INTRODUCTION  
As discussed in chapter one, the Salvador/Warts/Hippo (SWH) pathway is a controller of 
tissue and organ size which, when deregulated, can have tumourigenic effects. When active, 
the upstream members of the pathway function to suppress the activity of the YAP1/TAZ-
TEAD transcription factor complex. Mammalian upstream members of the pathway have 
been shown to act in a tumour suppressor role. Deregulation of these members are involved in 
neurofibromatosis through mutation of NF2, soft tissue sarcoma through hypermethylation of 
MST1/2, melanomas through MOBKL1A/B, and astrocytoma and breast cancers through 
hypermethylation of LATS1/2 (Rouleau et al, 1993; Tapon et al, 2002; Lai et al, 2005; Seidel 
et al, 2007; Jiang et al 2006; Takahashi et al, 2005; Kosaka et al, 2007; Sasaki et al, 2007). In 
addition, YAP1 overexpression has been observed in lung, medulloblastomas and 
oespophageal cancers (Dai et al, 2003; Fernandez-L et al, 2009; Imoto et al, 2009). Recently, 
a new human member of the SWH pathway was identified, KIBRA (kidney and brain 
protein), also known as WWC1 (WWC and C2 domain containing 1), the fly homologue of 
which has been shown to function in a tumour suppressor capacity in drosophila 
melanogaster (Yu et al, 2010; Genevet et al, 2010). Since hypermethylation is a common 
mechanism of disruption of the SWH pathway it is worth analysing this newly identified and 
previously unstudied in human cancer SWH pathway member. The work in this chapter will 
analyse the KIBRA methylation status across solid and haematological cancer cell lines and 
subsequent relevant primary tumour samples.  
  
265 
 
6.3 AIMS 
1. To assess the methylation status of KIBRA in major solid tumour cancer cell lines and 
haematological cancer cell lines  
2. To analyse the methylation status of KIBRA in relevant primary tumours of any of the 
cancer cell line types shown to be methylated. 
3. To access any association between observed methylation and any additional genetic or 
clinical features, where additional information is available. 
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6.4 RESULTS  
6.4.1 Analysis of KIBRA in cancer cell lines  
KIBRA has a CpG island of 1165bp containing 113 CpGs situated upstream and inclusive of 
the transcription start point. A 248bp region was analysed by CoBRA (figure 6.1) in a panel 
of 7 leukaemia, 7 colorectal, 5 breast, 10 renal, 4 glioma, 5 prostate and 15 lung cancer cell 
lines. Methylation was infrequent in solid tumours with digestion only observed in 1/7 
(14.3%) glioma cell lines (figure 6.2). No methylation was observed in non-cancerous brain 
samples.  
More frequent methylation was found in leukaemia lines with 4/7 (57.1%) showing either 
complete (3/4) or partial (1/4) methylation (figure 6.3). In addition, no methylation was 
identified in either control bone marrow or peripheral blood samples (figure 6.3). Analysis of 
expression pre and post treatment with 5-azaDC in leukaemia cell lines showed re-expression 
in methylated lines (figure 6.3). These results show frequent methylation of KIBRA in 
leukaemia lines that appears to be capable of repressing expression at the RNA level.  
6.4.2 Analysis of KIBRA in primary glioma tumour samples  
Due to the infrequent levels of methylation in glioma cell lines only high grade primary 
glioma tumours were initially analysed. Of the 20 grade IV glioblastoma multiforme (GBM) 
tumour samples analysed none showed methylation (figure 6.4). Coupled with the cell line 
analysis, these results show that this region of the KIBRA CpG island is unmethylated in a 
wide range of common solid tumours.  
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CACCTGGCGGAGGCAGAAGTCACAAACCCGGCGAGCTCAGAGCGGTGGAGCGGAGAGGAGGGACGGCACCCGGCTGCAGGG
AGGAGGGAGGCGGCAGCGGCAGCGGCGGCGTGGAGGGCGCAGCGCGCCGCGCGGCGGAGGAGGGCAGACGGCGGCGGCGGC
GGCGCTCGGCTCGCTCTGCCCGGCCGGCTGGGCGCGCACCCGGGCTCGCACCGCGCCGCTGCGGACGCACATGGCAGCGTG
AGAGGCCGGCGGCGGGAGGAGCGGGCGGCGCCGGGTCGGGGCTGCAGGGCCGCATGGACAGCGGCGCCACCCCGGCCGGCC
CCTACTAGGGCCCCCCATCTGCGGGCGCCACCCCCCGGATCATGGTGCCTCGGCGGCCGCCCGGGCTAAGAGCGGCCGGCT
GGAGCCGCTGAGCCCCCGCTGCGGCCGGGAGCTGCATGGGGGAGCGCCGGCAGCGCTTGGGAAGATGCCCCGGCCGGAGCT
GCCCCTGCCGGAGGGCTGGGAGGAGGCGCGCGACTTCGACGGCAAGGTCTACTACATAGACCACACGAACCGCACCACCAG
CTGGATCGACCCGCGGGACA
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Figure 6.1_KIBRA CoBRA region
A schematic of KIBRA 5’UTR and exon 1 is shown (blue) with the CpG island underneath (green). The region 
amplified by CoBRA primers is indicated with dotted lines, the region of which is assessed by BstUI digestion is shown 
in red. The sequence amplified by CoBRA is displayed underneath with CpGs numbered 1-51 and BstUI sites shown in 
red text. 
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Figure 6.2_CoBRA results for solid tumour cancer cell lines. 
CoBRA results are shown for three cell lines for each of the tumour types as indicated. All 
results are shown with undigested products (U) next to digested products (D). * indicates 
methylated samples. 
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Figure 6.3_CoBRA and expression results for leukaemia cell lines, normal bone marrow and normal blood. 
(a) CoBRA results are shown for three leukaemia cell lines, two normal blood samples and one normal bone marrow. 
Undigested PCR products (U) are run next to digested PCR products (D). (b) Expression results for KIBRA and GAPDH are 
shown pre (-) and post (+) treatment with 5-azaDC along with normal bone marrow for KIBRA.  * indicates methylated 
samples. 
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Figure 6.4_CoBRA results for primary glioma samples.
CoBRA results for five grade IV GBM samples are shown with
undigested PCR products (U) run next to digested products (D). A
positive digest is also shown to demonstrate effective BstUI digestion.
271 
 
6.4.3 Analysis of KIBRA in primary leukaemia samples 
A total of 70 childhood acute lymphocytic leukaemia (ALL) primary tumours consisting of 52 
B-ALL, 1 pre-B-ALL, 12 T-ALL and 5 unclassified were assessed. A high frequency of 
methylation was observed overall (38/65, 58.5%) with the greatest level in B-ALL (33/38, 
70%) samples compared to T-ALL (2/12, 16.7%) samples (p=0.0019) (figure 6.5). In order to 
confirm the CoBRA results and assess the pattern of methylation, clone sequencing of 
bisulphite modified DNA was performed. Results showed the region was highly methylated 
with little heterogeneity between the samples (figure 6.6). Neither normal blood nor bone 
marrow showed significant levels of methylation within the region (figure 6.6). B-ALL 
leukaemias commonly have a translocation between ETV6/RUNX1 {t(12;21)(p13;q22)} and 
KIBRA methylation strongly associates with this translocation in this cohort of samples (p = 
0.0082).  
6.4.4 Methylation and expression analysis in diagnosis and remission paired primary B-
ALL samples  
Five pairs of B-ALL ETV6/RUNX1 translocation positive samples from the diagnosis and 
remission stages of disease were analysed for methylation and expression. CoBRA analysis of 
B-ALL samples showed KIBRA methylation at diagnosis but not remission in all five pairs 
(figure 6.7a). In addition, RT-PCR showed expression of KIBRA mRNA at remission, when 
methylation was no longer present but not at diagnosis, when samples were all methylated 
(figure 6.7b). These results indicate that KIBRA methylation is specific for malignant cells and 
that methylation is capable of suppressing KIBRA mRNA expression in primary samples. 
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Figure 6.5_CoBRA results for primary ALL samples. 
CoBRA results are shown for five primary B-ALL samples (a) and five primary 
T-ALL samples (b). Undigested PCR products (U) are run next to digested PCR 
products (D). * indicates methylated samples. 
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Figure 6.6_Sequencing of primary ALL samples
A schematic of the location of the KIBRA CpG island in relation to KIBRA exon 1
is shown along with the position of the region being analysed by CoBRA. Clone
sequencing results are shown for four B-ALL samples (102935, 3413, 15467 and
101717), one normal blood and one normal bone marrow. Each line represents a
single allele, and black and white circles represent methylated and unmethylated
CpGs respectively. Methylaton indexes (MIs) were calculated as a percentage of
methylated CpGs out of total CpGs analysed.
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Figure 6.7_CoBRA and expression results for diagnosis and remission B-ALL samples. 
(a) CoBRA results are shown for three of the five diagnosis and remission paired B-ALL 
samples. Undigested PCR products (U) are shown next to digested PCR products (D). (b) 
KIBRA expression results are shown for diagnosis and remission samples along with 
GAPDH. 
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6.5 DISCUSSION  
This study has identified frequent methylation of KIBRA in childhood acute lymphocytic 
leukaemia (ALL) (58.5%) that was more frequent in B-ALL than T-ALL samples (70% 
compared to 16.7% respectively; p=0.0019). Methylation of KIBRA was also significantly 
more prevalent in samples harbouring the ETV6/RUNX1 translocation (p=0.0082). 
6.5.1 KIBRA methylation in childhood ALL  
In the western world, childhood ALL is the most common form of childhood leukaemia. In 
the UK, 31% of childhood cancers are leukaemias, of which 79% are of the ALL subtype 
(CRUK cancer statistics). Despite the disease having high survival rates of up to 80%, 
childhood ALL still accounts for 30% of all childhood cancer deaths in the UK (CRUK 
cancer statistics). The highest rates of survival are observed in children aged 1-9 years whilst 
infants (<1 year) have very high rates of treatment failure (Möricke et al, 2005; Pui et al, 
2008).  
ALL is split into two major types depending on the cell type of origin; B-cell ALL (B-ALL) 
and T-cell ALL (T-ALL). B-ALL cells express B-cell associated antigens such as CD79a, 
CD19 and HLA-DR whilst T-ALL cells express T-cell associated antigens such as CD3, 
CD7, CD2 and CD5. The vast majority of childhood ALL cases are B-ALL (80-85%) with 
the remainder being mostly T-ALL although some cancers are of an undetermined lineage, 
demonstrating features of both B- and T-cells. Chromosomal aberrations are a common 
feature of leukaemias with both changes in ploidy and genomic translocations frequent events. 
ALL patients demonstrating high hyperploidy (51-60 chromosomes per cell) have a 
favourable outcome, this is common in B-ALL (20-25% of B-ALL patients), whilst patients 
demonstrating hypodiploidy (less than 40 chromosomes per cell) have a poor prognosis 
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(Paulsson et al, 2009; Nachmann et al, 2007). Common translocation events in ALL include 
the t(12;21)(p13;q22) translocation producing the ETV6/RUNX1 fusion protein, the 
t(9;22)(q34;q11) translocation (Philadelphia chromosome) producing the BCR/ABL fusion 
protein, the t(1;19)(q23;p13.3) translocation producing the TCF3/PBX1 fusion protein and 
translocations involving the MLL (myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila)) gene at 11q23. BCR/ABL, TCF3/PBX1 and MLL translocations occur 
in 3%, 5% and 5% of childhood ALL cases respectively (Crist et al, 1990; Pui et al, 2003; 
Uckun et al, 1998). The most frequent translocation in childhood ALL is the ETV6/RUNX1 
translocation [t(12;21)(p13;q22)] (previously known as TEL/AML1). The ETV6/RUNX1 
translocation is a frequent and early event, occurring in 25% of all B-ALL cases, the 
translocation is associated with good prognosis and whilst it often occurs prenatally, it is not 
sufficient to cause childhood ALL alone (Greaves et al, 2003; Shurtleff et al, 1995; 
Armstrong and Look, 2005). In its wild type form, RUNX1 acts as a transcriptional activator 
of numerous genes including those, such as IL3 (interleukin 3) (Uchida et al, 1997), that are 
involved in haematopoietic development. Transcriptional activation of genes by RUNX1 is 
brought about by chromatin modifications, for example, the involvement of RUNX1 in 
myeloid differentiation is associated with its interaction with the histone acetyltransferase 
p300 (Kitabayashi et al, 1998). When fused with a portion of ETV6, the transcriptional 
repression domain within wild type ETV6 causes the normally RUNX1 activated genes to 
become transcriptionally repressed (Hiebert et al, 1996; Fears et al, 1997). ETV6 mediated 
repression of genes by the ETV6/RUNX1 fusion protein is achieved through nuclear receptor 
corepressor (N-CoR) HDAC complexes (Guidez et al, 2000).  
Hypermethylation is also a common event in haematological cancers. In childhood ALL, 
numerous genes have been shown to be highly methylated, including, among many others, 
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KLK10 (kallikrein related peptidase 10), SFRP1 (secreted frizzled-related protein 1), 
ADAMTS1 (ADAM metallopeptidase with thrombospondin type 1 motif, 1) and CDKN1A 
(cyclin-dependent kinase inhibitor 1A (p21, Cip1), all methylated in between 40% and 60% of 
cases (Roman-Gomez et al, 2005; Roman-Gomez et al, 2002). There have been numerous 
genome-wide methylation studies identifying further genes hypermethylated in ALL 
including a family of ephrin receptor tyrosine kinases and genes showing significant 
differences in methylation status between B-ALL and T-ALL (Dunwell et al, 2010; Kuang et 
al, 2008). Genome wide studies have also identified methylation profiles that predict relapse 
and discriminate between cytogenetic ALL subtypes (Milani et al, 2010) and higher levels of 
methylation in lymphoid lineage leukaemias rather than myeloid malignancies (Martín-
Subero et al, 2009b). The work in this chapter has identified frequent methylation in the 
KIBRA gene in childhood ALL, which is the first example of KIBRA methylation in human 
cancer. Significantly higher levels of methylation were observed in B-ALL cancers compared 
to T-ALL cancers (p=0.0019) suggesting a possible role in B-cell leukaemogenesis. However, 
it is important to note that the controls used for this study consisted of normal blood DNA and 
normal bone marrow DNA, neither of which are specific for either B or T lineage cells and 
therefore will not allow for comparison of methylation status between B-cell ALL and a pure 
sample of normal B-cell DNA, and likewise for T-ALL and T-cell DNA. Despite this, as gene 
specific hypomethylation is a relatively uncommon event in cancers it is unlikely that the 
subtype showing the higher frequency of KIBRA methylation, B-ALL, at 70.6%, is normally 
methylated in B-cells. In addition, the resulting increase in expression following methylation 
removal in cell lines and the methylation and corresponding loss of expression of KIBRA in 
diagnosis but not remission samples suggests KIBRA methylation events are likely to have 
some biological function on the leukaemic cells. KIBRA methylation also associated with the 
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ETV6/RUNX1 translocation event and it has been suggested that ETV6/RUNX1 leukaemias 
are more likely to have methylation of multiple genes than those without the translocation 
(Roman-Gomez et al, 2006). KIBRA methylation may therefore have a role in ETV6/RUNX1 
leukaemogenesis.  
6.5.2 KIBRA methylation as a deregulated member of the SWH pathway in 
haematological cancers  
Deregulation of the SWH pathway has been observed in many cancer types including breast, 
melanomas, neurofibromas, soft tissue sarcomas, and astrocytomas via numerous members of 
the pathway (Rouleau et al, 1993; Lai et al, 2005; Seidel et al, 2007; Jiang et al, 2006; 
Takahashi et al, 2005). This is the first report describing epigenetic inactivation of KIBRA, a 
newly identified upstream member of the SWH pathway in any human cancer. As no 
methylation was discovered in the panel of solid tumours looked at, inactivation of KIBRA by 
hypermethylation appears to be restricted to haematological cancers, although this cannot be 
said for certain as there are many types of cancer that have not been studied in this chapter. In 
particular, it would be interesting to look at neurofibromas as mutations in one of the binding 
partners of KIBRA, NF2, is involved in neurofibromatosis type 2 pathogenesis (Rouleau et al, 
1993).  
It has recently been shown that expression of the SWH pathway members MOBKL2A, 
MOBKL2B and LATS1 is downregulated and associates with lower survival in another 
haematological cancer, mantle cell lymphoma (Hartmann et al, 2010). A separate study has 
shown methylation of LATS1 in childhood and adulthood ALL (Roman-Gomez et al, 2004) 
suggesting the downregulation observed by Hartmann et al, 2010 could be due to 
methylation. In previous studies, methylation of large tumour suppressor 2 (LATS2) has also 
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been shown to be methylated in ALL with associated lower expression in primary leukaemia 
samples. Both childhood and adulthood cases were affected and in both cases lower 
expression associated with higher relapse and mortality. Unlike KIBRA, expression did not 
return in remission samples (Jiménez-Velasco et al, 2005). In addition, previous work form 
this laboratory identified methylation of FAT1 and YAP in primary childhood ALL samples 
(Dunwell, 2010). Taken together these results suggest deregulation of the SWH pathway may 
be a common event in haematological cancers. This may offer insight into the development of 
haematological cancers.  
6.5.3 KIBRA as an upstream member of the SWH pathway 
KIBRA was recently identified as forming part of the Kibra/Expanded/Merlin complex of the 
SWH pathway in flies (human homologues KIBRA, FRMD6 and NF2 respectively) (Yu et al, 
2010; Genevet et al, 2010; Baumgartner et al, 2010). The complex is thought to be 
predominantly located at the sub-apical region of the cell and upon binding with both Merlin 
and Expanded thought to recruit core SWH members to the apical membrane where they 
become activated. At present, it is unknown how members of the Kibra/Expanded/Merlin 
complex are regulated. Given the methylation of KIBRA in ALL but not common solid 
tumour types, it would be interesting to see if KIBRA behaved differently in haematological 
cells compared to other cell types. 
6.5.4 Conclusions and further work  
This study is the first description of KIBRA methylation in any human cancer. KIBRA 
methylation was a frequent event in childhood ALL but not in common solid tumours, 
suggesting haematological specific hypermethylation. Although the aims of this chapter have 
been met, it would be beneficial to show KIBRA expression reduced at the protein as well as 
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the RNA level and that loss of KIBRA results in tumourigenic characteristics in an ALL 
model. It would also be interesting to see if loss of KIBRA resulted in the same phenotypes in 
cells with and without the ETV6/RUNX1 translocation, to determine if KIBRA loss has a role 
in t(12;21) leukaemogensis.  
 
This work has now been published under Hill et al (2011) Epigenetics 6(3):326-332. A copy 
of this publication is provided at the back of this thesis.  
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CHAPTER 7 
DISCUSSION 
 
Cancer represents the largest cause of death worldwide, accounting for 7.5 million deaths in 
2008 (Jemal et al¸ 2011). In the UK, 309 500 people were diagnosed with cancer in 2008, 
breast and prostate cancer diagnoses being the most common in adult females and males, 
representing 31% and 24% of all adult female and male cancers respectively (CRUK cancer 
statistics). Although most commonly presenting in adulthood, cancer can also be a disease of 
childhood, the most common forms in children in the UK being leukaemias and brain and 
CNS cancers (CRUK cancer statistics). As a result of lifestyle changes and an aging 
population, the incidence of many cancers across the developed world has been, and continues 
to, increase. However, in the developed world, the numbers of deaths from cancer have been 
decreasing, primarily as a result of better disease understanding. The development of better 
screening methods for cancers, such as breast cancer through mammography and cervical 
cancer through cervical screening programs, have helped to both identify cancers earlier and 
identify patients most at risk who can be monitored more closely. Additionally in the case of 
cervical cancer, to identify pre-malignant lesions that can be treated before progression to 
malignancy. The identification of specific genetic alterations in cancers have also led to better 
disease outcomes through targeted therapies such as the treatment of ERBB2 overexpressing 
breast cancers with trastuzumab (Herceptin) (Hudis et al¸ 2007) and the recent clinical trial of 
Vemurafenib in melanoma patients with a specific BRAF mutation (V600E) (Chapman et al, 
2011). Despite the better outcome of a cancer diagnosis, continued identification of good 
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therapeutic targets and prognostic, diagnostic and treatment outcome markers are essential for 
benefitting patient outcome.  
Changes in DNA methylation are a hallmark of cancer genomes and a common mechanism of 
tumour suppressor gene inactivation. DNA methylation marks are also amenable to biomarker 
development, for example, the methylation status of MGMT is widely used to predict which 
glioma patients are most likely to benefit from alkylating dugs such as temolozide. 
Assessment of DNA methylation changes in cancer genomes can therefore highlight genes 
that may elucidate deregulated genes and pathways, and potential candidates for biomarker 
development. To aid in this field of research, the work in this thesis aimed to identify DNA 
methylation changes in sporadic cancers, presenting two studies aiming to identify genes 
hypermethylated in sporadic breast cancers and two studies looking at the methylation status 
of two candidate genes across multiple cancer types.  
7.1 Genome wide analysis of sporadic breast cancer  
Recent technological advances have developed multiple assays for genome wide analysis of 
DNA methylation. Two of the most recently developed methods are methylated DNA 
enrichment approaches and Illumina methylation array platforms. Chapters three and four 
have used two of the most up to date and comprehensive methods available at the time of 
study to assess methylation in sporadic breast cancer. 
Chapter three used the Methylated CpG Island Recovery Assay (MIRA) in conjunction with 
CpG island microarrays across five breast cancer cell lines. Sixteen genes were identified that 
showed frequent methylation in cell lines but not normal breast tissue DNA, of which nine 
were also frequently methylated in primary tumour samples. Of these nine, five genes 
demonstrated frequent, tumour specific methylation in a second cohort of sporadic ductal 
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breast tumour patient samples and re-expression following treatment with the de-methylating 
drug, 5-azaDC, in methylated cell lines. All five genes, CIDE-A, DBC1, EMILIN2, FBLN2 
and SALL1, are functionally good candidate genes to be involved in breast cancer 
tumourigenesis. Methylation of three of the five genes also showed an association with 
clinical features; EMILIN2 methylation associated with ER and PR positive tumours, relapse 
and worse disease free survival (DFS), whilst CIDE-A and FBLN2 methylation associated 
with ER or PR positive tumours respectively. In addition, decreased expression was observed 
in EMILIN2 methylated patient samples, suggesting a likely functional consequence of 
EMILIN2 hypermethylation. Hypermethylation in cancer tissue was novel for EMILIN2 and 
CIDE-A whilst methylation of the remaining genes, DBC1, FBLN2 and SALL1 had previously 
been observed in other cancers (Izumi et al, 2005; Dunwell et al, 2009; Kuang et al, 2008; 
Tong et al, 2010). Analysis of these genes in other solid tumours demonstrated frequent 
methylation for three of the genes, SALL1, FBLN2 and EMILIN2, in prostate cancers (SALL1 
and FBLN2), colorectal cancers (EMILIN2) and gliomas (FBLN2). This study represents the 
first example of using the methylated CpG island recovery assay (MIRA) in invasive breast 
cancer and one of the first examples of using methylated DNA enrichment based assays on 
invasive breast cancer. The study has shown the technique to be successful in identifying 
interesting methylated genes.  
Chapter four used the Illumina Infinium HumanMethylation27 array on a cohort of 39 
sporadic ductal breast carcinoma samples. The study demonstrated that global 
hypermethylation levels in a cohort of sporadic ductal breast tumour samples is significantly 
higher in relapsing tumours and those positive for ER and PR receptors. The association 
between high methylation levels and ER/PR status has also been demonstrated in two other 
studies that were published in the same year as this (Li et al, 2010; Holm et al, 2010). These 
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results may indicate a CIMP-like phenotype in this subset of tumours and suggest that ER/PR 
positive tumours are more susceptible to hypermethylation events, making them the most 
suitable breast cancer type to be treated with demethylating drugs such as ‘Vidaza® and 
‘Decitibine/Dacogen®’ if these treatments ever come to fruition in solid tumour therapy 
regimes. Whilst the methylation status of individual genes has previously been shown to 
correlate with relapse in breast cancer, I believe this is the first time a global increase in 
methylation has been shown to associate with relapse in breast cancer, although no 
association was observed with disease free survival.  
 The study was also able to identify individual genes where methylation status correlated with 
clinical features. Six genes, RECK, SFRP2, ITR, UGT3A1, ACADL and UAP1L1, were 
identified that showed significant association between methylation and relapse/DFS. Of these 
six, RECK, SFRP2 and ACADL were further characterised, showing tumour specific/enhanced 
methylation and reduced expression in primary tumour samples (RECK and ACADL only), 
suggesting these genes may also have functional consequences as well as being potential 
candidates with prognostic value. These results will be of particular interest to those in the 
clinical breast cancer research field. Eighteen genes (B3GAT1, TNFRSF10D, GRIA4, 
C1orf114, DNAJC6, C6orf145¸ CORIN, LAMA2, ITR, MCAM, C12orf34, NPY, COL1A2, 
RSNL2, ZNF660, ADAMTSL1, DPP4, MAT1A) were identified as being significantly more 
frequently methylated in ERPR expressing tumours. Further work on TNFRSF10D, COL1A2 
and C1orf114 demonstrated methylation is capable of reducing expression in cell lines, 
tumour specific/enhanced methylation for all three genes and significant loss in expression in 
methylated patient samples for C1orf114. The findings for C1orf114 are particularly 
interesting as it was also identified in the DCIS MIRA study (Tommasi et al, 2009) and 
therefore represents an uncharacterised gene with strong evidence towards a potential role in 
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breast cancer, making it an exciting candidate for further work. Analysis of candidate genes 
irrespective of any possible association with clinical features was also successful in 
identifying interesting genes; further analysis of the most highly methylated and genes with 
multiple probes identified four genes, COX7A1, SST, CDKL2, ZNF154, that showed 
correlation between expression and cell line methylation and subsequent specific/enhanced 
methylation in the tumour normal paired samples. These results have helped to identify 
further genes involved in breast cancer and given some insight into the global methylation 
changes of breast cancer.  
7.1.1 Experimental Design for Breast Cancer Array Analysis Studies  
The research carried out in chapters 3 and 4 utilised two of the most recently developed 
techniques, an affinity pull down approach (chapter 3) and an array based on direct 
hybridisation of bisulphite modified DNA (chapter 4). The fundamental design of these two 
studies exhibited substantial differences.  
The MIRA assay was carried out on a small number of breast cancer cell lines whilst the 
Infinium array was performed on a larger cohort of sporadic breast tumour patient samples. It 
is the differing array methodologies that ultimately led to the use of different sample types. 
The MIRA technique requires a large amount of starting material, 5μg, compared to the 0.5μg 
required for Infinium. Access to 5μg of patient material was simply not possible at the time of 
study and since cell lines offer the possibility of treatment with 5-azaDC to compare 
expression in relation to DNA methylation status they represent a useful starting material for 
this type of study. However, it is known that DNA hypermethylation is both increased in the 
number of genes and more expansive in terms of the level of methylation within a particular 
region in cell lines compared to patient tumour samples (Smiraglia et al, 2001), meaning 
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many genes may be identified as frequently methylated in cell lines that are not frequently 
methylated in primary tumours. Taking this into account, frequent methylation in cell lines 
was classed as >30% compared to >25% in primary tumours, however, despite this, a 
frequency of just under half (44%) of genes frequently methylated in breast cancer cell lines 
were not methylated in primary tumour samples, highlighting the major disadvantage to using 
cell line DNA as starting material for this study. In comparison, the Infinium array gave an 
initial quantitative measurement of methylation across a panel of 39 sporadic samples. Due to 
the number of samples used and the availability of clinical information for these samples, it 
was possible to use the data directly from the array to identify genes that are associated with 
particular clinical features. Therefore the use of primary samples conferred an advantage to 
finding clinically relevant methylation events, offering an advantage over using cell lines in 
this respect.  
When comparing methylation with expression, although only a small number of samples were 
analysed, the efficiencies of the two arrays appeared to be comparable; 88.9% (8/9) of genes 
analysed for expression in the MIRA study correlated with methylation whilst 83.3% (10/12) 
of genes analysed in the Infinium study correlated with methylation, suggesting the use of 
either platform is successful in identifying methylation events that are capable of affecting 
gene expression.  
The genes analysed by CoBRA in tumour/normal paired samples showed a greater level of 
specificity if identified through the MIRA study compared to the Infinium study. Whilst both 
assays showed tumour specific/enhanced methylation in many genes, genes identified through 
the MIRA assay showed less methylation in the associated normals compared to those 
identified in via the Infinium study, where many genes showed reduced methylation in 
adjacent normals compared to methylated tumours rather than having a complete 
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unmethylated status. This is most likely due to the MIRA assay design encompassing more 
probes per CpG island than the Infinium array and therefore giving results representative of a 
larger region.  
Use of affinity pull-down methods to isolate methylated DNA is a newly developed technique 
for assessing global methylation levels. The technique offers the advantage of not requiring 
bisulphite modification of DNA which may prove particularly useful for modification to a 
technique able to distinguish between 5-hydroxymethylcytosine (5hmC) and 5-
methylcytosine (5mC) in the future. However, there may be in-built biases to the regions of 
DNA that are most successfully isolated due to protein/antibody binding specificities. A 
recent study comparing MeDIP and methyl binding domain (MDB) protein affinity 
enrichment techniques suggested that MeDIP and MBD based techniques do indeed differ 
between preferred enrichment sites (Nair et al¸ 2011). MBD based techniques appear to 
preferentially pull-down dense CpG regions which may explain the high levels of Homeobox 
related genes in the MIRA studies (Rauch et al, 2006; Tommasi et al¸ 2009). Whilst this in no 
way suggests that the detection of tumour acquired methylation of these genes is not true, it 
may suggest that the enrichment of these genes within the lists could be artefacts of the 
technique. The opposite is true for MeDIP based approaches, with preferential enrichment of 
less dense CpG regions. Additionally, analysis of the MIRA results in chapter three in the 
high stringency gene list selected genes based on a very high number of probes being 
methylated which will bias the list towards larger CpG islands, highlighting the potential 
impact of using different methods of analysis. Nonetheless, the technique allows analysis of 
larger regions of DNA than the Infinium assays and is not limited by the assessment of 
specific CpGs by selective probe design.  
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The Infinium HumanMethylation27 array is designed to generate a quantitative measurement 
of a single CpG dinucleotide, however, the unmethylated and methylated bead types are 
designed like USP and MSP primers respectively, making binding of DNA to either bead type 
dependent on the methylation status of upstream CpGs. The β value therefore gives a 
quantitative measurement of the CpG when additional CpGs in the immediate vicinity are 
also either methylated or unmethylated, which, although a minor point, does confer an 
advantage to the assay if looking for wider methylation levels. As already mentioned, the 
technique suffers from the limitations imposed by specific probe design as opposed to pull-
down of any methylated DNA region. Whilst the MeDIP and MBD based techniques are 
often hybridised to microarrays, they lend themselves to sequencing based methods of 
analysis of isolated methylated fragments. This, when sequencing methods are more cost 
effective, will allow for the next step of methylome analysis.  
In summary, the method of use to assess global methylation levels depends greatly on the 
aims of the study. If the identification of clinically relevant genes is the main aim of a project 
then the Infinium assay is best suited due to the quantitative nature and amenability to the 
development of a diagnostic assay. If novel candidate genes are required then one of the 
methylated DNA enrichment assays are perhaps more suited due to the increased number of 
CpG islands in the array covering more features such as uncharacterised genes and miRNAs, 
however, a larger number of samples and the use of primary patient material would be more 
appropriate. The newly available Illumina Infinium HumanMethylation 450k array, covering 
a much wider selection of CpGs within gene related CpG islands, CpGs within CpG islands 
unrelated to genes, CpGs outside of CpG islands and CpGs related to other features such as 
miRNAs compared to the 27K array, will bridge the gap between higher coverage CpG island 
microarrays that are used with methylated DNA enrichment approaches and the lower 
289 
 
coverage direct bisulphite modified approaches. Although the use of different methodologies 
is useful due to a likely increase in the chances of identifying novel findings as any inherent 
biases in each method will be in part counteracted by using a different method, for the 
purposes of clinically relevant research, it may be advantageous for similar, more comparable 
platforms to be used by different groups. This will allow results to be pooled together to 
highlight the most promising candidates for further analysis as potential biomarkers. Having 
said this, for true comparisons to be made between studies, the method of data analysis as 
well as the array methodology needs to be more comparable and a more conformed approach 
to data analysis would perhaps benefit this field at present. Large cancer genome research 
consortiums, such as the TCGA (The Cancer Genome Research Atlas), are currently carrying 
out methylation studies on a large number of samples for those cancers with the greatest 
overall health impact, either because of uniformally bad prognosis, such as gliomas, or 
because of the sheer number of individuals affected by the disease, such as breast cancers. 
The TCGA are currently performing these analyses using the Infinium HumanMethylation27 
array. Data is now publically available for a number of these studies although publications of 
actual findings have not yet been produced in most cases. It will be interesting to see if results 
from smaller, similar studies are replicated in these large cohorts. Those that demonstrate 
replication in these large studies will be those candidates showing the greatest promise as 
potential biomarkers. However, these large studies may make it more desirable to smaller 
groups to obtain data using either different methodologies or using a different, more unusual 
cohort of samples.  
7.2 Candidate genes analysis of RASSF10 and KIBRA in multiple cancer types  
Work in this thesis also analysed the methylation status of two candidate genes, RASSF10 and 
KIBRA, both of which produced positive results. 
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RASSF10 hypermethylation was demonstrated in multiple common solid tumours, adding 
weight to it being a candidate tumour suppressor gene. This is exciting for researchers in the 
field of RASSF family members, particularly as it is a member of the N-terminal RASSFs, 
which, apart from RASSF8, show little evidence to behave as tumour suppressor genes like 
many of the classical RASSFs. As a newly characterised gene, it will also be interesting to see 
results from functional studies in addition to those described in Hill et al, (2011). The 
methylation work of RASSF10 focused on the highest methylated tumour type, gliomas, 
which showed a high level of methylation in grade III and IV tumours. A correlation was also 
observed between RASSF10 methylation and overall survival times in secondary grade IV 
gliomas. Methylation was also observed in the early lesions of secondary gliomas, suggesting 
methylation of RASSF10 is likely to be an early event. These results will be of interest to 
those in the basic science field of gliomagenesis and those investigating possible markers for 
clinical prognosis.  
Analysis of KIBRA methylation status across multiple cancer types identified frequent 
methylation in childhood ALL samples that correlated with the most common translocation 
within this type of leukaemia. This, as the first demonstration of hypermethylation of this 
newly identified member of the SWH pathway, will be of great interest to those working in 
the SWH pathway field. Not only does it indicate a possible tumour suppressor role for 
KIBRA in mammalian systems, the haematological cancer specific nature of hypermethylation 
may suggest KIBRA has differing functions in different cell types. The cancer specific nature 
of methylation and the association of KIBRA methylation with the ETV6/RUNX1 translocation 
will also be of interest to those working within the field of childhood ALL.  
The work here shows that a candidate gene approach for the identification of novel 
hypermethylated genes is successful when good candidates are chosen, for example, as in this 
291 
 
case when genes are known to be part of a particularly important pathway or family. This 
approach is a much cheaper way of identifying novel methylated genes and, due to the nature 
of the approach, when positive, will undoubtedly identify functionally relevant genes. The 
recent developments of genome wide techniques should therefore not stop small candidate 
genes studies that can produce just as interesting and relevant results.  
7.3 Final Conclusions  
Through the use of genome wide studies on breast cancer cell lines and clinically 
characterised sporadic breast tumour patient samples and candidate gene approaches, the 
research presented in this thesis has identified numerous genes hypermethylated in various 
cancers. Some of these genes, such as EMILIN2 and C1orf114 represent excellent candidates 
for further analysis in breast cancer. Other genes, such as RECK and ACADL, represent genes 
that warrant further analysis on a multi-variant level and in a much larger cohort to ascertain 
whether these targets would be useful as prognostic tests. Results from the candidate gene 
analyses have identified RASSF10 and KIBRA as new genes involved in gliomas and 
childhood ALL respectively which is exciting for those in the respective cancer fields but also 
the RASSF family and SWH pathway fields.  
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REACTION 
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REACTION 
F GAGATTTGATYGGGAATTTGAGAATAATT
RN ACRAAATATAACCCAAATACACAATACCTAA
R TCCRACCTCRCCATAAACRCTAAAAAAATT
F TATTYGTGATTGTGGATATYGGGATTAT
RN CCCRTAACCRAATTTCTAAACTTTCTTAA
R AACCTAACACCRAACRACAACRATAA
F GGTAGAGYGTTAGTTTTTAGAAAATTATATTTTTT
RN TTCCCTCAAAACACTCRCAAACTAAA
R CAATTACRAACCCRAAAAATCCCTAA
F GGTTTAATTGGATTGGTTATTGTAGTG
FN TAATYGAAGYGTTAGGTTAGTTTAGGT
R CCCCRCTCATACTACRAACAATAA
F GGAGGTATTGYGTTATTTAGGGTAAGATT
RN ATATCAAAAAAAACAAACCCACACAAAAARCAARCA
R AATTAAAARCTCCATCAAAATAACAAATCRCCTA
F GGTTTTTTYGTAGTGGGTTTYGAATTTTTTATT
FN TTGGTAGTTYGYGTTTTYGGGTGTAT
R CCRCRACTCCRCTACAAATCTAAA
F TGGGAGTTTGGGGYGAYGTTTTATT
FN TTTYGTTAYGTYGTTYGTTTAYGTYGATTAT
R AACCCCRAAATCCRAACAAAATCCTA
F AGGATTGGTTATGATTTTAATTGTTTYGATT
RN ACCTAACTAACRCAAAAAAAAACRTTTTAA 
R CATAATCCCRAACRACCTCCATAA 
F AATATATTAGTATTATATTAAGTTTTTATT
FN TAGTTTTTTGAGTTTTAGGTATAGGAATTT
R TAAATATAAACCAAACTACTAAAAACCAAA 
F ATTTTTYGGTAGGGGGYGAGTTTYGTAT
FN TTTYGGYGGGGYGTATTTTTATAYGTATT
R AACRCRAAAACCRCRCRAAACCTAA
F GGGTAATAGAGTAAGATTTTGTAAAGTGTAATATT
FN TTGGAGTTTGATTTTYGGGTGTTTATGATT
R CACRACCRTACRCTTATACTACAAAATATA
ABT1
BARHL2
BUB3
CCNJ
CD44
CDH24
CENPJ
CIDE-A
DBC1
DDEF2
DLGAP1
PRODUCT SIZE (bp)
54 54 STANDARD 473
PROGRAM
416
ANNEALING TEMPERATURE (°C)
PRIMER SEQUENCE (5'-3')PRIMER GENE 
54 54 TOUCHDOWN 480 348
53 53 STANDARD 625 494
56 56 STANDARD 521 435
54 54 STANDARD 425 311
54 54 STANDARD 456 401
55 55 STANDARD 438 367
52 52 STANDARD 448 360
53 53 STANDARD 315 247
55 55 STANDARD 542 437
54 54 STANDARD 622 494
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F GAATGAGTTATTGGAAATGTTGTAAYGTAGATT 
RN AAACACRCRAAACCAAAACCRTCTAAACTA 
R AAATACCCRAACTACRAACCRACRTAA 
F TAGGATTGTAGTAATTTTGYGGGTTAATYGTTTATT
FN TTAAGTTAGTTTAAGTTAATATTTTGGGTTGTTAATT
R AAATTCACCACTCTATTACRAATATTCATAA
F GGATTTTAATTTTTGGTTTTGTTTTGTGGG 
FN  AGTGTTAGGTTTGGTATTTAGAGGTTAGGT 
R ACCTCTATACCCRCATCTATACACTAA 
F TTTYGGGGTTTAGGTYGYGGTTTTAT
RN AAAAACCCARCTAAARCAAARCCRCAAAARCA
R CTCRATAATCATCTAAAACCCRAAAACRAAA
F AATTGGGGAGTYGTTATTATTTYGGTT
RN CTCRTTAAAAAACCCAAAAAAAATTCTTCACTAA
R CRATTCRACRTTAAAACTTTAAAATAAATATATA
F GTTAAATTGGTTTTGTTTGTTATTTGTATATTATT
RN AAAACRCRCCRAAAACAAAACCTTAAAATA
R AACRACTAAAATATTATCRATACTAAACATACTAA
F TAGGGTTTTAGGTTTYGTTTTTYGTTTYGATT
RN AACRCAACAACRACCRCACRTAAACTA
R TCRTCTAAACCTACRAAATCCRACRTATA
F TTTTTTAGTYGGGGGTTAAGGTTGTTATTAT
RN TAACCRAAAACRAAACAAACRCCATTAA
R AATTACAAACRACRACRACTACRAAAAACTA
F TYGTTATTAGTTTATTGTTTTTATTTTYGTAYGTAT
FN TATTYGGAGTATAGGTTATAATTTTTAGAAATT
R TCACCATTCRCACRATAAAACACATCCTTAA
F TTTTGGTTTAGTTTTYGGTTTYGAGTTT
FN TAGATTYGGTTTTTTAYGGTTYGATTGTT
R AAATCCTAAAACACRAAATCTAAATCRTTATA
F TTTAGTTTYGYGTTGYGYGAAGATT
RN AACRAACAACRCAACCAATACAAAAA
R CCRAAAAAAATACTCCRCRAATCAAA
F GAGGGGYGATGTTTTTAAGTATAGTATTTT
FN TYGTAYGTGTTYGTAGTTTTTTGGTTATTT
R AAAAATCCRCRCCRTTAAAAAAACRCAATA
EPSTI1
FBLN2 
FOXF2
FOXQ1
GSC
KLF11
EMILIN2 
KLF13
LYPD5
MAD1L1
NRXN2
ONECUT1
54 54 STANDARD 390 273
54 56 STANDARD 506 432
56 56 STANDARD 345 283
58 58 STANDARD 591 557
287362TOUCHDOWN5454
54 54 STANDARD 480 354
54 54 STANDARD 410 297
54 54 TOUCHDOWN 435 354
274374STANDARD5454
54 54 STANDARD 568 297
390552STANDARD5757
246424STANDARD5353
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F GAATTAAAGYGGGTTTTAGATAGTAATAGGTT
FN GTTYGTAGTTYGTGGGGTTGATTTTAT
R CAACTAAATTTCCCTAAAACTACAACRACAAATA
F TTTTTYGYGTATATTAGYGTTTTGAGTT
RN AATACACRAACACCRTCRCCATATTA
R ACCTACCRTAAAACCAATCCTTACAA
F AAAGGTGTTTATTTTTAGATAATAGTTGGATT
FN TATGTTYGGGTAGTTATAGGTGTATTATT
R CATAACAAAATAAAACTACTTACTATTCATAA
F TATTTTTTATTYGGGGYGGTTTAATTT 
RN TAACCCAATAAACCRACCRCRAAACTAA 
R ACRATTAATCATAAAAAAACTCTTTAAAAAACRATTAA 
F TYGTATTYGGGTTTYGTTATAGTYGTATT
RN AACCRCRCATAAAACTAAACAATTAAACTAATA
R CCTCRTCCRACTTAAAATACTAAAACTTAA
F TTTTGTTTAGAAAGGAAGGTTTAGAGAAT
RN TAAACTCCAATAAACACAAAACTCCTTA
R AAAACAAATAATATCATAATACACAATCCTATAA
F GTATTTATTTGAGTGTTAYGTAAGTTATTTTAATAT
RN ACACRCACRCRACAAAAACTACTAA
R ATCTAATCAAACACTAAAACRATAACACTAA
F TAGGGYGGTTTYGGGGTTTTYGTAT
RN CCAACCRACAACRAAACRACCCTAA
R CCRCCRAAAACCRACCCACTAAATA
TP53INP1
PHF2
POU4F1
SALL1
SALL3
SESN3
SIM2
PAX9
293371STANDARD5656
512582STANDARD5858
507626STANDARD5454
535614STANDARD5353
309369STANDARD5353
263432STANDARD5353
389537STANDARD5656
384497STANDARD5353
Appendix B.I_CoBRA primers used in the MIRA study
Primer sequences are shown for all genes analysed by CoBRA in the MIRA study (chapter 3). In each case forward (F), reverse (R) and nested (either forward
nested (FN) or reverse nested (RN)) primer sequences are shown. Annealing temperatures and product sizes are given for primary and secondary PCR
reactions. Also shown are whther the PCR was carried out using a the standard CoBRA PCR program or the touchdown CoBRA PCR program.
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GENE PRIMER PRIMER SEQUENCE 5'-3'
ANNEALING 
TEMPERATURE 
(°C)
PRODUCT 
SIZE (bp)
F ATCACAGACTAAGCGAGTCC 
R TAAGGCAGCCGATGAAGTCC
F ACTGCAGGAAACCAACGCG
R GAGTTGGGGACGGAGTTATG
F CACCGTCAAGGATTTACAACCAG
R GTCCATATACATGGTCAAAGCCTCC 
F CGCCAGGAACAAGAACTGG 
R CCTGGGCTCTGAGAATTGG
F GAGCTAAACCGGTTCACC
R GCCTTCATTTTTTGGAGTTCAG
F AATGGACCCTGCAAGCAGGTGTGCA 
R CAGGTGAGTGCCTTGTAGCAG 
F TCGTGCATGTTTCTCCTCAG 
R GCTGCTGCATACTGATTCCA 
F AAAAGAATCAGAGTGTCTCAAC
R CCATGCGCAACATGTAAAAC
F AGTATATGCTGGACATGTCC
R ATAGGGTCTTCTCGATCAGG
F AGCTAAAAATCCTCCAGAGC
R TGGTAGTTGAGCAGCACGAAGG
364
56 474
25856
SALL1
SESN3 
SIM2s
SIM2l
56CIDE-A 
COMP
DBC1
EMILIN2 
EPSTI1
FBLN2
46556
17856
26656
29656
33456
26056
21956
Appendix B.II_Expression primer sets used in the MIRA gene analysis
Forward (F) and reverse (R) primer sequences are shown for each gene analysed for
expression in chapter 3. Annealing temperatures and product sizes are also shown.
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Accession Gene Symbol GeneName SystematicName Probe Location 
Total number of 
cell lines  >10
no. Probes
1 ref|NM_005069|ref|SIM2:-1905|ref|NM_009586:-1905SIM2 single-minded homolog 2 (Drosophila) chr21:036991933-036991977 PROMOTER 5 39
2 ref|NM_005068|ref|SIM1:-4254|mgc|BC111931:-4457SIM1 single-minded homolog 1 (Drosophila) chr6:101022497-101022556 PROMOTER 5 34
3 ref|NM_001426|ref|EN1:-9626|ens|ENST00000295206:-9626EN1 engrailed homeobox 1 chr2:119331833-119331877 PROMOTER 5 27
4 ref|NM_003735|ref|PCDHGA12:-2843|ref|NM_032094:-2843|ref|NM_032091:6778|ref|NM_018927:10033|ref|NM_018913:14572|ref|NM_018926:19545|ref|NM_018921:24795|ref|NM_018925:29620PCDHGA12 protocadherin gamma subfamily A, 12 chr5:140787 6-14078752 PROMOTER 5 26
5 ref|NM_145285|ref|NKX2-3:-2736|mgc|BC025788:-2756NKX2-3 NK2 transcription factor related, locus 3 (Drosophila) chr10:101279919-101279968 PROMOTER 5 24
6 ref|NM_006194|ref|PAX9:-2922|mgc|BC001159:-3123|mgc|BC008699:2846|ens|ENST00000344665:11688PAX9 paired box gene 9 chr14:036197711-036197755 PROMOTER 5 24
7 ref|NM_005523|ref|HOXA11:-6945|ref|NM_000522:7945|mgc|BC040948:-6945HOXA11 homeobox A11 chr7:027198283-027198327 PROMOTER 5 23
8 ref|NM_012183|ref|FOXD3:-2624|ens|ENST00000335469:-2624FOXD3 forkhead box D3 chr1:063558671-063558715 PROMOTER 5 20
9 ref|NM_001604|ref|PAX6:-8903|ref|NM_000280:-8924|ens|ENST00000379129:-2273PAX6 paired box gene 6 (aniridia, keratitis) chr11:031798336-031798380 PROMOTER 5 20
10 ref|NM_032772|ref|ZNF503:-6274|ref|NM_001013696:12276|ens|ENST00000372505:4888|ens|ENST00000372509:6943|mgc|BC013011:-6413ZNF503 zinc finger protein 503 chr10:076837683-076837727 PROMOTER 5 20
11 ref|NM_001079668|ref|TITF1:-2594|ref|NM_003317:-3107|ens|ENST00000334440:1173TITF1 thyroid transcription factor 1 chr14:036061739-036061783 PROMOTER 5 18
12 ref|NM_021240|ref|DMRT3:-6042|ref|NM_021951:129232|mgc|BC113584:-6046DMRT3 doublesex and mab-3 related transcription factor 3 chr9:000960899-000960943 PROMOTER 5 16
13 ref|NM_001485|ref|GBX2:-1181|ens|ENST00000306318:-1181GBX2 gastrulation brain homeobox 2 chr2:236742543-236742602 PROMOTER 5 16
14 ref|NM_032391|ref|PRAC:-1317|ref|NM_006361:4912|mgc|BC030950:-1319PRAC small nuclear protein PRAC chr17:044156171-044156225 PROMOTER 5 16
15 ref|NM_020063|ref|BARHL2:-9684|mgc|BC126439:-9700BARHL2 BarH-like 2 (Drosophila) chr1:090965044-090965088 PROMOTER 5 14
16 ref|NM_138281|ref|DLX4:-3471|ref|NM_001934:-7037|mgc|BC016145:-3469|ens|ENST00000349695:427DLX4 distal-less homeobox 4 chr17:045398069-045398113 PROMOTER 5 14
17 ref|NM_173849|ref|GSC:-1154|mgc|BC063580:-1252GSC goosecoid chr14:094307384-094307428 PROMOTER 5 14
18 ref|NM_000325|ref|PITX2:-5978|ref|NM_153426:8276|mgc|BC013998:-5978|ens|ENST00000354925:12885PITX2 paired-like homeodomain transcription factor 2 chr4:111769654-111769708 PROMOTER 5 12
19 ref|NM_005519|ref|HMX2:-5216|mgc|BC132758:-5406|ens|ENST00000338905:6855HMX2 homeobox (H6 family) 2 chr10:124892389-124892434 PROMOTER 5 11
20 ref|NM_014360|ref|NKX2-8:-1586|mgc|BC041090:-1586|ens|ENST00000364525:9980NKX2-8 NK  transcription factor related, locus 8 (Drosophila) chr14:036123094-036123152 PROMOTER 5 11
21 ref|NM_020766|ref|PCDH19:-1093|ens|ENST00000373037:329PCDH19 protocadherin 19 chrX:099549877-099549926 PROMOTER 5 11
22 ref|NM_000738|ref|CHRM1:-4714|mgc|BC007740:-4993|ens|ENST00000350632:9975CHRM1 cholinergic receptor, muscarinic 1 chr11:062450280-062450324 PROMOTER 5 10
23 ref|NM_004122|ref|GHSR:-1245|ref|NM_198407:-1245|ens|ENST00000366448:-841GHSR growth hormone secretagogue receptor chr3:173650117-173650167 PROMOTER 5 10
24 ref|NM_016358|ref|IRX4:-2947|mgc|BC110912:-3059IRX4 iroquois homeobox protein 4 chr5:001938805-001938849 PROMOTER 5 10
25 ref|NM_004498|ref|ONECUT1:-1574|ens|ENST00000305901:-1574ONECUT1 one cut domain, family member 1 chr15:050871053-050871098 PROMOTER 5 10
26 ref|NM_032109|ref|OTP:-790|mgc|BC001800:-790OTP orthopedia homeobox chr5:076971045-076971092 PROMOTER 5 10
27 ref|NM_018902|ref|PCDHA11:-5271|ref|NM_031861:-5271|ref|NM_031859:6926|ref|NM_031857:15203|ref|NM_018911:21653|ref|NM_018910:28591|ref|NM_018909:34910|ref|NM_018908:41199PCDHA 1 protocadherin alpha 11 chr5:140222721-140222765 PROMOTER 5 10
28 ref|NM_000209|ref|PDX1:-2534|mgc|BC111592:-2651PDX1 pancreatic and duodenal homeobox 1 chr13:027389600-027389645 PROMOTER 5 10
29 ref|NM_017977|ref|AIM1L:-6117|ref|NM_173574:12528|ens|ENST00000327252:-6117AIM1L absent in melanoma 1-like chr1:026559303-026559347 PROMOTER 5 9
30 ref|NM_006898|ref|HOXD3:-795|mgc|BC008789:-5750|mgc|BC005124:-795HOXD3 homeobox D3 chr2:176736231-176736280 PROMOTER 5 9
31 mirna|hsa-mir-183|mirna|hsa-mir-183:-7398|mirna|hsa-mir-96:-7643hsa- ir-183 chr7:129209466-129209510 PROMOTER 5 9
32 ref|NM_198289|ref|CIDEA:-113|ref|NM_001279:305CIDEA cell death-inducing DFFA-like effector a chr18:012244652-012244696 PROMOTER 5 8
33 ref|NM_001989|ref|EVX1:-3016|ens|ENST00000222761:-3273EVX1 even-skipped homeobox 1 chr7:027245650-027245694 PROMOTER 5 8
34 ref|NM_001452|ref|FOXF2:-4946|ens|ENST00000259806:-4946FOXF2 forkhead box F2 chr6:001330099-001330143 PROMOTER 5 8
35 ref|NM_006562|ref|LBX1:-7469|mgc|BC069156:-7469LBX1 ladybird homeobox 1 chr10:102986147-102986205 PROMOTER 5 8
36 ref|NM_172337|ref|OTX2:-4104|ref|NM_021728:735OTX2 orthodenticle homeobox 2 chr14:056346176-056346229 PROMOTER 5 8
37 ref|NM_007374|ref|SIX6:-1925|mgc|BC069413:-1937SIX6 sine oculis homeobox homolog 6 (Drosophila) chr14:060043824-060043875 PROMOTER 5 8
38 ref|NM_199425|ref|VSX1:-1077|ref|NM_014588:-1077VSX1 visual system homeobox 1 homolog, CHX10-like (zebrafish) chr20:025011822-025011866 PROMOTER 5 8
39 ref|NM_006557|ref|DMRT2:-5627|ref|NM_181872:-5627|ens|ENST00000382251:-4368DMRT2 doublesex and mab-3 related transcription factor 2 chr9:001035959-001036013 PROMOTER 5 7
40 ref|NM_153038|ref|FLJ32447:-898|ref|NM_000438:1733|mgc|BC109388:-993FLJ32447 hypothetical protein LOC151278 chr2:222870183-222870240 PROMOTER 5 7
41 ref|NM_021973|ref|HAND2:-1269|mgc|BC122524:-5350|mgc|BC101406:-2117HAND2 heart and neural crest derivatives expressed 2 chr4:174689199-174689245 PROMOTER 5 7
42 ref|NM_019558|ref|HOXD8:-4860|ref|NM_014213:2529|ref|NM_002148:8125|mgc|BC090853:-5024|ens|ENST00000313266:4877HOXD8 homeobox D8 chr2:176697833-176697892 PROMOTER 5 7
43 ref|NM_018918|ref|PCDHGA5:-1|ref|NM_018919:-9754|ref|NM_018924:-6065|ref|NM_032054:-1|ref|NM_032096:4194|ref|NM_018917:9129|ref|NM_018922:14069|ref|NM_018916:20296PCDHGA5 protocadherin gamma subfamily A, 5 chr5:140724058- 40724102 PROMOTER 5 7
44 ref|NM_005413|ref|SIX3:-8915|ens|ENST00000260653:-8739SIX3 sine oculis homeobox homolog 3 (Drosophila) chr2:045013603-045013647 PROMOTER 5 7
45 ref|NM_000729|ref|CCK:-561|mgc|BC008283:-1517|mgc|BC111026:706CCK cholecystokinin chr3:042281937-042281983 PROMOTER 5 6
46 ref|NM_000522|ref|HOXA13:-5643|mgc|BC075791:-5643HOXA13 homeobox A13 chr7:027211864-027211923 PROMOTER 5 6
47 ref|NM_019102|ref|HOXA5:-1084|ref|NM_024014:2997|mgc|BC013682:-1097HOXA5 homeobox A5 chr7:027150867-027150926 PROMOTER 5 6
48 ref|NM_005946|ref|MT1A:-237|ref|NM_176870:5807|mgc|BC130315:-5276|mgc|BC029475:-240MT1A metallothionein 1A chr16:055229819-055229863 PROMOTER 5 6
49 ref|NM_004387|ref|NKX2-5:-1553|mgc|BC025711:-1622NKX2-5 NK2 transcription factor related, locus 5 (Drosophila) chr5:172596396-172596446 PROMOTER 5 6
50 ref|NM_020298|ref|ABCC9:-5813|ref|NM_005691:-5813|ens|ENST00000326684:-1274ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 chr12:021986684-021986733 PROMOTER 5 5
51 ref|NM_021570|ref|BARX1:-4632|mgc|BC064363:-4581BARX1 BarH-like homeobox 1 chr9:095762026-095762085 PROMOTER 5 5
52 ref|NM_001267|ref|CHAD:-605|ref|NM_025149:43330|mgc|BC036360:-703CHAD chondroadherin chr17:045901905-045901949 PROMOTER 5 5
53 ref|NM_022659|ref|EBF2:-7103|ens|ENST00000380737:679312EBF2 early B-cell  factor 2 chr8:025965385-025965440 PROMOTER 5 5
54 ref|NM_152393|ref|KBTBD5:-10|ref|NM_020707:16013|mgc|BC110491:-42|ens|ENST00000346949:-9017|ens|ENST00000310417:17126KBTBD5 kelch repeat and BTB (POZ) domain containing 5 chr3:042701982-042702026 PROMOTER 5 5
VII 
 
55 ref|NM_018916|ref|PCDHGA3:-72|ref|NM_018922:-6299|ref|NM_032011:-72|ref|NM_032009:5175|ref|NM_018912:13277PCDHGA3 protocadherin gamma subfamily A, chr5:140703684-140703740 PROMOTER 5 5
56 ref|NM_018920|ref|PCDHGA7:-104|ref|NM_014004:-9120|ref|NM_003736:-5089|ref|NM_032087:-104|ref|NM_032086:8712|ref|NM_018924:12401|ref|NM_018918:18465|ref|NM_018923:22660PCDHGA7 protocadherin gamma subfamily A, 7 chr5:140742524-140742569 PROMOTER 5 5
57 ref|NM_006237|ref|POU4F1:-4425|ref|NM_024546:51194|ens|ENST00000377208:-4425POU4F1 POU domain, class 4, transcription factor 1 chr13:078080099-078080144 PROMOTER 5 5
58 ref|NM_013435|ref|RAX:-369|ens|ENST00000256852:-377RAX retina and anterior neural fold homeobox chr18:055091952-055091996 PROMOTER 5 5
59 ref|NM_002968|ref|SALL1:-2745|ens|ENST00000251020:-2776SALL1 sal-l ike 1 (Drosophila) chr16:049745400-049745459 PROMOTER 5 5
60 ref|NM_080717|ref|TBX5:-371|ref|NM_080718:-4915|ref|NM_181486:-2729|ref|NM_000192:-371|ens|ENST00000334280:-2475TBX5 T-box 5 chr12:113330972-113331031 PROMOTER 5 5
61 ref|NM_138700|ref|TRIM40:-9191|mgc|BC060785:-8566TRIM40 tripartite motif-containing 40 chr6:030203273-030203321 PROMOTER 5 5
62 ref|NM_152343|ref|C17orf46:-377|ref|NM_003954:54558|ens|ENST00000326967:713|ens|ENST00000376926:2068|mgc|BC028124:-422C17orf46 chromo ome 17 open reading frame 46 chr17:040695617-040695661 PROMOTER 5 4
63 ref|NM_152377|ref|C1orf87:-144|mgc|BC027878:-144C1orf87 chromosome 1 open reading frame 87 chr1:060312136-060312180 PROMOTER 5 4
64 ref|NM_012261|ref|C20orf103:-7330|mgc|BC050727:-7361C20orf103 chromosome 20 open reading frame 103 chr20:009435912-009435968 PROMOTER 5 4
65 ref|NM_022778|ref|CCDC21:-9164|mgc|BC064528:-9164CCDC21 coiled-coil domain containing 21 chr1:026424092-026424138 PROMOTER 5 4
66 ref|NM_004364|ref|CEBPA:-1630|ens|ENST00000320232:1174|ens|ENST00000328368:-1746CEBPA CCAAT/enhancer binding protein (C/EBP), alpha chr19:038486768-038486812 PROMOTER 5 4
67 ref|NM_004474|ref|FOXD2:-2451|ens|ENST00000334793:-2451FOXD2 forkhead box D2 chr1:047671802-047671846 PROMOTER 5 4
68 ref|NM_018926|ref|PCDHGB6:-330|ref|NM_018927:-9842|ref|NM_018913:-5303|ref|NM_032100:-330|ref|NM_032089:4920|ref|NM_018925:9745|ref|NM_032088:15957|ref|NM_003736:19988PCDHGB6 protocadherin gamma subfamily B, 6 chr5 40767594-140767653 PROMOTER 5 4
69 ref|NM_005986|ref|SOX1:-9582|ens|ENST00000375709:-9632|ens|ENST00000363202:5939SOX1 SRY (sex determining region Y)-box 1 chr13:111760308-111760354 PROMOTER 5 4
70 ref|NM_031912|ref|SYT15:-673|ref|NM_181519:-673|ens|ENST00000374328:-2621SYT15 synaptotagmin XV chr10:046391257-046391303 PROMOTER 5 4
71 ref|NM_152476|ref|ZNF560:-18|mgc|BC141584:312841|mgc|BC101040:-53ZNF560 zinc finger protein 560 chr19:009470275-009470319 PROMOTER 5 4
72 ref|NM_182703|ref|ANKDD1A:-6344ANKDD1A ankyrin repeat and death domain containing 1A chr15:062984784-062984834 PROMOTER 5 3
73 ref|NM_001007793|ref|BUB3:-2813|ref|NM_004725:-2813|ref|NM_005519:3419BUB BUB3 budding uninhibited by benzimidazoles 3 homolog (yeast) chr10:124901023-124901070 PROMOTER 5 3
74 ref|NM_133483|ref|GEFT:-989|ref|NM_133489:-9464|ref|NM_182947:-989|ref|NM_178502:5625|ref|NM_024779:19172|ens|ENST00000300189:128GEFT RAC/CDC42 xchange factor chr12:056290473-056290517 PROMOTER 5 3
75 ref|NM_030661|ref|HOXA3:-3238|ref|NM_153632:-8836|ref|NM_153631:4187|ens|ENST00000297027:7486|mgc|BC015180:-3238HOXA3 homeobox A3 chr7:027128948-027129007 PROMOTER 5 3
76 ref|NM_022658|ref|HOXC8:-3557|ref|NM_006897:5456|mgc|BC053898:-3557|ens|ENST00000303450:10040HOXC8 homeobox C8 chr12:052685570-052685629 PROMOTER 5 3
77 ref|NM_145805|ref|ISL2:-1434|mgc|BC011967:-1446ISL2 ISL2 transcription factor, LIM/homeodomain, (islet-2) chr15:074414745-074414789 PROMOTER 5 3
78 ref|NM_030915|ref|LBH:-835|mgc|BC126434:-863LBH limb bud and heart development homolog (mouse) chr2:030307042-030307088 PROMOTER 5 3
79 ref|NM_005583|ref|LYL1:-1928|ref|NM_002501:109026|ref|NM_017722:11723|ens|ENST00000360105:79799|mgc|BC002796:-1928LYL1 lymphoblastic leukemia derived sequence 1 chr19:013076587-013076631 PROMOTER 5 3
80 ref|NM_005461|ref|MAFB:-1544|mgc|BC028098:-1909MAFB v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) chr20:038752812-038752856 PROMOTER 5 3
81 ref|NM_005947|ref|MT1B:-8426|ref|NM_005946:4807|ref|NM_176870:10851|mgc|BC069421:-8431|mgc|BC130315:-232|ens|ENST00000379816:-5358MT1B metallothionein 1B chr16:055234863-055234907 PROMOTER 5 3
82 ref|NM_004350|ref|RUNX3:-1928|ref|NM_001031680:32803|ens|ENST00000308873:-2330RUNX3 runt-related transcription factor 3 chr1:025131262-025131309 PROMOTER 5 3
83 ref|NM_171999|ref|SALL3:-2822|ens|ENST00000299466:-2822SALL3 sal-l ike 3 (Drosophila) chr18:074838411-074838469 PROMOTER 5 3
84 ref|NM_005627|ref|SGK:-1716|mgc|BC001263:-1731SGK serum/glucocorticoid regulated kinase chr6:134539389-134539433 PROMOTER 5 3
85 ref|NM_003181|ref|T:-939|mgc|BC098425:-940T T, brachyury homolog (mouse) chr6:166503036-166503084 PROMOTER 5 3
86 ref|NM_173084|ref|TRIM59:-626|mgc|BC109259:-639TRIM59 tripartite motif-containing 59 chr3:161650924-161650968 PROMOTER 5 3
87 ref|NM_138931|ref|BCL6:-1262|ref|NM_001706:7965BCL6 B-cell  CLL/lymphoma 6 (zinc finger protein 51) chr3:188938175-188938234 PROMOTER 5 2
88 ref|NM_057158|ref|DUSP4:-1173|ref|NM_001394:690|ens|ENST00000240101:-1173DUSP4 dual specificity phosphatase 4 chr8:029263392-029263437 PROMOTER 5 2
89 ref|NM_005226|ref|EDG3:-413|ref|NM_001001938:106|ens|ENST00000375848:-2844EDG3 endothelial differentiation, sphingolipid G-protein-coupled receptor, 3 chr9:090795739-090795798 PROMOTER 5 2
90 ref|NM_005228|ref|EGFR:-389|ref|NM_201282:-389EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) chr7:055053802-055053856 PROMOTER 5 2
91 ref|NM_183412|ref|FBXO44:-5199|ref|NM_012168:5507|ens|ENST00000251546:-5199FBXO44 F-box protein 44 chr1:011631797-011631841 PROMOTER 5 2
92 ref|NM_021032|ref|FGF12:-465|ens|ENST00000264730:361FGF12 fibroblast growth factor 12 chr3:193609142-193609201 PROMOTER 5 2
93 ref|NM_006735|ref|HOXA2:-918|ref|NM_153620:-7687|ref|NM_153632:10304|mgc|BC130571:-1164HOXA2 homeobox A2 chr7:027109815-027109859 PROMOTER 5 2
94 ref|NM_017550|ref|MIER2:-529|mgc|BC028203:-529MIER2 mesoderm induction early response 1, family member 2 chr19:000296298-000296342 PROMOTER 5 2
95 ref|NM_198504|ref|PAQR9:-1120|mgc|BC118666:-1120PAQR9 progestin and adipoQ receptor family member IX chr3:144165959-144166018 PROMOTER 5 2
96 ref|NM_001025300|ref|RAB12:-475|ens|ENST00000329286:-467RAB12 RAB12, member RAS oncogene family chr18:008598945-008598989 PROMOTER 5 2
97 ref|NM_017793|ref|RPP25:-1780|mgc|BC002497:-2462RPP25 ribonuclease P 25kDa subunit chr15:073038585-073038631 PROMOTER 5 2
98 ref|NM_003030|ref|SHOX2:-670|ref|NM_006884:2440SHOX2 short stature homeobox 2 chr3:159304168-159304212 PROMOTER 5 2
99 ref|NM_001080508|ref|TBX18:-8846|mgc|BC132715:-8791TBX18 T-box 18 chr6:085539442-085539486 PROMOTER 5 2
100 ref|NM_019110|ref|NM_001007531|ref|ZKSCAN4:-7018|ref|C6orf194:-77|ref|NM_001023560:-7872|mgc|BC038240:-124|mgc|BC014031:-7018ZKSCAN4-C6orf194 zinc finger with KRAB and S AN domains 4 chr6:028334977-028335021 DIVERGENT_PROMOTER 5 2
101 ref|NM_014292|ref|CBX6:-810|mgc|BC064900:-862CBX6 chromobox homolog 6 chr22:037598992-037599036 PROMOTER 5 1
102 ref|NM_001793|ref|CDH3:-1857|mgc|BC014462:-1977CDH3 cadherin 3, type 1, P-cadherin (placental) chr16:067234397-067234441 PROMOTER 5 1
103 ref|NM_018451|ref|CENPJ:-9252|mgc|BC113662:-9423|ens|ENST00000381871:36074CENPJ centromere protein J chr13:024404315-024404359 PROMOTER 5 1
104 ref|NM_001824|ref|CKM:-1087|mgc|BC007462:-1088|ens|ENST00000321418:9161CKM creatine kinase, muscle chr19:050519039-050519083 PROMOTER 5 1
105 ref|NM_130773|ref|CNTNAP5:-700|ref|NM_138996:-700CNTNAP5 contactin associated protein-like 5 chr2:124498611-124498655 PROMOTER 5 1
106 ref|NM_005251|ref|FOXC2:-1333|mgc|BC111589:-1332|ens|ENST00000301007:10683|ens|ENST00000360900:400FOXC2 forkhead box C2 (MFH-1, mesenchyme forkhead 1) chr16:085157085-085157133 PROMOTER 5 1
107 ref|NM_002196|ref|INSM1:-2564|ref|NM_015585:313005|ens|ENST00000310227:-2564|ens|ENST00000377289:140096|ens|ENST00000377297:280095INSM1 i sulinoma-associated chr20:020294171-020294230 PROMOTER 5 1
108 ref|NM_006437|ref|PARP4:-177|ens|ENST00000381989:-177PARP4 poly (ADP-ribose) polymerase family, member 4 chr13:023985096-023985155 PROMOTER 5 1
109 ref|NM_018935|ref|PCDHB15:-3363|mgc|BC038797:-3197|ens|ENST00000274705:7846PCDHB15 protocadherin beta 15 chr5:140601943-140601992 PROMOTER 5 1
110 ref|NM_003736|ref|PCDHGB4:-111|ref|NM_014004:-4142|ref|NM_032098:-111|ref|NM_032087:4874|ref|NM_018919:13690|ref|NM_018924:17379|ref|NM_018918:23443|ref|NM_018923:27638PCDHGB4 protocadherin gamma subfamily B, 4 chr5:140747497-14074755 PROMOTER 5 1
111 ref|NM_018927|ref|PCDHGB7:-138|ref|NM_018914:-3393|ref|NM_032101:-138|ref|NM_032090:4401|ref|NM_018926:9374|ref|NM_018921:14624|ref|NM_018925:19449|ref|NM_032088:25661PCDHGB7 protocadherin gamma subfamily B, 7 chr5:140777305-140777349 PROMOTER 5 1
VIII 
 
  
112 ref|NM_080392|ref|PTP4A2:-6563|ref|NM_080391:-6563PTP4A2 protein tyrosine phosphatase type IVA, member 2 chr1:032183113-032183164 PROMOTER 5 1
113 ref|NM_133327|ref|SEMA6B:-7869|ref|NM_032108:-7869|mgc|BC142617:-6658SEMA6B sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B chr19:004517343-004517402 PROMOTER 5 1
114 ref|NM_001043|ref|SLC6A2:-29|ens|ENST00000219833:-29SLC6A2 solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 chr16:054248005-054248049 PROMOTER 5 1
115 ref|NM_003081|ref|SNAP25:-1371|ref|NM_130811:-1371SNAP25 synaptosomal-associated protein, 25kDa chr20:010146077-010146134 PROMOTER 5 1
116 ref|NM_053053|ref|TADA1L:-8095|mgc|BC015401:-8095TADA1L transcriptional adaptor 1 (HFI1 homolog, yeast)-l ike chr1:165120176-165120221 PROMOTER 5 1
117 ref|NM_014383|ref|ZBTB32:-8583|mgc|BC017700:-9088ZBTB32 zinc finger and BTB domain containing 32 chr19:040887064-040887108 PROMOTER 5 1
118 ref|NM_018008|ref|FEZF2:-612|mgc|BC022464:-612FEZF2 FEZ family zinc finger 2 chr3:062334646-062334701 PROMOTER 4 13
119 ref|NM_004789|ref|LHX2:-1972|mgc|BC093662:-2632LHX2 LIM homeobox 2 chr9:125811708-125811767 PROMOTER 4 13
120 ref|NM_006361|ref|HOXB13:-4615|mgc|BC007092:-4685HOXB13 homeobox B13 chr17:044165697-044165753 PROMOTER 4 11
121 ref|NM_021926|ref|ALX4:-6660|ens|ENST00000329255:-6757ALX4 aristaless-like homeobox 4 chr11:044294929-044294975 PROMOTER 4 10
122 ref|NM_020649|ref|CBX8:-2492|mgc|BC008937:-2570CBX8 chromobox homolog 8 (Pc class homolog, Drosophila) chr17:075387953-075388002 PROMOTER 4 10
123 ref|NM_002509|ref|NKX2-2:-9192|mgc|BC075092:-9521NKX2-2 NK2 transcription factor related, locus 2 (Drosophila) chr20:021451830-021451882 PROMOTER 4 10
124 ref|NM_003269|ref|NR2E1:-1639|ens|ENST00000368983:-3604|mgc|BC028031:-2142NR2E1 nuclear receptor subfamily 2, group E, member 1 chr6:108592291-108592339 PROMOTER 4 10
125 ref|NM_152380|ref|TBX15:-3575|ens|ENST00000369431:-5336|mgc|BC122553:-3757TBX15 T-box 15 chr1:119337255-119337299 PROMOTER 4 10
126 ref|NM_003948|ref|CDKL2:-364|mgc|BC093646:-840CDKL2 cyclin-dependent kinase-like 2 (CDC2-related kinase) chr4:076775087-076775131 PROMOTER 4 9
127 ref|NM_002398|ref|MEIS1:-9112|mgc|BC036511:-9273MEIS1 Meis homeobox 1 chr2:066506899-066506948 PROMOTER 4 9
128 ref|NM_003222|ref|TFAP2C:-1824|mgc|BC035664:-1865TFAP2C transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma) chr20:054635918-054635962 PROMOTER 4 9
129 ref|NM_002148|ref|HOXD10:-3891|ref|NM_014213:-9487|ref|NM_021192:5517|mgc|BC074760:-3912HOXD10 homeobox D10 chr2:176685824-176685868 PROMOTER 4 8
130 ref|NM_014562|ref|OTX1:-2042|ref|NM_015252:342790|mgc|BC007621:-2070OTX1 orthodenticle homeobox 1 chr2:063129400-063129453 PROMOTER 4 8
131 ref|NM_002052|ref|GATA4:-3450|mgc|BC105108:-7441|ens|ENST00000259090:-3450GATA4 GATA binding protein 4 chr8:011595682-011595741 PROMOTER 4 7
132 ref|NM_018896|ref|CACNA1G:-2074|ref|NM_198376:-2074|ref|NM_022827:11813CACNA1G calcium channel, voltage-dependent, T type, alpha 1G subunit chr17:045991351-045991395 PROMOTER 4 6
133 ref|NM_032040|ref|CCDC8:-61|mgc|BC025243:-612CCDC8 coiled-coil domain containing 8 chr19:051608720-051608764 PROMOTER 4 6
134 ref|NM_012182|ref|FOXB1:-346|mgc|BC113710:-1025FOXB1 forkhead box B1 chr15:058083339-058083393 PROMOTER 4 6
135 ref|NM_000817|ref|GAD1:-1539|ref|NM_013445:-1539GAD1 glutamate decarboxylase 1 (brain, 67kDa) chr2:171379884-171379928 PROMOTER 4 6
136 ref|NM_004821|ref|HAND1:-4546|mgc|BC021190:-4577HAND1 heart and neural crest derivatives expressed 1 chr5:153842538-153842588 PROMOTER 4 6
137 ref|NM_024014|ref|HOXA6:-169|ref|NM_019102:-4250|ref|NM_006896:8759|mgc|BC069497:-169HOXA6 homeobox A6 chr7:027154040-027154084 PROMOTER 4 6
138 ref|NM_024337|ref|IRX1:-4100|ens|ENST00000302006:-4100IRX1 iroquois homeobox protein 1 chr5:003645038-003645097 PROMOTER 4 6
139 ref|NM_001004317|ref|LIN28B:-4067|ens|ENST00000345080:-4067LIN28B lin-28 homolog B (C. elegans) chr6:105507526-105507570 PROMOTER 4 6
140 ref|NM_031439|ref|SOX7:-2400|mgc|BC071947:-2412SOX7 SRY (sex determining region Y)-box 7 chr8:010627804-010627861 PROMOTER 4 6
141 ref|NM_003433|ref|ZNF132:-36|ens|ENST00000354635:23317|ens|ENST00000253024:89549|mgc|BC109107:-242ZNF132 zinc finger protein 132 chr19:063643415-063643459 PROMOTER 4 6
142 ref|NM_000697|ref|ALOX12:-144|mgc|BC069557:-145|ens|ENST00000363995:8472ALOX12 arachidonate 12-lipoxygenase chr17:006839961-006840005 PROMOTER 4 5
143 ref|NM_001878|ref|CRABP2:-993|mgc|BC001109:-1007CRABP2 cellular retinoic acid binding protein 2 chr1:154942970-154943014 PROMOTER 4 5
144 ref|NM_004496|ref|FOXA1:-3439|mgc|BC033890:-3690FOXA1 forkhead box A1 chr14:037137657-037137701 PROMOTER 4 5
145 ref|NM_004473|ref|FOXE1:-1033|ens|ENST00000313408:-1186FOXE1 forkhead box E1 (thyroid transcription factor 2) chr9:099654302-099654347 PROMOTER 4 5
146 ref|NM_001039132|ref|ICAM4:-135|ref|NM_003259:-3140|ref|NM_001544:-135|ref|NM_000201:15736ICAM4 intercellular adhesion molecule 4 (Landsteiner-Wiener blood group) chr19:010258491-010258538 PROMOTER 4 5
147 ref|NM_145260|ref|OSR1:-2811|mgc|BC025712:-2811OSR1 odd-skipped related 1 (Drosophila) chr2:019424640-019424688 PROMOTER 4 5
148 ref|NM_175738|ref|RAB37:-81|mgc|BC040547:-84RAB37 RAB37, member RAS oncogene family chr17:070178761-070178805 PROMOTER 4 5
149 ref|NM_000346|ref|SOX9:-5097|mgc|BC007951:-5240SOX9 SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal) chr17:067623636-067623680 PROMOTER 4 5
150 ref|NM_003199|ref|TCF4:-1483|ref|NM_001083962:-1483|mgc|BC125084:-2975TCF4 transcription factor 4 chr18:051408312-051408371 PROMOTER 4 5
151 ref|NM_012138|ref|AATF:-2906|ref|NM_005568:8770|mgc|BC000591:-3026AATF apoptosis antagonizing transcription factor chr17:032377352-032377411 PROMOTER 4 4
152 ref|NM_003658|ref|BARX2:-1336|mgc|BC111432:-1413BARX2 BarH-like homeobox 2 chr11:128749686-128749730 PROMOTER 4 4
153 ref|NM_174978|ref|C14orf39:-189|mgc|BC125070:-203C14orf39 chromosome 14 open reading frame 39 chr14:060022669-060022713 PROMOTER 4 4
154 ref|NM_005257|ref|GATA6:-2934|ens|ENST00000269216:-2934GATA6 GATA binding protein 6 chr18:018000454-018000504 PROMOTER 4 4
155 ref|NM_024016|ref|HOXB8:-5071|ref|NM_004502:-8989|ref|NM_024017:6463|mgc|BC141560:-5306HOXB8 homeobox B8 chr17:044052345-044052398 PROMOTER 4 4
156 ref|NM_006680|ref|ME3:-170|ref|NM_001014811:-357ME3 malic enzyme 3, NADP(+)-dependent, mitochondrial chr11:086061223-086061267 PROMOTER 4 4
157 ref|NM_000278|ref|PAX2:-7787|ref|NM_003987:-7787PAX2 paired box gene 2 chr10:102487511-102487558 PROMOTER 4 4
158 ref|NM_178012|ref|TUBB2B:-4377|ens|ENST00000350739:6489|mgc|BC063610:-4377TUBB2B tubulin, beta 2B chr6:003177225-003177269 PROMOTER 4 4
159 ref|NM_018338|ref|WDR52:-6|ref|NM_144718:73657|mgc|BC101582:-27WDR52 WD repeat domain 52 chr3:114643014-114643058 PROMOTER 4 4
160 ref|NM_024967|ref|ZNF556:-8057|ref|NM_152791:17794|mgc|BC009374:-8077ZNF556 zinc finger protein 556 chr19:002810253-002810297 PROMOTER 4 4
161 ref|NM_024833|ref|ZNF671:-107|mgc|BC025728:-148ZNF671 zinc finger protein 671 chr19:062930878-062930926 PROMOTER 4 4
162 ref|NM_139056|ref|ADAMTS16:-615|mgc|BC140297:-753ADAMTS16 ADAM metallopeptidase with thrombospondin type 1 motif, 16 chr5:005192805-005192849 PROMOTER 4 3
163 ref|NM_014272|ref|ADAMTS7:-559|mgc|BC061631:-559ADAMTS7 ADAM metallopeptidase with thrombospondin type 1 motif, 7 chr15:076891365-076891409 PROMOTER 4 3
164 ref|NM_020926|ref|BCOR:-9800|ref|NM_017745:-9800|mgc|BC114220:70126BCOR BCL6 co-repressor chrX:039851378-039851422 PROMOTER 4 3
165 ref|NM_133468|ref|BMPER:-926|mgc|BC060868:-1578BMPER BMP binding endothelial regulator chr7:033910092-033910151 PROMOTER 4 3
166 ref|NM_021179|ref|C1orf114:-162|mgc|BC026073:-120C1orf114 chromosome 1 open reading frame 114 chr1:167663430-167663482 PROMOTER 4 3
167 ref|NM_024007|ref|EBF1:-4926|ens|ENST00000377536:5605|mgc|BC041178:-4996EBF1 early B-cell  factor 1 chr5:158464250-158464297 PROMOTER 4 3
168 ref|NM_005895|ref|GOLGA3:-9233|ref|NM_018223:49663|mgc|BC142658:-9095|ens|ENST00000376580:-1134GOLGA3 golgi autoantigen, golgin subfamily a, 3 chr12:131924571-131924617 PROMOTER 4 3
IX 
 
  
169 ref|NM_003535|ref|HIST1H3J:-81|ref|NM_003527:-2551|ref|NM_003514:2312|mgc|BC111921:-81|ens|ENST00000364464:6692HIST1H3J histone clu ter 1, H3j chr6:027966601-027966660 PROMOTER 4 3
170 ref|NM_018953|ref|HOXC5:-1658|ref|NM_004503:2980|ref|NM_153693:14532|mirna|hsa-mir-615:-2560HOXC5 homeobox C5 chr12:052711417-052711463 PROMOTER 4 3
171 ref|NM_022123|ref|NPAS3:-5580|ref|NM_173159:-5644NPAS3 neuronal PAS domain protein 3 chr14:032472605-032472653 PROMOTER 4 3
172 ref|NM_175747|ref|OLIG3:-2876|mgc|BC051352:-2886OLIG3 oligodendrocyte transcription factor 3 chr6:137860078-137860122 PROMOTER 4 3
173 ref|NM_004248|ref|PRLHR:-7|mgc|BC101490:-337PRLHR prolactin releasing hormone receptor chr10:120345135-120345179 PROMOTER 4 3
174 ref|NM_000312|ref|PROC:-2306|mgc|BC034377:-2324PROC protein C (inactivator of coagulation factors Va and VIIIa) chr2:127890158-127890202 PROMOTER 4 3
175 ref|NM_022454|ref|SOX17:-4131|mgc|BC140307:-4333SOX17 SRY (sex determining region Y)-box 17 chr8:055528894-055528938 PROMOTER 4 3
176 ref|NM_020417|ref|TBX20:-3923|ref|NM_001077653:-3923TBX20 T-box 20 chr7:035263668-035263712 PROMOTER 4 3
177 ref|NM_020064|ref|BARHL1:-2688|ref|NM_207417:169694|ens|ENST00000263610:-2688BARHL1 BarH-like 1 (Drosophila) chr9:134445103-134445147 PROMOTER 4 2
178 ref|NM_152732|ref|C6orf206:-156|ref|NM_014628:9077|ref|NM_001003690:15375|mgc|BC029519:-156|ens|ENST00000372173:11722C6orf206 chromosome 6 open readi g frame 2 6 chr6:043720609-043720653 PROMOTER 4 2
179 ref|NM_053056|ref|CCND1:-3062|mgc|BC023620:-3135CCND1 cyclin D1 chr11:069161969-069162013 PROMOTER 4 2
180 ref|NM_152890|ref|COL24A1:-55|mgc|BC113654:-58COL24A1 collagen, type XXIV, alpha 1 chr1:086394736-086394792 PROMOTER 4 2
181 ref|NM_030594|ref|CPEB1:-874|mgc|BC050629:-874CPEB1 cytoplasmic polyadenylation element binding protein 1 chr15:081114628-081114686 PROMOTER 4 2
182 ref|NM_004952|ref|EFNA3:-7973|ref|NM_182690:7162|ref|NM_207197:19613|mgc|BC110406:-7983EFNA3 ephrin-A3 chr1:153309976-153310020 PROMOTER 4 2
183 ref|NM_001451|ref|FOXF1:-2678|mgc|BC089442:-2689FOXF1 forkhead box F1 chr16:085098933-085098977 PROMOTER 4 2
184 ref|NM_001463|ref|FRZB:-281|ens|ENST00000346289:-6789|mgc|BC027855:-429FRZB frizzled-related protein chr2:183440000-183440049 PROMOTER 4 2
185 ref|NM_145657|ref|GSH1:-3063|ens|ENST00000302945:-3063GSH1 GS homeobox 1 chr13:027261690-027261742 PROMOTER 4 2
186 ref|NM_003532|ref|HIST1H3E:-41|ref|NM_021052:8194|ref|NM_003518:-8469|ref|NM_005320:9875|mgc|BC052981:844HIST H3E histone cluster 1, H3e chr6:026333291-026333350 PROMOTER 4 2
187 ref|NM_173860|ref|HOXC12:-4813|ref|NM_017410:11325|ens|ENST00000243103:-4813HOXC12 homeobox C12 chr12:052630142-052630192 PROMOTER 4 2
188 ref|NM_025251|ref|KIAA1688:-5980KIAA1688 KIAA1688 protein chr8:145815654-145815698 PROMOTER 4 2
189 ref|NM_005372|ref|MOS:-3642|mgc|BC069569:-3642MOS v-mos Moloney murine sarcoma viral oncogene homolog chr8:057192711-057192763 PROMOTER 4 2
190 ref|NM_006162|ref|NFATC1:-2317|ref|NM_172387:-6871|ref|NM_172388:-2317NFATC1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 chr18:075254420-075254464 PROMOTER 4 2
191 ref|NM_001008564|ref|NUPL1:-117|ref|NM_001008565:-117NUPL1 nucleoporin l ike 1 chr13:024773519-024773578 PROMOTER 4 2
192 ref|NM_006902|ref|PRRX1:-2792|ref|NM_022716:-2792PRRX1 paired related homeobox 1 chr1:168897122-168897167 PROMOTER 4 2
193 ref|NM_004586|ref|RPS6KA3:-1503|mgc|BC096301:-1503RPS6KA3 ribosomal protein S6 kinase, 90kDa, polypeptide 3 chrX:020196152-020196196 PROMOTER 4 2
194 ref|NM_144665|ref|SESN3:-1371|mgc|BC017296:-1407SESN3 sestrin 3 chr11:094605243-094605287 PROMOTER 4 2
195 ref|NM_032291|ref|SGIP1:-1125|mgc|BC040516:-366SGIP1 SH3-domain GRB2-like (endophilin) interacting protein 1 chr1:066771265-066771309 PROMOTER 4 2
196 ref|NM_205848|ref|SYT6:-667|ens|ENST00000369546:-2077|mgc|BC044948:-667SYT6 synaptotagmin VI chr1:114498640-114498684 PROMOTER 4 2
197 ref|NM_030788|ref|TM7SF4:-9901|mgc|BC069349:-9901TM7SF4 transmembrane 7 superfamily member 4 chr8:105411302-105411354 PROMOTER 4 2
198 ref|NM_000262|ref|NM_001002034|ref|NAGA:-3187|ref|FAM109B:-294|ref|NM_033318:-5738|mgc|BC104176:-1629|mgc|BC000095:-3578|ens|ENST00000321753:-294|ens|ENST00000348202:2205NAGA-FAM109B N-acetylgalactosaminidase, alpha- chr22:0 0799884-040799928 DIVERGENT_PROMOTER 4 2
199 ref|NM_017879|ref|NM_001010879|ref|ZNF416:-4459|ref|ZIK1:-925|mgc|BC103957:-925|mgc|BC000130:-4459ZNF416-ZIK1 zinc finger protein 416 chr19:062786492-062786536 DIVERGENT_PROMOTER 4 2
200 ref|NM_005502|ref|ABCA1:-412|mgc|BC141816:-422ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 chr9:106730640-106730699 PROMOTER 4 1
201 ref|NM_001117|ref|ADCYAP1:-894|mgc|BC093837:-824ADCYAP1 adenylate cyclase activating polypeptide 1 (pituitary) chr18:000894464-000894520 PROMOTER 4 1
202 ref|NM_130768|ref|ASZ1:-173|mgc|BC126186:-180ASZ1 ankyrin repeat, SAM and basic leucine zipper domain containing 1 chr7:116854930-116854974 PROMOTER 4 1
203 ref|NM_001166|ref|BIRC2:-111|ref|NM_182962:29661|mgc|BC016174:-2703|mgc|BC028578:-255|mgc|BC037420:22739BIRC2 baculoviral IAP repeat-containing 2 chr11:101723042-101723086 PROMOTER 4 1
204 ref|NM_024600|ref|C16orf30:-305|ref|NM_014714:73375|mgc|BC105785:-236|mgc|BC004932:5184C16orf30 chromosome 16 open reading frame 30 chr16:001523904-001523948 PROMOTER 4 1
205 ref|NM_031448|ref|C19orf12:-9173|ref|NM_001031726:-9662C1 orf12 chromosome 19 open reading frame 12 chr19:034907436-034907495 PROMOTER 4 1
206 ref|NM_032648|ref|C1orf90:-6791|ref|NM_003757:18056|mgc|BC004269:-6807|mgc|BC041632:-193C1orf90 chromosome 1 open reading frame 90 chr1:032478591-032478635 PROMOTER 4 1
207 ref|NM_207406|ref|CCDC4:-40|mgc|BC128592:-735CCDC4 coiled-coil domain containing 4 chr4:041849665-041849720 PROMOTER 4 1
208 ref|NM_014516|ref|CNOT3:-148|ref|NM_015629:22464|ens|ENST00000358389:-6440|mgc|BC016474:-182CNOT3 CCR4-NOT transcription complex, subunit 3 chr19:059333090-059333134 PROMOTER 4 1
209 ref|NM_030820|ref|COL21A1:-126|mgc|BC126108:-271|ens|ENST00000370819:146388COL21A1 collagen, type XXI, alpha 1 chr6:056220441-056220485 PROMOTER 4 1
210 ref|NM_001848|ref|COL6A1:-9107|mgc|BC052575:-9127COL6A1 collagen, type VI, alpha 1 chr21:046216961-046217005 PROMOTER 4 1
211 ref|NM_024027|ref|COLEC11:-164|ref|NM_199235:-164COLEC11 collectin sub-family member 11 chr2:003620325-003620369 PROMOTER 4 1
212 ref|NM_000499|ref|CYP1A1:-1362|ens|ENST00000268062:-3801|mgc|BC023019:-1406CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 chr15:072806266-072806318 PROMOTER 4 1
213 ref|NM_019074|ref|DLL4:-2103|mgc|BC106950:-2287DLL4 delta-like 4 (Drosophila) chr15:039006706-039006765 PROMOTER 4 1
214 ref|NM_001038493|ref|DLX1:-4072|ref|NM_178120:-4072|ref|NM_199227:81332DLX1 distal-less homeobox 1 chr2:172654359-172654403 PROMOTER 4 1
215 ref|NM_015268|ref|DNAJC13:-456DNAJC13 DnaJ (Hsp40) homolog, subfamily C, member 13 chr3:133618764-133618808 PROMOTER 4 1
216 ref|NM_001039350|ref|DPP6:-279DPP6 dipeptidyl-peptidase 6 chr7:153215050-153215094 PROMOTER 4 1
217 ref|NM_152403|ref|EGFLAM:-739|mgc|BC063822:-876EGFLAM EGF-like, fibronectin type III and laminin G domains chr5:038293528-038293572 PROMOTER 4 1
218 ref|NM_173160|ref|FXYD4:-9427|mgc|BC054876:-9425FXYD4 FXYD domain containing ion transport regulator 4 chr10:043177643-043177697 PROMOTER 4 1
219 ref|NM_005754|ref|G3BP1:-1189|ref|NM_198395:-1189G3BP1 GTPase activating protein (SH3 domain) binding protein 1 chr5:151130455-151130503 PROMOTER 4 1
220 ref|NM_002040|ref|GABPA:-96|ref|NM_001003696:363|mgc|BC035031:-92GABPA GA binding protein transcription factor, alpha subunit 60kDa chr21:026029451-026029496 PROMOTER 4 1
221 ref|NM_002729|ref|HHEX:-860|mgc|BC050638:-920HHEX hematopoietically expressed homeobox chr10:094438777-094438824 PROMOTER 4 1
222 ref|NM_014212|ref|HOXC11:-7169|ref|NM_173860:11027|mgc|BC001543:-7188HOXC11 homeobox C11 chr12:052645983-052646032 PROMOTER 4 1
223 ref|NM_021193|ref|HOXD12:-516|ref|NM_021192:-8070|ref|NM_000523:6482|mgc|BC121103:-516HOXD12 homeobox D12 chr2:176672237-176672281 PROMOTER 4 1
224 ref|NM_016257|ref|HPCAL4:-208|mgc|BC030827:-213HPCAL4 hippocalcin l ike 4 chr1:039929862-039929906 PROMOTER 4 1
225 ref|NM_024336|ref|IRX3:-1249|mgc|BC023667:-1282IRX3 iroquois homeobox protein 3 chr16:052879099-052879158 PROMOTER 4 1
X 
 
 
 
226 ref|NM_003597|ref|KLF11:-877|mgc|BC074922:-1007KLF11 Kruppel-l ike factor 11 chr2:010100230-010100280 PROMOTER 4 1
227 ref|NM_016269|ref|LEF1:-3435|mgc|BC040559:-4068LEF1 lymphoid enhancer-binding factor 1 chr4:109312434-109312491 PROMOTER 4 1
228 ref|NM_001007125|ref|LOC198437:-119|ref|NM_000913:4344|mgc|BC038433:-537|mgc|BC036837:-119LOC198437 bA299N6.3 chr20:062186247-062186303 PROMOTER 4 1
229 ref|NM_014628|ref|MAD2L1BP:-6003|ref|NM_001003690:295|mgc|BC002904:-6033|ens|ENST00000372173:-3358MAD2L1BP MAD2L1 binding protein chr6:043705522-043705581 PROMOTER 4 1
230 ref|NM_012301|ref|MAGI2:-799|ens|ENST00000344634:-1053MAGI2 membrane associated guanylate kinase, WW and PDZ domain containing 2 chr7:078921596-078921655 PROMOTER 4 1
231 ref|NM_016060|ref|MED31:-3332|mgc|BC012539:-3333MED31 mediator of RNA polymerase II transcription, subunit 31 homolog (S. cerevisiae) chr17:006498960-006499004 PROMOTER 4 1
232 ref|NM_177524|ref|MEST:-117|ref|NM_002402:-6009|mgc|BC090049:-266MEST mesoderm specific transcript homolog (mouse) chr7:129913135-129913194 PROMOTER 4 1
233 ref|NM_022746|ref|MOSC1:-291|ref|NM_017898:38304|mgc|BC010619:-291MOSC1 MOCO sulphurase C-terminal domain containing 1 chr1:219026573-219026632 PROMOTER 4 1
234 ref|NM_001584|ref|MPPED2:-3717|mgc|BC031582:2780MPPED2 metallophosphoesterase domain containing 2 chr11:030562310-030562356 PROMOTER 4 1
235 ref|NM_002440|ref|MSH4:-126|mgc|BC033030:-63|mirna|U45B:7342|mirna|U45A:8930MSH4 mutS homolog 4 (E. coli) chr1:076035068-076035114 PROMOTER 4 1
236 ref|NM_000256|ref|MYBPC3:-2674|ens|ENST00000366271:-563|mgc|BC142685:-2694MYBPC3 myosin binding protein C, cardiac chr11:047333481-047333525 PROMOTER 4 1
237 ref|NM_020443|ref|NAV1:-341|ens|ENST00000295624:-341|ens|ENST00000367302:24508NAV1 neuron navigator 1 chr1:199883708-199883755 PROMOTER 4 1
238 ref|NM_002500|ref|NEUROD1:-2422|mgc|BC009046:-2590NEUROD1 neurogenic differentiation 1 chr2:182256025-182256072 PROMOTER 4 1
239 ref|NM_007361|ref|NID2:-864|ref|NM_016039:80618|mgc|BC035608:-1044NID2 nidogen 2 (osteonidogen) chr14:051606531-051606590 PROMOTER 4 1
240 ref|NM_177400|ref|NKX6-2:-2611|ref|NM_005539:250796|mgc|BC101635:-2611NKX6-2 NK6 transcription factor related, locus 2 (Drosophila) chr10:134452116-134452160 PROMOTER 4 1
241 ref|NM_178864|ref|NPAS4:-426|mgc|BC105001:-513NPAS4 neuronal PAS domain protein 4 chr11:065944601-065944647 PROMOTER 4 1
242 ref|NM_005285|ref|NPBWR1:-354|mgc|BC069117:-354|ens|ENST00000331251:1121NPBWR1 neuropeptides B/W receptor 1 chr8:054014637-054014696 PROMOTER 4 1
243 ref|NM_012226|ref|P2RX2:-8290|ref|NM_016318:-8290|ens|ENST00000376608:-5707P2RX2 purinergic receptor P2X, l igand-gated ion channel, 2 chr12:131697163-131697207 PROMOTER 4 1
244 ref|NM_016223|ref|PACSIN3:-667|mgc|BC007914:-686PACSIN3 protein kinase C and casein kinase substrate in neurons 3 chr11:047165175-047165227 PROMOTER 4 1
245 ref|NM_013942|ref|PAX3:-4926|ref|NM_153038:5761|ref|NM_000438:-4926PAX3 paired box gene 3 (Waardenburg syndrome 1) chr2:222876845-222876895 PROMOTER 4 1
246 ref|NM_020992|ref|PDLIM1:-4464|mgc|BC018755:-4549PDLIM1 PDZ and LIM domain 1 (elfin) chr10:097045210-097045260 PROMOTER 4 1
247 ref|NM_006211|ref|PENK:-390|mgc|BC032505:-390PENK proenkephalin chr8:057521511-057521555 PROMOTER 4 1
248 ref|NM_002741|ref|PKN1:-1425|ref|NM_213560:-8345|mgc|BC040061:-1428PKN1 protein kinase N1 chr19:014403711-014403770 PROMOTER 4 1
249 ref|NM_153819|ref|RASGRP2:-561|ref|NM_001098671:-1859|ref|NM_005609:14698RASGRP2 RAS guanyl releasing protein 2 (calcium and DAG-regulated) chr11:064270043-064270087 PROMOTER 4 1
250 ref|NM_213594|ref|RFX4:-2390|ens|ENST00000357881:-2390RFX4 regulatory factor X, 4 (influences HLA class II expression) chr12:105498750-105498794 PROMOTER 4 1
251 ref|NM_007218|ref|RNF139:-294|mgc|BC064636:-427RNF139 ring finger protein 139 chr8:125555865-125555924 PROMOTER 4 1
252 ref|NM_003013|ref|SFRP2:-3533|mgc|BC008666:-3553SFRP2 secreted frizzled-related protein 2 chr4:154933182-154933241 PROMOTER 4 1
253 ref|NM_000451|ref|SHOX:-3925|ref|NM_006883:-3925SHOX short stature homeobox chrY:000501132-000501175 PROMOTER 4 1
254 ref|NM_000340|ref|SLC2A2:-1602|ens|ENST00000382808:-9955|mgc|BC060041:-1861SLC A2 solute carrier family 2 (facil itated glucose transporter), member 2 chr3:172229035-172229094 PROMOTER 4 1
255 ref|NM_018018|ref|SLC38A4:-5415|ens|ENST00000266579:-5411SLC38A4 solute carrier family 38, member 4 chr12:045511388-045511446 PROMOTER 4 1
256 ref|NM_032034|ref|SLC4A11:-176|mgc|BC110540:-203|ens|ENST00000380049:1287SLC4A11 solute carrier family 4, sodium bicarbonate transporter-like, member 11 chr20:003166524-003166574 PROMOTER 4 1
257 ref|NM_018967|ref|SNTG1:-1861SNTG1 syntrophin, gamma 1 chr8:050985264-050985312 PROMOTER 4 1
258 ref|NM_006946|ref|SPTBN2:-7583|ens|ENST00000309996:-7583SPTBN2 spectrin, beta, non-erythrocytic 2 chr11:066253004-066253054 PROMOTER 4 1
259 ref|NM_005078|ref|TLE3:-3813|mgc|BC041831:-4028|mgc|BC043247:-2715TLE3 transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila) chr15:068180002-068180048 PROMOTER 4 1
260 ref|NM_033285|ref|TP53INP1:-838|mgc|BC074813:-9228|ens|ENST00000342697:-835TP53INP1 tumor protein p53 inducible nuclear protein 1 chr8:096031583-096031627 PROMOTER 4 1
261 ref|NM_006953|ref|UPK3A:-139|mgc|BC108900:-122UPK3A uroplakin 3A chr22:044059391-044059435 PROMOTER 4 1
262 ref|NM_153453|ref|VGLL2:-1849|ref|NM_182645:-1865VGLL2 vestigial l ike 2 (Drosophila) chr6:117691542-117691586 PROMOTER 4 1
263 ref|NM_003451|ref|ZNF177:-172|mgc|BC141584:177067ZNF177 zinc finger protein 177 chr19:009334494-009334553 PROMOTER 4 1
264 ref|NM_032423|ref|ZNF528:-29|mgc|BC101712:-4133|ens|ENST00000360465:-29ZNF528 zinc finger protein 528 chr19:057592881-057592925 PROMOTER 4 1
265 ref|NM_014630|ref|ZNF592:-662|mgc|BC094688:-710ZNF592 zinc finger protein 592 chr15:083092136-083092182 PROMOTER 4 1
266 ref|NM_033410|ref|ZNF764:-3254|ref|NM_001024683:10890|mgc|BC008821:-3254ZNF764 zinc finger protein 764 chr16:030480317-030480361 PROMOTER 4 1
267 ref|NM_138740|ref|NM_014847|ref|C1orf43:-278|ref|UBAP2L:-4006|ref|NM_015449:-278|mgc|BC003170:-4006|ens|ENST00000368504:129C orf 3-UBAP2L chromosome 1 open reading frame 43 chr1:152460153-152460197 DIVERGENT_PROMOTER 4 1
268 ref|NM_021259|ref|NM_001045548|ref|TMEM8:-973|ref|LOC441743:-3867|ens|ENST00000382941:-6518|ens|ENST00000332361:-3882|mgc|BC021557:-1039TMEM8-LOC441743 transmembrane protein 8 (five membrane-spanning domains) chr16:000372852-000372911 DIVERGENT_PROMOTER 4 1
Appendix B.III_High stringency gene list
This table shows the list of genes identified through the high stringency analysis of the MIRA array. Gene names, accession numbers, gene product names,
CpG location (systematic name), location of the probe with respect the promoter or divergent promoter classification, the number of cell lines with >10 fold
difference between tumour and normal and the number of probes meeting this criteria for each gene are shown.
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 PRIMARY 
REACTION 
 SECONDARY 
REACTION 
 PRIMARY 
REACTION 
 SECONDARY 
REACTION 
F GGGTTTTTAGAGTTATGTTTGGTTAATTTTATTATT
FN GGAYGTTAAAAAGGTTTAGAGTTGTTTYGA
RN AACRATCAACTAAACRTCCACCTATAATA
R AAACRTACRACCATATCCRAAACACAAA
F AGAGATAGTTATAAGAGGGAAATTTTATAATTAATAT
RN CCTCTTACCTATATAAAATACRACRACTAA
R CCCACCAATACCAAACTCRATAAT
F AAGGTAGAAAGGYGTTTTTTGAYGAGAATT
FN GGTTTTGAGTTAATTATGGTTYGTGAYGAT
R ACACTTAAAAAAACCACRAACCRCATACTA
F GTTTGAGGGYGTTTYGGTTTATTYGATTAT
FN GYGTTTAATTTTTGGGAGTTTYGAAGGATT
R ACCTAACRCCCTCACCCTAAATAAATCTAA
F GGAGTTTTTTATTTTATAAGTGGTTTATAGGGT
FN AATTTTGTTTATGTTGGGGTTGTAGAGTAT
R TACAAACTCCTTATATCRCAAAACCCCTAA
F GAGTTGGAATAYGGTTTTATGYGTTTTTTTAT
RN AAATAAAAAACTCCRACCCAACCCATAA
R CTATTTAACRAAAAATCCCAAACCCTAAAAATAA
F ATTTTGTTTAYGTTYGGYGATTTYGGGATT
FN TATTTATYGATAYGGGTTTTTTTTTYGGTATTGATT
R ATCCCRCCCCCRAAAAACAAAATTACTA
F TTTATTTATGTTTGGTAATTTAGTAGAAATTTYGGAT
RN TCCRAAAAAAACTAATCACTACTTTCTAAATCTAA
R ACCCRAAAAAACAAAATAAACCRTTAACTAA
F GTTYGAGTYGTTGTAYGGTYGTTTTTAT
FN AAGTYGTYGTAGTGTTTTGATATTTTTGTYGATT
R ACRACRATACCAAAATCRTTATCCAAAAAAAACTTATAA
C1orf114
CDKL2
CLDN6
COL1A2
COX7A1
RECK
SFRP2
SFRP5
ACADL
PRODUCT SIZE (bp)
PROGRAM
ANNEALING TEMPERATURE (°C)
PRIMER SEQUENCE (5'-3')PRIMER GENE 
55 55 TOUCHDOWN 484 207
56 56 TOUCHDOWN 479 376
55 55 TOUCHDOWN 564 389
56 56 TOUCHDOWN 577 494
57 57 TOUCHDOWN 423 254
57 57 TOUCHDOWN 375 259
55 55 TOUCHDOWN 553 475
56 56 TOUCHDOWN 380 350
55 55 TOUCHDOWN 450 339
XII 
 
 
 
 
 
  
F GTTGTTTTAGGGYGTAAAGAGATGATATT
RN AAAACRCAACAACRAAAATTCCAAACCTAA
R CTTCRCCTAAAAAACRAAACCATACTAA
F TTTAAAATAGAGGGAGAYGGTTGAGAGTAT
RN CCRAAAAACRTCRAAAAAATCTCCTTACCTC
R ACTAAACATCCCTTACRTCCAAACCAATAA
F ATGGGTTTTTAGTGTTTTTTTTGGAGTTTA
FN ATTYGGAATTAAATYGTAGGTTTTGGGTTA
R CAAATAARATATTCCCCAACCAAAA
F GGYGGTTATTTTAGTTTTTTTGAGGTGTGTTTAT
FN ATAGGGATYGTTGTTTTYGGGTTTTTATT
R CATCCTCACAATAACAATACAACCCTAAA
ZNF154
TNFRSF10D
SIPA1
SST 56 56 TOUCHDOWN 361 299
54 55 TOUCHDOWN 307 249
55 55 TOUCHDOWN 567 408
55 55 TOUCHDOWN 597 494
Appendix C.I_CoBRA primers used in the Infinium study
Primer sequences are shown for all genes analysed by CoBRA/sequencing in the Infinium study (chapter 4). In each case forward (F), reverse (R)
and nested (either forward nested (FN) or reverse nested (RN)) primer sequences are shown. Annealing temperatures and product sizes are given
for primary and secondary PCR reactions. Also shown are whether the PCR was carried out using the standard CoBRA PCR program or the
touchdown CoBRA PCR program.
XIII 
 
GENE PRIMER SEQUENCE (5'-3')
ANNEALING 
TEMPERATURE (°C)
PRODUCT 
SIZE (bp)
F ATCATCACCTCCCACAGCAT
R GTAGTCGTCCACGCCGTACT
F TTGGCAAAACAGTTGCTCAC
R ATTGGCTGAACTCTGGCATC
F AATTCAGCGAGCAAAGGAAA
R CGAAAAGGTTTGGCTTCTGA
F TCAAATGGATGGATTTGCTG
R GCTTGGATTCCTTGTGTGGT
F CCTGGCTTAAAGGGACACAA
R GCTGGTCAGCCCTGTAGAAG
F TGGACAGAGGAGGACTACGC
R AGGCCAGCGTTTATTGACAC
F TACCCGAAGAATTGGTCCAG
R ACCCCAGCATCATAGACAGC
F CCGAGTGTGCTTCTGTCAAG
R GGAAATGATGAGGGCAGAGA
F AGGACAACGACCTTTGCATC
R CAAGCTGTCTTTGAGCCACA
F AGTTTGACCAGCCACTCTCC
R CCATAGCCGGGTTTGAGTTA
F CAGGAAATCCAAGGTCAGGA
R AGCCTGCCTCATCTTCTTCA
F ACGAAAGCGTCTAAGCCTTG
R TTTTTCTCCAAGGTGCTGCT
265
324
369
363
398
290
231
333
271
330
367
305
56ZNF154 
56
56
56
56
56
56
56
56
56
COX7A1 
LAMA2
RECK 
SFRP2 
SST 
TNFRSF10D
ABCA3 56
ACADL 
C1orf114 
CDKL2 
COL1A2 
56
Appendix C.II_Expression primer sets used in the Infinium gene analysis
Forward (F) and reverse (R) primer sequences are shown for each gene analysed for
expression in chapter 4. Annealing temperatures and product sizes are also shown.
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Appendix C.III_List of 291 methylated probes from the Illumina Infinium study in
chapter 4.
The table shows all 291 probes that were classified as hypermethylated from the Illumina
Infinium study (chapter 3). In each case, gene symbol, probe name, the number of samples
meeting the criteria of having a difference value of 0.4 and a β-values of 0.5 are shown
along with the number of samples meeting either of these criteria (Meth+). In addition, the
chromosome number is shown and whether the probe is within a true or false CpG island.
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 PRIMARY 
REACTION 
 SECONDARY 
REACTION 
 PRIMARY 
REACTION 
 SECONDARY 
REACTION 
F TTGTTTTTGTTGTTTTYGTYGTTTTAGTAGATT
FN GTGTGGATTTGTTAGGAAGAGAAGT
RN CTATTTCTCCTAAATCATAACCAAACTAA
R CRATTAAACTTATCCAATTTACAAAAACCTTA
55RASSF10
PRODUCT SIZE (bp)
TOUCHDOWN 
(PRIMARY) 
STANDARD 
(SECONDARY)
638 42656
GENE PRIMER PRIMER SEQUENCE (5'-3')
ANNEALING TEMPERATURE (°C)
PROGRAM
Appendix D.I_RASSF10 CoBRA primer sequences 
The above table shows the primer sequences used for RASSF10 CoBRA analysis. Annealing temperatures, program details and 
product sizes are also given. 
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F CGAGAGCGCGTTTAGTTTCGTT
R CGATTAAACCCGTACTTCGCTAA
F GGGGGTTTTGTGAGAGTGTGTTT
R CCCAATTAAACCCATACTTCCTAA
F TTTCGACGTTCGTAGGTTTTCGC
R GCACTCTTCCGAAAACGAAACG
F TTTGTGTTTTGATGTTTGTAGGTTTTTGT
R AACTCCACACTCTTCCAAAAACAAAACA
93
58
192
204
MGMT 
MSP 58
STANDARD 
81
USP 58
RASSF1A STANDARD 
MSP
USP
58
GENE PRIMER SEQUENCE (5'-3') PROGRAM
ANNEALING 
TEMPERATURE (°C)
PRODUCT SIZE (bp)PRIMER 
Appendix D.II_RASSF1A and MGMT MSP primer sequences 
The above table shows the primer sequences used for RASSF1A and MGMT MSP analysis. Pirmer sequences for RASSF1A 
and MGMT were taken from Honorio et al, 2003 and Esteller et al, 2000a respectively. Annealing temperatures, program 
details and product sizes are also given. 
 XX 
 
 
 
 
 
 
  
GENE PRIMER SEQUENCE (5'-3')
ANNEALING 
TEMPERATURE 
(°C)
PRODUCT SIZE (bp)
F GTTCAGCAGGAGGAGTTGCT
R CGTCAGCTCCAAAGTGTGCAA
RASSF10 56 317
Appendix D.III_Expression primers used for RASSF10 expression analysis
Forward (F) and reverse (R) primer sequences are shown for expression analysis of
RASSF10. Annealing temperature and product size are also shown.
 XXI 
 
 
 
 
 
 
  
 PRIMARY 
REACTION 
 SECONDARY 
REACTION 
 PRIMARY 
REACTION 
 SECONDARY 
REACTION 
F GTATTTGGYGGAGGTAGAAGTTATAAATT
RN CATAATCCRAAAAATAACRCCCRCAAATAA
R TATCCCRCRAATCRACCAACTAATAATA
426
GENE PRIMER PRIMER SEQUENCE (5'-3')
ANNEALING TEMPERATURE (°C)
PROGRAM
PRODUCT SIZE (bp)
KIBRA 55 55 TOUCH 638
Appendix E.I_KIBRA CoBRA primer sequences 
The above table shows the primer sequences used for KIBRA CoBRA analysis. Annealing temperatures, program details and 
product sizes are also given. 
 XXII 
 
 
 
 
 
 
  
GENE PRIMER SEQUENCE (5'-3')
ANNEALING 
TEMPERATURE 
(°C)
PRODUCT 
SIZE (bp) 
F AAACAGAGCAGGGAGCTCAA
R CCCATCCATATCAGGTGAGG
KIBRA 56 263
Appendix E.II_Expression primers used for KIBRA expression analysis
Forward (F) and reverse (R) primer sequences are shown for expression
analysis of KIBRA. Annealing temperature and product size are also shown.
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